


**CUMULATIVE
SUPPLEMENT 9
SEPTEMBER 2014**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Medical Products and Tobacco
Office of Generic Drugs**

2014

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

Cumulative Supplement 9

September 2014

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION.....	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content	iv
1.3 Applicant Name Changes	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Legend	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

**CUMULATIVE SUPPLEMENT 9
September 2014**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 34th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
WEST WARD INC (WEST WARD)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
WEST WARD PHARMACEUTICAL CORP (WEST WARD PHARMS CORP)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
WEST WARD PHARMACEUTICAL CORP (WEST WARD PHARMS)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
MARSAM PHARMACEUTICALS LLC (MARSAM PHARMS LLC)	WATSON LABORATORIES INC (WATSON LABS INC)
WATSON LABORATORIES INC (WATSON LABS)	ACTAVIS LABORATORIES INC (ACTAVIS LABS FL INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following

explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2012) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2013</u>	<u>MAR 2014</u>	<u>JUN 2014</u>	<u>SEPT 2014</u>	<u>DEC 2014</u>
DRUG PRODUCTS LISTED	15711	15885	15823	15974	
SINGLE SOURCE	2517 (16.0%)	2540 (16.0%)	2516 (15.9%)	2536 (15.9%)	
MULTISOURCE	13194 (84.0%)	13345 (84.0%)	13307 (84.1%)	13438 (84.1%)	
THERAPEUTICALLY EQUIVALENT	13055 (83.1%)	13208 (83.1%)	13169 (83.2%)	13304 (83.3%)	
NOT THERAPEUTICALLY EQUIVALENT	139 (0.9%)	137 (0.9%)	138 (0.9%)	134 (0.8%)	
EXCEPTIONS ¹	78 (0.5%)	78 (0.5%)	78 (0.5%)	77 (0.5%)	
NEW MOLECULAR ENTITIES APPROVED	20	12	6	17	
NUMBER OF APPLICANTS	866	873	889	899	

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.

CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET; ORAL
TRIUMEQ

+ VIIV HLTHCARE EQ 600MG BASE; EQ 50MG BASE; 300MG N205551 001 Aug 22, 2014 Aug NEWA

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE; ORAL
ACAMPROSATE CALCIUM

AB MYLAN PHARMS INC 333MG A200142 001 Mar 11, 2014 Feb NEWA

ACARBOSE

TABLET; ORAL
ACARBOSE

AB STRIDES PHARMA 25MG A090912 001 Jul 27, 2011 Aug CAHN
AB 50MG A090912 002 Jul 27, 2011 Aug CAHN
AB 100MG A090912 003 Jul 27, 2011 Aug CAHN

ACEBUTOLOL HYDROCHLORIDE

CAPSULE; ORAL
ACEBUTOLOL HYDROCHLORIDE

@ WATSON LABS EQ 200MG BASE A074007 001 Oct 18, 1995 May DISC
@ EQ 400MG BASE A074007 002 Oct 18, 1995 May DISC

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL
PHRENILIN FORTE

@ VALEANT 650MG; 50MG A088831 001 Jun 19, 1985 Apr DISC

TABLET; ORAL
BUTAPAP

@ MIKART 650MG; 50MG A089988 001 Oct 26, 1992 Apr DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL
ESGIC-PLUS

@ MIKART 500MG; 50MG; 40MG A040085 001 Mar 28, 1996 Apr DISC

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

@ MIKART 750MG; 50MG; 40MG A040496 001 Dec 23, 2003 Apr DISC
@ MIRROR PHARMS 325MG; 50MG; 40MG A040864 001 Dec 01, 2008 Mar DISC
AA + VINTAGE PHARMS 325MG; 50MG; 40MG A040511 001 Aug 27, 2003 Mar CRLD
@ 500MG; 50MG; 40MG A040513 001 Aug 25, 2003 Apr DISC
@ WATSON LABS 500MG; 50MG; 40MG A040267 001 Jul 30, 1998 Jan DISC
ESGIC-PLUS
@ MIKART 500MG; 50MG; 40MG A089451 001 May 23, 1988 Apr DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

>A> AB HIKMA INTL PHARMS 325MG; 50MG; 40MG; 30MG A075618 001 Mar 23, 2001 Sep CAHN
>D> AB HIKMA PHARMS LLC 325MG; 50MG; 40MG; 30MG A075618 001 Mar 23, 2001 Sep CAHN
PHRENILIN WITH CAFFEINE AND CODEINE
@ VALEANT 325MG; 50MG; 40MG; 30MG A074911 001 Aug 22, 2001 Mar DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ MALLINCKRODT 500MG/15ML; 7.5MG/15ML A040418 001 Jun 27, 2001 Jan DISC
@ MIKART 500MG/15ML; 7.5MG/15ML A081051 001 Aug 28, 1992 Apr DISC
@ PHARM ASSOC 500MG/15ML; 7.5MG/15ML A040182 001 Mar 13, 1998 Apr DISC
AA VINTAGE PHARMS 325MG/15ML; 7.5MG/15ML A040894 001 Jul 19, 2011 Feb CAHN
@ 500MG/15ML; 7.5MG/15ML A040520 001 Oct 30, 2003 Apr DISC

TABLET; ORAL

ANEXSIA

@ MALLINCKRODT 500MG; 5MG A089160 001 Apr 23, 1987 Jan DISC
@ 750MG; 10MG A040468 001 Oct 31, 2002 Jan DISC

ANEXSIA 7.5/650

@ MALLINCKRODT 650MG; 7.5MG A089725 001 Sep 30, 1987 Jan DISC
HYDROCODONE BITARTRATE AND ACETAMINOPHEN
@ AMNEAL PHARMS NY 500MG; 5MG A040729 001 Aug 25, 2006 Apr DISC

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@	500MG; 7.5MG	A 040748	001	Aug 25, 2006	Apr	DISC
	@	500MG; 10MG	A 040813	001	Feb 23, 2007	Apr	DISC
	@	650MG; 7.5MG	A 040754	001	Aug 25, 2006	Apr	DISC
	@	650MG; 10MG	A 040757	001	Aug 25, 2006	Apr	DISC
	@	750MG; 7.5MG	A 040769	001	Aug 28, 2006	Apr	DISC
	@ CARACO	500MG; 5MG	A 090265	001	Dec 23, 2008	Apr	DISC
	@	500MG; 7.5MG	A 090265	002	Dec 23, 2008	Apr	DISC
	@	500MG; 10MG	A 090265	003	Dec 23, 2008	Apr	DISC
	@	650MG; 7.5MG	A 090380	001	Dec 23, 2008	Apr	DISC
	@	650MG; 10MG	A 090380	002	Dec 23, 2008	Apr	DISC
	@	660MG; 10MG	A 090380	003	Dec 23, 2008	Apr	DISC
	@	750MG; 7.5MG	A 090380	004	Dec 23, 2008	Apr	DISC
	@ MALLINCKRODT	500MG; 5MG	A 040084	002	Jun 01, 1995	Jan	DISC
	@	500MG; 7.5MG	A 040201	001	Feb 27, 1998	Jan	DISC
	@	500MG; 10MG	A 040201	002	Feb 27, 1998	Jan	DISC
	@	650MG; 10MG	A 040084	004	Oct 16, 1996	Jan	DISC
	@	660MG; 10MG	A 040084	003	Jul 29, 1996	Jan	DISC
	@	750MG; 7.5MG	A 040084	001	Jun 01, 1995	Jan	DISC
	@ MIKART	500MG; 7.5MG	A 089699	001	Aug 25, 1989	Apr	DISC
	@	650MG; 7.5MG	A 089689	001	Jun 29, 1988	Apr	DISC
	@	650MG; 10MG	A 081223	001	May 29, 1992	Apr	DISC
AA	SUN PHARM INDS INC	325MG; 5MG	A 090118	001	Dec 23, 2008	Jun	CAHN
AA		325MG; 7.5MG	A 090118	002	Dec 23, 2008	Jun	CAHN
AA		325MG; 10MG	A 090118	003	Dec 23, 2008	Jun	CAHN
AA	VINTAGE PHARMS	300MG; 5MG	A 090415	001	Jan 24, 2011	Feb	CAHN
AA		300MG; 7.5MG	A 090415	002	Jan 24, 2011	Feb	CAHN
AA		300MG; 10MG	A 090415	003	Jan 24, 2011	Feb	CAHN
	@	500MG; 2.5MG	A 040144	002	Apr 25, 1997	Apr	DISC
	@	500MG; 5MG	A 089971	001	Dec 02, 1988	Apr	DISC
	@	500MG; 7.5MG	A 040144	001	Feb 22, 1996	Apr	DISC
	@	500MG; 10MG	A 040356	001	May 31, 2000	Apr	DISC
	@	650MG; 7.5MG	A 040155	001	Apr 14, 1997	Jan	DISC
	@	650MG; 10MG	A 040143	001	Feb 22, 1996	Apr	DISC
	@	660MG; 10MG	A 040358	001	May 31, 2000	Apr	DISC
	@	750MG; 7.5MG	A 040157	001	Apr 12, 1996	Jan	DISC
	@ WATSON LABS	500MG; 2.5MG	A 081079	001	Aug 30, 1991	Apr	DISC
	@	500MG; 5MG	A 089883	001	Dec 01, 1988	Apr	DISC
	@	500MG; 7.5MG	A 081080	001	Aug 30, 1991	Jan	DISC
	@	650MG; 7.5MG	A 040094	001	Sep 29, 1995	Apr	DISC
	@	650MG; 10MG	A 040094	002	Sep 29, 1995	Apr	DISC
	@	660MG; 10MG	A 040094	003	Aug 08, 2000	Apr	DISC
	@	750MG; 7.5MG	A 081083	001	Aug 30, 1991	Jan	DISC
	@	750MG; 10MG	A 040094	004	Mar 22, 1999	Apr	DISC
	@ WATSON LABS FLORIDA	660MG; 10MG	A 040495	001	May 28, 2003	Apr	DISC
	LORTAB						
	@ UCB INC	500MG; 5MG	A 087722	001	Jul 09, 1982	Apr	DISC
	@	500MG; 10MG	A 040100	001	Jan 26, 1996	Apr	DISC
	ZYDONE						
	@ VINTAGE PHARMS LLC	400MG; 5MG	A 040288	001	Nov 27, 1998	Apr	DISC
	@	400MG; 7.5MG	A 040288	002	Nov 27, 1998	Apr	DISC
	@	400MG; 10MG	A 040288	003	Nov 27, 1998	Apr	DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

	@ ACTAVIS ELIZABETH	500MG; 5MG	A 040199	001	Dec 30, 1998	Aug	CAHN
	@ DURAMED PHARMS BARR	500MG; 5MG	A 040289	001	Mar 16, 1999	Apr	DISC
	@ MALLINCKRODT	500MG; 5MG	A 040257	001	Aug 04, 1998	Jan	DISC
	@ VINTAGE PHARMS	500MG; 5MG	A 040106	001	Jul 30, 1996	Apr	DISC
	@ WATSON LABS	500MG; 5MG	A 040234	001	Oct 30, 1997	Jan	DISC
	ROXILOX						
	@ ROXANE	500MG; 5MG	A 040061	001	Jul 03, 1995	Apr	DISC
	TYLOX						
	@ JANSSEN PHARMS	500MG; 5MG	A 088790	001	Dec 12, 1984	Apr	DISC

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

>A>	@ ACTAVIS ELIZABETH	325MG; 5MG	A 040203	001	Mar 15, 1999	Sep	CAHN
>A>	@	325MG; 7.5MG	A 040800	001	Apr 03, 2012	Sep	CAHN
>A>	@	325MG; 10MG	A 040800	002	Apr 03, 2012	Sep	CAHN
>D>	@ ACTAVIS TOTOWA	325MG; 5MG	A 040203	001	Mar 15, 1999	Sep	CAHN
>D>	@	325MG; 7.5MG	A 040800	001	Apr 03, 2012	Sep	CAHN

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

>D>	@	325MG;7.5MG	A040800	001	Apr 03, 2012	Aug	DISC
	@	325MG;10MG	A040800	002	Apr 03, 2012	Sep	CAHN
	@	325MG;10MG	A040800	002	Apr 03, 2012	Aug	DISC
	@	AMNEAL PHARMS NY 500MG;7.5MG	A040789	001	Nov 27, 2007	Apr	DISC
	@	650MG;10MG	A040789	002	Nov 27, 2007	Apr	DISC
	@	COASTAL PHARMS 500MG;7.5MG	A090177	005	Oct 20, 2008	Apr	DISC
	@	650MG;10MG	A090177	006	Oct 20, 2008	Apr	DISC
	@	MALLINCKRODT 500MG;7.5MG	A040550	001	Jun 30, 2004	Apr	DISC
	@	650MG;10MG	A040550	002	Jun 30, 2004	Apr	DISC
	@	MIKART 400MG;5MG	A040687	001	Apr 27, 2006	Apr	DISC
	@	400MG;7.5MG	A040698	001	Apr 27, 2006	Apr	DISC
	@	400MG;10MG	A040692	001	Apr 27, 2006	Apr	DISC
	@	500MG;10MG	A040676	001	Apr 19, 2006	Apr	DISC
AA		RHODES PHARMS 325MG;7.5MG	A201278	001	Aug 28, 2014	Aug	NEWA
AA		325MG;7.5MG	A201278	002	Aug 28, 2014	Aug	NEWA
AA		325MG;10MG	A201278	003	Aug 28, 2014	Aug	NEWA
AA		SUN PHARM INDS INC 325MG;2.5MG	A090535	001	Dec 26, 2013	Jul	CAHN
AA		325MG;5MG	A090535	002	Dec 26, 2013	Jul	CAHN
AA		325MG;7.5MG	A090535	003	Dec 26, 2013	Jul	CAHN
AA		325MG;10MG	A090535	004	Dec 26, 2013	Jul	CAHN
	@	WATSON LABS 500MG;7.5MG	A040371	001	Dec 29, 2000	Jan	DISC
	@	650MG;10MG	A040371	002	Dec 29, 2000	Jan	DISC
		PERCOCET					
	@	VINTAGE PHARMS LLC 500MG;7.5MG	A040341	001	Jul 26, 1999	Jan	DISC
	@	650MG;10MG	A040341	002	Jul 26, 1999	Jan	DISC

TABLET, EXTENDED RELEASE;ORAL

XARTEMIS XR

+	MALLINCKRODT INC	325MG;7.5MG	N204031	001	Mar 11, 2014	Mar	NEWA
---	------------------	-------------	---------	-----	--------------	-----	------

ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE

@	GAVIS PHARMS	650MG;EQ 25MG BASE	A076202	001	Aug 02, 2002	Apr	DISC
@	WATSON LABS	650MG;EQ 25MG BASE	A074699	001	Mar 24, 2000	Apr	DISC

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB	ALLIED PHARMA INC	325MG;37.5MG	A202076	001	Mar 30, 2012	Apr	CAHN
AB	APOTEX INC	325MG;37.5MG	A078778	001	Apr 07, 2014	Mar	NEWA
AB	SUN PHARM INDS INC	325MG;37.5MG	A077184	001	Dec 16, 2005	Jul	CAHN
	@	WATSON LABS 325MG;37.5MG	A076914	001	Jul 26, 2006	May	DISC

ACETAZOLAMIDE

TABLET;ORAL

DIAMOX

@	TEVA BRANDED PHARM	125MG	N008943	001		Jul	CAHN
@		250MG	N008943	002		Jul	CAHN

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

AP	EUROHLTH INTL	EQ 500MG BASE/VIAL	A040089	001	Feb 28, 1995	Aug	CAHN
----	---------------	--------------------	---------	-----	--------------	-----	------

ACETOHEXAMIDE

TABLET;ORAL

ACETOHEXAMIDE

@	WATSON LABS	250MG	A071893	001	Nov 25, 1987	May	DISC
@		500MG	A071894	001	Nov 25, 1987	May	DISC

ACETYLCYSTEINE

SOLUTION;INHALATION, ORAL

ACETYLCYSTEINE

AN	INNOPHARMA LICENSING	10%	A204674	001	Feb 11, 2014	Jan	NEWA
	@	ROXANE 10%	A072323	001	Apr 30, 1992	Aug	DISC
AN		10%	A072323	001	Apr 30, 1992	Jun	CAHN
	@	20%	A072324	001	Apr 30, 1992	Aug	DISC
AN		20%	A072324	001	Apr 30, 1992	Jun	CAHN

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDECAPSULE; ORAL
SEMPREX-D

+ AUXILIUM PHARMS LLC 8MG; 60MG N019806 001 Mar 25, 1994 Apr CAHN

ACYCLOVIRCAPSULE; ORAL
ACYCLOVIRAB CADILA PHARMS LTD 200MG A201445 001 Mar 06, 2014 Feb NEWA
ZOVIRAX

AB + DELCOR ASSET 200MG N018828 001 Jan 25, 1985 Jun CAHN

OINTMENT; TOPICAL
ACYCLOVIR

AB AMNEAL PHARMS 5% A204605 001 Jun 18, 2014 Jun NEWA

TABLET; BUCCAL
SITAVIG

+ INNOCUTIS HOLDINGS 50MG N203791 001 Apr 12, 2013 Apr CMFD

+ 50MG N203791 001 Apr 12, 2013 Apr CAHN

TABLET; ORAL
ACYCLOVIR

AB ZYDUS PHARMS USA INC 400MG A204314 001 Aug 19, 2014 Aug NEWA

AB 800MG A204314 002 Aug 19, 2014 Aug NEWA

ZOVIRAX

AB DELCOR ASSET 400MG N020089 001 Apr 30, 1991 Jun CAHN

AB + 800MG N020089 002 Apr 30, 1991 Jun CAHN

ACYCLOVIR SODIUMINJECTABLE; INJECTION
ACYCLOVIR SODIUM

+ BEDFORD EQ 1GM BASE/VIAL A074596 001 Apr 22, 1997 Feb CRLD

@ HIKMA MAPLE EQ 1GM BASE/VIAL A074913 002 Oct 15, 1997 Feb DISC

@ EQ 500MG BASE/VIAL A074913 001 Oct 15, 1997 Feb DISC

ADENOSINEINJECTABLE; INJECTION
ADENOSCAN

>D> AP + ASTELLAS 3MG/ML N020059 001 May 18, 1995 Sep CDFR

ADENOSINE

AP AGILA SPECLTS 3MG/ML A078640 001 Mar 21, 2014 Mar NEWA

AP 3MG/ML A078686 001 May 13, 2009 Feb CAHN

>D> AP HOSPIRA INC 3MG/ML A203883 001 Mar 24, 2014 Sep CDFR

AP 3MG/ML A203883 001 Mar 24, 2014 Mar NEWA

>D> AP SAGENT STRIDES 3MG/ML A090212 001 Mar 28, 2014 Sep CDFR

AP 3MG/ML A090212 001 Mar 28, 2014 Mar NEWA

>D> AP TEVA PHARMS USA 3MG/ML A077425 001 Aug 29, 2013 Sep CDFR

>A> SOLUTION; IV (INFUSION)

>A> ADENOSCAN

>A> AP + ASTELLAS 3MG/ML N020059 001 May 18, 1995 Sep CDFR

>A> AP + 60MG/20ML (3MG/ML) N020059 001 May 18, 1995 Sep CPOT

>A> AP + 90MG/30ML (3MG/ML) N020059 002 May 18, 1995 Sep NEWA

ADENOSINE

>A> AP AKORN 60MG/20ML (3MG/ML) A090450 001 Oct 02, 2014 Sep NEWA

>A> AP 90MG/30ML (3MG/ML) A090450 002 Oct 02, 2014 Sep NEWA

>A> AP EMCURE PHARMS LTD 60MG/20ML (3MG/ML) A202313 001 Sep 15, 2014 Sep NEWA

>A> AP 90MG/30ML (3MG/ML) A202313 002 Sep 15, 2014 Sep NEWA

>A> AP HOSPIRA INC 3MG/ML A203883 001 Mar 24, 2014 Sep CDFR

>A> AP 60MG/20ML (3MG/ML) A203883 001 Mar 24, 2014 Sep CPOT

>A> AP 90MG/30ML (3MG/ML) A203883 002 Mar 24, 2014 Sep NEWA

>A> AP SAGENT STRIDES 3MG/ML A090212 001 Mar 28, 2014 Sep CDFR

>A> AP 60MG/20ML (3MG/ML) A090212 001 Mar 28, 2014 Sep CPOT

>A> AP 90MG/30ML (3MG/ML) A090212 002 Mar 28, 2014 Sep NEWA

>A> AP TEVA PHARMS USA 3MG/ML A077425 001 Aug 29, 2013 Sep CDFR

>A> AP 60MG/20ML (3MG/ML) A077425 001 Aug 29, 2013 Sep CPOT

>A> AP 90MG/30ML (3MG/ML) A077425 002 Aug 29, 2013 Sep NEWA

ALBUTEROL SULFATEAEROSOL, METERED; INHALATION
VENTOLIN HFA

>D> BX + GLAXO GRP LTD EQ 0.09MG BASE/INH N020983 001 Apr 19, 2001 Sep CAHN

>A> BX + GLAXOSMITHKLINE EQ 0.09MG BASE/INH N020983 001 Apr 19, 2001 Sep CAHN

SOLUTION; INHALATION

ACCUNEB

AN	+	MYLAN SPECLT	EQ 0.021% BASE	N020949	002	Apr 30, 2001	May CAHN
AN	+		EQ 0.042% BASE	N020949	001	Apr 30, 2001	May CAHN

TABLET; ORAL

ALBUTEROL SULFATE

@ WATSON LABS

EQ 2MG BASE

A072764 001 Aug 28, 1991 May DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

DUONEB

AN	+	MYLAN SPECLT	EQ 0.083% BASE; 0.017%	N020950	001	Mar 21, 2001	May CAHN
----	---	--------------	------------------------	---------	-----	--------------	----------

ALISKIREN HEMIFUMARATE; VALSARTAN

TABLET; ORAL

VALTURNA

@ NOVARTIS

EQ 150MG BASE; 160MG

N022217 001 Sep 16, 2009 May DISC

@

EQ 300MG BASE; 320MG

N022217 002 Sep 16, 2009 May DISC

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB		SUN PHARM INDS INC	100MG	A078390	001	Aug 30, 2007	Jul CAHN
----	--	--------------------	-------	---------	-----	--------------	----------

AB			300MG	A078390	002	Aug 30, 2007	Jul CAHN
----	--	--	-------	---------	-----	--------------	----------

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALLOPURINOL SODIUM

AP		EUROHLTH INTL	EQ 500MG BASE/VIAL	A076870	001	Aug 26, 2004	Aug CAHN
----	--	---------------	--------------------	---------	-----	--------------	----------

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB		VINTAGE PHARMS	0.25MG	A090248	001	Sep 17, 2010	Feb CAHN
----	--	----------------	--------	---------	-----	--------------	----------

AB			0.5MG	A090248	002	Sep 17, 2010	Feb CAHN
----	--	--	-------	---------	-----	--------------	----------

AB			1MG	A090248	003	Sep 17, 2010	Feb CAHN
----	--	--	-----	---------	-----	--------------	----------

AB			2MG	A090248	004	Sep 17, 2010	Feb CAHN
----	--	--	-----	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB		ANI PHARMS INC	0.5MG	A077725	001	Jul 31, 2006	Jan CAHN
----	--	----------------	-------	---------	-----	--------------	----------

@

0.5MG

A077979 001 Feb 28, 2007 Jan CAHN

AB			1MG	A077725	002	Jul 31, 2006	Jan CAHN
----	--	--	-----	---------	-----	--------------	----------

@

1MG

A077979 002 Feb 28, 2007 Jan CAHN

AB			2MG	A077725	004	Jul 31, 2006	Jan CAHN
----	--	--	-----	---------	-----	--------------	----------

@

2MG

A077979 003 Feb 28, 2007 Jan CAHN

AB			3MG	A077725	003	Jul 31, 2006	Jan CAHN
----	--	--	-----	---------	-----	--------------	----------

@

3MG

A077979 004 Feb 28, 2007 Jan CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

ALPRAZOLAM

>D>	AB		PAR PHARM	1MG	A078088	003	Jan 09, 2009	Sep CRLD
-----	----	--	-----------	-----	---------	-----	--------------	----------

>A>	AB	+		1MG	A078088	003	Jan 09, 2009	Sep CRLD
-----	----	---	--	-----	---------	-----	--------------	----------

>D> NIRAVAM

>D>	AB		UCB INC	0.25MG	N021726	001	Jan 19, 2005	Sep DISC
-----	----	--	---------	--------	---------	-----	--------------	----------

>A>		@		0.25MG	N021726	001	Jan 19, 2005	Sep DISC
-----	--	---	--	--------	---------	-----	--------------	----------

>D>	AB			0.5MG	N021726	002	Jan 19, 2005	Sep DISC
-----	----	--	--	-------	---------	-----	--------------	----------

>A>		@		0.5MG	N021726	002	Jan 19, 2005	Sep DISC
-----	--	---	--	-------	---------	-----	--------------	----------

>D>	AB	+		1MG	N021726	003	Jan 19, 2005	Sep DISC
-----	----	---	--	-----	---------	-----	--------------	----------

>A>		@		1MG	N021726	003	Jan 19, 2005	Sep DISC
-----	--	---	--	-----	---------	-----	--------------	----------

>D>	AB			2MG	N021726	004	Jan 19, 2005	Sep DISC
-----	----	--	--	-----	---------	-----	--------------	----------

>A>		@		2MG	N021726	004	Jan 19, 2005	Sep DISC
-----	--	---	--	-----	---------	-----	--------------	----------

ALPROSTADIL

INJECTABLE; INJECTION

ALPROSTADIL

AP		EUROHLTH INTL	0.5MG/ML	A074815	001	Jan 20, 1998	Aug CAHN
----	--	---------------	----------	---------	-----	--------------	----------

EDEX

@ AUXILIUM PHARMS LLC

0.005MG/VIAL

N020649 001 Jun 12, 1997 Apr CAHN

AP			0.01MG/VIAL	N020649	002	Jun 12, 1997	Apr CAHN
----	--	--	-------------	---------	-----	--------------	----------

+			0.01MG/VIAL	N020649	005	Jul 30, 1998	Apr CAHN
---	--	--	-------------	---------	-----	--------------	----------

AP			0.02MG/VIAL	N020649	003	Jun 12, 1997	Apr CAHN
----	--	--	-------------	---------	-----	--------------	----------

+			0.02MG/VIAL	N020649	006	Jul 30, 1998	Apr CAHN
---	--	--	-------------	---------	-----	--------------	----------

AP	+		0.04MG/VIAL	N020649	004	Jun 12, 1997	Apr CAHN
----	---	--	-------------	---------	-----	--------------	----------

INJECTABLE; INJECTION							
EDEX							
+		0.04MG/VIAL		N020649	007	Jul 30, 1998	Apr CAHN
<u>AMANTADINE HYDROCHLORIDE</u>							
CAPSULE; ORAL							
AMANTADINE HYDROCHLORIDE							
	@ ACTAVIS ELIZABETH	100MG		A077659	001	Feb 23, 2006	Aug CAHN
AB	+ SANDOZ	100MG		A071293	001	Feb 18, 1987	Feb CRLD
AB	USL PHARMA	100MG		A070589	001	Aug 05, 1986	Feb CRLD
<u>AMBENONIUM CHLORIDE</u>							
TABLET; ORAL							
MYTELASE							
	@ SANOFI AVENTIS US	10MG		N010155	002		Jun DISC
<u>AMIKACIN SULFATE</u>							
INJECTABLE; INJECTION							
AMIKACIN SULFATE							
AP	+ EUROHLTH INTL	EQ 50MG BASE/ML		A063313	001	Apr 11, 1994	Aug CAHN
AP	+	EQ 250MG BASE/ML		A063315	001	Apr 11, 1994	Aug CAHN
<u>AMINO ACIDS</u>							
INJECTABLE; INJECTION							
HEPATASOL 8%							
	@ BAXTER HLTHCARE	8% (8GM/100ML)		A020360	001	Apr 04, 1996	Jul DISC
RENAMIN W/O ELECTROLYTES							
	@ BAXTER HLTHCARE	6.5% (6.5GM/100ML)		N017493	007	Oct 15, 1982	Jul DISC
TRAVASOL 10% W/O ELECTROLYTES							
	@ BAXTER HLTHCARE	10% (10GM/100ML)		N017493	006		Jul DISC
TRAVASOL 5.5% W/O ELECTROLYTES							
	@ BAXTER HLTHCARE	5.5% (5.5GM/100ML)		N017493	004		Jul DISC
TRAVASOL 8.5% W/O ELECTROLYTES							
	@ BAXTER HLTHCARE	8.5% (8.5GM/100ML)		N017493	005		Jul DISC
<u>AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL</u>							
EMULSION; IV (INFUSION)							
KABIVEN IN PLASTIC CONTAINER							
	FRESENIUS KABI USA	3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (1026ML)		N200656	004	Aug 25, 2014	Aug NEWA
		3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (1540ML)		N200656	005	Aug 25, 2014	Aug NEWA
		3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (2053ML)		N200656	006	Aug 25, 2014	Aug NEWA
+		3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (2566ML)		N200656	007	Aug 25, 2014	Aug NEWA
PERIKABIVEN IN PLASTIC CONTAINER							
	FRESENIUS KABI USA	2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML; 124MG/100ML; 170MG/100ML; 105MG/100ML; 3.5GM/100ML (1440ML)		N200656	001	Aug 25, 2014	Aug NEWA
		2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML; 124MG/100ML; 170MG/100ML; 105MG/100ML; 3.5GM/100ML (1920ML)		N200656	002	Aug 25, 2014	Aug NEWA
		2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML; 124MG/100ML; 170MG/100ML; 105MG/100ML; 3.5GM/100ML (2400ML)		N200656	003	Aug 25, 2014	Aug NEWA
<u>AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE</u>							
INJECTABLE; INJECTION							
TRAVASOL 3.5% W/ ELECTROLYTES							
	@ BAXTER HLTHCARE	3.5%; 51MG/100ML; 131MG/100ML; 218MG/100ML; 35MG/100ML		N017493	003		Jul DISC
TRAVASOL 5.5% W/ ELECTROLYTES							
	@ BAXTER HLTHCARE	5.5%; 102MG/100ML; 522MG/100ML; 431MG/100ML; 224MG/100ML		N017493	001		Jul DISC

INJECTABLE; INJECTION

TRAVASOL 8.5% W/ ELECTROLYTES

@ BAXTER HLTHCARE	8.5%; 102MG/100ML; 522MG/100ML; 594MG	N017493	002		Jul	DISC
	/100ML; 154MG/100ML					

AMINOHIPPURATE SODIUM

INJECTABLE; INJECTION

AMINOHIPPURATE SODIUM

@ MERCK	20%	N005619	001		Jun	DISC
---------	-----	---------	-----	--	-----	------

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

@ PAR STERILE PRODUCTS	50MG/ML	A076394	001	Apr 25, 2003	May	CAHN
------------------------	---------	---------	-----	--------------	-----	------

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	MUTUAL PHARM	10MG	A089399	002	Jul 14, 1987	Jun	CMS1
AB		50MG	A089399	003	Jul 14, 1987	Jun	CMS1
AB		75MG	A089399	004	Jul 14, 1987	Jun	CMS1
AB		100MG	A089399	005	Jul 14, 1987	Jun	CMS1
AB		100MG	A089399	006	Jul 14, 1987	Jun	CMS1
AB		150MG	A089399	006	Jul 14, 1987	Jul	CPOT
AB	SUN PHARM INDS INC	10MG	A040816	002	Jun 27, 2008	Jul	CAHN
AB		25MG	A040816	001	Jun 27, 2008	Jul	CAHN
AB		50MG	A040816	003	Jun 27, 2008	Jul	CAHN
AB		75MG	A040816	004	Jun 27, 2008	Jul	CAHN
AB		100MG	A040816	005	Jun 27, 2008	Jul	CAHN
AB		150MG	A040816	006	Jun 27, 2008	Jul	CAHN
	AMITRIPTYLINE HYDROCHORIDE						
AB	ACCORD HLTHCARE	10MG	A202446	001	Jun 04, 2014	May	NEWA
AB		25MG	A202446	002	Jun 04, 2014	May	NEWA
AB		50MG	A202446	003	Jun 04, 2014	May	NEWA
AB		75MG	A202446	004	Jun 04, 2014	May	NEWA
AB		100MG	A202446	005	Jun 04, 2014	May	NEWA
AB		150MG	A202446	006	Jun 04, 2014	May	NEWA

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

@ PURACAP PHARM	EQ 2.5MG BASE	A078131	001	Sep 04, 2007	Feb	DISC	
@	EQ 5MG BASE	A078131	002	Sep 04, 2007	Feb	DISC	
@	EQ 10MG BASE	A078131	003	Sep 04, 2007	Feb	DISC	
AB	SUN PHARM INDS INC	EQ 2.5MG BASE	A078231	001	Nov 30, 2007	Jul	CAHN
AB		EQ 5MG BASE	A078231	002	Nov 30, 2007	Jul	CAHN
AB		EQ 10MG BASE	A078231	003	Nov 30, 2007	Jul	CAHN
AB	VIVIMED LABS	EQ 2.5MG BASE	A077516	001	Jul 11, 2007	Apr	CAHN
AB		EQ 5MG BASE	A077516	002	Jul 11, 2007	Apr	CAHN
AB		EQ 10MG BASE	A077516	003	Jul 11, 2007	Apr	CAHN

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB	DR REDDYS LABS LTD	EQ 2.5MG BASE; EQ 10MG BASE	A203874	001	Mar 07, 2014	Feb	NEWA
AB		EQ 2.5MG BASE; EQ 20MG BASE	A203874	002	Mar 07, 2014	Feb	NEWA
AB		EQ 2.5MG BASE; EQ 40MG BASE	A203874	003	Mar 07, 2014	Feb	NEWA
AB		EQ 5MG BASE; EQ 10MG BASE	A203874	004	Mar 07, 2014	Feb	NEWA
AB		EQ 5MG BASE; EQ 20MG BASE	A203874	005	Mar 07, 2014	Feb	NEWA
AB		EQ 5MG BASE; EQ 40MG BASE	A203874	006	Mar 07, 2014	Feb	NEWA
AB		EQ 5MG BASE; EQ 80MG BASE	A203874	007	Mar 07, 2014	Feb	NEWA
AB		EQ 10MG BASE; EQ 10MG BASE	A203874	008	Mar 07, 2014	Feb	NEWA
AB		EQ 10MG BASE; EQ 20MG BASE	A203874	009	Mar 07, 2014	Feb	NEWA
AB		EQ 10MG BASE; EQ 40MG BASE	A203874	010	Mar 07, 2014	Feb	NEWA
AB		EQ 10MG BASE; EQ 80MG BASE	A203874	011	Mar 07, 2014	Feb	NEWA

AMLODIPINE BESYLATE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND AMLODIPINE

AB	MYLAN PHARMS INC	EQ 5MG BASE; 40MG	A202516	001	Aug 26, 2014	Aug	NEWA
AB		EQ 5MG BASE; 80MG	A202516	003	Aug 26, 2014	Aug	NEWA
AB		EQ 10MG BASE; 40MG	A202516	002	Aug 26, 2014	Aug	NEWA
AB		EQ 10MG BASE; 80MG	A202516	004	Aug 26, 2014	Aug	NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS
AMMONIA N 13

AP	JOHNS HOPKINS UNIV	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204514	001	Aug 19, 2014	Aug NEWA
>A>	SHERTECH LABS LLC	3.75-260mCi/ML	A204366	001	Sep 19, 2014	Sep NEWA
AP	UCSF RODIOPHARM	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204496	001	Mar 28, 2014	Mar NEWA
AP	UNIV TX MD ANDERSON	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203933	001	Jun 27, 2014	Jun NEWA
AP	WA UNIV SCH MED	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204506	001	Feb 07, 2014	Jan NEWA

AMOXICILLIN

FOR SUSPENSION;ORAL
AMOXICILLIN

>A>	AB	AUROBINDO PHARMA LTD	125MG/5ML	A204030	001	Sep 15, 2014	Sep NEWA
>A>	AB		250MG/5ML	A204030	002	Sep 15, 2014	Sep NEWA
		TABLET, EXTENDED RELEASE;ORAL					
		MOXATAG					
	+	PRAGMA PHARMS LLC	775MG	N050813	001	Jan 23, 2008	Apr CAHN

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

AB	SANDOZ	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	A202588	001	Mar 04, 2014	Feb NEWA
----	--------	--	---------	-----	--------------	----------

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

	+	GASTROENTERO	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011	Mar CDFR
--	---	--------------	--	---------	-----	--------------	----------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A>	AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A040456	001	May 06, 2003	Sep CAHN
>A>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A040456	002	May 06, 2003	Sep CAHN
>A>	AB		5MG;5MG;5MG;5MG	A040456	003	May 06, 2003	Sep CAHN
>A>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A040456	004	May 06, 2003	Sep CAHN
>D>	AB	WATSON LABS	1.25MG;1.25MG;1.25MG;1.25MG	A040456	001	May 06, 2003	Sep CAHN
	AB		1.25MG;1.25MG;1.25MG;1.25MG	A040456	001	May 06, 2003	Apr CMFD
>D>	AB		2.5MG;2.5MG;2.5MG;2.5MG	A040456	002	May 06, 2003	Sep CAHN
	AB		2.5MG;2.5MG;2.5MG;2.5MG	A040456	002	May 06, 2003	Apr CMFD
>D>	AB		5MG;5MG;5MG;5MG	A040456	003	May 06, 2003	Sep CAHN
	AB		5MG;5MG;5MG;5MG	A040456	003	May 06, 2003	Apr CMFD
>D>	AB		7.5MG;7.5MG;7.5MG;7.5MG	A040456	004	May 06, 2003	Sep CAHN
	AB		7.5MG;7.5MG;7.5MG;7.5MG	A040456	004	May 06, 2003	Apr CMFD

AMPHETAMINE SULFATE

TABLET;ORAL

AMPHETAMINE SULFATE

>D>		ARBOR PHARMS INC	5MG	A200166	001	Aug 09, 2012	Sep CAHN
>D>	+		10MG	A200166	002	Aug 09, 2012	Sep CAHN
>A>		ARBOR PHARMS LLC	5MG	A200166	001	Aug 09, 2012	Sep CAHN
>A>	+		10MG	A200166	002	Aug 09, 2012	Sep CAHN

AMPICILLIN SODIUM

INJECTABLE;INJECTION
AMPICILLIN SODIUM

AP	AGILA SPECLTS	EQ 10GM BASE/VIAL	A202198	001	Apr 07, 2014	Mar NEWA	
AP	ANTIBIOTICE	EQ 1GM BASE/VIAL	A090354	003	Dec 28, 2009	Jun CMFD	
AP		EQ 2GM BASE/VIAL	A090354	004	Dec 28, 2009	Jun CMFD	
AP		EQ 250MG BASE/VIAL	A090354	001	Dec 28, 2009	Jun CMFD	
AP		EQ 500MG BASE/VIAL	A090354	002	Dec 28, 2009	Jun CMFD	
AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A062719	002	May 12, 1987	Feb CAHN	
AP		EQ 2GM BASE/VIAL	A062797	002	Jul 12, 1993	Feb CAHN	
AP		EQ 10GM BASE/VIAL	A201404	001	Dec 20, 2013	Jan CPOT	
AP		EQ 125MG BASE/VIAL	A062797	001	Jul 12, 1993	Feb CAHN	
AP		EQ 250MG BASE/VIAL	A062719	001	May 12, 1987	Feb CAHN	
AP		EQ 500MG BASE/VIAL	A062719	003	May 12, 1987	Feb CAHN	
>D>	AP	SANDOZ	EQ 1GM BASE/VIAL	A062738	001	Feb 19, 1987	Sep CDFR
>D>	AP		EQ 2GM BASE/VIAL	A062738	002	Feb 19, 1987	Sep CDFR
AP	STRIDES ARCOLAB LTD	EQ 1GM BASE/VIAL	A201025	003	Apr 09, 2014	Mar NEWA	
AP		EQ 2GM BASE/VIAL	A201025	004	Apr 09, 2014	Mar NEWA	

INJECTABLE; INJECTION
AMPICILLIN SODIUM

AP		EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Mar NEWA
AP		EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Mar NEWA
POWDER; INTRAVENOUS AMPICILLIN SODIUM						
>A>	AP	+ SANDOZ	EQ 1GM BASE/VIAL	A062738	001	Feb 19, 1987 Sep CRLD
>A>	AP		EQ 1GM BASE/VIAL	A062738	001	Feb 19, 1987 Sep CDFR
>A>	AP	+	EQ 2GM BASE/VIAL	A062738	002	Feb 19, 1987 Sep CRLD
>A>	AP		EQ 2GM BASE/VIAL	A062738	002	Feb 19, 1987 Sep CDFR

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION
AMPICILLIN AND SULBACTAM

AP	AGILA SPECLTS	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A201024	001	Apr 07, 2014	Mar NEWA
AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A201024	002	Apr 07, 2014	Mar NEWA
AP		EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL	A202197	001	Apr 07, 2014	Mar NEWA
AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A065222	001	Nov 29, 2005	Feb CAHN
AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A065222	002	Nov 29, 2005	Feb CAHN
AP		EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL	A065314	001	Nov 27, 2006	Feb CAHN
AP	MUSTAFA NEVZAT ILAC	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A065316	001	Jun 29, 2007	May CAHN
AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A065316	002	Jun 29, 2007	May CAHN

ANASTROZOLE

TABLET; ORAL
ANASTROZOLE

@ WATSON LABS	1MG	A078984	001	Jun 28, 2010	May DISC
---------------	-----	---------	-----	--------------	----------

APREMILAST

TABLET; ORAL
OTEZLA

CELGENE CORP	10MG	N205437	001	Mar 21, 2014	Mar NEWA
	20MG	N205437	002	Mar 21, 2014	Mar NEWA
+	30MG	N205437	003	Mar 21, 2014	Mar NEWA

ARGATROBAN

INJECTABLE; INJECTION
ARGATROBAN

AP	MYLAN INSTITUTIONAL	250MG/2.5ML (100MG/ML)	A202626	001	Jun 30, 2014	Jun NEWA
AP	PAR STERILE PRODUCTS	250MG/2.5ML (100MG/ML)	A091665	001	Jun 30, 2014	Jun NEWA

ARMODAFINIL

TABLET; ORAL
ARMODAFINIL

AB	WATSON LABS INC	200MG	A200156	004	Aug 29, 2012	May CTEC
	NUVIGIL					
AB	CEPHALON	200MG	N021875	005	Mar 26, 2009	May CMFD

ASENAPINE MALEATE

TABLET; SUBLINGUAL
SAPHRIS

FOREST LABS INC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Feb CAHN
+	EQ 10MG BASE	N022117	002	Aug 13, 2009	Feb CAHN

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL
BUTALBITAL, ASPIRIN AND CAFFEINE

AA	+	HIKMA INTL PHARMS	325MG; 50MG; 40MG	A086162	002	Feb 16, 1984 Aug CAHN
----	---	-------------------	-------------------	---------	-----	-----------------------

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
@ WATSON LABS

325MG; 50MG; 40MG; 30MG	A074359	001	Aug 31, 1995	Mar DISC
-------------------------	---------	-----	--------------	----------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

@ STEVENS J

385MG; 30MG; 25MG

A074988 001 Apr 30, 1999 Mar DISC

@

770MG; 60MG; 50MG

A074988 002 Apr 30, 1999 Mar DISC

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

@ MIRROR PHARMS

325MG; 200MG; 16MG

A040860 001 Jan 07, 2010 Mar DISC

@ PROSAM LABS

325MG; 200MG; 16MG

A040283 001 Dec 29, 1998 Mar DISC

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

@ WATSON LABS

325MG; 4.5MG; 0.38MG

A040255 001 Feb 27, 1998 May DISC

ATAZANAVIR SULFATE

CAPSULE; ORAL

ATAZANAVIR SULFATE

TEVA PHARMS USA

EQ 100MG BASE

A091673 001 Apr 22, 2014 Aug CTEC

AB

EQ 100MG BASE

A091673 001 Apr 22, 2014 Apr NEWA

AB

EQ 150MG BASE

A091673 002 Apr 22, 2014 Apr NEWA

AB

EQ 200MG BASE

A091673 003 Apr 22, 2014 Apr NEWA

AB

EQ 300MG BASE

A091673 004 Apr 22, 2014 Apr NEWA

REYATAZ

@ BRISTOL MYERS SQUIBB

EQ 100MG BASE

N021567 001 Jun 20, 2003 Aug DISC

AB

EQ 100MG BASE

N021567 001 Jun 20, 2003 Apr CFTG

AB

EQ 150MG BASE

N021567 002 Jun 20, 2003 Apr CFTG

AB

EQ 200MG BASE

N021567 003 Jun 20, 2003 Apr CFTG

AB

+

EQ 300MG BASE

N021567 004 Oct 16, 2006 Apr CFTG

POWDER; ORAL

REYATAZ

+

BRISTOL MYERS SQUIBB

EQ 50MG BASE/PACKET

N206352 001 Jun 02, 2014 Jun NEWA

ATENOLOL

TABLET; ORAL

ATENOLOL

AB

MYLAN

50MG

A073457 003 Jan 24, 1992 Apr CMS1

AB

SUN PHARM INDS INC

25MG

A078210 001 Jul 10, 2007 Jul CAHN

AB

50MG

A078210 002 Jul 10, 2007 Jul CAHN

AB

100MG

A078210 003 Jul 10, 2007 Jul CAHN

ATOVAQUONE

SUSPENSION; ORAL

ATOVAQUONE

AB

AMNEAL PHARMS

750MG/5ML

A202960 001 Mar 18, 2014 Mar NEWA

MEPRON

AB

+

GLAXOSMITHKLINE LLC

750MG/5ML

N020500 001 Feb 08, 1995 Mar CFTG

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB

MYLAN PHARMS INC

62.5MG; 25MG

A202362 001 May 27, 2014 May NEWA

AB

250MG; 100MG

A202362 002 May 27, 2014 May NEWA

MALARONE PEDIATRIC

AB

GLAXOSMITHKLINE

62.5MG; 25MG

N021078 002 Jul 14, 2000 May CTEC

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP

+

EUROHLTH INTL

10MG/ML

A074901 001 Jul 18, 1997 Aug CAHN

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP

+

EUROHLTH INTL

10MG/ML

A074900 001 Jul 18, 1997 Aug CAHN

ATROPINE SULFATE

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
ATROPINE SULFATE ANSYR PLASTIC SYRINGE

+ HOSPIRA 0.05MG/ML

N021146 002 Jul 09, 2001 May CRLD

SOLUTION/DROPS;OPHTHALMIC

ATROPINE SULFATE

AKORN 1%

N206289 001 Jul 18, 2014 Jul NEWA

AZATHIOPRINE SODIUM

INJECTABLE;INJECTION
AZATHIOPRINE SODIUM

+ EUROHLTH INTL EQ 100MG BASE/VIAL

A074419 001 Mar 31, 1995 Aug CAHN

AZELESTINE HYDROCHLORIDE

SPRAY;NASAL

AZELESTINE HYDROCHLORIDE

AB PERRIGO ISRAEL EQ 0.1876MG BASE/SPRAY

A202743 001 May 08, 2014 Apr NEWA

SPRAY, METERED;NASAL

AZELESTINE HYDROCHLORIDE

AB PERRIGO ISRAEL EQ 0.1876MG BASE/SPRAY

A202743 001 May 08, 2014 Jun CDFR

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

EDARBI

ARBOR PHARMS IRELAND EQ 40MG MEDOXOMIL

N200796 001 Feb 25, 2011 Feb CAHN

+ EQ 80MG MEDOXOMIL

N200796 002 Feb 25, 2011 Feb CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

EDARBYCLOR

ARBOR PHARMS IRELAND EQ 40MG MEDOXOMIL;12.5MG

N202331 001 Dec 20, 2011 Feb CAHN

+ EQ 40MG MEDOXOMIL;25MG

N202331 002 Dec 20, 2011 Feb CAHN

AZTREONAM

INJECTABLE;INJECTION

AZTREONAM

AP EUROHLTH INTL 1GM/VIAL

A065286 001 Mar 23, 2011 Aug CAHN

AP 2GM/VIAL

A065286 002 Mar 23, 2011 Aug CAHN

BACITRACIN

INJECTABLE;INJECTION

BACITRACIN

AP XELLIA PHARMS APS 50,000 UNITS/VIAL

A203177 001 Aug 25, 2014 Aug NEWA

OINTMENT;OPHTHALMIC

BACITRACIN

+ PERRIGO CO TENNESSEE 500 UNITS/GM

A061212 001 Feb CTEC

BACLOFEN

TABLET;ORAL

BACLOFEN

AB SUN PHARM INDS INC 20MG

A077862 002 Aug 14, 2006 Jul CAHN

BELINOSTAT

POWDER;IV (INFUSION)

BELEODAQ

+ SPECTRUM PHARMS 500MG/VIAL

N206256 001 Jul 03, 2014 Jul NEWA

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB APOTEX INC 5MG;6.25MG

A078794 001 Aug 21, 2014 Aug NEWA

AB 10MG;12.5MG

A078794 002 Aug 21, 2014 Aug NEWA

AB 20MG;12.5MG

A078794 003 Aug 21, 2014 Aug NEWA

AB 20MG;25MG

A078794 004 Aug 21, 2014 Aug NEWA

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

NADOLOL AND BENDROFLUMETHIAZIDE

AB	MYLAN	5MG; 40MG	A078688	001	Feb 15, 2008	Jan CTNA
AB		5MG; 80MG	A078688	002	Feb 15, 2008	Jan CTNA

BENZONATATE

CAPSULE; ORAL

BENZONATATE

>D>	MIKART	150MG	A040851	002	Nov 09, 2009	Sep CTEC
>A> AA		150MG	A040851	002	Nov 09, 2009	Sep CTEC
AA	SUN PHARM INDS INC	100MG	A040587	001	Mar 19, 2008	Jun CAHN
AA		200MG	A040587	002	Mar 19, 2008	Jun CAHN
>A> AA	THEPHARMANETWORK LLC	150MG	A201209	001	Sep 24, 2014	Sep NEWA

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLIN

AB	+ VALEANT BERMUDA	5%;EQ 1% BASE	N050756	001	Dec 21, 2000	Mar CRLD
	@	5%;EQ 1% BASE	N050756	002	Apr 20, 2007	Jul DISC
	+	5%;EQ 1% BASE	N050756	002	Apr 20, 2007	Mar CTEC

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC

BEPREVE

+	BAUSCH AND LOMB INC	1.5%	N022288	001	Sep 08, 2009	Apr CAHN
---	---------------------	------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION; TOPICAL

LOTRISONE

AB	+ MERCK SHARP DOHME	EQ 0.05% BASE; 1%	N020010	001	Dec 08, 2000	Jan CAHN
----	---------------------	-------------------	---------	-----	--------------	----------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

>D> AT	BAUSCH AND LOMB	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Sep CAHN
>A> AT	IGI LABS INC	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Sep CAHN

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

	@ ACTAVIS ELIZABETH	5MG	A040552	001	Oct 28, 2004	Jul CAHN
	@	10MG	A040553	001	Oct 28, 2004	Jul CAHN
	@	25MG	A040554	001	Oct 28, 2004	Jul CAHN
	@	50MG	A040551	001	Oct 28, 2004	Jul CAHN
AA	SUN PHARM INDS INC	5MG	A040897	001	Apr 22, 2009	Jun CAHN
AA		10MG	A040897	002	Apr 22, 2009	Jun CAHN
AA		25MG	A040897	003	Apr 22, 2009	Jun CAHN
AA		50MG	A040897	004	Apr 22, 2009	Jun CAHN
	DUVOID					
	@ WELLSPRING PHARM	10MG	A086262	001		Mar DISC
	@	25MG	A086263	001		Mar DISC
	@	50MG	A085882	003		Mar DISC

BEXAROTENE

CAPSULE; ORAL

BEXAROTENE

	@ BANNER PHARMACAPS	75MG	A203174	001	Aug 12, 2014	Aug DISC
AB		75MG	A203174	001	Aug 12, 2014	Jul NEWA
	TARGRETIN					
	+ VALEANT LUXEMBOURG	75MG	N021055	001	Dec 29, 1999	Aug CTEC
AB	+	75MG	N021055	001	Dec 29, 1999	Jul CFTG

BICALUTAMIDE

TABLET; ORAL

BICALUTAMIDE

AB	ACTAVIS ELIZABETH	50MG	A078634	001	Aug 28, 2009	Aug CAHN
	@ ROXANE	50MG	A078285	001	Mar 24, 2011	Jun DISC

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

		FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL								
>D>		HALFLYTELY								
>D>	AA	+	BRAINTREE	5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2	N021551	003	Jul 16, 2010	Sep	DISC	
				.86GM;N/A,5.6GM						
>A>		@		5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2	N021551	003	Jul 16, 2010	Sep	DISC	
				.86GM;N/A,5.6GM						
	AA	+		5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2	N021551	003	Jul 16, 2010	Aug	CFTG	
				.86GM;N/A,5.6GM						
		PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE, AND BISACODYL								
>D>	AA		NOVEL LABS INC	5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2	A202217	001	Aug 20, 2014	Sep	CRLD	
				.86GM;N/A,5.6GM						
>A>		+		5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2	A202217	001	Aug 20, 2014	Sep	CRLD	
				.86GM;N/A,5.6GM						
	AA			5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2	A202217	001	Aug 20, 2014	Aug	NEWA	
				.86GM;N/A,5.6GM						

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE;ORAL

PYLERA

+	FOREST LABS INC	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Apr	CAHN
+	FOREST RES INST INC	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Mar	CAHN

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL

HELIDAC

@	PROMETHEUS LABS	262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,	N050719	001	Aug 15, 1996	Aug	DISC
		N/A,500MG					

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

@	WATSON LABS	2.5MG;6.25MG	A075469	001	Sep 25, 2000	May	DISC
@		5MG;6.25MG	A075469	002	Sep 25, 2000	May	DISC
@		10MG;6.25MG	A075469	003	Sep 25, 2000	May	DISC

BLEOMYCIN SULFATE

INJECTABLE;INJECTION

BLEOMYCIN SULFATE

AP	EUROHLTH INTL	EQ 15 UNITS BASE/VIAL	A065042	002	Oct 17, 2001	Aug	CAHN
AP		EQ 30 UNITS BASE/VIAL	A065042	001	Oct 17, 2001	Aug	CAHN

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMDAY

AT	+	BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Apr	CAHN
AT	+	ISTA PHARMS INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Jan	CFTG
BROMFENAC SODIUM								
AT1		APOTEX INC	EQ 0.09% ACID	A202435	001	Jun 19, 2014	Jun	NEWA
AT			EQ 0.09% ACID	A202620	001	Jun 23, 2014	Jun	NEWA
AT1		COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	Jan	CTEC
AT		HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Jan	NEWA
AT1		LUITPOLD	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Jan	CTEC
XIBROM								
	@	BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	001	Mar 24, 2005	Apr	CAHN

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMFED-DM

AA	+	WOCKHARDT	2MG/5ML;10MG/5ML;30MG/5ML	A088811	001	Jun 07, 1985	Jun	CTEC		
		BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE								
AA		PADDOCK LLC	2MG/5ML;10MG/5ML;30MG/5ML	A205292	001	Jul 15, 2014	Jun	NEWA		
AA		VINTAGE PHARMS	2MG/5ML;10MG/5ML;30MG/5ML	A202940	001	Jul 21, 2014	Jul	NEWA		

BUDESONIDE

CAPSULE;ORAL

BUDESONIDE

AB		BARR LABS DIV TEVA	3MG	A090379	001	Apr 02, 2014	Mar	NEWA		
		SPRAY, METERED;NASAL								
		BUDESONIDE								
AB		APOTEX INC	0.032MG/INH	A078949	001	May 12, 2014	Apr	NEWA		

SPRAY, METERED;NASAL									
RHINOCORT									
AB	+ ASTRAZENECA	0.032MG/INH	N020746	001	Oct 01, 1999	Apr	CFTG		
TABLET, EXTENDED RELEASE;ORAL									
UCERIS									
	+ SALIX PHARMS INC	9MG	N203634	001	Jan 14, 2013	Feb	CAHN		
	+ SANTARUS INC	9MG	N203634	001	Jan 14, 2013	Mar	CAHN		
<u>BUPIVACAINE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
BUPIVACAINE HYDROCHLORIDE									
	@ HOSPIRA	0.75%	A070587	001	Mar 03, 1987	Jul	DISC		
<u>BUPRENORPHINE</u>									
FILM, EXTENDED RELEASE;TRANSDERMAL									
BUTRANS									
	PURDUE PHARMA LP	7.5MCG/HR	N021306	005	Jun 30, 2014	Jun	NEWA		
<u>BUPRENORPHINE HYDROCHLORIDE</u>									
INJECTABLE;INJECTION									
BUPRENORPHINE HYDROCHLORIDE									
AP	EUROHLTH INTL	EQ 0.3MG BASE/ML	A076931	001	Mar 02, 2005	Aug	CAHN		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE</u>									
FILM;BUCCAL									
BUNAVAIL									
	BIODELIVERY SCI INTL	EQ 2.1MG BASE;EQ 0.3MG BASE	N205637	001	Jun 06, 2014	Jun	NEWA		
		EQ 4.2MG BASE;EQ 0.7MG BASE	N205637	002	Jun 06, 2014	Jun	NEWA		
	+	EQ 6.3MG BASE;EQ 1MG BASE	N205637	003	Jun 06, 2014	Jun	NEWA		
TABLET;SUBLINGUAL									
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE									
AB	ROXANE	EQ 2MG BASE;EQ 0.5MG BASE	A203326	001	Jun 27, 2014	Jun	NEWA		
AB	TEVA PHARMS USA	EQ 2MG BASE;EQ 0.5MG BASE	A091149	001	Sep 08, 2014	Aug	NEWA		
AB		EQ 8MG BASE;EQ 2MG BASE	A091149	002	Sep 08, 2014	Aug	NEWA		
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDRODHCLORIDE									
AB	ROXANE	EQ 8MG BASE;EQ 2MG BASE	A203326	002	Jun 27, 2014	Jun	NEWA		
<u>BUPROPION HYDROCHLORIDE</u>									
TABLET, EXTENDED RELEASE;ORAL									
BUPROPION HYDROCHLORIDE									
AB1	JUBILANT GENERICS	100MG	A202774	001	Oct 11, 2013	Jul	CAHN		
AB1		150MG	A202774	002	Oct 11, 2013	Jul	CAHN		
AB2		150MG	A202775	001	Oct 11, 2013	Aug	CAHN		
AB1		200MG	A202774	003	Oct 11, 2013	Jul	CAHN		
AB3	ZYDUS PHARMS USA INC	300MG	A201567	001	Jan 17, 2014	Jan	NEWA		
>A>	<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE</u>								
>A>	TABLET, EXTENDED RELEASE;ORAL								
>A>	CONTRAVE								
>A>	+ TAKEDA PHARMS USA	90MG;8MG	N200063	001	Sep 10, 2014	Sep	NEWA		
<u>BUSPIRONE HYDROCHLORIDE</u>									
TABLET;ORAL									
BUSPIRONE HYDROCHLORIDE									
AB	STRIDES ARCOLAB LTD	5MG	A202330	001	Aug 25, 2014	Aug	NEWA		
AB		10MG	A202330	002	Aug 25, 2014	Aug	NEWA		
AB		15MG	A202330	003	Aug 25, 2014	Aug	NEWA		
AB		30MG	A202330	004	Aug 25, 2014	Aug	NEWA		
AB	ZYDUS PHARMS USA INC	5MG	A078888	001	Feb 07, 2014	Jan	NEWA		
AB		10MG	A078888	002	Feb 07, 2014	Jan	NEWA		
AB		15MG	A078888	003	Feb 07, 2014	Jan	NEWA		
AB		30MG	A078888	004	Feb 07, 2014	Jan	NEWA		
<u>BUTENAFINE HYDROCHLORIDE</u>									
CREAM;TOPICAL									
MENTAX-TC									
	@ MYLAN	1%	N021408	001	Oct 17, 2002	Jun	DISC		

BUTOCONAZOLE NITRATECREAM;VAGINAL
GYNAZOLE-1

@ LUMARA HEALTH INC 2% N019881 001 Feb 07, 1997 May CAHN

BUTORPHANOL TARTRATEINJECTABLE;INJECTION
BUTORPHANOL TARTRATE

@ HIKMA FARMACEUTICA 2MG/ML A078247 001 Apr 29, 2009 May DISC

CAFFEINE CITRATESOLUTION;INTRAVENOUS
CAFCITAP + EUROHLTH INTL EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N020793 001 Sep 21, 1999 Aug CAHN
CAFFEINE CITRATEAP EXELA PHARMA SCIENCE EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A077233 001 Sep 21, 2006 Feb CAHN
SOLUTION;ORALAA + EUROHLTH INTL EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N020793 002 Apr 12, 2000 Aug CAHN
CAFFEINE CITRATE

AA EXELA PHARMA SCS LLC EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A077304 001 Sep 21, 2006 Feb CAHN

CAFFEINE; ERGOTAMINE TARTRATE

TABLET;ORAL

ERGOTAMINE TARTRATE AND CAFFEINE

>A> AA HIKMA INTL PHARMS 100MG;1MG A040510 001 Sep 17, 2004 Sep CAHN

>D> AA HIKMA PHARMS LLC 100MG;1MG A040510 001 Sep 17, 2004 Sep CAHN

CALCIPOTRIENESOLUTION;TOPICAL
CALCIPOTRIENEAT + HI TECH PHARMA 0.005% A077579 001 Nov 19, 2009 May DISC
TOLMAR 0.005% A077029 001 Nov 20, 2009 Apr CRLDDOVONEX
@ LEO PHARM 0.005% N020611 001 Mar 03, 1997 Apr DISCCALCITONIN SALMONINJECTABLE;INJECTION
MIACALCIN

>D> @ NOVARTIS 100 IU/ML N017808 001 Jul 03, 1986 Sep CAHN

>D> + 200 IU/ML N017808 002 Mar 29, 1991 Sep CAHN

>A> @ SEBELA IRELAND LTD 100 IU/ML N017808 001 Jul 03, 1986 Sep CAHN

>A> + 200 IU/ML N017808 002 Mar 29, 1991 Sep CAHN

SPRAY, METERED;NASAL
MIACALCIN

>D> AB + NOVARTIS 200 IU/SPRAY N020313 002 Aug 17, 1995 Sep CAHN

>A> AB + SEBELA IRELAND LTD 200 IU/SPRAY N020313 002 Aug 17, 1995 Sep CAHN

CALCITRIOLINJECTABLE;INJECTION
CALCITRIOL

@ TEVA PARENTERAL 0.002MG/ML A075823 002 Mar 31, 2003 Feb DISC

CALCIUM ACETATECAPSULE;ORAL
CALCIUM ACETATE

>A> AB AMNEAL PHARMS EQ 169MG CALCIUM A201658 001 Oct 06, 2014 Sep NEWA

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 33MG/100ML;5GM/100ML;30MG/100ML;86 N016695 001 Jul DISC
0MG/100MLCANAGLIFLOZIN; METFORMIN HYDROCHLORIDETABLET;ORAL
INVOKAMET

JANSSSEN PHARMS 50MG;500MG N204353 001 Aug 08, 2014 Aug NEWA

50MG;1GM N204353 002 Aug 08, 2014 Aug NEWA

150MG;500MG N204353 003 Aug 08, 2014 Aug NEWA

+ 150MG;1GM N204353 004 Aug 08, 2014 Aug NEWA

CAPECITABINE

TABLET; ORAL

CAPECITABINE

AB	MYLAN PHARMS INC	150MG	A090943	001	Aug 08, 2014	Jul NEWA
AB		500MG	A090943	002	Aug 08, 2014	Jul NEWA

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

@	DAVA PHARMS INC	12.5MG	A074423	001	Feb 13, 1996	May CAHN
@		25MG	A074423	002	Feb 13, 1996	May CAHN
@		50MG	A074423	003	Feb 13, 1996	May CAHN
@		100MG	A074423	004	Feb 13, 1996	May CAHN
@	WATSON LABS	12.5MG	A074451	001	Feb 13, 1996	Mar DISC
@		25MG	A074451	002	Feb 13, 1996	Mar DISC
@		50MG	A074451	003	Feb 13, 1996	Mar DISC
@		100MG	A074451	004	Feb 13, 1996	Mar DISC

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPOZIDE 25/15

@	APOTHECON	25MG;15MG	N018709	001	Oct 12, 1984	Mar DISC
---	-----------	-----------	---------	-----	--------------	----------

CAPOZIDE 25/25

@	APOTHECON	25MG;25MG	N018709	002	Oct 12, 1984	Mar DISC
---	-----------	-----------	---------	-----	--------------	----------

CAPOZIDE 50/15

@	APOTHECON	50MG;15MG	N018709	004	Oct 12, 1984	Mar DISC
---	-----------	-----------	---------	-----	--------------	----------

CAPOZIDE 50/25

@	APOTHECON	50MG;25MG	N018709	003	Oct 12, 1984	Mar DISC
---	-----------	-----------	---------	-----	--------------	----------

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

AB	+	MYLAN	25MG;25MG	A074896	002	Dec 29, 1997	Mar CRLD
AB	+		50MG;15MG	A074896	004	Dec 29, 1997	Mar CRLD

CARBIDOPA

TABLET; ORAL

CARBIDOPA

AB	AMERIGEN PHARMS LTD	25MG	A203261	001	Mar 10, 2014	Feb NEWA
AB	+	LODOSYN				
AB	+	ATON	25MG	N017830	001	Feb CFTG

CARBIDOPA; LEVODOPA

TABLET, ORALLY DISINTEGRATING; ORAL

CARBIDOPA AND LEVODOPA

@	IMPAX LABS	10MG;100MG	A090631	001	Jun 08, 2010	Aug DISC	
@		25MG;100MG	A090631	002	Jun 08, 2010	Aug DISC	
@		25MG;250MG	A090631	003	Jun 08, 2010	Aug DISC	
AB	+	MYLAN	25MG;250MG	A078893	003	Sep 18, 2008	Aug CRLD
	PARCOPA						
@	UCB INC	10MG;100MG	A076699	001	Aug 27, 2004	Aug DISC	
@		25MG;100MG	A076699	002	Aug 27, 2004	Aug DISC	
@		25MG;250MG	A076699	003	Aug 27, 2004	Aug DISC	

CARBINOXAMINE MALEATE

SOLUTION; ORAL

CARBINOXAMINE MALEATE

AA	VINTAGE PHARMS	4MG/5ML	A040814	001	Feb 26, 2008	Feb CAHN
----	----------------	---------	---------	-----	--------------	----------

TABLET; ORAL

CARBINOXAMINE MALEATE

>D>	AA	LYNROSE LABS	4MG	A090756	001	May 27, 2011	Sep CAHN
>A>	AA	MISSION PHARMACAL CO	4MG	A090756	001	May 27, 2011	Sep CAHN
	AA	VINTAGE PHARMS	4MG	A040639	002	May 30, 2008	Feb CAHN

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

@	BEDFORD	50MG/VIAL	A076099	001	Oct 14, 2004	May DISC
@		150MG/VIAL	A076099	002	Oct 14, 2004	May DISC
@		450MG/VIAL	A076099	003	Oct 14, 2004	May DISC
@	CIPLA LTD	50MG/VIAL	A077383	001	Jan 27, 2006	May DISC
@		150MG/VIAL	A077383	002	Jan 27, 2006	May DISC
@		450MG/VIAL	A077383	003	Jan 27, 2006	May DISC
@	EUROHLTH INTL	50MG/VIAL	A076099	001	Oct 14, 2004	Aug CAHN

INJECTABLE; INJECTION
CARBOPLATIN

@	150MG/VIAL	A076099	002	Oct 14, 2004	Aug CAHN
@	450MG/VIAL	A076099	003	Oct 14, 2004	Aug CAHN
@ FRESenius KABI USA	50MG/VIAL	A076235	001	Oct 14, 2004	May DISC
@	150MG/VIAL	A076235	002	Oct 14, 2004	May DISC
@	450MG/VIAL	A076235	003	Oct 14, 2004	May DISC
@ ONCO THERAPIES LTD	50MG/VIAL	A091510	001	May 29, 2012	May DISC
@	150MG/VIAL	A091510	002	May 29, 2012	May DISC
@	450MG/VIAL	A091510	003	May 29, 2012	May DISC
@ SANDOZ	50MG/VIAL	A076959	001	Mar 18, 2005	May DISC
@	150MG/VIAL	A076959	002	Mar 18, 2005	May DISC
@	450MG/VIAL	A076959	003	Mar 18, 2005	May DISC
@ WATSON LABS	50MG/VIAL	A076162	001	Oct 14, 2004	May DISC
@	150MG/VIAL	A076162	002	Oct 14, 2004	May DISC
@	450MG/VIAL	A076162	003	Oct 14, 2004	May DISC

INJECTABLE; IV (INFUSION)
CARBOPLATIN

AP	ACTAVIS ELIZABETH	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Aug CAHN
AP		150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Aug CAHN
AP		450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Aug CAHN
AP		600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Aug CAHN
AP	EUROHLTH INTL	50MG/5ML (10MG/ML)	A077244	001	Oct 15, 2004	Aug CAHN
AP		150MG/15ML (10MG/ML)	A077244	002	Oct 15, 2004	Aug CAHN
AP		450MG/45ML (10MG/ML)	A077244	003	Oct 15, 2004	Aug CAHN
AP		600MG/60ML (10MG/ML)	A077244	004	Jan 20, 2006	Aug CAHN
AP +	PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077269	001	Oct 14, 2004	Feb CAHN
AP +		150MG/15ML (10MG/ML)	A077269	002	Oct 14, 2004	Feb CAHN
AP +		450MG/45ML (10MG/ML)	A077269	003	Oct 14, 2004	Feb CAHN
AP +		600MG/60ML (10MG/ML)	A077269	004	Dec 28, 2007	Feb CAHN

CARISOPRODOL

TABLET; ORAL
CARISOPRODOL

AA	SCIEGEN PHARMS INC	350MG	A203374	001	Jan 27, 2014	Jan NEWA
----	--------------------	-------	---------	-----	--------------	----------

CARVEDILOL

TABLET; ORAL
CARVEDILOL

AB	SUN PHARM INDS INC	3.125MG	A077346	004	Sep 05, 2007	Jul CAHN
AB		6.25MG	A077346	001	Sep 05, 2007	Jul CAHN
AB		12.5MG	A077346	002	Sep 05, 2007	Jul CAHN
AB		25MG	A077346	003	Sep 05, 2007	Jul CAHN

CEFACTOR

FOR SUSPENSION; ORAL
CEFACTOR

AB	+ YUNG SHIN PHARM	EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012	Jan CRLD
----	-------------------	-------------------	---------	-----	--------------	----------

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL
CEFADROXIL

@ ANI PHARMS INC	EQ 125MG BASE/5ML	A062698	001	Mar 01, 1989	Jan CAHN
@	EQ 250MG BASE/5ML	A062698	002	Mar 01, 1989	Jan CAHN
@	EQ 250MG BASE/5ML	A065278	001	Jan 20, 2006	Jan CAHN
@	EQ 500MG BASE/5ML	A062698	003	Mar 01, 1989	Jan CAHN
@	EQ 500MG BASE/5ML	A065278	002	Jan 20, 2006	Jan CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	ACS DOBFAR	EQ 20GM BASE/VIAL	A065306	002	Aug 18, 2014	Aug NEWA
@	STERI PHARMA	EQ 1GM BASE/VIAL	A063208	001	Dec 27, 1991	Mar DISC

CEFTAZIDIME

INJECTABLE; INJECTION
FORTAZ

AP	+ COVIS INJECTABLES	1GM/VIAL	N050578	002	Jul 19, 1985	May CAHN
AP	+	2GM/VIAL	N050578	003	Jul 19, 1985	May CAHN
AP	+	6GM/VIAL	N050578	004	Jul 19, 1985	May CAHN
AP	+	500MG/VIAL	N050578	001	Jul 19, 1985	May CAHN

CEFTAZIDIME SODIUM

INJECTABLE;INJECTION
FORTAZ IN PLASTIC CONTAINER

@ COVIS INJECTABLES	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Apr CAHN
+	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Apr CAHN
+	EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Apr CAHN

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION
CEFTRIAXONE

AP	@ AGILA SPECLTS	EQ 10GM BASE/VIAL	A091068	001	Jan 07, 2013	Aug DISC
		EQ 10GM BASE/VIAL	A091068	001	Jan 07, 2013	Feb CAHN
	SAMSON MEDCL	EQ 100GM BASE/VIAL	A090057	001	Apr 25, 2014	Apr NEWA

CEFTRIAXONE IN PLASTIC CONTAINER

>D>	BAXTER HLTHCARE	EQ 20MG BASE/ML	A065224	001	Aug 23, 2005	Sep CRLD
>A>	+	EQ 20MG BASE/ML	A065224	001	Aug 23, 2005	Sep CRLD
>D>		EQ 40MG BASE/ML	A065224	002	Aug 23, 2005	Sep CRLD
>A>	+	EQ 40MG BASE/ML	A065224	002	Aug 23, 2005	Sep CRLD

CEFUROXIME SODIUM

INJECTABLE;INJECTION
ZINACEF

AP	+	COVIS INJECTABLES	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Apr CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Apr CAHN

ZINACEF IN PLASTIC CONTAINER

@ COVIS INJECTABLES	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	May CAHN
+	EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	May CAHN

CELECOXIB

CAPSULE;ORAL
CELEBREX

AB	GD SEARLE	50MG	N020998	004	Dec 15, 2006	May CFTG
AB		100MG	N020998	001	Dec 31, 1998	May CFTG
AB		200MG	N020998	002	Dec 31, 1998	May CFTG
AB	+	400MG	N020998	003	Aug 29, 2002	May CFTG

CELECOXIB

AB	MYLAN PHARMS INC	50MG	A078857	001	May 30, 2014	May NEWA
AB	TEVA	50MG	A076898	001	May 30, 2014	May NEWA
AB		100MG	A076898	002	May 30, 2014	May NEWA
AB		200MG	A076898	003	May 30, 2014	May NEWA
AB		400MG	A076898	004	May 30, 2014	May NEWA

CEPHALEXIN

CAPSULE;ORAL
CEPHALEXIN

@ FACTA FARMA	EQ 250MG BASE	A062118	001		Jun DISC
@	EQ 500MG BASE	A062118	002		Jun DISC
@ STEVENS J	EQ 250MG BASE	A062870	001	Mar 17, 1988	Mar DISC

FOR SUSPENSION;ORAL

CEPHALEXIN

@ FACTA FARMA	EQ 125MG BASE/5ML	A062117	002		Jun DISC	
@	EQ 250MG BASE/5ML	A062117	003		Jun DISC	
>D> AB	HIKMA PHARMS	EQ 125MG BASE/5ML	A065444	001	Aug 28, 2009	Sep DISC
>A>	@	EQ 125MG BASE/5ML	A065444	001	Aug 28, 2009	Sep DISC
>D> AB		EQ 250MG BASE/5ML	A065444	002	Aug 28, 2009	Sep DISC
>A>	@	EQ 250MG BASE/5ML	A065444	002	Aug 28, 2009	Sep DISC
>D> AB	TEVA	EQ 250MG BASE/5ML	A062703	002	Feb 13, 1987	Sep CRLD
>A> AB	+	EQ 250MG BASE/5ML	A062703	002	Feb 13, 1987	Sep CRLD
>D> AB	YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065336	001	Jul 25, 2007	Sep DISC
>A>	@	EQ 125MG BASE/5ML	A065336	001	Jul 25, 2007	Sep DISC
>D> AB		EQ 250MG BASE/5ML	A065336	002	Jul 25, 2007	Sep DISC
>A>	@	EQ 250MG BASE/5ML	A065336	002	Jul 25, 2007	Sep DISC

CERITINIB

CAPSULE;ORAL
ZYKADIA

+	NOVARTIS PHARMS CORP	150MG	N205755	001	Apr 29, 2014	Apr NEWA
---	----------------------	-------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

>D>	AA	CARACO	5MG/5ML	A090191	001	Nov 12, 2009	Sep CAHN
>A>	AA	SUN PHARM INDS INC	5MG/5ML	A090191	001	Nov 12, 2009	Sep CAHN

CEVIMELINE HYDROCHLORIDE

CAPSULE; ORAL

CEVIMELINE HYDROCHLORIDE

AB		PACK PHARMS LLC	30MG	A203775	001	Jun 04, 2014	May NEWA
----	--	-----------------	------	---------	-----	--------------	----------

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

@ WATSON LABS

5MG

A086383 001

May DISC

@

10MG

A086294 001

May DISC

@

25MG

A086382 001

May DISC

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLOROPROCAINE HYDROCHLORIDE

AP EUROHLTH INTL

2%

A040273 001

Sep 09, 1998

Aug CAHN

AP

3%

A040273 002

Sep 09, 1998

Aug CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE; INJECTION

CHLOROTHIAZIDE SODIUM

AP MYLAN INSTITUTIONAL EQ 500MG BASE/VIAL

A202493 001

Jun 18, 2014

Jun NEWA

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA PADDOCK LLC 4MG/5ML; 5MG/5ML; 60MG/5ML

A204627 001

Apr 29, 2014

Apr NEWA

ZUTRIPRO

AA + CYPRESS PHARM 4MG/5ML; 5MG/5ML; 60MG/5ML

N022439 001

Jun 08, 2011

Apr CFTG

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE; ORAL

TUSSICAPS

ECR PHARMA

EQ 4MG MALEATE; EQ 5MG BITARTRATE

A077273 002

Sep 24, 2007

Jul CAHN

+

EQ 8MG MALEATE; EQ 10MG BITARTRATE

A077273 001

Sep 24, 2007

Jul CAHN

SUSPENSION, EXTENDED RELEASE; ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX

>D> AB CORNERSTONE THERAP EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML

A091671 001

Jun 29, 2012

Sep CAHN

>A> AB NEOS THERAP INC EQ 8MG MALEATE/5ML; EQ 10MG BITARTRATE/5ML

A091671 001

Jun 29, 2012

Sep CAHN

CHLORPROPAMIDE

TABLET; ORAL

CHLORPROPAMIDE

@ ANI PHARMS INC

100MG

A088768 001

Oct 11, 1984

Jan CAHN

@

100MG

A088812 001

Oct 19, 1984

Jan CAHN

@

100MG

A088840 001

Oct 25, 1984

Feb CAHN

@

100MG

A088918 001

Oct 16, 1984

Jan CAHN

AB

100MG

A088921 001

Apr 12, 1985

Jan CAHN

@

100MG

A089446 001

Nov 17, 1986

Jan CAHN

@

250MG

A088813 001

Oct 19, 1984

Jan CAHN

@

250MG

A088919 001

Oct 16, 1984

Jan CAHN

AB

250MG

A088922 001

Apr 12, 1985

Jan CAHN

@

250MG

A089447 001

Nov 17, 1986

Jan CAHN

@ TEVA PHARMS USA

250MG

A087353 001

Apr CAHN

GLUCAMIDE

@ ANI PHARMS INC

250MG

A088641 001

Oct 11, 1984

Jan CAHN

@ TEVA PHARMS USA

250MG

A088641 001

Oct 11, 1984

Apr CAHN

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

@ ACTAVIS ELIZABETH	250MG	A088928	001	May 08, 1987	Jun CAHN
@	500MG	A040113	001	Sep 29, 1995	Aug CAHN
@ WATSON LABS	500MG	A040137	001	Aug 09, 1996	May DISC
@	500MG	A081040	001	Aug 22, 1989	May DISC

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB	TARO	0.77%	A076790	001	Apr 12, 2005	Mar CMFD
	@	0.77%	A076790	001	Apr 12, 2005	Feb DISC

GEL; TOPICAL

LOPROX

AB	+ CNTY LINE PHARMS	0.77%	N020519	001	Jul 21, 1997	Jul CAHN
----	--------------------	-------	---------	-----	--------------	----------

SHAMPOO; TOPICAL

CICLOPIROX

AT	ACTAVIS MID ATLANTIC	1%	A090490	001	Nov 24, 2009	Aug CAHN
----	----------------------	----	---------	-----	--------------	----------

CILASTATIN SODIUM; IMIPENEM

>D> INJECTABLE; INJECTION

>D> IMIPENEM AND CILASTATIN

>D> AP	ACS DOBFAR	EQ 250MG BASE/VIAL; 250MG/VIAL	A090577	001	Dec 21, 2011	Sep CDFR
>D> AP		EQ 500MG BASE/VIAL; 500MG/VIAL	A090577	002	Dec 21, 2011	Sep CDFR
>D> AP	HOSPIRA INC	EQ 250MG BASE/VIAL; 250MG/VIAL	A090825	001	Nov 16, 2011	Sep CDFR
>D> AP		EQ 500MG BASE/VIAL; 500MG/VIAL	A090825	002	Nov 16, 2011	Sep CDFR
>D> AP		EQ 500MG BASE/VIAL; 500MG/VIAL	A091007	001	Nov 16, 2011	Sep CDFR

PRIMAXIN

>D> AP	MERCK	EQ 250MG BASE/VIAL; 250MG/VIAL	A062756	001	Jan 08, 1987	Sep DISC
>A>	@	EQ 250MG BASE/VIAL; 250MG/VIAL	A062756	001	Jan 08, 1987	Sep DISC
>D> AP	+	EQ 250MG BASE/VIAL; 250MG/VIAL	N050587	001	Nov 26, 1985	Sep CDFR
>D> AP		EQ 500MG BASE/VIAL; 500MG/VIAL	A062756	002	Jan 08, 1987	Sep DISC
>A>	@	EQ 500MG BASE/VIAL; 500MG/VIAL	A062756	002	Jan 08, 1987	Sep DISC
>D> AP	+	EQ 500MG BASE/VIAL; 500MG/VIAL	N050587	002	Nov 26, 1985	Sep CDFR
>D> AP		EQ 500MG BASE/VIAL; 500MG/VIAL	N050630	001	Dec 14, 1990	Sep CDFR
>D>	@	EQ 750MG BASE/VIAL; 750MG/VIAL	N050630	002	Dec 14, 1990	Sep CDFR

POWDER; INTRAMUSCULAR

PRIMAXIN

>A>	MERCK	EQ 500MG BASE/VIAL; 500MG/VIAL	N050630	001	Dec 14, 1990	Sep CTEC
>A> AP		EQ 500MG BASE/VIAL; 500MG/VIAL	N050630	001	Dec 14, 1990	Sep CDFR
>A>	@	EQ 750MG BASE/VIAL; 750MG/VIAL	N050630	002	Dec 14, 1990	Sep CDFR

POWDER; INTRAVENOUS

IMIPENEM AND CILASTATIN

>A> AP	ACS DOBFAR	EQ 250MG BASE/VIAL; 250MG/VIAL	A090577	001	Dec 21, 2011	Sep CDFR
>A> AP		EQ 500MG BASE/VIAL; 500MG/VIAL	A090577	002	Dec 21, 2011	Sep CDFR
>A> AP	HOSPIRA INC	EQ 250MG BASE/VIAL; 250MG/VIAL	A090825	001	Nov 16, 2011	Sep CDFR
>A> AP		EQ 500MG BASE/VIAL; 500MG/VIAL	A090825	002	Nov 16, 2011	Sep CDFR
>A> AP		EQ 500MG BASE/VIAL; 500MG/VIAL	A091007	001	Nov 16, 2011	Sep CDFR

PRIMAXIN

>A> AP	+	MERCK	EQ 250MG BASE/VIAL; 250MG/VIAL	N050587	001	Nov 26, 1985	Sep CDFR
>A> AP	+		EQ 500MG BASE/VIAL; 500MG/VIAL	N050587	002	Nov 26, 1985	Sep CDFR

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

@ ACTAVIS ELIZABETH	100MG	A077028	002	Nov 26, 2004	Aug CAHN
---------------------	-------	---------	-----	--------------	----------

CIMETIDINE

TABLET; ORAL

CIMETIDINE

>A>	@ CYCLE PHARMS LTD	300MG	A074361	001	Dec 23, 1994	Sep CAHN
>A>	@	400MG	A074361	002	Dec 23, 1994	Sep CAHN
>A>	@	800MG	A074371	001	Dec 23, 1994	Sep CAHN
	@ DAVA PHARMS INC	300MG	A074340	001	Jun 23, 1995	Jul DISC
	@	400MG	A074340	002	Jun 23, 1995	Jul DISC
>D> AB		800MG	A074339	001	Jun 23, 1995	Sep DISC
>A>	@	800MG	A074339	001	Jun 23, 1995	Sep DISC
	@ IVAX SUB TEVA PHARMS	200MG	A074424	001	Jul 28, 1995	Jul DISC
	@	300MG	A074424	002	Jul 28, 1995	Jul DISC
	@	400MG	A074424	003	Jul 28, 1995	Jul DISC

TABLET;ORAL
CIMETIDINE

	@	800MG	A074424	004	Jul 28, 1995	Jul	DISC
AB	+	MYLAN 800MG	A074246	004	May 17, 1994	Jul	CRLD
	@	PLIVA 200MG	A074568	001	Feb 27, 1997	Jul	DISC
	@	300MG	A074568	002	Feb 27, 1997	Jul	DISC
	@	400MG	A074568	003	Feb 27, 1997	Jul	DISC
>D>	@	ROXANE 300MG	A074361	001	Dec 23, 1994	Sep	CAHN
>D>	@	400MG	A074361	002	Dec 23, 1994	Sep	CAHN
>D>	@	800MG	A074371	001	Dec 23, 1994	Sep	CAHN

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL
CIMETIDINE HYDROCHLORIDE

AA	ANI PHARMS INC	EQ 300MG BASE/5ML	A074610	001	Sep 26, 1996	Jan	CAHN
	@	EQ 300MG BASE/5ML	A074859	001	Jul 09, 1998	Feb	CAHN
	@	EQ 300MG BASE/5ML	A075110	001	Jun 18, 1998	Jan	CAHN
>A>	@	CYCLE PHARMS LTD EQ 300MG BASE/5ML	A074541	001	Aug 05, 1997	Sep	CAHN
>D>	@	ROXANE EQ 300MG BASE/5ML	A074541	001	Aug 05, 1997	Sep	CAHN

CIPROFLOXACIN

FOR SUSPENSION;ORAL
CIPRO

AB	BAYER HLTHCARE	250MG/5ML	N020780	001	Sep 26, 1997	Feb	CFTG
AB	+	500MG/5ML	N020780	002	Sep 26, 1997	Feb	CFTG
	CIPROFLOXACIN						
AB	LUPIN LTD	250MG/5ML	A200563	001	Mar 05, 2014	Feb	NEWA
AB		500MG/5ML	A200563	002	Mar 05, 2014	Feb	NEWA

CIPROFLOXACIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC
CIPROFLOXACIN HYDROCHLORIDE

>D>	AT	BAUSCH AND LOMB EQ 0.3% BASE	A076754	001	Jun 09, 2004	Sep	CAHN
>A>	AT	IGI LABS INC EQ 0.3% BASE	A076754	001	Jun 09, 2004	Sep	CAHN
	AT	WATSON LABS INC EQ 0.3% BASE	A076673	001	Jan 21, 2005	Apr	CAHN

CISPLATIN

INJECTABLE;INJECTION
CISPLATIN

AP	EUROHLTH INTL	1MG/ML	A075036	001	Nov 07, 2000	Aug	CAHN
AP	PHARMACHEMIE BV	1MG/ML	A074656	001	May 16, 2000	Feb	CAHN

CITALOPRAM HYDROBROMIDE

TABLET;ORAL
CITALOPRAM HYDROBROMIDE

AB	SUN PHARM INDS INC	EQ 10MG BASE	A077032	001	Nov 12, 2004	Jul	CAHN
AB		EQ 20MG BASE	A077032	002	Nov 12, 2004	Jul	CAHN
AB		EQ 40MG BASE	A077032	003	Nov 12, 2004	Jul	CAHN
	@	WATSON LABS EQ 10MG BASE	A077034	001	Jun 30, 2005	May	DISC
	@	EQ 20MG BASE	A077034	002	Jun 30, 2005	May	DISC
	@	EQ 40MG BASE	A077034	003	Jun 30, 2005	May	DISC

CLADRIBINE

INJECTABLE;INJECTION
CLADRIBINE

AP	EUROHLTH INTL	1MG/ML	A075405	001	Feb 28, 2000	Aug	CAHN
----	---------------	--------	---------	-----	--------------	-----	------

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL
CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 75MG BASE/5ML	A203513	001	Mar 13, 2014	Feb	NEWA
----	---------------	------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE

CREAM;VAGINAL
CLINDESSE

+	LUMARA HEALTH INC	EQ 2% BASE	N050793	001	Nov 30, 2004	May	CAHN
---	-------------------	------------	---------	-----	--------------	-----	------

SOLUTION;TOPICAL
CLINDAMYCIN PHOSPHATE

AB	ACTAVIS MID ATLANTIC	EQ 1% BASE	A062811	001	Sep 01, 1988	Apr	CMFD
AT	G AND W LABS INC	EQ 1% BASE	A062811	001	Sep 01, 1988	Jun	CTEC
AB		EQ 1% BASE	A062811	001	Sep 01, 1988	May	CAHN
	@	VINTAGE PHARMS EQ 1% BASE	A062930	001	Jun 28, 1989	Feb	CAHN

CLOBETASOL PROPIONATEAEROSOL, FOAM; TOPICAL
OLUX

AB1	+	DELCOR ASSET	0.05%	N021142	001	May 26, 2000	Jun CAHN
-----	---	--------------	-------	---------	-----	--------------	----------

CLONAZEPAMTABLET; ORAL
CLONAZEPAM

AB		SUN PHARM INDS INC	0.5MG	A075423	001	Apr 27, 2001	Jul CAHN
AB			1MG	A075423	002	Apr 27, 2001	Jul CAHN
AB			2MG	A075423	003	Apr 27, 2001	Jul CAHN

TABLET, ORALLY DISINTEGRATING; ORAL
CLONAZEPAM

AB		SUN PHARM INDS INC	0.125MG	A078654	001	Aug 27, 2014	Aug NEWA
AB			0.25MG	A078654	002	Aug 27, 2014	Aug NEWA
AB			0.5MG	A078654	003	Aug 27, 2014	Aug NEWA
AB			1MG	A078654	004	Aug 27, 2014	Aug NEWA
AB			2MG	A078654	005	Aug 27, 2014	Aug NEWA

CLONIDINEFILM, EXTENDED RELEASE; TRANSDERMAL
CLONIDINE

AB		WATSON LABS INC	0.1MG/24HR	A090873	001	May 06, 2014	Apr NEWA
AB			0.2MG/24HR	A090873	002	May 06, 2014	Apr NEWA
AB			0.3MG/24HR	A090873	003	May 06, 2014	Apr NEWA

CLONIDINE HYDROCHLORIDEINJECTABLE; INJECTION
CLONIDINE HYDROCHLORIDE

AP		ZYDUS PHARMS USA INC	1MG/10ML (0.1MG/ML)	A202601	001	Feb 20, 2014	Feb NEWA
AP			5MG/10ML (0.5MG/ML)	A202601	002	Feb 20, 2014	Feb NEWA

TABLET; ORAL
CLONIDINE HYDROCHLORIDE

AB		CARACO	0.1MG	A090329	001	Jul 03, 2014	Jun NEWA
AB			0.2MG	A090329	002	Jul 03, 2014	Jun NEWA
AB			0.3MG	A090329	003	Jul 03, 2014	Jun NEWA
AB		SUN PHARM INDS INC	0.1MG	A090329	001	Jul 03, 2014	Jul CAHN
AB			0.2MG	A090329	002	Jul 03, 2014	Jul CAHN
AB			0.3MG	A090329	003	Jul 03, 2014	Jul CAHN
		@ WATSON LABS	0.3MG	A070963	001	Jul 08, 1986	May DISC

TABLET, EXTENDED RELEASE; ORAL
CLONIDINE HYDROCHLORIDE

AB		ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014	Mar NEWA
AB			0.2MG	A202983	002	Apr 02, 2014	Mar NEWA

CLOPIDOGRELTABLET; ORAL
CLOPIDOGREL

AB		AMNEAL PHARMS	75MG	A203751	001	Apr 11, 2014	Mar NEWA
----	--	---------------	------	---------	-----	--------------	----------

CLOPIDOGREL BISULFATETABLET; ORAL
CLOPIDOGREL BISULFATE

AB		ACTAVIS ELIZABETH	EQ 75MG BASE	A090307	001	May 28, 2013	Aug CAHN
AB		APOTEX INC	EQ 300MG BASE	A076274	002	Mar 04, 2014	Feb NEWA
AB		MACLEODS PHARMS LTD	EQ 75MG BASE	A202928	001	Feb 10, 2014	Jan NEWA
>A>	AB	SCIEGEN PHARMS INC	EQ 75MG BASE	A204165	001	Sep 15, 2014	Sep NEWA
>A>	AB		EQ 300MG BASE	A204165	002	Sep 15, 2014	Sep NEWA

CLORAZEPATE DIPOTASSIUMTABLET; ORAL
CLORAZEPATE DIPOTASSIUM

		@ WATSON LABS	3.75MG	A071852	001	Feb 09, 1988	May DISC
		@	7.5MG	A071853	001	Feb 09, 1988	May DISC
		@	15MG	A071854	001	Feb 09, 1988	May DISC

CLOZAPINETABLET; ORAL
CLOZAPINE

AB	IVAX SUB TEVA PHARMS	12.5MG	A074949	003	Jul 31, 2003	Mar CTEC
AB		200MG	A076809	001	Dec 16, 2005	Mar CTEC
AB	MYLAN	12.5MG	A075417	003	Apr 15, 2010	Mar NEWA
AB		50MG	A075417	004	Apr 15, 2010	Mar NEWA
AB		200MG	A075417	005	Apr 15, 2010	Mar NEWA
AB	SUN PHARM INDS INC	25MG	A075713	001	Nov 15, 2002	Jul CAHN
AB		50MG	A075713	003	Aug 19, 2005	Jul CAHN
AB		100MG	A075713	002	Nov 15, 2002	Jul CAHN

COBICISTAT

TABLET; ORAL

TYBOST

>A>	+	GILEAD SCIENCES INC	150MG	N203094	001	Sep 24, 2014	Sep NEWA
-----	---	---------------------	-------	---------	-----	--------------	----------

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

>D>	AA	CARACO	10MG/5ML; 6.25MG/5ML	A090180	001	Mar 17, 2010	Sep CAHN
>A>	AA	SUN PHARM INDS INC	10MG/5ML; 6.25MG/5ML	A090180	001	Mar 17, 2010	Sep CAHN

CODEINE SULFATE

TABLET; ORAL

CODEINE SULFATE

AB	LANNETT HOLDINGS INC	15MG	A203046	001	Jun 13, 2014	Jun NEWA
AB		30MG	A203046	002	Jun 13, 2014	Jun NEWA
AB		60MG	A203046	003	Jun 13, 2014	Jun NEWA
AB	ROXANE	15MG	N022402	001	Jul 16, 2009	Jun CFTG
AB		30MG	N022402	002	Jul 16, 2009	Jun CFTG
AB	+	60MG	N022402	003	Jul 16, 2009	Jun CFTG

COLCHICINE

CAPSULE; ORAL

MITIGARE

>A>		HIKMA PHARMS LLC	0.6MG	N204820	001	Sep 26, 2014	Sep NEWA
-----	--	------------------	-------	---------	-----	--------------	----------

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

AP	SAGENT PHARMS	EQ 150MG BASE/VIAL	A201365	001	Feb 19, 2014	Feb NEWA
	COLY-MYCIN M					
AP	+	PAR STERILE PRODUCTS	EQ 150MG BASE/VIAL	N050108	002	Apr CAHN

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS; OTIC

COLY-MYCIN S

+	PAR STERILE PRODUCTS	EQ 3MG BASE/ML; 10MG/ML; EQ 3.3MG BASE/ML; 0.5MG/ML	N050356	001		Apr CAHN
---	----------------------	---	---------	-----	--	----------

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

VAPRISOL

@ CUMBERLAND PHARMS 20MG/4ML (5MG/ML)

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

+	CUMBERLAND PHARMS	20MG/100ML (0.2MG/ML)	N021697	001	Dec 29, 2005	Feb CAHN
---	-------------------	-----------------------	---------	-----	--------------	----------

+	CUMBERLAND PHARMS	20MG/100ML (0.2MG/ML)	N021697	002	Oct 08, 2008	Feb CAHN
---	-------------------	-----------------------	---------	-----	--------------	----------

CORTISONE ACETATE

TABLET; ORAL

CORTISONE ACETATE

>A>	+	HIKMA INTL PHARMS	25MG	A080776	002		Sep CAHN
>D>	+	HIKMA PHARMS LLC	25MG	A080776	002		Sep CAHN

COSYNTROPIN

SOLUTION; INTRAVENOUS

COSYNTROPIN

>D>	SANDOZ	0.25MG/ML (0.25MG/ML)	N022028	001	Feb 21, 2008	Sep DISC
>A>	@	0.25MG/ML (0.25MG/ML)	N022028	001	Feb 21, 2008	Sep DISC

CROMOLYN SODIUMSOLUTION; INHALATION
CROMOLYN SODIUM

AN	MYLAN SPECLT	10MG/ML	A074209	001	Apr 26, 1994	May CAHN
	@ WATSON LABS	10MG/ML	A076469	001	Jun 17, 2005	May DISC

SOLUTION/DROPS; OPHTHALMIC
CROMOLYN SODIUM

AT	+ AKORN	4%	A074706	001	Apr 29, 1998	Jun CRLD
	OPTICROM					
	@ ALLERGAN	4%	N018155	001	Oct 03, 1984	Jun DISC

CYCLOPHOSPHAMIDEINJECTABLE; INJECTION
NEOSAR

>A>	@ BEDFORD	1GM/VIAL	A087442	004	Jul 08, 1983	Sep CAHN
>A>	@	2GM/VIAL	A087442	005	Mar 30, 1989	Sep CAHN
>A>	@	100MG/VIAL	A087442	001	Feb 16, 1982	Sep CAHN
>A>	@	200MG/VIAL	A087442	002	Feb 16, 1982	Sep CAHN
>A>	@	500MG/VIAL	A087442	003	Feb 16, 1982	Sep CAHN
>D>	@ TEVA PARENTERAL	1GM/VIAL	A087442	004	Jul 08, 1983	Sep CAHN
>D>	@	2GM/VIAL	A087442	005	Mar 30, 1989	Sep CAHN
>D>	@	100MG/VIAL	A087442	001	Feb 16, 1982	Sep CAHN
>D>	@	200MG/VIAL	A087442	002	Feb 16, 1982	Sep CAHN
>D>	@	500MG/VIAL	A087442	003	Feb 16, 1982	Sep CAHN

CYCLOSPORINEINJECTABLE; INJECTION
CYCLOSPORINE

AP	EUROHLTH INTL	50MG/ML	A065004	001	Oct 29, 1999	Aug CAHN
----	---------------	---------	---------	-----	--------------	----------

CYSTEAMINE BITARTRATECAPSULE, DELAYED RELEASE; ORAL
PROCYSBI

	RAPTOR INC	EQ 25MG BASE	N203389	001	Apr 30, 2013	Aug CAHN
+		EQ 75MG BASE	N203389	002	Apr 30, 2013	Aug CAHN

CYTARABINEINJECTABLE; INJECTION
CYTARABINE

AP	EUROHLTH INTL	1GM/VIAL	A074245	001	Aug 31, 1994	Aug CAHN
AP		2GM/VIAL	A074245	002	Aug 31, 1994	Aug CAHN
AP		100MG/VIAL	A071471	001	Aug 02, 1989	Aug CAHN
AP		500MG/VIAL	A071472	001	Aug 02, 1989	Aug CAHN

DACARBAZINEINJECTABLE; INJECTION
DACARBAZINE

AP	EUROHLTH INTL	200MG/VIAL	A075812	001	Jun 15, 2001	Aug CAHN
AP		500MG/VIAL	A075812	002	Oct 31, 2002	Aug CAHN

DACTINOMYCININJECTABLE; INJECTION
DACTINOMYCIN

AP	EUROHLTH INTL	0.5MG/VIAL	A090304	001	Mar 16, 2010	Aug CAHN
----	---------------	------------	---------	-----	--------------	----------

DALBAVANCIN HYDROCHLORIDEINJECTABLE; IV (INFUSION)
DALVANCE

+	DURATA THERAPS INTL	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	May NEWA
---	---------------------	--------------------	---------	-----	--------------	----------

DANTROLENE SODIUMCAPSULE; ORAL
DANTRIUM

AB	PAR STERILE PRODUCTS	25MG	N017443	001		Mar CAHN
AB		50MG	N017443	003		Mar CAHN
AB	+	100MG	N017443	002		Mar CAHN

FOR SUSPENSION; INTRAVENOUS
RYANODEX

	EAGLE PHARMS	250MG/VIAL	N205579	001	Jul 22, 2014	Jul NEWA
--	--------------	------------	---------	-----	--------------	----------

INJECTABLE; INJECTION									
DANTRIUM									
AP	+	PAR STERILE PRODUCTS	20MG/VIAL		N018264	001		Apr	CAHN
REVONTO									
AP		US WORLDMEDS	20MG/VIAL		A078378	001	Jul 24, 2007	Mar	CTNA
<u>DAPAGLIFLOZIN</u>									
TABLET; ORAL									
FARXIGA									
		ASTRAZENECA AB	5MG		N202293	001	Jan 08, 2014	Feb	CAHN
	+		10MG		N202293	002	Jan 08, 2014	Feb	CAHN
		BRISTOL MYERS SQUIBB	5MG		N202293	001	Jan 08, 2014	Jan	NEWA
	+		10MG		N202293	002	Jan 08, 2014	Jan	NEWA
<u>DAPTOMYCIN</u>									
INJECTABLE; IV (INFUSION)									
CUBICIN									
>D>	+	CUBIST	500MG/VIAL		N021572	002	Sep 12, 2003	Sep	CFTG
>A>	AP	+	500MG/VIAL		N021572	002	Sep 12, 2003	Sep	CFTG
>A>	DAPTOMYCIN								
>A>	AP	HOSPIRA INC	500MG/VIAL		A202857	001	Sep 12, 2014	Sep	NEWA
<u>DAUNORUBICIN HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
CERUBIDINE									
AP	+	EUROHLTH INTL	EQ 20MG BASE/VIAL		A064103	001	Feb 03, 1995	Aug	CAHN
DAUNORUBICIN HYDROCHLORIDE									
AP	+	EUROHLTH INTL	EQ 5MG BASE/ML		N050731	001	Jan 30, 1998	Aug	CAHN
<u>DECITABINE</u>									
INJECTABLE; INTRAVENOUS									
DECITABINE									
AP		SANDOZ	50MG/VIAL		A202969	001	Aug 28, 2014	Aug	NEWA
POWDER; INTRAVENOUS									
DECITABINE									
	+	SUN PHARMA GLOBAL	50MG/VIAL		N205582	001	Jan 28, 2014	Jan	NEWA
<u>DEFEROXAMINE MESYLATE</u>									
INJECTABLE; INJECTION									
DEFEROXAMINE MESYLATE									
AP		EUROHLTH INTL	2GM/VIAL		A078086	002	May 30, 2007	Aug	CAHN
AP			500MG/VIAL		A078086	001	May 30, 2007	Aug	CAHN
	@	WATSON LABS	2GM/VIAL		A076806	002	Mar 31, 2006	May	DISC
	@		500MG/VIAL		A076806	001	Mar 31, 2006	May	DISC
<u>DESIPRAMINE HYDROCHLORIDE</u>									
TABLET; ORAL									
DESIPRAMINE HYDROCHLORIDE									
AB		ACTAVIS ELIZABETH	10MG		A074430	001	Feb 09, 1996	Aug	CAHN
AB			25MG		A071601	001	Jun 05, 1987	Aug	CAHN
AB			50MG		A071588	001	Jun 05, 1987	Aug	CAHN
AB			75MG		A071602	001	Oct 05, 1987	Aug	CAHN
AB			100MG		A071766	001	Oct 05, 1987	Aug	CAHN
AB			150MG		A074430	002	Feb 09, 1996	Aug	CAHN
	@	ANI PHARMS INC	25MG		A071800	001	Dec 08, 1987	Jan	CAHN
	@		50MG		A071801	001	Dec 08, 1987	Jan	CAHN
	@		75MG		A071802	001	Dec 08, 1987	Jan	CAHN
	@		100MG		A071803	001	May 29, 1997	Feb	CAHN
	@		150MG		A071804	001	May 29, 1997	Feb	CAHN
<u>DESLORATADINE</u>									
SOLUTION; ORAL									
CLARINEX									
	+	MERCK SHARP DOHME	0.5MG/ML		N021300	001	Sep 01, 2004	May	CDFR
<u>DESMOPRESSIN ACETATE</u>									
SPRAY, METERED; NASAL									
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)									
AB		SUN PHARMA GLOBAL	0.01MG/SPRAY		A078271	001	Dec 23, 2013	Jan	CMS2

TABLET;ORAL

DESMOPRESSIN ACETATE

AB	MYLAN PHARMS INC	0.1MG	A200653	001	Jun 27, 2014	Jun NEWA
AB		0.2MG	A200653	002	Jun 27, 2014	Jun NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

KARIVA

>D>	AB	BARR	0.15MG,N/A;0.02MG,0.01MG	A075863	001	Apr 05, 2002	Sep CRLD
>A>	AB	+	0.15MG,N/A;0.02MG,0.01MG	A075863	001	Apr 05, 2002	Sep CRLD
>D>		MIRCETTE					
>D>	AB	+	TEVA BRANDED PHARM	N020713	001	Apr 22, 1998	Sep DISC
>A>		@	0.15MG,N/A;0.02MG,0.01MG	N020713	001	Apr 22, 1998	Sep DISC

DESONIDE

AEROSOL, FOAM;TOPICAL

VERDESO

+	AQUA PHARMS	0.05%	N021978	001	Sep 19, 2006	May CAHN
---	-------------	-------	---------	-----	--------------	----------

DESOXIMETASONE

OINTMENT;TOPICAL

DESOXIMETASONE

AB	VERSAPHARM INC	0.25%	A201005	001	Apr 24, 2014	Apr NEWA
----	----------------	-------	---------	-----	--------------	----------

DESVENLAFAXINE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE

BC	SUN PHARMA GLOBAL	50MG	N205583	001	Jan 28, 2014	Jan NEWA
BC	+	100MG	N205583	002	Jan 28, 2014	Jan NEWA

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE

+	SUN PHARMA GLOBAL	EQ 50MG BASE	N205583	001	Jan 28, 2014	Jun CTNA
+		EQ 100MG BASE	N205583	002	Jan 28, 2014	Jun CTNA
	@ TEVA PHARMS USA	EQ 50MG BASE	N205208	001	Oct 11, 2013	Jun DISC
+		EQ 50MG BASE	N205208	001	Oct 11, 2013	Jun CTNA
	@	EQ 100MG BASE	N205208	002	Oct 11, 2013	Jun DISC
+		EQ 100MG BASE	N205208	002	Oct 11, 2013	Jun CTNA
	DESVENLAFAXINE FUMARATE					
+	SUN PHARMA GLOBAL	EQ 50MG BASE	N205583	001	Jan 28, 2014	Feb CTEC
+		EQ 100MG BASE	N205583	002	Jan 28, 2014	Feb CTEC

DEXCHLORPHENIRAMINE MALEATE

TABLET;ORAL

DEXCHLORPHENIRAMINE MALEATE

@	ANI PHARMS INC	2MG	A088682	001	Jan 17, 1986	Jan CAHN
---	----------------	-----	---------	-----	--------------	----------

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE;ORAL

DEXILANT

	TAKEDA PHARMS USA	30MG	N022287	001	Jan 30, 2009	Jun CAHN
+		60MG	N022287	002	Jan 30, 2009	Jun CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

AP	MYLAN INSTITUTIONAL	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A202881	001	Aug 18, 2014	Aug NEWA	
AP	PAR STERILE PRODUCTS	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A203972	001	Aug 18, 2014	Aug NEWA	
	PRECEDEX						
AP	+	HOSPIRA	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	N021038	001	Dec 17, 1999	Aug CFTG

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

AB	TEVA PHARMS USA	15MG	A078908	004	May 19, 2014	May NEWA
AB		30MG	A202731	003	May 19, 2014	May NEWA
AB	WATSON LABS INC	15MG	A079108	003	May 19, 2014	May NEWA

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION
DEXRAZOXANE HYDROCHLORIDE

AP	EUROHLTH INTL	EQ 250MG BASE/VIAL	A076068	001	Sep 28, 2004	Aug CAHN
AP		EQ 500MG BASE/VIAL	A076068	002	Sep 28, 2004	Aug CAHN

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
DEXTROAMPHETAMINE SULFATE

AA	COREPHARMA	5MG	A090652	001	Mar 07, 2014	Feb NEWA
AA		10MG	A090652	002	Mar 07, 2014	Feb NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETH W/ DEXTROMETHORPHAN

>D> AA	+	ACTAVIS MID ATLANTIC	15MG/5ML; 6.25MG/5ML	A088762	001	Oct 31, 1984	Sep DISC
>A>	@		15MG/5ML; 6.25MG/5ML	A088762	001	Oct 31, 1984	Sep DISC
		PROMETHAZINE DM					
>D> AA		VINTAGE	15MG/5ML; 6.25MG/5ML	A040649	001	Feb 14, 2006	Sep CRLD
>A> AA	+		15MG/5ML; 6.25MG/5ML	A040649	001	Feb 14, 2006	Sep CRLD
		PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE					
>D> AA		AMNEAL PHARMS	15MG/5ML; 6.25MG/5ML	A090575	001	Feb 08, 2011	Sep DISC
>A>	@		15MG/5ML; 6.25MG/5ML	A090575	001	Feb 08, 2011	Sep DISC
>D> AA		TRIS PHARMA INC	15MG/5ML; 6.25MG/5ML	A091687	001	Jun 28, 2012	Sep DISC
>A>	@		15MG/5ML; 6.25MG/5ML	A091687	001	Jun 28, 2012	Sep DISC

DIAZEPAM

CONCENTRATE; ORAL
DIAZEPAM

AA		LANNETT HOLDINGS INC	5MG/ML	A204433	001	Apr 14, 2014	Mar NEWA
		DIAZEPAM INTENSOL					
AA	+	ROXANE	5MG/ML	A071415	001	Apr 03, 1987	Mar CFTG
		TABLET; ORAL					
		DIAZEPAM					
	@	DAVA PHARMS INC	2MG	A070226	001	Sep 26, 1985	Mar DISC

DICLOFENAC POTASSIUM

FOR SOLUTION; ORAL
CAMBIA

+	DEPOMED INC	50MG	N022165	001	Jun 17, 2009	Jan CAHN
---	-------------	------	---------	-----	--------------	----------

DICLOFENAC SODIUM

SOLUTION; TOPICAL
DICLOFENAC SODIUM

AT		APOTEX INC	1.5%	A202027	001	May 27, 2014	May NEWA
		PENNSAID					
AT	+	MALLINCKRODT	1.5%	N020947	001	Nov 04, 2009	May CFTG
	+	MALLINCKRODT INC	2%	N204623	001	Jan 16, 2014	Jan NEWA

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL
DICLOFENAC SODIUM AND MISOPROSTOL

AB		EAGLE PHARMS	50MG; 0.2MG	A200540	001	Mar 14, 2014	Mar NEWA
AB			75MG; 0.2MG	A200540	002	Mar 14, 2014	Mar NEWA

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

		BENTYL					
AB	+	FOREST LABS INC	10MG	N007409	003	Oct 15, 1984	Apr CAHN
		INJECTABLE; INJECTION					
		BENTYL					
AP	+	FOREST LABS INC	10MG/ML	N008370	001	Oct 15, 1984	Apr CAHN
		BENTYL PRESERVATIVE FREE					
AP	+	FOREST LABS INC	10MG/ML	N008370	002	Oct 15, 1984	Apr CAHN
		DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE-FREE)					
AP		EUROHLTH INTL	10MG/ML	A040465	001	Jun 30, 2003	Aug CAHN
		TABLET; ORAL					
		BENTYL					
AB	+	FOREST LABS INC	20MG	N007409	001	Oct 15, 1984	Apr CAHN

DIGOXININJECTABLE; INJECTION
LANOXIN

AP + COVIS INJECTABLES 0.25MG/ML N009330 002 Apr CAHN

LANOXIN PEDIATRIC

+ COVIS INJECTABLES 0.1MG/ML N009330 004 Apr CAHN

TABLET; ORAL

DIGOXIN

>A> AB HIKMA INTL PHARMS 0.125MG A077002 002 Oct 30, 2007 Sep CAHN

>A> AB 0.25MG A077002 001 Oct 30, 2007 Sep CAHN

>D> AB HIKMA PHARMS 0.125MG A077002 002 Oct 30, 2007 Sep CAHN

>D> AB 0.25MG A077002 001 Oct 30, 2007 Sep CAHN

>D> @ MYLAN PHARMS INC 0.125MG A040282 001 Dec 23, 1999 Sep CMFD

>A> 0.125MG A040282 001 Dec 23, 1999 Sep CMFD

>D> @ 0.25MG A040282 002 Dec 23, 1999 Sep CMFD

>A> 0.25MG A040282 002 Dec 23, 1999 Sep CMFD

@ SUN PHARM INDS INC 0.125MG A076363 001 Jan 31, 2003 Jul CAHN

@ 0.25MG A076363 002 Jan 31, 2003 Jul CAHN

LANOXIN

COVIS PHARMA 0.0625MG N020405 001 Sep 30, 1997 Jan CMFD

0.1875MG N020405 003 Sep 30, 1997 Jan CMFD

DILTIAZEM HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HYDROCHLORIDE

>A> AB3 ACTAVIS ELIZABETH 360MG A202463 001 Dec 07, 2012 Sep CAHN

>D> AB3 ACTAVIS INC 360MG A202463 001 Dec 07, 2012 Sep CAHN

@ NESHER PHARMS 120MG A076563 002 Sep 12, 2006 Mar DISC

@ 180MG A076563 003 Sep 12, 2006 Mar DISC

@ 240MG A076563 004 Sep 12, 2006 Mar DISC

@ 300MG A076563 005 Sep 12, 2006 Mar DISC

@ 360MG A076563 006 Sep 12, 2006 Mar DISC

@ 420MG A076563 001 Sep 12, 2006 Mar DISC

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

@ AGILA SPECLTS 5MG/ML A075375 001 Sep 30, 1999 Feb CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

@ INTL MEDICATION 50MG/ML A084094 001 Jun DISC

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AKPRO

@ AKORN 0.1% A074382 001 Sep 29, 1995 Jun DISC

DIPIVEFRIN HYDROCHLORIDE

@ FALCON PHARMS 0.1% A073636 001 Jun 30, 1994 Jun DISC

PROPINE

@ ALLERGAN 0.1% N018239 001 Jun DISC

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

@ GLENMARK GENERICS 25MG A088999 001 Feb 05, 1991 Mar DISC

@ 50MG A089000 001 Feb 05, 1991 Mar DISC

@ 75MG A089001 001 Feb 05, 1991 Mar DISC

@ WATSON LABS 50MG A087160 001 Jun 07, 1996 May DISC

DISULFIRAM

TABLET; ORAL

DISULFIRAM

AB ROXANE 250MG A202652 001 Feb 05, 2014 Jan NEWA

AB 500MG A202652 002 Feb 05, 2014 Jan NEWA

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

AB AUROBINDO PHARMA LTD EQ 250MG VALPROIC ACID A202419 001 Jun 02, 2014 May NEWA

AB EQ 500MG VALPROIC ACID A202419 002 Jun 02, 2014 May NEWA

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
DOBUTAMINE HYDROCHLORIDE

AP	EUROHLTH INTL	EQ 12.5MG BASE/ML	A074277	001	Oct 31, 1994	Aug CAHN
	@ WATSON LABS	EQ 12.5MG BASE/ML	A074114	001	Nov 30, 1993	May DISC

DOCETAXEL

INJECTABLE; INJECTION
DOCETAXEL

	ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011	Jul CTEC
		80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011	Jul CTEC
AP	+	160MG/8ML (20MG/ML)	N201195	005	Apr 20, 2012	Aug CRLD
	PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014	Mar NEWA
		80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014	Mar NEWA
		130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014	Mar NEWA
		200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014	Mar NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL
DONEPEZIL HYDROCHLORIDE

AB	JUBILANT GENERICS	5MG	A090768	001	May 31, 2011	Jul CAHN
AB		10MG	A090768	002	May 31, 2011	Jul CAHN
AB	MACLEODS PHARMS LTD	23MG	A202631	001	Jan 22, 2014	Jan NEWA

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE

>A>	AT	WATSON LABS INC	EQ 2% BASE	A202053	001	Sep 11, 2014	Sep NEWA
-----	----	-----------------	------------	---------	-----	--------------	----------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

>A>	AT	AKORN INC	EQ 2% BASE; EQ 0.5% BASE	A203058	001	Sep 22, 2014	Sep NEWA
	AT	WATSON LABS INC	EQ 2% BASE; EQ 0.5% BASE	A202054	001	Sep 03, 2014	Aug NEWA

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION
DOXAPRAM HYDROCHLORIDE
@ WATSON LABS

	20MG/ML	A073529	001	Jan 30, 1992	May DISC
--	---------	---------	-----	--------------	----------

DOXAZOSIN MESYLATE

TABLET; ORAL
DOXAZOSIN MESYLATE

AB	ACCORD HLTHCARE	EQ 1MG BASE	A202824	001	Jun 11, 2014	May NEWA
AB		EQ 2MG BASE	A202824	002	Jun 11, 2014	May NEWA
AB		EQ 4MG BASE	A202824	003	Jun 11, 2014	May NEWA
AB		EQ 8MG BASE	A202824	004	Jun 11, 2014	May NEWA

DOXERCALCIFEROL

INJECTABLE; INJECTION
DOXERCALCIFEROL

AP	SANDOZ	4MCG/2ML (2MCG/ML)	A091333	001	May 05, 2014	Apr NEWA
AP		4MCG/2ML (2MCG/ML)	A200926	001	Feb 04, 2014	Jan NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
DOXORUBICIN HYDROCHLORIDE

AP	ACTAVIS INC	2MG/ML	A203622	001	Jun 27, 2014	Jun NEWA	
AP	+	EUROHLTH INTL	2MG/ML	A062975	001	Mar 17, 1989	Aug CAHN
AP	+	10MG/VIAL	A062921	001	Mar 17, 1989	Aug CAHN	
AP	+	20MG/VIAL	A062921	002	Mar 17, 1989	Aug CAHN	
AP	+	50MG/VIAL	A062921	003	Mar 17, 1989	Aug CAHN	
AP	+	200MG/100ML	A064097	001	Sep 13, 1994	Aug CAHN	
AP	PHARMACHEMIE BV	2MG/ML	A063336	001	Feb 28, 1995	Feb CAHN	
AP		10MG/VIAL	A063097	001	May 21, 1990	Feb CAHN	
AP		20MG/VIAL	A063097	002	May 21, 1990	Feb CAHN	
AP		50MG/VIAL	A063097	003	May 21, 1990	Feb CAHN	
AP		200MG/100ML	A063336	004	Feb 28, 1995	Feb CAHN	

DOXYCYCLINECAPSULE;ORAL
DOXYCYCLINE

AB	LUPIN LTD	EQ 50MG BASE	A204234	001	Mar 05, 2014	Feb NEWA
AB		EQ 75MG BASE	A204234	002	Mar 05, 2014	Feb NEWA
AB		EQ 100MG BASE	A204234	003	Mar 05, 2014	Feb NEWA
	@ WATSON LABS	EQ 50MG BASE	A065041	001	Apr 28, 2000	May DISC
	@	EQ 100MG BASE	A065041	002	Apr 28, 2000	May DISC
	ORACEA					
+	GALDERMA LABS LP	40MG	N050805	001	May 26, 2006	Jul CTEC

DOXYCYCLINE HYCLATECAPSULE;ORAL
DOXYCYCLINE HYCLATE

>A>	+	HIKMA INTL PHARMS	EQ 20MG BASE	A065103	001	May 13, 2005	Sep CAHN
>A>	AB		EQ 50MG BASE	A062396	002	Nov 07, 1984	Sep CAHN
>A>	AB		EQ 100MG BASE	A062396	001	May 07, 1984	Sep CAHN
>D>	AB	HIKMA PHARMS	EQ 50MG BASE	A062396	002	Nov 07, 1984	Sep CAHN
>D>	AB		EQ 100MG BASE	A062396	001	May 07, 1984	Sep CAHN
>D>	+	HIKMA PHARMS LLC	EQ 20MG BASE	A065103	001	May 13, 2005	Sep CAHN
	AB	MYLAN	EQ 50MG BASE	A062337	001	Mar 29, 1982	Jul CMFD
	AB		EQ 100MG BASE	A062337	002	Mar 29, 1982	Jul CMFD

INJECTABLE;INJECTION
DOXYCYCLINE

AP	+	EUROHLTH INTL	EQ 100MG BASE/VIAL	A062569	001	Mar 09, 1988	Aug CAHN
	@		EQ 200MG BASE/VIAL	A062569	002	Mar 09, 1988	Aug CAHN

TABLET;ORAL
ACTICLATE

		AQUA PHARMS LLC	EQ 75MG BASE	N205931	001	Jul 25, 2014	Jul NEWA	
			EQ 150MG BASE	N205931	002	Jul 25, 2014	Jul NEWA	
		DOXYCYCLINE HYCLATE						
>A>	AB	+	HIKMA INTL PHARMS	EQ 100MG BASE	A065095	001	Jul 02, 2003	Sep CAHN
>D>	AB	+	HIKMA PHARMS	EQ 100MG BASE	A065095	001	Jul 02, 2003	Sep CAHN
	AB		MYLAN	EQ 100MG BASE	A062432	001	Feb 15, 1983	Jul CMFD

TABLET, DELAYED RELEASE;ORAL
DORYX

AB		MAYNE PHARMA	EQ 150MG BASE	N050795	003	Jun 20, 2008	Feb CRLD
	+		EQ 200MG BASE	N050795	005	Apr 11, 2013	Feb CRLD

DRONABINOLCAPSULE;ORAL
DRONABINOL

AB		AKORN INC	2.5MG	A079217	001	Jun 20, 2014	Jun NEWA
AB			5MG	A079217	002	Jun 20, 2014	Jun NEWA
AB			10MG	A079217	003	Jun 20, 2014	Jun NEWA

DROSPIRENONE; ETHINYL ESTRADIOLTABLET;ORAL
NIKKI

AB		LUPIN LTD	3MG;0.02MG	A201661	001	May 27, 2014	May NEWA
----	--	-----------	------------	---------	-----	--------------	----------

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUMTABLET;ORAL
BEYAZ

		BAYER HLTHCARE	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	N022532	001	Sep 24, 2010	Jul CRLD
		SAFYRAL					
+		BAYER HLTHCARE	3MG,N/A;0.03MG,N/A;0.451MG,0.451MG	N022574	001	Dec 16, 2010	Jul CRLD

DROXIDOPACAPSULE;ORAL
NORTHERA

		CHELSEA THERAPS INC	100MG	N203202	001	Feb 18, 2014	Feb NEWA
			200MG	N203202	002	Feb 18, 2014	Feb NEWA
	+		300MG	N203202	003	Feb 18, 2014	Feb NEWA
		LUNDBECK NA LTD	100MG	N203202	001	Feb 18, 2014	Jun CAHN
			200MG	N203202	002	Feb 18, 2014	Jun CAHN
	+		300MG	N203202	003	Feb 18, 2014	Jun CAHN

DULOXETINE HYDROCHLORIDECAPSULE, DELAYED REL PELLETS;ORAL
DULOXETINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 20MG BASE	A202949	001	Jun 09, 2014	May NEWA
AB		EQ 30MG BASE	A202949	002	Jun 09, 2014	May NEWA
AB		EQ 60MG BASE	A202949	003	Jun 09, 2014	May NEWA
AB	APOTEX INC	EQ 20MG BASE	A202045	001	Jun 11, 2014	May NEWA
AB		EQ 30MG BASE	A202045	002	Jun 11, 2014	May NEWA
AB		EQ 60MG BASE	A202045	003	Jun 11, 2014	May NEWA
AB	BRECKENRIDGE PHARM	EQ 20MG BASE	A203088	001	Jun 11, 2014	May NEWA
AB		EQ 30MG BASE	A203088	002	Jun 11, 2014	May NEWA
AB		EQ 60MG BASE	A203088	003	Jun 11, 2014	May NEWA

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDECAPSULE;ORAL
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB	ANCHEN PHARMS	0.5MG;0.4MG	A202509	001	Feb 26, 2014	Feb NEWA
	JALYN					
AB	+ GLAXOSMITHKLINE	0.5MG;0.4MG	N022460	001	Jun 14, 2010	Feb CFTG

ECONAZOLE NITRATEAEROSOL, FOAM;TOPICAL
ECOZA

	+ VELDANA MEDICAL SA	1%	N205175	001	Oct 24, 2013	Feb CAHN
	CREAM;TOPICAL					
	SPECTAZOLE					
	@ MERZ PHARMS LLC	1%	N018751	001	Dec 23, 1982	Jan CAHN

EFINACONAZOLESOLUTION;TOPICAL
JUBLIA

	+ DOW PHARM	10%	N203567	001	Jun 06, 2014	Jun NEWA
--	-------------	-----	---------	-----	--------------	----------

ELIGLUSTAT TARTRATECAPSULE;ORAL
CERDELGA

	+ GENZYME CORP	EQ 84MG BASE	N205494	001	Aug 19, 2014	Aug NEWA
--	----------------	--------------	---------	-----	--------------	----------

>A> ELVITEGRAVIR>A> TABLET;ORAL
>A> VITEKTA

>A>	GILEAD SCIENCES INC	85MG	N203093	001	Sep 24, 2014	Sep NEWA
>A>	+	150MG	N203093	002	Sep 24, 2014	Sep NEWA

EMPAGLIFLOZINTABLET;ORAL
JARDIANCE

	BOEHRINGER INGELHEIM	10MG	N204629	001	Aug 01, 2014	Aug NEWA
	+	25MG	N204629	002	Aug 01, 2014	Aug NEWA

ENALAPRIL MALEATETABLET;ORAL
ENALAPRIL MALEATE

	@ WATSON LABS	2.5MG	A075501	001	Aug 22, 2000	May DISC
	@	5MG	A075501	002	Aug 22, 2000	May DISC
	@	10MG	A075501	003	Aug 22, 2000	May DISC
	@	20MG	A075501	004	Aug 22, 2000	May DISC

ENOXAPARIN SODIUMINJECTABLE;SUBCUTANEOUS
ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP	TEVA	30MG/0.3ML (100MG/ML)	A076726	001	Jun 23, 2014	Jun NEWA
AP		40MG/0.4ML (100MG/ML)	A076726	002	Jun 23, 2014	Jun NEWA
AP		60MG/0.6ML (100MG/ML)	A076726	003	Jun 23, 2014	Jun NEWA
AP		80MG/0.8ML (100MG/ML)	A076726	004	Jun 23, 2014	Jun NEWA
AP		100MG/ML (100MG/ML)	A076726	005	Jun 23, 2014	Jun NEWA
AP		120MG/0.8ML (150MG/ML)	A076726	006	Jun 23, 2014	Jun NEWA
AP		150MG/ML (150MG/ML)	A076726	007	Jun 23, 2014	Jun NEWA

ENTECAVIRTABLET; ORAL
BARACLUDE

AB		BRISTOL MYERS SQUIBB	0.5MG	N021797	001	Mar 29, 2005	Aug CFTG
AB	+		1MG	N021797	002	Mar 29, 2005	Aug CFTG
		ENTECAVIR					
AB		TEVA PHARMS USA	0.5MG	A202122	001	Aug 26, 2014	Aug NEWA
AB			1MG	A202122	002	Aug 26, 2014	Aug NEWA

EPINASTINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
EPINASTINE HYDROCHLORIDE

>A>	AT	GAVIS PHARMS LLC	0.05%	A090951	001	Oct 31, 2011	Sep CAHN
>D>	AT	TESA PHARMS LLC	0.05%	A090951	001	Oct 31, 2011	Sep CAHN
	AT		0.05%	A090951	001	Oct 31, 2011	Jul CAHN

EPINEPHRINEINJECTABLE; INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS
ADRENALIN

	+	PAR STERILE PRODUCTS	1MG/ML	N204200	001	Dec 07, 2012	Apr CAHN
		INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS					
		ADRENALIN					
	+	PAR STERILE PRODUCTS	30MG/30ML (1MG/ML)	N204640	001	Dec 18, 2013	Apr CAHN

EPINEPHRINE HYDROCHLORIDEINJECTABLE; INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS
ADRENALIN

	+	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jul CAIN
		INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS					
		ADRENALIN					
	+	PAR STERILE PRODUCTS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Jul CAIN
		SOLUTION; IV (INFUSION)					
		EPINEPHRINE					
		BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Jul NEWA

EPIRUBICIN HYDROCHLORIDEINJECTABLE; INJECTION
EPIRUBICIN HYDROCHLORIDE

AP		ACTAVIS ELIZABETH	10MG/5ML (2MG/ML)	A065445	001	Sep 18, 2008	Aug CAHN
AP			50MG/25ML (2MG/ML)	A065445	002	Sep 18, 2008	Aug CAHN
AP			200MG/100ML (2MG/ML)	A065445	003	Sep 18, 2008	Aug CAHN
AP		EUROHLTH INTL	50MG/25ML (2MG/ML)	A065289	001	Jun 27, 2007	Aug CAHN
AP			200MG/100ML (2MG/ML)	A065289	002	Jun 27, 2007	Aug CAHN
		@ HOSPIRA	50MG/25ML (2MG/ML)	A065343	002	Apr 19, 2007	May DISC
		@ MUSTAFA NEVSAT	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011	Mar DISC
		@	200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011	Mar DISC
		INJECTABLE; IV (INFUSION)					
		EPIRUBICIN HYDROCHLORIDE					
		@ HOSPIRA	50MG/VIAL	N050807	001	Sep 15, 2006	Jun DISC

ERGOCALCIFEROLCAPSULE; ORAL
ERGOCALCIFEROL

AA		STRIDES PHARMA	50,000 IU	A090455	001	Aug 03, 2010	Aug CAHN
----	--	----------------	-----------	---------	-----	--------------	----------

ERGOLOID MESYLATESTABLET; SUBLINGUAL
ERGOLOID MESYLATES
@ WATSON LABS

0.5MG	A087233	001		May DISC
-------	---------	-----	--	----------

ERLOTINIB HYDROCHLORIDETABLET; ORAL
ERLOTINIB HYDROCHLORIDE

AB		MYLAN PHARMS INC	EQ 25MG BASE	A091002	001	Jun 11, 2014	May NEWA
AB			EQ 100MG BASE	A091002	002	Jun 11, 2014	May NEWA
AB			EQ 150MG BASE	A091002	003	Jun 11, 2014	May NEWA
		TARCEVA					
AB		OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004	May CFTG
AB			EQ 100MG BASE	N021743	002	Nov 18, 2004	May CFTG
AB	+		EQ 150MG BASE	N021743	003	Nov 18, 2004	May CFTG

ERYTHROMYCINCAPSULE, DELAYED REL PELLETS;ORAL
ERYTHROMYCIN

>D>	AB	ARBOR PHARMS INC	250MG	A 062746	001	Dec 22, 1986	Sep CAHN
>A>	AB	ARBOR PHARMS LLC	250MG	A 062746	001	Dec 22, 1986	Sep CAHN

SWAB;TOPICAL

ERYTHROMYCIN

@ FOUGERA PHARMS 2%

A 065320 001 Jul 25, 2006 May DISC

TABLET;ORAL

ERYTHROMYCIN

>D>		ARBOR PHARMS INC	250MG	A 061621	001		Sep CAHN
>D>	+		500MG	A 061621	002		Sep CAHN
>A>		ARBOR PHARMS LLC	250MG	A 061621	001		Sep CAHN
>A>	+		500MG	A 061621	002		Sep CAHN

TABLET, COATED PARTICLES;ORAL

PCE

>D>		ARBOR PHARMS INC	333MG	N 050611	001	Sep 09, 1986	Sep CAHN
>D>	+		500MG	N 050611	002	Aug 22, 1990	Sep CAHN
>A>		ARBOR PHARMS LLC	333MG	N 050611	001	Sep 09, 1986	Sep CAHN
>A>	+		500MG	N 050611	002	Aug 22, 1990	Sep CAHN

TABLET, DELAYED RELEASE;ORAL

ERY-TAB

>D>	+	ARBOR PHARMS LLC	333MG	A 062298	003	Mar 29, 1982	Sep CRLD
>D>	+		333MG	A 062298	003	Mar 29, 1982	Sep CRLD
>D>	+		333MG	A 062298	003	Mar 29, 1982	Sep CRLD
>D>	+		333MG	A 062298	003	Mar 29, 1982	Sep CRLD
>D>	+		333MG	A 062298	003	Mar 29, 1982	Sep CRLD
>A>			333MG	A 062298	003	Mar 29, 1982	Sep CRLD
>D>			500MG	A 062298	002		Sep CRLD
>A>	+		500MG	A 062298	002		Sep CRLD

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

E.E.S.

>D>	AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	N 050207	001		Sep CAHN
>A>	AB	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	N 050207	001		Sep CAHN

ERYPED

>D>	AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	N 050207	003	Mar 30, 1987	Sep CAHN
>D>	+		EQ 400MG BASE/5ML	N 050207	002		Sep CAHN
>A>	AB	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	N 050207	003	Mar 30, 1987	Sep CAHN
>A>	+		EQ 400MG BASE/5ML	N 050207	002		Sep CAHN

SUSPENSION;ORAL

E.E.S. 200

>D>	AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	A 061639	001		Sep CAHN
>A>	AB	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	A 061639	001		Sep CAHN

E.E.S. 400

>D>	AB	+	ARBOR PHARMS INC	EQ 400MG BASE/5ML	A 061639	002	Sep CAHN
>A>	AB	+	ARBOR PHARMS LLC	EQ 400MG BASE/5ML	A 061639	002	Sep CAHN

PEDIAMYCIN

>D>	AB	ARBOR PHARMS INC	EQ 200MG BASE/5ML	A 062304	001		Sep CAHN
>A>	AB	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	A 062304	001		Sep CAHN

PEDIAMYCIN 400

>D>	AB	ARBOR PHARMS INC	EQ 400MG BASE/5ML	A 062304	002		Sep CAHN
>A>	AB	ARBOR PHARMS LLC	EQ 400MG BASE/5ML	A 062304	002		Sep CAHN

TABLET;ORAL

E.E.S. 400

>D>		@ ARBOR PHARMS INC	EQ 400MG BASE	A 061905	001		Sep CAHN
>D>	BX	+	EQ 400MG BASE	A 061905	002	Aug 12, 1982	Sep CAHN
>A>		@ ARBOR PHARMS LLC	EQ 400MG BASE	A 061905	001		Sep CAHN
>A>	BX	+	EQ 400MG BASE	A 061905	002	Aug 12, 1982	Sep CAHN

ERYTHROMYCIN ETHYLSUCCINATE

>D>	BX	+	ARBOR PHARMS INC	EQ 400MG BASE	A 061904	001	Sep CAHN
>A>	BX	+	ARBOR PHARMS LLC	EQ 400MG BASE	A 061904	001	Sep CAHN

ERYTHROMYCIN LACTOBIONATE

INJECTABLE;INJECTION

ERYTHROCIN

	+	HOSPIRA	EQ 1GM BASE/VIAL	A 062638	002	Oct 31, 1986	May CTEC
--	---	---------	------------------	----------	-----	--------------	----------

ERYTHROMYCIN STEARATE

TABLET;ORAL

ERYTHROCIN STEARATE

>D>	@ ARBOR PHARMS INC	EQ 125MG BASE	A 060359	002		Sep CAHN
>D>	+	EQ 250MG BASE	A 060359	001		Sep CAHN
>D>	@	EQ 500MG BASE	A 060359	003		Sep CAHN
>A>	@ ARBOR PHARMS LLC	EQ 125MG BASE	A 060359	002		Sep CAHN
>A>	+	EQ 250MG BASE	A 060359	001		Sep CAHN
>A>	@	EQ 500MG BASE	A 060359	003		Sep CAHN
	ERYTHROMYCIN STEARATE					
	@ ANI PHARMS INC	EQ 250MG BASE	A 061461	001		Feb CAHN
	@	EQ 250MG BASE	A 061591	001		Jan CAHN
	@	EQ 500MG BASE	A 061461	002		Feb CAHN
	@	EQ 500MG BASE	A 063179	001	May 15, 1990	Feb CAHN

ESCITALOPRAM OXALATE

TABLET;ORAL

ESCITALOPRAM OXALATE

AB	JUBILANT GENERICS	EQ 5MG BASE	A 202280	001	Sep 12, 2012	Aug CAHN
AB		EQ 10MG BASE	A 202280	002	Sep 12, 2012	Aug CAHN
AB		EQ 20MG BASE	A 202280	003	Sep 12, 2012	Aug CAHN
AB	TEVA PHARMS USA	EQ 5MG BASE	A 076765	001	Mar 14, 2012	Feb CAHN
AB		EQ 10MG BASE	A 076765	002	Mar 14, 2012	Feb CAHN
AB		EQ 20MG BASE	A 076765	003	Mar 14, 2012	Feb CAHN

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

ESMOLOL HYDROCHLORIDE

AP	EUROHLTH INTL	10MG/ML	A 076323	001	Aug 10, 2004	Aug CAHN
----	---------------	---------	----------	-----	--------------	----------

ESTRADIOL

GEL;TOPICAL

ESTROGEL

@ ASCEND THERAPS US

0.06%

N 021166 001 Feb 09, 2004 May CAHN

GEL;TRANSDERMAL

DIVIGEL

VERTICAL PHARMS LLC

0.1% (0.25GM/PACKET)

N 022038 001 Jun 04, 2007 Apr CAHN

0.1% (0.5GM/PACKET)

N 022038 002 Jun 04, 2007 Apr CAHN

+

0.1% (1GM/PACKET)

N 022038 003 Jun 04, 2007 Apr CAHN

GEL, METERED;TRANSDERMAL

ESTROGEL

+ ASCEND THERAPS US

0.06% (1.25GM/ACTIVATION)

N 021166 002 Feb 09, 2004 May CAHN

SPRAY;TRANSDERMAL

EVAMIST

+ LUMARA HEALTH INC

1.53MG/SPRAY

N 022014 001 Jul 27, 2007 May CAHN

ESTRADIOL CYPIONATE

INJECTABLE;INJECTION

DEPO-ESTRADIOL

+ PHARMACIA AND UPJOHN

5MG/ML

A 085470 003

May CTEC

ESTRADIOL CYPIONATE

@ WATSON LABS

5MG/ML

A 085620 001

May DISC

ESTRADIOL VALERATE

INJECTABLE;INJECTION

DELESTROGEN

AO + PAR STERILE PRODUCTS 10MG/ML

N 009402 002

Apr CAHN

AO + 20MG/ML

N 009402 004

Apr CAHN

AO + 40MG/ML

N 009402 003

Apr CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

ACTIVEVLLA

AB AMNEAL PHARMS LLC 0.5MG;0.1MG

N 020907 002 Dec 28, 2006

Jun CAHN

AB + 1MG;0.5MG

N 020907 001 Nov 18, 1998

Jun CAHN

ESTRADIOL; NORGESTIMATE

TABLET; ORAL

ESTRADIOL AND NORGESTIMATE

>D>	AB	BARR	1MG, 1MG; N/A, 0.09MG	A076812	001	Apr 29, 2005	Sep CRLD	
>A>	AB	+	1MG, 1MG; N/A, 0.09MG	A076812	001	Apr 29, 2005	Sep CRLD	
>D>		PREFEST						
>D>	AB	+	TEVA WOMENS	1MG, 1MG; N/A, 0.09MG	N021040	001	Oct 22, 1999	Sep DISC
>A>		@	1MG, 1MG; N/A, 0.09MG	N021040	001	Oct 22, 1999	Sep DISC	

ESTROPIPATE

TABLET; ORAL

ESTROPIPATE

@ WATSON LABS

6MG

A081216 001 Sep 23, 1993 May DISC

OGEN 5

PHARMACIA AND UPJOHN

6MG

A083220 004 May CTEC

ORTHO-EST

@ SUN PHARM INDS INC

0.75MG

A089567 001 Feb 27, 1991 Jun CAHN

@

1.5MG

A089582 001 Jul 17, 1991 Jun CAHN

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

AB DR REDDYS LABS LTD

1MG

A091024 001 Apr 15, 2014 Mar NEWA

AB

2MG

A091024 002 Apr 15, 2014 Mar NEWA

AB

3MG

A091024 003 Apr 15, 2014 Mar NEWA

AB GLENMARK GENERICS

1MG

A091166 001 Apr 15, 2014 Mar NEWA

AB

2MG

A091166 002 Apr 15, 2014 Mar NEWA

AB

3MG

A091166 003 Apr 15, 2014 Mar NEWA

AB LUPIN LTD

1MG

A091124 001 Sep 13, 2011 Mar CMFD

AB

2MG

A091124 002 Sep 13, 2011 Mar CMFD

AB

3MG

A091124 003 Sep 13, 2011 Mar CMFD

AB ORCHID HLTHCARE

1MG

A091113 001 Jun 10, 2014 May NEWA

AB

2MG

A091113 002 Jun 10, 2014 May NEWA

AB

3MG

A091113 003 Jun 10, 2014 May NEWA

AB ROXANE

1MG

A091153 001 Apr 15, 2014 Mar NEWA

AB

2MG

A091153 002 Apr 15, 2014 Mar NEWA

AB

3MG

A091153 003 Apr 15, 2014 Mar NEWA

AB TEVA

1MG

A091169 001 May 23, 2011 Jan CMFD

AB

2MG

A091169 002 May 23, 2011 Jan CMFD

AB

3MG

A091169 003 May 23, 2011 Jan CMFD

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL

NUVARING

+ ORGANON USA INC 0.015MG/24HR; 0.12MG/24HR

N021187 001 Oct 03, 2001 Apr CPOT

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

SETLAKIN

>A> AB NOVAST LABS LTD 0.03MG; 0.15MG

A090716 001 Sep 15, 2014 Sep NEWA

TABLET; ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1 HAUPT PHARMA 0.02MG; 0.1MG

A201108 001 Feb 05, 2014 Jan NEWA

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

ORTHO EVRA

AB + JANSSEN PHARMS 0.035MG/24HR; 0.15MG/24HR

N021180 001 Nov 20, 2001 Mar CFTG

+ 0.035MG/24HR; 0.15MG/24HR

N021180 001 Nov 20, 2001 Mar CPOT

XULANE

AB MYLAN TECHNOLOGIES 0.035MG/24HR; 0.15MG/24HR

A200910 001 Apr 16, 2014 Mar NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/35E-21

@ WATSON LABS 0.035MG; 1MG

A071480 001 Apr 12, 1988 May DISC

NORETHINDRONE AND ETHINYL ESTRADIOL

@ WATSON LABS 0.035MG; 0.4MG

A078379 001 Feb 23, 2010 May DISC

@

0.035MG; 1MG

A070685 001 Jan 29, 1987 May DISC

TABLET;ORAL-21							
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)							
	@ WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071043	001	Apr 01, 1988	May	DISC
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)							
	@ WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071041	001	Sep 24, 1991	May	DISC
TABLET;ORAL-28							
NORETHIN 1/35E-28							
	@ WATSON LABS	0.035MG;1MG	A071481	001	Apr 12, 1988	May	DISC
NORETHINDRONE AND ETHINYL ESTRADIOL							
	@ WATSON LABS	0.035MG,0.035MG,0.035MG;0.5MG,0.75 MG,1MG	A076393	001	Feb 04, 2010	May	DISC
NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)							
	@ WATSON LABS	0.035MG,0.035MG;0.5MG,1MG	A071042	001	Sep 24, 1991	May	DISC
TABLET, CHEWABLE;ORAL							
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB	FAMY CARE LTD	0.025MG;0.8MG	A203371	001	Apr 23, 2014	Apr	NEWA
AB	+ WARNER CHILCOTT	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Apr	CFTG
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE</u>							
TABLET;ORAL-21							
GILDESS 1.5/30							
AB	VINTAGE PHARMS LLC	0.03MG;1.5MG	A077075	002	Jul 24, 2012	Mar	NEWA
GILDESS 1/20							
AB	VINTAGE PHARMS LLC	0.02MG;1MG	A077077	002	Jul 24, 2012	Mar	NEWA
LARIN 1.5/30							
AB	NOVAST LABS LTD	0.03MG;1.5MG	A202996	001	Mar 20, 2014	Mar	NEWA
LOESTRIN 21 1.5/30							
	@ WARNER CHILCOTT LLC	0.03MG;1.5MG	N017875	001		May	DISC
LOESTRIN 21 1/20							
	@ WARNER CHILCOTT LLC	0.02MG;1MG	N017876	001		May	DISC
TABLET;ORAL-28							
LOESTRIN FE 1.5/30							
	@ WARNER CHILCOTT LLC	0.03MG;1.5MG	N017355	001		May	DISC
LOESTRIN FE 1/20							
	@ WARNER CHILCOTT	0.02MG;1MG	N017354	001		May	DISC
MICROGESTIN FE 1.5/30							
AB	+ WATSON LABS	0.03MG;1.5MG	A075548	001	Feb 05, 2001	May	CRLD
<u>ETHINYL ESTRADIOL; NORGESTIMATE</u>							
TABLET;ORAL-28							
NORGESTIMATE AND ETHINYL ESTRADIOL							
	@ WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.2 15MG,0.25MG	A090479	001	Mar 09, 2011	May	DISC
	@	0.035MG,0.035MG,0.035MG;0.18MG,0.2 15MG,0.25MG	A076626	001	Aug 17, 2006	May	DISC
	@	0.035MG;0.25MG	A076627	001	Aug 17, 2006	May	DISC
<u>ETHINYL ESTRADIOL; NORGESTREL</u>							
TABLET;ORAL-21							
LOW-OGESTREL-21							
	@ WATSON LABS	0.03MG;0.3MG	A075288	001	Jul 28, 1999	May	DISC
TABLET;ORAL-28							
LOW-OGESTREL-28							
	@ WATSON LABS	0.03MG;0.3MG	A075288	002	Jul 28, 1999	May	DISC
<u>ETHIODIZED OIL</u>							
OIL;INTRALYMPHATIC, INTRAUTERINE							
ETHIODOL							
+	GUERBET	99%	N009190	001		Apr	CMFD
LIPIODOL							
+	GUERBET	99%	N009190	001		Apr	CTNA
<u>ETODOLAC</u>							
CAPSULE;ORAL							
ETODOLAC							
	@ ANI PHARMS INC	200MG	A074899	001	Jul 08, 1997	Feb	CAHN
	@	200MG	A075126	001	Sep 16, 1999	Jan	CAHN
	@	300MG	A074899	002	Jul 08, 1997	Feb	CAHN
AB		300MG	A075126	002	Sep 16, 1999	Jan	CAHN

TABLET, EXTENDED RELEASE;ORAL
ETODOLAC

AB	ZYDUS PHARMS USA INC	400MG	A091134	001	Jan 23, 2014	May NEWA
AB		500MG	A091134	002	Jan 23, 2014	May NEWA
AB		600MG	A091134	003	Jan 23, 2014	May NEWA

ETOMIDATE

INJECTABLE;INJECTION
ETOMIDATE

AP	AGILA SPECLTS	2MG/ML	A078289	001	Jan 02, 2009	Feb CAHN
AP	EMCURE PHARMS LTD	2MG/ML	A204618	001	Aug 13, 2014	Aug NEWA
AP	PAR STERILE PRODUCTS	2MG/ML	A091297	001	Jun 20, 2012	Jul CAHN
AP	ZYDUS PHARMS USA INC	2MG/ML	A202360	001	Jul 18, 2014	Jul NEWA

ETOPOSIDE

CAPSULE;ORAL
VEPESID

>D>	@ CORDEN PHARMA	50MG	N019557	001	Dec 30, 1986	Sep CAHN
>D>	@	100MG	N019557	002	Dec 30, 1986	Sep CAHN
>A>	@ DAVA PHARMS INC	50MG	N019557	001	Dec 30, 1986	Sep CAHN
>A>	@	100MG	N019557	002	Dec 30, 1986	Sep CAHN

INJECTABLE;INJECTION
ETOPOSIDE

AP	EUROHLTH INTL	20MG/ML	A074290	001	Jul 17, 1995	Aug CAHN
	@ PHARMACHEMIE BV	20MG/ML	A074227	001	Feb 22, 1996	Feb CAHN
	@ TEVA PHARMS USA	20MG/ML	A074284	001	Feb 10, 1994	May DISC

EXEMESTANE

TABLET;ORAL
EXEMESTANE

AB	ALVOGEN INC	25MG	A200898	001	Jul 28, 2014	Aug CAHN
AB	EIRGEN PHARMA LTD	25MG	A200898	001	Jul 28, 2014	Jul NEWA

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
BYDUREON

+	ASTRAZENECA AB	2MG/VIAL	N022200	001	Jan 27, 2012	Jun CAHN
---	----------------	----------	---------	-----	--------------	----------

INJECTABLE;SUBCUTANEOUS
BYETTA

+	ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005	Mar CAHN
+		600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005	Mar CAHN

FAMCICLOVIR

TABLET;ORAL
FAMCICLOVIR

>A> AB	HETERO LABS LTD V	125MG	A202438	001	Sep 10, 2014	Sep NEWA
>A> AB		250MG	A202438	002	Sep 10, 2014	Sep NEWA
>A> AB		500MG	A202438	003	Sep 10, 2014	Sep NEWA

FAMOTIDINE

FOR SUSPENSION;ORAL
FAMOTIDINE

AB	HI-TECH PHARMA CO	40MG/5ML	A201995	001	May 30, 2014	May NEWA
----	-------------------	----------	---------	-----	--------------	----------

INJECTABLE;INJECTION

	FAMOTIDINE PRESERVATIVE FREE					
AP	BEDFORD LABS	10MG/ML	A075825	001	Apr 17, 2001	Feb CAHN

FENOFIBRATE

TABLET;ORAL
FENOGLIDE

	SANTARUS INC	40MG	N022118	001	Aug 10, 2007	Feb CAHN
+		120MG	N022118	002	Aug 10, 2007	Feb CAHN

TRIGLIDE

@	SKYEPHARMA AG	50MG	N021350	001	May 07, 2005	May DISC
---	---------------	------	---------	-----	--------------	----------

FENOLDOPAM MESYLATE

INJECTABLE;INJECTION
FENOLDOPAM MESYLATE

AP	EUROHLTH INTL	EQ 10MG BASE/ML	A076582	001	Oct 12, 2004	Aug CAHN
----	---------------	-----------------	---------	-----	--------------	----------

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

@ NOVEN 100MCG/HR

A077775 004 Oct 16, 2009 Apr DISC

FENTANYL-25

@ NOVEN 25MCG/HR

A077775 001 Oct 16, 2009 Apr DISC

FENTANYL-50

@ NOVEN 50MCG/HR

A077775 002 Oct 16, 2009 Apr DISC

FENTANYL-75

@ NOVEN 75MCG/HR

A077775 003 Oct 16, 2009 Apr DISC

FENTANYL CITRATE

TABLET;BUCCAL

FENTANYL CITRATE

@ WATSON LABS EQ 0.1MG BASE

A079075 001 Jan 07, 2011 May DISC

@ EQ 0.2MG BASE

A079075 002 Jan 07, 2011 May DISC

@ EQ 0.4MG BASE

A079075 003 Jan 07, 2011 May DISC

@ EQ 0.6MG BASE

A079075 004 Jan 07, 2011 May DISC

@ EQ 0.8MG BASE

A079075 005 Jan 07, 2011 May DISC

TABLET;BUCCAL, SUBLINGUAL

FENTANYL CITRATE

@ WATSON LABS EQ 0.1MG BASE

A079075 001 Jan 07, 2011 Jun CDFR

@ EQ 0.2MG BASE

A079075 002 Jan 07, 2011 Jun CDFR

@ EQ 0.4MG BASE

A079075 003 Jan 07, 2011 Jun CDFR

@ EQ 0.6MG BASE

A079075 004 Jan 07, 2011 Jun CDFR

@ EQ 0.8MG BASE

A079075 005 Jan 07, 2011 Jun CDFR

FENTORA

CEPHALON

EQ 0.1MG BASE

N021947 001 Sep 25, 2006 Jun CTEC

EQ 0.2MG BASE

N021947 002 Sep 25, 2006 Jun CTEC

+

EQ 0.4MG BASE

N021947 003 Sep 25, 2006 Jun CTEC

EQ 0.6MG BASE

N021947 004 Sep 25, 2006 Jun CTEC

EQ 0.8MG BASE

N021947 005 Sep 25, 2006 Jun CTEC

TABLET;SUBLINGUAL

FENTANYL CITRATE

@ WATSON LABS EQ 0.1MG BASE

A079075 001 Jan 07, 2011 May CDFR

@ EQ 0.2MG BASE

A079075 002 Jan 07, 2011 May CDFR

@ EQ 0.4MG BASE

A079075 003 Jan 07, 2011 May CDFR

@ EQ 0.6MG BASE

A079075 004 Jan 07, 2011 May CDFR

@ EQ 0.8MG BASE

A079075 005 Jan 07, 2011 May CDFR

>A>

FERRIC CITRATE

>A>

TABLET;ORAL

>A>

FERRIC CITRATE

>A>

+ KERYX BIOPHARMS

EQ 210MG IRON

N205874 001 Sep 05, 2014 Sep NEWA

FIDAXOMICIN

TABLET;ORAL

DIFICID

+ CUBIST PHARMS

200MG

N201699 001 May 27, 2011 Jul CAHN

FINASTERIDE

TABLET;ORAL

FINASTERIDE

AB ACTAVIS ELIZABETH

1MG

A078371 001 Nov 05, 2013 Aug CAHN

AB

5MG

A077914 001 Mar 28, 2007 Aug CAHN

FLECAINIDE ACETATE

TABLET;ORAL

TAMBOCOR

@ CNTY LINE PHARMS

50MG

N018830 004 Aug 23, 1988 Jul CAHN

@ 100MG

N018830 001 Oct 31, 1985 Jul CAHN

@ 150MG

N018830 003 Jun 03, 1988 Jul CAHN

@ 200MG

N018830 002 Oct 31, 1985 Jul CAHN

FLORBETABEN F-18

SOLUTION;INTRAVENOUS

NEURACEQ

+ PIRAMAL IMAGING

30ML (1.4-135mCi/ML)

N204677 001 Mar 19, 2014 Mar NEWA

FLOXURIDINEINJECTABLE; INJECTION
FLOXURIDINE

AP	+	EUROHLTH INTL	500MG/VIAL	A075387	001	Apr 16, 2000	Aug CAHN
----	---	---------------	------------	---------	-----	--------------	----------

FLUCONAZOLEINJECTABLE; INJECTION
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
@ TEVA PHARMS 200MG/100ML (2MG/ML)
@ 400MG/200ML (2MG/ML)

A076837	001	Jan 13, 2005	Apr DISC
A076837	002	Jan 13, 2005	Apr DISC

FLUDARABINE PHOSPHATEINJECTABLE; INJECTION
FLUDARABINE PHOSPHATE

AP		ACTAVIS ELIZABETH	50MG/VIAL	A078610	001	Feb 11, 2009	Aug CAHN
AP		MUSTAFA NEVZAT ILAC	50MG/2ML (25MG/ML)	A090724	001	Sep 27, 2010	May CAHN

FLUDEOXYGLUCOSE F-18INJECTABLE; INTRAVENOUS
FLUDEOXYGLUCOSE F18

AP		ESSENTIAL ISOTOPES	20-300mCi/ML	A203946	001	Feb 05, 2014	Jan NEWA
AP		LANTHEUS MEDICAL	20-200mCi/ML	A203664	001	Feb 04, 2014	Jan NEWA
>A> AP		MA GENERAL HOSP	20-300mCi/ML	A204333	001	Sep 25, 2014	Sep NEWA
AP		UCSF RODIOPHARM	20-300mCi/ML	A203902	001	May 09, 2014	Apr NEWA
AP		UIHC PET IMAGING	20-300mCi/ML	A203990	001	Aug 06, 2014	Jul NEWA
	@	WEILL MEDCL COLL	10-100mCi/ML	N021768	001	Aug 05, 2004	Feb DISC
AP		WUSM CYCLOTRON	20-300mCi/ML	A203935	001	Feb 05, 2014	Jan NEWA

FLUDROCORTISONE ACETATETABLET; ORAL
FLUDROCORTISONE ACETATE

AB		HIKMA PHARMS	0.1MG	A091302	001	Jul 22, 2011	Jan CAHN
----	--	--------------	-------	---------	-----	--------------	----------

FLUNISOLIDEAEROSOL, METERED; INHALATION
AEROSPAN HFA

+	MEDA PHARMS INC	0.078MG/INH	N021247	001	Jan 27, 2006	Aug CPOT
+		EQ 78MG BASE/INH	N021247	001	Jan 27, 2006	Mar CAHN

>A> FLUOCINOLONE ACETONIDEIMPLANT; INTRAVITREAL
ILUVIEN

>A>	+	ALIMERA SCIENCES INC	0.19MG	N201923	001	Sep 26, 2014	Sep NEWA
-----	---	----------------------	--------	---------	-----	--------------	----------

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATECREAM; TOPICAL
NEO-SYNALAR

+	MEDIMETRIKS PHARMS	0.025%; EQ 3.5MG BASE/GM	A060700	001		Apr CMFD
---	--------------------	--------------------------	---------	-----	--	----------

FLUOCINONIDECREAM; TOPICAL
FLUOCINONIDE

AB		FOUGERA PHARMS INC	0.1%	A200735	001	Jul 14, 2014	Jun NEWA
AB		GLENMARK GENERICS	0.1%	A091282	001	Jul 14, 2014	Jun NEWA
AB		TARO	0.1%	A200734	001	Jul 14, 2014	Jun NEWA

SOLUTION; TOPICAL
FLUOCINONIDE

AT		G AND W LABS INC	0.05%	A071535	001	Dec 02, 1988	May CAHN
		LIDEX					
AT		CNTY LINE PHARMS	0.05%	N018849	001	Apr 06, 1984	Apr CMFD

FLUOXETINE HYDROCHLORIDECAPSULE; ORAL
FLUOXETINE HYDROCHLORIDE

AB2		ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008	Jan CAHN
AB2			EQ 20MG BASE	A076287	002	May 20, 2008	Jan CAHN

TABLET; ORAL
SARAFEM

AB1		WARNER CHILCOTT LLC	EQ 10MG BASE	N021860	001	May 19, 2006	Jan CFTG
AB1			EQ 15MG BASE	N021860	002	May 19, 2006	Jan CFTG
AB1	+		EQ 20MG BASE	N021860	003	May 19, 2006	Jan CFTG

TABLET;ORAL
SELFEMRA

AB1	TEVA PHARMS USA	EQ 10MG BASE	A200151	001	Feb 03, 2014	Jan NEWA
AB1		EQ 15MG BASE	A200151	002	Feb 03, 2014	Jan NEWA
AB1		EQ 20MG BASE	A200151	003	Feb 03, 2014	Jan NEWA

FLUPHENAZINE DECANOATE

INJECTABLE;INJECTION
FLUPHENAZINE DECANOATE

AO	EUROHLTH INTL	25MG/ML	A074531	001	Aug 30, 1996	Aug CAHN
AO	PAR STERILE PRODUCTS	25MG/ML	A203732	001	Jul 03, 2014	Jun NEWA

FLUPHENAZINE HYDROCHLORIDE

ELIXIR;ORAL
FLUPHENAZINE HYDROCHLORIDE

@ ANI PHARMS INC	2.5MG/5ML	A081310	001	Apr 29, 1993	Feb CAHN
------------------	-----------	---------	-----	--------------	----------

FLURANDRENOLIDE

TAPE;TOPICAL
CORDRAN

>A>	+	WATSON LABS INC	0.004MG/SQ CM	N016455	001	Sep CAHN
>D>	+	WATSON PHARMS	0.004MG/SQ CM	N016455	001	Sep CAHN

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL
FLURAZEPAM HYDROCHLORIDE

MYLAN PHARMS INC	15MG	A070345	002	Nov 27, 1985	May CTEC
+	30MG	A070345	001	Nov 27, 1985	May CTEC
@ WATSON LABS	15MG	A071205	001	Nov 25, 1986	May DISC
@	30MG	A071068	001	Nov 25, 1986	May DISC
@	30MG	A072369	001	Mar 30, 1989	May DISC

FLURBIPROFEN

TABLET;ORAL
FLURBIPROFEN

AB	SUN PHARM INDS INC	50MG	A075058	001	Apr 27, 2001	Jul CAHN
AB		100MG	A075058	002	Apr 27, 2001	Jul CAHN

FLUTICASONE FUROATE

POWDER;INHALATION
ARNUITY ELLIPTA

GLAXOSMITHKLINE	0.1MG/INH	N205625	001	Aug 20, 2014	Aug NEWA
+	0.2MG/INH	N205625	002	Aug 20, 2014	Aug NEWA

FLUVOXAMINE MALEATE

TABLET;ORAL
FLUVOXAMINE MALEATE

@ SUN PHARM INDS INC	25MG	A075900	001	Feb 23, 2006	Jul CAHN
@	50MG	A075900	002	Feb 23, 2006	Jul CAHN
@	100MG	A075900	003	Feb 23, 2006	Jul CAHN

FOLIC ACID

TABLET;ORAL
FOLIC ACID

AA	CADILA PHARMS LTD	1 MG	A202437	001	Jan 27, 2014	Jan NEWA
----	-------------------	------	---------	-----	--------------	----------

FOLLITROPIN ALFA/BETA

INJECTABLE;SUBCUTANEOUS
GONAL-F RFF REDI-JECT

+	EMD SERONO	300 IU/0.5ML	N021684	001	May 25, 2004	May CTNA
+		450 IU/0.75ML	N021684	002	May 25, 2004	May CTNA
+		900 IU/1.5ML	N021684	003	May 25, 2004	May CTNA

FOMEPIZOLE

INJECTABLE;INJECTION
FOMEPIZOLE

@ MYLAN INSTITUTIONAL	1.5GM/1.5ML (1GM/ML)	A079033	001	Apr 07, 2009	Jun DISC
-----------------------	----------------------	---------	-----	--------------	----------

FONDAPARINUX SODIUMINJECTABLE;SUBCUTANEOUS
ARIXTRA

AP	+	AGI	2.5MG/0.5ML	N021345	001	Dec 07, 2001	May CAHN
AP	+		5MG/0.4ML	N021345	002	May 28, 2004	May CAHN
AP	+		7.5MG/0.6ML	N021345	003	May 28, 2004	May CAHN
AP	+		10MG/0.8ML	N021345	004	May 28, 2004	May CAHN

FOSINOPRIL SODIUM

TABLET;ORAL

FOSINOPRIL SODIUM

@	WATSON LABS	10MG	A077531	001	Aug 31, 2006	May DISC
@		20MG	A077531	002	Aug 31, 2006	May DISC
@		40MG	A077531	003	Aug 31, 2006	May DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB		EMCURE PHARMS INDIA	10MG;12.5MG	A079025	001	Sep 17, 2010	Feb CAIN
AB	+		20MG;12.5MG	A079025	002	Sep 17, 2010	Feb CAIN

FOSINOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	+	EMCURE PHARMS INDIA	20MG;12.5MG	A079025	002	Sep 17, 2010	Jan CRLD
----	---	---------------------	-------------	---------	-----	--------------	----------

FOSPHENYTOIN SODIUM

INJECTABLE;INJECTION

CEREBYX

AP		PARKE DAVIS	EQ 50MG PHENYTOIN NA/ML	N020450	001	Aug 05, 1996	Feb CMFD
AP		FOSPHENYTOIN SODIUM					
AP		AGILA SPECLTS	EQ 50MG PHENYTOIN NA/ML	A078736	001	Jun 08, 2010	Feb CAHN
AP		AMNEAL PHARMS CO	EQ 50MG PHENYTOIN NA/ML	A078476	001	Mar 18, 2008	Jun CAHN

FROVATRIPTAN SUCCINATE

TABLET;ORAL

FROVA

AB	+	ENDO PHARMS	EQ 2.5MG BASE	N021006	001	Nov 08, 2001	Aug CFTG
AB		FROVATRIPTAN SUCCINATE					
AB		MYLAN PHARMS INC	EQ 2.5MG BASE	A202931	001	Aug 28, 2014	Aug NEWA

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

AP		CLARIS LIFESCIENCES	10MG/ML	A202747	001	Jan 27, 2014	Jan NEWA
AP		EMCURE PHARMS LTD	10MG/ML	A203428	001	Aug 26, 2014	Aug NEWA

TABLET;ORAL

FUROSEMIDE

AB		CARACO	20MG	A091258	001	Apr 01, 2014	Mar NEWA
AB			40MG	A091258	002	Apr 01, 2014	Mar NEWA
AB			80MG	A091258	003	Apr 01, 2014	Mar NEWA
AB		SUN PHARM INDS INC	20MG	A091258	001	Apr 01, 2014	Jul CAHN
AB			40MG	A091258	002	Apr 01, 2014	Jul CAHN
AB			80MG	A091258	003	Apr 01, 2014	Jul CAHN
	@	WATSON LABS	20MG	A070412	001	Feb 26, 1986	May DISC
	@		20MG	A070449	001	Nov 22, 1985	May DISC
	@		20MG	A071379	001	Jan 02, 1987	May DISC
	@		40MG	A070450	001	Nov 22, 1985	May DISC
	@		80MG	A070528	001	Jan 07, 1986	May DISC
	@		80MG	A071594	001	Feb 09, 1988	May DISC

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

@	WATSON LABS	100MG	A075485	003	May 11, 2007	May DISC
@		300MG	A075485	002	May 11, 2007	May DISC
@		400MG	A075485	001	May 11, 2007	May DISC

TABLET;ORAL

GABAPENTIN

AB		ACI HEALTHCARE LTD	600MG	A203244	002	Jul 12, 2013	Feb CAHN
AB			800MG	A203244	001	Jul 12, 2013	Feb CAHN

GALANTAMINE HYDROBROMIDE

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

@ YABAO PHARM EQ 4MG BASE
 @ EQ 8MG BASE
 @ EQ 12MG BASE

A077604 001 Feb 06, 2009 May CAHN
 A077604 002 Feb 06, 2009 May CAHN
 A077604 003 Feb 06, 2009 May CAHN

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

GANCICLOVIR SODIUM

@ EUROHLTH INTL EQ 500MG BASE/VIAL

A076222 001 Jul 16, 2003 Aug CAHN

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

AT HI-TECH PHARMA CO 0.5%
 ZYMAR

A203189 001 Sep 03, 2014 Aug NEWA

>D> AT + ALLERGAN 0.3%
 >A> + 0.3%

N021493 001 Mar 28, 2003 Sep CTEC
 N021493 001 Mar 28, 2003 Sep CTEC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

AP ACTAVIS ELIZABETH EQ 1GM BASE/VIAL
 AP EQ 200MG BASE/VIAL

A079160 002 Jul 25, 2011 Aug CAHN
 A079160 001 Jul 25, 2011 Aug CAHN

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

AB SUN PHARM INDS INC 600MG
 @ WATSON LABS 600MG

A079239 001 Dec 29, 2008 Jun CAHN
 A074442 001 Apr 28, 1995 May DISC

GLATIRAMER ACETATEINJECTABLE; SUBCUTANEOUS
COPAXONE

+ TEVA PHARMS USA 40MG/ML

N020622 003 Jan 28, 2014 Jan NEWA

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

@ WATSON LABS 1MG
 @ 2MG
 @ 4MG

A077280 001 Feb 03, 2006 May DISC
 A077280 002 Feb 03, 2006 May DISC
 A077280 003 Feb 03, 2006 May DISC

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

AB SUN PHARM INDS INC 5MG
 AB 10MG
 @ WATSON LABS 5MG
 @ 10MG

A077820 001 Jul 11, 2006 Jul CAHN
 A077820 002 Jul 11, 2006 Jul CAHN
 A074370 001 Nov 22, 1994 May DISC
 A074370 002 Nov 22, 1994 May DISC

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB SUN PHARM INDS INC 2.5MG; 250MG
 AB 2.5MG; 500MG
 AB 5MG; 500MG

A077620 001 Jan 11, 2008 Jul CAHN
 A077620 002 Jan 11, 2008 Jul CAHN
 A077620 003 Jan 11, 2008 Jul CAHN

GLYBURIDE

TABLET; ORAL

GLYBURIDE

@ ACTAVIS ELIZABETH 1.5MG
 @ 3MG
 @ 6MG

A075947 001 Nov 14, 2002 Aug CAHN
 A075947 002 Nov 14, 2002 Aug CAHN
 A075947 003 Nov 14, 2002 Aug CAHN

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

AA	STASON PHARMS	1MG	A091182	001	Feb 03, 2014	Jan NEWA
AA		2MG	A091182	002	Feb 03, 2014	Jan NEWA
AA	VINTAGE PHARMS	1MG	A090020	001	Oct 19, 2011	Feb CAHN
AA		2MG	A090020	002	Oct 19, 2011	Feb CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP	BANNER PHARMACAPS	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Aug CAHN
>A> AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Sep CAHN
>D> AP	DSM PHARMS INC	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Sep CAHN
	@ SANDOZ	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808	001	Apr 29, 2008	Jun CAHN
AP	SANDOZ INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078835	001	Jun 30, 2008	Jun CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078835	002	Jun 30, 2008	Jun CAHN
	GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP	BANNER PHARMACAPS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Aug CAHN
	SOLUTION; ORAL					
	GRANISOL					
	@ PEDIATRAX	EQ 2MG BASE/10ML	A078334	001	Feb 28, 2008	Jul DISC
	+	EQ 2MG BASE/10ML	A078334	001	Feb 28, 2008	Jul CTNA

GRISEOFULVIN, ULTRAMICROSIZE

TABLET; ORAL

GRIS-PEG

>D> AB	PEDINOL	125MG	N050475	001		Sep CAHN
>D> AB	+	250MG	N050475	002		Sep CAHN
>A> AB	VALEANT PHARMS INC	125MG	N050475	001		Sep CAHN
>A> AB	+	250MG	N050475	002		Sep CAHN

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

	ANI PHARMS INC	EQ 4MG BASE	A074149	001	Apr 07, 1995	Jan CAHN
	@	EQ 4MG BASE	A074267	001	Jun 01, 1994	Mar CAHN
	+	EQ 8MG BASE	A074149	002	Apr 07, 1995	Jan CAHN
	@	EQ 8MG BASE	A074267	002	Jun 01, 1994	Mar CAHN

HALOBETASOL PROPIONATE

OINTMENT; TOPICAL

HALOBETASOL PROPIONATE

AB	TARO	0.05%	A076994	001	Dec 16, 2004	Apr CMFD
----	------	-------	---------	-----	--------------	----------

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

AO	AGILA SPECLTS	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000	Feb CMFD
AO		EQ 100MG BASE/ML	A075440	002	Feb 28, 2000	Feb CMFD
AO	EUROHLTH INTL	EQ 50MG BASE/ML	A074811	001	Jan 30, 1998	Aug CAHN
AO		EQ 100MG BASE/ML	A075305	001	Sep 28, 1998	Aug CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

AP	EUROHLTH INTL	EQ 5MG BASE/ML	A075858	001	Jun 18, 2001	Aug CAHN
----	---------------	----------------	---------	-----	--------------	----------

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM

	+	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	020	Mar 31, 2011	Mar NEWA
	+	HOSPIRA	5,000 UNITS/ML	A088100	001	Apr 28, 1983	Mar CRLD
	+	PFIZER	1,000 UNITS/ML	N201370	001	Jul 21, 2011	Mar CRLD
	+		5,000 UNITS/ML	N201370	002	Jul 21, 2011	Mar CRLD
	+		10,000 UNITS/ML	N201370	003	Jul 21, 2011	Mar CRLD
AP		SHENZHEN TECHDOW	1,000 UNITS/ML	A202957	001	Jun 12, 2014	Jun NEWA
AP			5,000 UNITS/ML	A202733	001	Jun 12, 2014	Jun NEWA
AP			5,000 UNITS/ML	A202957	002	Jun 12, 2014	Jun NEWA
AP			10,000 UNITS/ML	A203198	001	Jun 12, 2014	Jun NEWA

INJECTABLE; INJECTION
HEPARIN SODIUM

AP		20,000 UNITS/ML	A203198	002	Jun 12, 2014	Jun NEWA
		HEPARIN SODIUM IN PLASTIC CONTAINER				
AP	+	FRESENIUS KABI USA 1,000 UNITS/ML	N017029	013	Dec 05, 1985	Jun CTEC
	+	1,000 UNITS/ML	N017029	013	Dec 05, 1985	Mar CTEC
AP	+	10,000 UNITS/ML	N017029	015	Dec 05, 1985	Jun CTEC
	+	10,000 UNITS/ML	N017029	015	Dec 05, 1985	Mar CTEC
AP	+	20,000 UNITS/ML	N017029	016	Dec 05, 1985	Jun CTEC
	+	20,000 UNITS/ML	N017029	016	Dec 05, 1985	Mar CTEC
		HEPARIN SODIUM PRESERVATIVE FREE				
	+	FRESENIUS KABI USA 10,000 UNITS/ML	N017029	019	Nov 22, 2010	Mar NEWA
	+	HOSPIRA 10,000 UNITS/ML	A089522	001	May 04, 1987	Mar CTEC
	+	PFIZER 1,000 UNITS/ML	N201370	004	Jul 21, 2011	Mar CRLD
AP		SHENZHEN TECHDOW 1,000 UNITS/ML	A202732	001	Jun 12, 2014	Jun NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE
@ ACTAVIS ELIZABETH 1.5MG; 5MG

A040295 001 Dec 01, 2000 Aug CAHN

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL
HYDRALAZINE HYDROCHLORIDE

	@	ACTAVIS ELIZABETH 25MG	A088560	001	Oct 04, 1984	Aug CAHN
	@	50MG	A088649	001	Oct 18, 1984	Aug CAHN
>A>	AA	CADILA PHARMS LTD 25MG	A203845	001	Sep 18, 2014	Sep NEWA
>A>	AA	50MG	A203845	002	Sep 18, 2014	Sep NEWA
>A>	AA	100MG	A203845	003	Sep 18, 2014	Sep NEWA
		STRIDES PHARMA 25MG	A200770	001	May 03, 2013	Aug CAHN
		50MG	A200770	002	May 03, 2013	Aug CAHN
		100MG	A200770	003	May 03, 2013	Aug CAHN
	@	WATSON LABS 25MG	A084504	001		May DISC
	@	50MG	A084503	001		May DISC

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL
BIDIL

>D>	+	ARBOR PHARMS INC 37.5MG; 20MG	N020727	001	Jun 23, 2005	Sep CAHN
>A>	+	ARBOR PHARMS LLC 37.5MG; 20MG	N020727	001	Jun 23, 2005	Sep CAHN

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
HYDROCHLOROTHIAZIDE

AB		CARACO 12.5MG	A090651	001	Apr 07, 2014	Mar NEWA
>A>	@	HIKMA INTL PHARMS 12.5MG	A077885	001	Nov 26, 2007	Sep CAHN
>D>	@	HIKMA PHARMS LLC 12.5MG	A077885	001	Nov 26, 2007	Sep CAHN
AB		SUN PHARM INDS INC 12.5MG	A090651	001	Apr 07, 2014	Jul CAHN

TABLET; ORAL

		HYDROCHLOROTHIAZIDE				
AB		SCIEGEN PHARMS INC 25MG	A203018	001	Jul 23, 2014	Jul NEWA
AB		50MG	A203018	002	Jul 23, 2014	Jul NEWA
AB		SUN PHARM INDS INC 12.5MG	A040857	001	May 30, 2008	Jul CAHN
AB		25MG	A040810	001	Mar 27, 2007	Jul CAHN
AB		50MG	A040810	002	Mar 27, 2007	Jul CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL
IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB		PRINSTON INC 12.5MG; 150MG	A203072	001	May 09, 2014	Apr NEWA
AB		12.5MG; 300MG	A203072	002	May 09, 2014	Apr NEWA

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL
LISINAPRIL AND HYDROCHLOROTHIAZIDE

>A>	AB	HIKMA INTL PHARMS 12.5MG; 10MG	A076265	001	Jul 08, 2002	Sep CAHN
>A>	AB	12.5MG; 20MG	A076265	002	Jul 08, 2002	Sep CAHN
>A>	AB	25MG; 20MG	A076265	003	Jul 08, 2002	Sep CAHN
>D>	AB	HIKMA PHARMS LLC 12.5MG; 10MG	A076265	001	Jul 08, 2002	Sep CAHN
>D>	AB	12.5MG; 20MG	A076265	002	Jul 08, 2002	Sep CAHN
>D>	AB	25MG; 20MG	A076265	003	Jul 08, 2002	Sep CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

@ WATSON LABS 12.5MG; 50MG

A200180 001 Jan 12, 2011 May DISC

@ 12.5MG; 100MG

A200180 002 Jan 12, 2011 May DISC

@ 25MG; 100MG

A200180 003 Jan 12, 2011 May DISC

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

MYLAN 15MG; 250MG

A070265 002 Jan 23, 1986 Mar CMS1

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

COVIS PHARMA SARL 12.5MG; EQ 25MG TARTRATE

N021956 001 Aug 28, 2006 Jun CAHN

12.5MG; EQ 50MG TARTRATE

N021956 002 Aug 28, 2006 Jun CAHN

+ 12.5MG; EQ 100MG TARTRATE

N021956 003 Aug 28, 2006 Jun CAHN

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB HERITAGE PHARMS INC 12.5MG; 7.5MG

A202150 001 Mar 07, 2014 Apr CAHN

AB 12.5MG; 15MG

A202150 002 Mar 07, 2014 Apr CAHN

AB 25MG; 15MG

A202150 003 Mar 07, 2014 Apr CAHN

AB INDICUS PHARMA 12.5MG; 7.5MG

A202150 001 Mar 07, 2014 Feb NEWA

AB 12.5MG; 15MG

A202150 002 Mar 07, 2014 Feb NEWA

AB 25MG; 15MG

A202150 003 Mar 07, 2014 Feb NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB MYLAN 25MG; 40MG

A070947 002 Mar 04, 1987 Mar CMS1

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

@ WATSON LABS 25MG; 25MG

A087398 001 May DISC

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

AB BOEHRINGER INGELHEIM 12.5MG; 40MG

N021162 001 Nov 17, 2000 Feb CFTG

AB 12.5MG; 80MG

N021162 002 Nov 17, 2000 Feb CFTG

AB + 25MG; 80MG

N021162 003 Apr 19, 2004 Feb CFTG

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB ALEMBIC PHARMS LTD 12.5MG; 40MG

A203010 001 Feb 25, 2014 Feb NEWA

AB 12.5MG; 80MG

A203010 002 Feb 25, 2014 Feb NEWA

AB 25MG; 80MG

A203010 003 Feb 25, 2014 Feb NEWA

AB LUPIN LTD 12.5MG; 40MG

A091351 001 Aug 07, 2014 Jul NEWA

AB 12.5MG; 80MG

A091351 002 Aug 07, 2014 Jul NEWA

AB 25MG; 80MG

A091351 003 Aug 07, 2014 Jul NEWA

AB MYLAN PHARMS INC 12.5MG; 40MG

A091648 001 Feb 25, 2014 Feb NEWA

AB 12.5MG; 80MG

A091648 002 Feb 25, 2014 Feb NEWA

AB 25MG; 80MG

A091648 003 Feb 25, 2014 Feb NEWA

AB TORRENT PHARMS LTD 12.5MG; 40MG

A201192 001 Feb 25, 2014 Feb NEWA

AB 12.5MG; 80MG

A201192 002 Feb 25, 2014 Feb NEWA

AB 25MG; 80MG

A201192 003 Feb 25, 2014 Feb NEWA

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA PADDOCK LLC 5MG/5ML; 60MG/5ML

A204658 001 Apr 29, 2014 Apr NEWA

REZIRA

AA + CYPRESS PHARM 5MG/5ML; 60MG/5ML

N022442 001 Jun 08, 2011 Apr CFTG

HYDROCORTISONE

CREAM; TOPICAL						
HYDROCORTISONE						
	@ TARO	1%	A086155	001		Mar DISC
LOTION; TOPICAL						
ALA-CORT						
	@ CROWN LABS	1%	A083201	001		Mar DISC
NUTRACORT						
	@ DOW PHARM	1%	A080443	003		Mar DISC
TABLET; ORAL						
HYDROCORTISONE						
>A>	@ HIKMA INTL PHARMS	20MG	A083365	001		Sep CAHN
>D>	@ HIKMA PHARMS LLC	20MG	A083365	001		Sep CAHN

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%

@ VINTAGE PHARMS	1%;1%	A089440	001	May 17, 1988	Feb CAHN
------------------	-------	---------	-----	--------------	----------

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

HYDROCORTISONE BUTYRATE

AB2	GLENMARK GENERICS	0.1%	A202145	001	Sep 27, 2013	Aug CTEC
AB1	TARO PHARM INDS	0.1%	A076654	001	Aug 03, 2005	Aug CTEC
LOCOID						
AB1	+ PRECISION DERMAT	0.1%	N018514	001	Mar 31, 1982	Aug CTEC
LOCOID LIPOCREAM						
AB2	+ PRECISION DERMAT	0.1%	N020769	001	Sep 08, 1997	Aug CTEC

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

EXALGO

AB	MALLINCKRODT INC	8MG	N021217	001	Mar 01, 2010	Apr CFTG
AB		12MG	N021217	002	Mar 01, 2010	Apr CFTG
AB		16MG	N021217	003	Mar 01, 2010	Apr CFTG
HYDROMORPHONE HYDROCHLORIDE						
AB	ACTAVIS LABS FL INC	8MG	A202144	001	May 12, 2014	Apr NEWA
AB		12MG	A202144	002	May 12, 2014	Apr NEWA
AB		16MG	A202144	003	May 12, 2014	Apr NEWA

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

@ WATSON LABS	200MG	A040133	001	Nov 30, 1995	May DISC
---------------	-------	---------	-----	--------------	----------

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

MAKENA

+ LUMARA HEALTH INC	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	May CAHN
---------------------	-----------------------	---------	-----	--------------	----------

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

	@ ACTAVIS ELIZABETH	10MG	A089071	001	Jul 22, 1986	Aug CAHN
	@	25MG	A089072	001	Jul 22, 1986	Aug CAHN
	@	50MG	A089073	001	Jul 22, 1986	Aug CAHN
AB	EMCURE PHARMS USA	10MG	A204279	001	Aug 20, 2014	Aug NEWA
AB		25MG	A204279	002	Aug 20, 2014	Aug NEWA
AB		50MG	A204279	003	Aug 20, 2014	Aug NEWA
AB	SUN PHARM INDS INC	10MG	A040899	001	Jun 10, 2008	Jun CAHN
AB		25MG	A040899	002	Jun 10, 2008	Jun CAHN
AB		50MG	A040899	003	Jun 10, 2008	Jun CAHN
	@ WATSON LABS	10MG	A081149	001	Mar 18, 1994	May DISC
	@	25MG	A081150	001	Mar 18, 1994	May DISC
	@	50MG	A081151	001	Mar 18, 1994	May DISC

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

AB	EMCURE PHARMS USA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Jun CPOT
AB		EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Jun CPOT
	@ WATSON LABS	EQ 25MG HYDROCHLORIDE	A081165	001	Jul 31, 1991	May DISC

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

BONIVA

AP	+ ROCHE	EQ 3MG BASE/3ML	N021858	001	Jan 06, 2006	Feb CFTG
	IBANDRONATE SODIUM					
AP	AGILA SPECLTS	EQ 3MG BASE/3ML	A202671	001	Sep 02, 2014	Aug NEWA
AP	EMCURE PHARMS LTD	EQ 3MG BASE/3ML	A203987	001	Sep 02, 2014	Aug NEWA
AP	SAGENT PHARMS	EQ 3MG BASE/3ML	A202235	001	Sep 02, 2014	Aug NEWA
AP	SUN PHARM INDS LTD	EQ 3MG BASE/3ML	A090853	001	Feb 14, 2014	Feb NEWA

IBUPROFEN

TABLET;ORAL

IBUPROFEN

@ WATSON LABS

400MG

A070436 001 Aug 21, 1985 May DISC

@

600MG

A070437 001 Aug 21, 1985 May DISC

IDARUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

IDARUBICIN HYDROCHLORIDE

AP	EUROHLTH INTL	1MG/ML	A065275	001	Dec 14, 2006	Aug CAHN
AP		1MG/ML	A065288	001	May 15, 2007	Aug CAHN

IDELALISIB

TABLET;ORAL

ZYDELIG

GILEAD SCIENCES INC

100MG

N205858 001 Jul 23, 2014 Jul NEWA

+

150MG

N205858 002 Jul 23, 2014 Jul NEWA

IFOSFAMIDE

INJECTABLE;INJECTION

IFOSFAMIDE

AP	EUROHLTH INTL	1GM/20ML (50MG/ML)	A076619	001	Jun 29, 2011	Aug CAHN
AP		3GM/60ML (50MG/ML)	A076619	002	Jun 29, 2011	Aug CAHN

IMIQUIMOD

CREAM;TOPICAL

IMIQUIMOD

AB	STRIDES ARCOLAB LTD	5%	A202002	001	Jun 24, 2014	Jun NEWA
AB	STRIDES PHARMA	5%	A202002	001	Jun 24, 2014	Aug CAHN

INAMRINONE LACTATE

INJECTABLE;INJECTION

AMRINONE LACTATE

	+ EUROHLTH INTL	EQ 5MG BASE/ML	A075513	001	May 09, 2000	Aug CAHN
--	-----------------	----------------	---------	-----	--------------	----------

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

@ AMERIGEN PHARMS LTD

1.25MG

A075201 001 Dec 04, 1998 Jul CAHN

@

2.5MG

A075201 002 Dec 04, 1998 Jul CAHN

@ WATSON LABS

1.25MG

A074585 001 Sep 26, 1996 May DISC

@

2.5MG

A074585 002 Sep 26, 1996 May DISC

INDOMETHACIN

CAPSULE;ORAL

INDOCIN

@ IROKO PHARMS LLC

25MG

N016059 001

May CAHN

@

50MG

N016059 002

May CAHN

INDOMETHACIN

>A>	@ CYCLE PHARMS LTD	25MG	A070353	001	Jun 18, 1985	Sep CAHN
>A>	@	50MG	A070354	001	Jun 18, 1985	Sep CAHN
>D>	@ ROXANE	25MG	A070353	001	Jun 18, 1985	Sep CAHN
>D>	@	50MG	A070354	001	Jun 18, 1985	Sep CAHN
AB	SUN PHARM INDS INC	25MG	A091401	001	Mar 28, 2013	Jun CAHN

CAPSULE;ORAL							
INDOMETHACIN							
AB		50MG	A091401	002	Mar 28, 2013	Jun	CAHN
TIVORBEX							
	IROKO PHARMS LLC	20MG	N204768	001	Feb 24, 2014	Feb	NEWA
+		40MG	N204768	002	Feb 24, 2014	Feb	NEWA
CAPSULE, EXTENDED RELEASE;ORAL							
INDOMETHACIN							
AB	MYLAN PHARMS INC	75MG	A202139	001	Mar 20, 2014	Mar	NEWA
SUSPENSION;ORAL							
INDOMETHACIN							
>A>	@ CYCLE PHARMS LTD	25MG/5ML	A071412	001	Mar 18, 1987	Sep	CAHN
>D>	@ ROXANE	25MG/5ML	A071412	001	Mar 18, 1987	Sep	CAHN
<u>INDOMETHACIN SODIUM</u>							
INJECTABLE;INJECTION							
INDOMETHACIN SODIUM							
AP	EUROHLTH INTL	EQ 1MG BASE/VIAL	A078713	001	Jul 16, 2008	Aug	CAHN
<u>INSULIN ASPART RECOMBINANT</u>							
INJECTABLE;SUBCUTANEOUS							
NOVOLOG FLEXTOUCH							
+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	005	Oct 31, 2013	Feb	NEWA
<u>INSULIN DETEMIR RECOMBINANT</u>							
INJECTABLE;SUBCUTANEOUS							
LEVEMIR FLEXTOUCH							
+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	005	Oct 31, 2013	Feb	NEWA
<u>INSULIN RECOMBINANT HUMAN</u>							
POWDER;INHALATION							
AFREZZA							
	MANNKIND	4 UNITS/INH	N022472	001	Jun 27, 2014	Jun	NEWA
+		8 UNITS/INH	N022472	002	Jun 27, 2014	Jun	NEWA
<u>IPRATROPIUM BROMIDE</u>							
SOLUTION;INHALATION							
IPRATROPIUM BROMIDE							
AN	+ MYLAN SPECLT	0.02%	A074755	001	Jan 10, 1997	Mar	CAHN
SPRAY, METERED;NASAL							
IPRATROPIUM BROMIDE							
AB	MYLAN SPECLT	0.021MG/SPRAY	A075552	001	Mar 31, 2003	May	CAHN
AB		0.042MG/SPRAY	A075553	001	Mar 31, 2003	May	CAHN
<u>IRINOTECAN HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
IRINOTECAN HYDROCHLORIDE							
AP	ACTAVIS ELIZABETH	40MG/2ML (20MG/ML)	A078589	001	Feb 27, 2008	Aug	CAHN
AP		100MG/5ML (20MG/ML)	A078589	002	Feb 27, 2008	Aug	CAHN
AP	MUSTAFA NEVZAT ILAC	40MG/2ML (20MG/ML)	A090393	002	May 13, 2011	May	CAHN
AP		100MG/5ML (20MG/ML)	A090393	003	May 13, 2011	May	CAHN
<u>ISOFLURANE</u>							
LIQUID;INHALATION							
ISOFLURANE							
AN	PIRAMAL ENT	99.9%	A074502	001	Jun 27, 1995	Feb	CAHN
<u>ISONIAZID</u>							
TABLET;ORAL							
ISONIAZID							
>A>	@ HIKMA INTL PHARMS	100MG	A080212	001		Sep	CAHN
>A>	@	300MG	A087425	001		Sep	CAHN
>D>	@ HIKMA PHARMS LLC	100MG	A080212	001		Sep	CAHN
>D>	@	300MG	A087425	001		Sep	CAHN
<u>ISONIAZID; RIFAMPIN</u>							
CAPSULE;ORAL							
RIFAMPIN AND ISONIAZID							
>A>	@ HIKMA INTL PHARMS	150MG;300MG	A065221	001	Jul 29, 2005	Sep	CAHN
>D>	@ HIKMA PHARMS LLC	150MG;300MG	A065221	001	Jul 29, 2005	Sep	CAHN

ISOSORBIDE DINITRATE

		CAPSULE, EXTENDED RELEASE;ORAL DILATRATE-SR							
		+ AUXILIUM PHARMS LLC	40MG	N019790	001	Sep 02, 1988	Apr	CAHN	
		TABLET;ORAL ISOSORBIDE DINITRATE							
AB		HIKMA INTL PHARMS	5MG	A086067	001	Oct 29, 1987	Jul	CAHN	
AB			10MG	A086066	001	Oct 29, 1987	Jul	CAHN	
AB			20MG	A088088	001	Nov 02, 1987	Jul	CAHN	
AB			30MG	A040591	001	Jan 10, 2007	Jul	CAHN	
		TABLET;SUBLINGUAL ISOSORBIDE DINITRATE							
		@ HIKMA INTL PHARMS	2.5MG	A086054	001	Oct 29, 1987	Jul	CAHN	
		@	5MG	A086055	001	Nov 02, 1987	Jul	CAHN	
		TABLET, EXTENDED RELEASE;ORAL ISOSORBIDE DINITRATE							
AB		+ SUN PHARM INDS INC	40MG	A040009	001	Dec 30, 1998	Jul	CAHN	

ISOSORBIDE MONONITRATE

		TABLET;ORAL ISOSORBIDE MONONITRATE							
AB		ANI PHARMS INC	20MG	A075147	001	Nov 27, 1998	Jan	CAHN	
		TABLET, EXTENDED RELEASE;ORAL ISOSORBIDE MONONITRATE							
		@ ACTAVIS ELIZABETH	30MG	A075306	001	Dec 31, 1998	May	DISC	
		@	60MG	A075306	002	Dec 31, 1998	May	DISC	

ISOSULFAN BLUE

		INJECTABLE;INJECTION ISOSULFAN BLUE							
>D>	AP	MYLAN INSTITUTIONAL	1%	A090874	001	Jul 20, 2010	Sep	CRLD	
>A>		+	1%	A090874	001	Jul 20, 2010	Sep	CRLD	
>D>		LYMPHAZURIN							
>D>	AP	+ COVIDIEN	1%	N018310	001		Sep	DISC	
>A>		@	1%	N018310	001		Sep	DISC	

ISRADIPINE

		CAPSULE;ORAL ISRADIPINE							
AB		MIKAH PHARMA	2.5MG	A077169	001	Apr 24, 2006	May	CMFD	
		@	2.5MG	A077169	001	Apr 24, 2006	Feb	DISC	
AB			5MG	A077169	002	Apr 24, 2006	May	CMFD	
		@	5MG	A077169	002	Apr 24, 2006	Feb	DISC	
AB		WATSON LABS	2.5MG	A077317	001	Jan 05, 2006	May	CTEC	
			2.5MG	A077317	001	Jan 05, 2006	Feb	CTEC	
AB		+	5MG	A077317	002	Jan 05, 2006	May	CTEC	
		+	5MG	A077317	002	Jan 05, 2006	Feb	CTEC	

KETAMINE HYDROCHLORIDE

		INJECTABLE;INJECTION KETALAR							
AP		+ PAR STERILE PRODUCTS	EQ 10MG BASE/ML	N016812	001		Apr	CAHN	
AP		+	EQ 50MG BASE/ML	N016812	002		Apr	CAHN	
AP		+	EQ 100MG BASE/ML	N016812	003		Apr	CAHN	
		KETAMINE HYDROCHLORIDE							
AP		EUROHLTH INTL	EQ 50MG BASE/ML	A074524	001	Mar 22, 1996	Aug	CAHN	
AP			EQ 100MG BASE/ML	A074524	002	Mar 22, 1996	Aug	CAHN	

KETOCONAZOLE

		AEROSOL, FOAM;TOPICAL EXTINA							
AT		+ DELCOR ASSET CORP	2%	N021738	001	Jun 12, 2007	Jun	CAHN	
		TABLET;ORAL NIZORAL							
AB		+ JANSSEN PHARMS	200MG	N018533	001		Mar	CAHN	

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP	AGILA SPECLTS	15MG/ML	A201155	001	Aug 04, 2014	Jul	NEWA
AP		30MG/ML	A201155	002	Aug 04, 2014	Jul	NEWA
	@ BEDFORD	15MG/ML	A075222	001	Apr 26, 1999	Jul	DISC
	@	30MG/ML	A075222	002	Apr 26, 1999	Jul	DISC
	@	30MG/ML	A075228	001	Apr 26, 1999	Jul	DISC
	@ HIKMA MAPLE	15MG/ML	A075299	001	Nov 03, 1999	Jun	DISC
	@	15MG/ML	A075772	001	Jul 21, 2004	Jun	DISC
	@	30MG/ML	A075299	002	Nov 03, 1999	Jun	DISC
	@	30MG/ML	A075772	002	Jul 21, 2004	Jun	DISC
AP	+ HOSPIRA	15MG/ML	A074802	001	Jun 05, 1997	Jul	CRLD
AP	+	30MG/ML	A074802	002	Jun 05, 1997	Jul	CRLD
	@ SANDOZ	15MG/ML	A076271	001	Oct 06, 2004	Jul	DISC
	@ SUN PHARMA GLOBAL	15MG/ML	A078737	001	Oct 06, 2008	Jul	DISC
	@	30MG/ML	A078737	002	Oct 06, 2008	Jul	DISC
	@ WOCKHARDT	30MG/ML	A077943	001	Mar 27, 2007	Jun	DISC

SOLUTION/DROPS; OPHTHALMIC

ACUVAIL

AT	+ ALLERGAN	0.45%	N022427	001	Jul 22, 2009	Jan	CFTG
	KETOROLAC TROMETHAMINE						
	@ AKORN	0.45%	A203376	001	Feb 10, 2014	Feb	DISC
AT		0.45%	A203376	001	Feb 10, 2014	Jan	NEWA

TABLET; ORAL

KETOROLAC TROMETHAMINE

>A>	@ CYCLE PHARMS LTD	10MG	A074790	001	Jun 26, 1997	Sep	CAHN
>D>	@ ROXANE	10MG	A074790	001	Jun 26, 1997	Sep	CAHN

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IRRIGATION

OMIDRIA

+	OMEROS	EQ 2.88MG BASE/ML; EQ 10.16MG BASE/ML	N205388	001	May 30, 2014	Jun	CPOT
+		EQ 4.24MG BASE/ML; EQ 12.4MG BASE/ML	N205388	001	May 30, 2014	May	NEWA

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

AP	EUROHLTH INTL	5MG/ML	A075303	001	May 28, 1999	Aug	CAHN
----	---------------	--------	---------	-----	--------------	-----	------

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	HETERO LABS LTD V	150MG; 300MG	A203259	001	Feb 03, 2014	Jan	NEWA
AB	MYLAN PHARMS INC	150MG; 300MG	A204005	001	Aug 28, 2014	Aug	NEWA

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

	@ ACTAVIS ELIZABETH	25MG	A078669	001	Apr 08, 2011	Aug	CAHN
	@	100MG	A078669	002	Apr 08, 2011	Aug	CAHN
	@	150MG	A078669	003	Apr 08, 2011	Aug	CAHN
	@	200MG	A078669	004	Apr 08, 2011	Aug	CAHN
	@ ACTAVIS TOTOWA	25MG	A078669	001	Apr 08, 2011	May	DISC
	@	100MG	A078669	002	Apr 08, 2011	May	DISC
	@	150MG	A078669	003	Apr 08, 2011	May	DISC
	@	200MG	A078669	004	Apr 08, 2011	May	DISC
	@ PHARMASCIENCE INC	25MG	A078310	001	Feb 04, 2009	Jul	DISC
BX		25MG	A078310	001	Feb 04, 2009	Jul	CAHN
	@	100MG	A078310	002	Feb 04, 2009	Jul	DISC
BX		100MG	A078310	002	Feb 04, 2009	Jul	CAHN
	@	150MG	A078310	003	Feb 04, 2009	Jul	DISC
BX		150MG	A078310	003	Feb 04, 2009	Jul	CAHN
	@	200MG	A078310	004	Feb 04, 2009	Jul	DISC
BX		200MG	A078310	004	Feb 04, 2009	Jul	CAHN

TABLET, CHEWABLE; ORAL

LAMOTRIGINE

AB	ALEMBIC PHARMS LTD	5MG	A201168	001	Jun 12, 2014	May	NEWA
AB		25MG	A201168	002	Jun 12, 2014	May	NEWA
AB	JUBILANT GENERICS	5MG	A200220	001	Feb 28, 2011	Jul	CAHN

TABLET, CHEWABLE;ORAL
LAMOTRIGINE

AB 25MG A200220 002 Feb 28, 2011 Jul CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
LAMOTRIGINE

AB IMPAX LABS INC 25MG A200828 001 Jul 15, 2013 Jul CAHN
AB 50MG A200828 002 Jul 15, 2013 Jul CAHN
AB 100MG A200828 003 Jul 15, 2013 Jul CAHN
AB 200MG A200828 004 Jul 15, 2013 Jul CAHN

LANSOPRAZOLE

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL
LANSOPRAZOLE

@ ANI PHARMS INC 15MG A078730 001 Oct 15, 2010 Jan CAHN
@ 30MG A078730 002 Oct 15, 2010 Jan CAHN

LANTHANUM CARBONATE

>A> POWDER;ORAL
>A> FOSRENOL
>A> + SHIRE DEV LLC EQ 1GM BASE N204734 002 Sep 24, 2014 Sep NEWA
>A> EQ 750MG BASE N204734 001 Sep 24, 2014 Sep NEWA

LEDIPASVIR; SOFOSBUVIR

TABLET;ORAL

>A> HARVONI
>A> + GILEAD SCIENCES INC 90MG;400MG N205834 001 Oct 10, 2014 Sep NEWA

LETROZOLE

TABLET;ORAL

LETROZOLE
@ ACTAVIS ELIZABETH 2.5MG A090292 001 Jul 13, 2011 Aug CAHN
@ ACTAVIS TOTOWA 2.5MG A090292 001 Jul 13, 2011 May DISC

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION
LEUCOVORIN CALCIUM

AP + EUROHLTH INTL EQ 50MG BASE/VIAL A089384 001 Sep 14, 1987 Aug CAHN
AP + EQ 100MG BASE/VIAL A089717 001 Mar 28, 1988 Aug CAHN
LEUCOVORIN CALCIUM PRESERVATIVE FREE
+ EUROHLTH INTL EQ 10MG BASE/ML A040347 001 Apr 25, 2000 Aug CAHN
AP + EQ 200MG BASE/VIAL A040056 001 May 23, 1995 Aug CAHN
AP + EQ 350MG BASE/VIAL A040335 001 Apr 20, 2000 Aug CAHN

LEUPROLIDE ACETATE

INJECTABLE;INJECTION
LUPRON DEPOT

+ ABBVIE ENDOCRINE INC 3.75MG N020011 002 Oct 26, 1995 May NEWA

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION

LEVALBUTEROL HYDROCHLORIDE

AN MYLAN SPECLT EQ 0.0103% BASE A077800 001 Mar 15, 2013 May CAHN
AN EQ 0.021% BASE A077800 002 Mar 15, 2013 May CAHN
AN EQ 0.042% BASE A077800 003 Mar 15, 2013 May CAHN
>A> AN TEVA PARENTERAL EQ 0.25% BASE A200875 001 Sep 11, 2014 Sep NEWA
AN WATSON LABS INC EQ 0.0103% BASE A077756 003 Apr 09, 2008 Jun CMFD
@ EQ 0.0103% BASE A077756 003 Apr 09, 2008 May DISC
AN EQ 0.021% BASE A077756 001 Apr 09, 2008 Jun CMFD
@ EQ 0.021% BASE A077756 001 Apr 09, 2008 May DISC
AN EQ 0.042% BASE A077756 002 Apr 09, 2008 Jun CMFD
@ EQ 0.042% BASE A077756 002 Apr 09, 2008 May DISC

LEVETIRACETAM

TABLET;ORAL

LEVETIRACETAM

@ SANDOZ 1GM A077324 004 Jan 15, 2009 Jun DISC
@ 250MG A077324 001 Jan 15, 2009 Jun DISC
@ 500MG A077324 002 Jan 15, 2009 Jun DISC
@ 750MG A077324 003 Jan 15, 2009 Jun DISC
AB VINTAGE PHARMS 250MG A077319 001 Mar 20, 2009 Feb CAHN
AB 500MG A077319 002 Mar 20, 2009 Feb CAHN
AB 750MG A077319 003 Mar 20, 2009 Feb CAHN

TABLET;ORAL

LEVETIRACETAM

@ WATSON LABS INC 1GM

A078797 001 Jan 15, 2009 May DISC

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

AB VINTAGE PHARMS 500MG

A201464 001 May 25, 2012 Feb CAHN

AB 750MG

A201464 002 May 25, 2012 Feb CAHN

LEVOCARNITINE

INJECTABLE;INJECTION

LEVOCARNITINE

AP EUROHLTH INTL 200MG/ML

A075567 001 Mar 29, 2001 Aug CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AA APOTEX INC 2.5MG/5ML

A202915 001 Aug 21, 2014 Aug NEWA

AA L PERRIGO CO 2.5MG/5ML

A091263 001 Nov 07, 2011 Jan CAHN

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

@ SANDOZ 5MG

A090486 001 Mar 26, 2013 May DISC

AB SCIEGEN PHARMS INC 5MG

A203646 001 Sep 09, 2014 Aug NEWA

LEVOFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

IQUIX

@ SANTEN 1.5%

N021571 001 Mar 01, 2004 Jun DISC

LEVOFLOXACIN

AT WATSON LABS INC 0.5%

A076826 001 Feb 10, 2011 May CAHN

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

>D> AB LUPIN LTD 0.75MG

A091328 001 Jan 23, 2013 Sep DISC

>A> @ 0.75MG

A091328 001 Jan 23, 2013 Sep DISC

@ WATSON LABS 0.75MG

A078666 001 Jun 24, 2009 Aug DISC

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

+ ROXANE 2MG

A074278 001 Mar 31, 2000 Feb CRLD

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

AP AGILA SPECLTS 2%

A202242 001 Apr 11, 2014 Mar NEWA

LIDOPEN

@ MERIDIAN MEDCL TECHN 10%

N017549 001 Mar DISC

XYLOCAINE PRESERVATIVE FREE

@ FRESENIUS KABI USA 10%

N016801 003 Jun DISC

+ 10%

N016801 003 Mar CTEC

JELLY;TOPICAL

ANESTACON

@ BANNER PHARMACAPS 2%

A080429 001 Jun CAHN

@ DSM PHARMS INC 2%

A080429 001 Jan CAHN

GLYDO

AT SAGENT PHARMS 2%

A201094 001 Apr 28, 2014 Apr NEWA

LIDOCAINE HYDROCHLORIDE

AT WATSON LABS INC 2%

A040837 001 Mar 23, 2011 May CAHN

SOLUTION;TOPICAL

LIDOCAINE HYDROCHLORIDE

AT IGI LABS INC 4%

A204494 001 Mar 12, 2014 Feb NEWA

SYSTEM;INTRADERMAL

ZINGO

POWDER PHARMS 0.5MG

N022114 001 Aug 16, 2007 Mar CMFD

LIDOCAINE; PRILOCAINECREAM; TOPICAL
EMLA

AB	+	WATSON LABS INC	2.5%;2.5%	N019941	001	Dec 30, 1992	May CAHN
----	---	-----------------	-----------	---------	-----	--------------	----------

LIOTHYRONINE SODIUMINJECTABLE; INJECTION
TRIOSTAT

AP	+	PAR STERILE PRODUCTS	EQ 0.01MG BASE/ML	N020105	001	Dec 31, 1991	Apr CAHN
----	---	----------------------	-------------------	---------	-----	--------------	----------

LISINOPRILTABLET; ORAL
LISINOPRIL

AB		HIKMA INTL PHARMS	2.5MG	A076063	001	Jul 01, 2002	Jul CAHN
AB			5MG	A076063	002	Jul 01, 2002	Jul CAHN
AB			10MG	A076063	003	Jul 01, 2002	Jul CAHN
AB			20MG	A076063	004	Jul 01, 2002	Jul CAHN
AB			30MG	A076063	006	Jun 27, 2003	Jul CAHN
AB			40MG	A076063	005	Jul 01, 2002	Jul CAHN

LITHIUM CARBONATECAPSULE; ORAL
LITHIUM CARBONATE

>A>	AB		HIKMA INTL PHARMS	150MG	A076243	002	Feb 24, 2003	Sep CAHN
>A>	AB			300MG	A076243	001	Jun 27, 2002	Sep CAHN
>D>	AB		HIKMA PHARMS LLC	150MG	A076243	002	Feb 24, 2003	Sep CAHN
>D>	AB			300MG	A076243	001	Jun 27, 2002	Sep CAHN

TABLET; ORAL

LITHIUM CARBONATE

>A>		@	HIKMA INTL PHARMS	300MG	A078715	001	Dec 28, 2010	Sep CAHN
>D>		@	HIKMA PHARMS LLC	300MG	A078715	001	Dec 28, 2010	Sep CAHN

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

>A>	AB		HIKMA INTL PHARMS	450MG	A076490	001	Jun 17, 2003	Sep CAHN
>D>	AB		HIKMA PHARMS LLC	450MG	A076490	001	Jun 17, 2003	Sep CAHN

LITHOBID

AB	+	ANI PHARMS INC	300MG	N018027	001		Jun CAHN
----	---	----------------	-------	---------	-----	--	----------

LOMUSTINECAPSULE; ORAL
GLEOSTINE

			CORDEN PHARMA	10MG	N017588	001		Aug CTNA
				40MG	N017588	002		Aug CTNA
		+		100MG	N017588	003		Aug CTNA

LORAZEPAMINJECTABLE; INJECTION
ATIVAN

AP	+	HIKMA MAPLE	2MG/ML	N018140	001		Jun CAHN
AP	+		4MG/ML	N018140	002		Jun CAHN

TABLET; ORAL

LORAZEPAM

	@	WATSON LABS	1MG	A071118	001	Jul 24, 1986	May DISC
--	---	-------------	-----	---------	-----	--------------	----------

LOTEPREDNOL ETABONATEGEL; OPHTHALMIC
LOTEMAX

+	BAUSCH AND LOMB INC	0.5%	N202872	001	Sep 28, 2012	Feb CAHN
---	---------------------	------	---------	-----	--------------	----------

LUBIPROSTONECAPSULE; ORAL
AMITIZA

		SUCAMPO PHARMA LLC	8MCG	N021908	002	Apr 29, 2008	Aug CAHN
+			24MCG	N021908	001	Jan 31, 2006	Aug CAHN

LULICONAZOLECREAM; TOPICAL
LUZU

+	MEDICIS	1%	N204153	001	Nov 14, 2013	Jan	CRLD
---	---------	----	---------	-----	--------------	-----	------

MAFENIDE ACETATEFOR SOLUTION; TOPICAL
MAFENIDE ACETATE

AT	PAR FORM	5%	A201511	001	Feb 12, 2013	Aug	CTEC
----	----------	----	---------	-----	--------------	-----	------

SULFAMYLON

AT	+	MYLAN INSTITUTIONAL	5%	N019832	003	Jun 05, 1998	Aug	CTEC
----	---	---------------------	----	---------	-----	--------------	-----	------

MAGNESIUM SULFATEINJECTABLE; INJECTION
MAGNESIUM SULFATE

AP	+	HOSPIRA	500MG/ML	A075151	001	Apr 25, 2000	Jun	CRLD
----	---	---------	----------	---------	-----	--------------	-----	------

MALATHIONLOTION; TOPICAL
MALATHION

@	MYLAN PHARMS INC	0.5%	A078743	001	Mar 06, 2009	Mar	DISC
---	------------------	------	---------	-----	--------------	-----	------

MANNITOLPOWDER; INHALATION
ARIDOL KIT

>D>	+	PHARMAXIS LTD	N/A, 5MG, 10MG, 20MG, 40MG	N022368	001	Oct 05, 2010	Sep	DISC
-----	---	---------------	----------------------------	---------	-----	--------------	-----	------

>A>	@		N/A, 5MG, 10MG, 20MG, 40MG	N022368	001	Oct 05, 2010	Sep	DISC
-----	---	--	----------------------------	---------	-----	--------------	-----	------

MEBENDAZOLETABLET, CHEWABLE; ORAL
MEBENDAZOLE

+	AMEDRA PHARMS LLC	100MG	A073580	001	Jan 04, 1995	Jun	CAHN
---	-------------------	-------	---------	-----	--------------	-----	------

MECHLORETHAMINE HYDROCHLORIDEGEL; TOPICAL
VALCHLOR

+	ACTELION PHARMS LTD	EQ 0.016% BASE	N202317	001	Aug 23, 2013	Jun	CPOT
---	---------------------	----------------	---------	-----	--------------	-----	------

MECLIZINE HYDROCHLORIDETABLET; ORAL
MECLIZINE HYDROCHLORIDE
@ WATSON LABS

25MG	A085740	001		May	DISC
------	---------	-----	--	-----	------

MEDROXYPROGESTERONE ACETATETABLET; ORAL
MEDROXYPROGESTERONE ACETATE
@ USL PHARMA

10MG	A088484	001	Jul 26, 1984	Mar	DISC
------	---------	-----	--------------	-----	------

MEFENAMIC ACIDCAPSULE; ORAL
MEFENAMIC ACID

AB	VINTAGE PHARMS LLC	250MG	A091608	001	Jun 02, 2014	May	NEWA
----	--------------------	-------	---------	-----	--------------	-----	------

MEGESTROL ACETATESUSPENSION; ORAL
MEGACE ES

AB	+	PAR PHARM	125MG/ML	N021778	001	Jul 05, 2005	Aug	CFTG
----	---	-----------	----------	---------	-----	--------------	-----	------

MEGESTROL ACETATE

AB	TWI PHARMS INC	125MG/ML	A203139	001	Aug 27, 2014	Aug	NEWA
----	----------------	----------	---------	-----	--------------	-----	------

MELOXICAMTABLET; ORAL
MELOXICAM

AB	STRIDES PHARMA	7.5MG	A077928	001	May 13, 2009	Aug	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

AB		15MG	A077928	002	May 13, 2009	Aug	CAHN
----	--	------	---------	-----	--------------	-----	------

AB	SUN PHARM INDS INC	7.5MG	A077937	001	Jul 19, 2006	Jul	CAHN
----	--------------------	-------	---------	-----	--------------	-----	------

AB		15MG	A077937	002	Jul 19, 2006	Jul	CAHN
----	--	------	---------	-----	--------------	-----	------

@	YABAO PHARM	7.5MG	A077933	001	Jul 19, 2006	May	CAHN
---	-------------	-------	---------	-----	--------------	-----	------

@		15MG	A077933	002	Jul 19, 2006	May	CAHN
---	--	------	---------	-----	--------------	-----	------

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION
MELPHALAN HYDROCHLORIDE

AP	EUROHLTH INTL	EQ 50MG BASE/VIAL	A090303	001	Oct 28, 2010	Aug CAHN
----	---------------	-------------------	---------	-----	--------------	----------

MEMANTINE HYDROCHLORIDE

TABLET; ORAL
MEMANTINE HYDROCHLORIDE

	@ DR REDDYS LABS LTD	5MG	A090048	001	Apr 14, 2010	Jul DISC
AB		5MG	A090048	001	Apr 14, 2010	Jun CMFD
	@	10MG	A090048	002	Apr 14, 2010	Jul DISC
AB		10MG	A090048	002	Apr 14, 2010	Jun CMFD
	NAMENDA					
>D>	@ FOREST LABS	5MG	N021487	001	Oct 16, 2003	Sep CMFD
>A> AB		5MG	N021487	001	Oct 16, 2003	Sep CMFD
	@	5MG	N021487	001	Oct 16, 2003	Aug DISC
		5MG	N021487	001	Oct 16, 2003	Jul CTEC
AB		5MG	N021487	001	Oct 16, 2003	Jun CTEC
>D>	@	10MG	N021487	002	Oct 16, 2003	Sep CMFD
>A> AB	+	10MG	N021487	002	Oct 16, 2003	Sep CMFD
	@	10MG	N021487	002	Oct 16, 2003	Aug DISC
	+	10MG	N021487	002	Oct 16, 2003	Jul CTEC
AB	+	10MG	N021487	002	Oct 16, 2003	Jun CTEC

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HYDROCHLORIDE

	@ WATSON LABS	50MG/ML	A073444	001	Mar 17, 1992	May DISC
	@	100MG/ML	A073445	001	Mar 17, 1992	May DISC
	MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE					
	@ INTL MEDICATION	10MG/ML	A081309	001	Aug 30, 1993	Mar DISC
	@ WATSON LABS	10MG/ML	A073443	001	Mar 17, 1992	May DISC

TABLET; ORAL

	MEPERIDINE HYDROCHLORIDE					
AA	SUN PHARM INDS INC	50MG	A040446	001	Aug 08, 2002	Jul CAHN
AA		100MG	A040446	002	Aug 08, 2002	Jul CAHN
	@ WATSON LABS	50MG	A040186	001	Jun 30, 1997	May DISC
	@	100MG	A040186	002	Jun 30, 1997	May DISC

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPIVACAINE HYDROCHLORIDE

	@ WATSON LABS	1%	A088769	001	Nov 20, 1984	May DISC
	@	2%	A088770	001	Nov 20, 1984	May DISC

MERCAPTOPURINE

SUSPENSION; ORAL
PURIXAN

+	NOVA LABS LTD	20MG/ML	N205919	001	Apr 28, 2014	Apr NEWA
---	---------------	---------	---------	-----	--------------	----------

MESALAMINE

SUPPOSITORY; RECTAL
CANASA

+	FOREST LABS INC	1GM	N021252	002	Nov 05, 2004	Apr CAHN
	@	500MG	N021252	001	Jan 05, 2001	Apr CAHN

MESNA

INJECTABLE; INTRAVENOUS
MESNA

AP	AGILA SPECLTS	100MG/ML	A203364	001	Jul 18, 2014	Jul NEWA
AP	EUROHLTH INTL	100MG/ML	A075739	001	Jan 09, 2004	Aug CAHN

METAPROTERENOL SULFATE

SOLUTION; INHALATION
METAPROTERENOL SULFATE

AN	+	MYLAN SPECLT	0.4%	A071786	001	Aug 05, 1988	May CAHN
AN	+		0.6%	A070804	001	Aug 17, 1987	May CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB	ATLAS PHARMS LLC	1GM	A076033	003	Jan 24, 2002	May CAHN
AB		500MG	A076033	001	Jan 24, 2002	May CAHN
AB		850MG	A076033	002	Jan 24, 2002	May CAHN
AB	SUN PHARM INDS INC	1GM	A075967	003	Jan 29, 2002	Jul CAHN
AB		500MG	A075967	001	Jan 29, 2002	Jul CAHN
AB		850MG	A075967	002	Jan 29, 2002	Jul CAHN
	@ WATSON LABS	1GM	A075979	003	Jan 24, 2002	May DISC
	@	500MG	A075979	001	Jan 24, 2002	May DISC
	@	850MG	A075979	002	Jan 24, 2002	May DISC
AB	ZYDUS HLTHCARE	1GM	A203686	003	Aug 28, 2014	Aug NEWA
AB		500MG	A203686	001	Aug 28, 2014	Aug NEWA
AB		850MG	A203686	002	Aug 28, 2014	Aug NEWA
TABLET, EXTENDED RELEASE; ORAL						
GLUMETZA						
+	SALIX PHARMS INC	1GM	N021748	002	Jun 03, 2005	Feb CTEC
		500MG	N021748	001	Jun 03, 2005	Feb CTEC
+	SANTARUS INC	1GM	N021748	002	Jun 03, 2005	Mar CAHN
		500MG	N021748	001	Jun 03, 2005	Mar CAHN

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB	TEVA PHARMS USA	500MG;EQ 15MG BASE	A091155	001	Mar 10, 2014	Feb NEWA
AB		850MG;EQ 15MG BASE	A091155	002	Mar 10, 2014	Feb NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

AB	SB PHARMCO	1GM;EQ 2MG BASE	N021410	004	Aug 25, 2003	Apr CFTG
AB	+	1GM;EQ 4MG BASE	N021410	005	Aug 25, 2003	Apr CFTG
AB		500MG;EQ 2MG BASE	N021410	002	Oct 10, 2002	Apr CFTG
AB		500MG;EQ 4MG BASE	N021410	003	Oct 10, 2002	Apr CFTG
ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE						
AB	TEVA	1GM;EQ 4MG BASE	A077337	004	May 07, 2014	Apr NEWA
AB		1GM;EQ 2MG BASE	A077337	003	May 07, 2014	Apr NEWA
AB		500MG;EQ 2MG BASE	A077337	001	May 07, 2014	Apr NEWA
AB		500MG;EQ 4MG BASE	A077337	002	May 07, 2014	Apr NEWA

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

	ASTRAZENECA AB	1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010	Apr CAHN
+		1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010	Apr CAHN
		500MG;EQ 5MG BASE	N200678	001	Nov 05, 2010	Apr CAHN

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

AB	ANI PHARMS INC	25MG	A040001	001	Jun 30, 1993	Jan CAHN
AB		50MG	A040001	002	Jun 30, 1993	Jan CAHN

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	SUN PHARM INDS INC	5MG	A040870	001	Sep 25, 2007	Jul CAHN
AB		10MG	A040870	002	Sep 25, 2007	Jul CAHN
AB	VINTAGE PHARMS	5MG	A202068	001	Mar 07, 2012	Feb CAHN
AB		10MG	A202068	002	Mar 07, 2012	Feb CAHN

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

AA	HIKMA INTL PHARMS	500MG	A085159	001		Jul CAHN
AA		750MG	A085123	001		Jul CAHN
	@ WATSON LABS	500MG	A085180	001		May DISC
	@	750MG	A085192	001		May DISC
ROBAXIN						
AA	+	AUXILIUM PHARMS LLC	500MG	N011011	004	Apr CAHN

TABLET;ORAL							
ROBAXIN-750							
AA	+	AUXILIUM PHARMS LLC	750MG	N011011	006		Apr CAHN
<u>METHOHEXITAL SODIUM</u>							
INJECTABLE;INJECTION							
BREVITAL SODIUM							
	+	PAR STERILE PRODUCTS	2.5GM/VIAL	N011559	002		Apr CAHN
	@		5GM/VIAL	N011559	003		Apr CAHN
	+		200MG/VIAL	N011559	004	Dec 21, 2012	Apr CAHN
	+		500MG/VIAL	N011559	001		Apr CAHN
<u>METHOTREXATE</u>							
SOLUTION;SUBCUTANEOUS							
RASUVO							
		MEDAC PHARMA INC	7.5MG/0.15ML	N205776	001	Jul 10, 2014	Jul NEWA
			10MG/0.20ML	N205776	002	Jul 10, 2014	Jul NEWA
			12.5MG/0.25ML	N205776	003	Jul 10, 2014	Jul NEWA
			15MG/0.30ML	N205776	004	Jul 10, 2014	Jul NEWA
			17.5MG/0.35ML	N205776	005	Jul 10, 2014	Jul NEWA
			20MG/0.4ML	N205776	006	Jul 10, 2014	Jul NEWA
			22.5MG/0.45ML	N205776	007	Jul 10, 2014	Jul NEWA
			25MG/0.5ML	N205776	008	Jul 10, 2014	Jul NEWA
			27.5MG/0.55ML	N205776	009	Jul 10, 2014	Jul NEWA
			30MG/0.6ML	N205776	010	Jul 10, 2014	Jul NEWA
<u>METHOTREXATE SODIUM</u>							
INJECTABLE;INJECTION							
METHOTREXATE SODIUM							
AP	+	EUROHLTH INTL	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341	001	Sep 16, 1986	Aug CAHN
	+		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986	Aug CAHN
METHOTREXATE SODIUM PRESERVATIVE FREE							
	+	EUROHLTH INTL	EQ 1GM BASE/VIAL	A040632	001	Aug 12, 2005	Aug CAHN
AP	+		EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A089340	001	Sep 16, 1986	Aug CAHN
AP	+		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A089343	001	Sep 16, 1986	Aug CAHN
<u>METHOXSALLEN</u>							
CAPSULE;ORAL							
METHOXSALLEN							
AB		STRIDES ARCOLAB LTD	10MG	A202687	001	Jun 05, 2014	May NEWA
AB		STRIDES PHARMA	10MG	A202687	001	Jun 05, 2014	Aug CAHN
OXSORALEN-ULTRA							
AB	+	DOW PHARM	10MG	N019600	001	Oct 30, 1986	May CTEC
<u>METHSCOPOLAMINE BROMIDE</u>							
TABLET;ORAL							
METHSCOPOLAMINE BROMIDE							
AA		VINTAGE PHARMS	2.5MG	A040624	001	Dec 28, 2006	Feb CAHN
AA			5MG	A040624	002	Dec 28, 2006	Feb CAHN
<u>METHYLDOPA</u>							
TABLET;ORAL							
METHYLDOPA							
AB		MYLAN	250MG	A070076	002	Apr 18, 1985	Apr CMS1
<u>METHYLERGONOVINE MALEATE</u>							
INJECTABLE;INJECTION							
METHERGINE							
AP	+	EDISON THERAPS LLC	0.2MG/ML	N006035	004		Feb CAHN
TABLET;ORAL							
METHERGINE							
AB	+	EDISON THERAPS LLC	0.2MG	N006035	003		Feb CAHN
<u>METHYLPHENIDATE HYDROCHLORIDE</u>							
SOLUTION;ORAL							
METHYLPHENIDATE HYDROCHLORIDE							
>D> AA		CARACO	5MG/5ML	A201466	001	Nov 12, 2013	Sep CAHN
>D> AA			10MG/5ML	A201466	002	Nov 12, 2013	Sep CAHN
>A> AA		SUN PHARM INDS INC	5MG/5ML	A201466	001	Nov 12, 2013	Sep CAHN

SOLUTION;ORAL							
METHYLPHENIDATE HYDROCHLORIDE							
>A>	AA	10MG/5ML	A201466	002	Nov 12, 2013	Sep	CAHN
TABLET;ORAL							
METHYLPHENIDATE HYDROCHLORIDE							
AB	COREPHARMA	5MG	A091159	001	Mar 12, 2014	Feb	NEWA
AB		10MG	A091159	002	Mar 12, 2014	Feb	NEWA
AB		20MG	A091159	003	Mar 12, 2014	Feb	NEWA
AB	SUN PHARM INDS INC	5MG	A090710	001	Mar 15, 2012	Jun	CAHN
AB		10MG	A090710	002	Mar 15, 2012	Jun	CAHN
AB		20MG	A090710	003	Mar 15, 2012	Jun	CAHN
>A>	AB	VINTAGE PHARMS	A202892	001	Sep 23, 2014	Sep	NEWA
>A>	AB	10MG	A202892	002	Sep 23, 2014	Sep	NEWA
>A>	AB	20MG	A202892	003	Sep 23, 2014	Sep	NEWA
TABLET, EXTENDED RELEASE;ORAL							
METHYLPHENIDATE HYDROCHLORIDE							
@ WATSON LABS		20MG	A040410	001	Feb 09, 2001	May	DISC
<u>METOCLOPRAMIDE HYDROCHLORIDE</u>							
TABLET, ORALLY DISINTEGRATING;ORAL							
METOCLOPRAMIDE HYDROCHLORIDE							
AB	NOVEL LABS INC	EQ 5MG BASE	A202191	001	Aug 15, 2014	Aug	NEWA
		EQ 10MG BASE	A202191	002	Aug 15, 2014	Aug	NEWA
METOZOLV ODT							
AB	+ SALIX PHARMS	EQ 5MG BASE	N022246	001	Sep 04, 2009	Aug	CFTG
<u>METOPROLOL SUCCINATE</u>							
TABLET, EXTENDED RELEASE;ORAL							
METOPROLOL SUCCINATE							
AB	REDDYS	EQ 100MG TARTRATE	A078889	001	Aug 15, 2012	Aug	CPOT
AB		EQ 200MG TARTRATE	A078889	002	Aug 15, 2012	Aug	CPOT
<u>METOPROLOL TARTRATE</u>							
INJECTABLE;INJECTION							
METOPROLOL TARTRATE							
AP	GLAND PHARMA LTD	1MG/ML	A204205	001	Aug 27, 2014	Aug	NEWA
TABLET;ORAL							
METOPROLOL TARTRATE							
AB	SUN PHARM INDS INC	25MG	A076670	001	Jan 15, 2004	Jul	CAHN
AB		50MG	A074644	001	Dec 10, 1996	Jul	CAHN
AB		100MG	A074644	002	Dec 10, 1996	Jul	CAHN
<u>METRONIDAZOLE</u>							
GEL;VAGINAL							
METRONIDAZOLE							
	VALEANT PHARM NORTH	1.3%	N205223	001	Mar 24, 2014	Mar	NEWA
>D>	WATSON LABS INC	1.3%	N205223	001	Mar 24, 2014	Sep	CRLD
>A>	+	1.3%	N205223	001	Mar 24, 2014	Sep	CRLD
		1.3%	N205223	001	Mar 24, 2014	Jun	CAHN
TABLET;ORAL							
METRONIDAZOLE							
AB	UNICHEM LABS LTD	250MG	A203458	001	Jan 22, 2014	Jan	NEWA
AB		500MG	A203458	002	Jan 22, 2014	Jan	NEWA
	@ VIVIMED LABS	250MG	A070040	001	Jan 29, 1985	Apr	CAHN
	@	500MG	A070039	001	Jan 29, 1985	Apr	CAHN
	@ WATSON LABS	250MG	N018764	001	Sep 17, 1982	May	DISC
	@	500MG	N018764	002	Dec 20, 1982	May	DISC
AB	WATSON LABS INC	500MG	A070044	001	Feb 08, 1985	Mar	CAHN
<u>MICONAZOLE</u>							
TABLET;BUCCAL							
ORAVIG							
	+ BIOALLIANCE PHARMA	50MG	N022404	001	Apr 16, 2010	Apr	CAHN
<u>MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE</u>							
OINTMENT;TOPICAL							
VUSION							
	+ DELCOR ASSET	0.25%;81.35%;15%	N021026	001	Feb 16, 2006	Jun	CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP	BEDFORD LABS	EQ 1MG BASE/ML	A075421	002	Jun 20, 2000	Apr CAHN
AP		EQ 5MG BASE/ML	A075421	001	Jun 20, 2000	Apr CAHN
	MIDAZOLAM HYDROCHLORIDE	PRESERVATIVE FREE				
AP	BD RX	EQ 1MG BASE/ML	A203460	001	Aug 22, 2014	Aug NEWA
AP		EQ 5MG BASE/ML	A203460	002	Aug 22, 2014	Aug NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

AP	HOSPIRA INC	EQ 1MG BASE/ML	A203280	001	Sep 03, 2014	Aug NEWA
----	-------------	----------------	---------	-----	--------------	----------

MILTEFOSINE

CAPSULE; ORAL

IMPAVIDO

>A>	+ KNIGHT THERAPS	50MG	N204684	001	Mar 19, 2014	Sep CRLD
>A>		50MG	N204684	001	Mar 19, 2014	Sep CAHN
>D>	PALADIN THERAP	50MG	N204684	001	Mar 19, 2014	Sep CAHN
		50MG	N204684	001	Mar 19, 2014	Mar NEWA

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL

DYNACIN

	@ CNTY LINE PHARMS	EQ 50MG BASE	A063066	001	Aug 14, 1990	Aug CAHN
AB		EQ 75MG BASE	A063067	002	Sep 15, 1999	Jul CAHN
AB		EQ 100MG BASE	A063067	001	Jul 31, 1990	Jul CAHN
AB	MEDICIS	EQ 75MG BASE	A063067	002	Sep 15, 1999	May CAHN
AB		EQ 100MG BASE	A063067	001	Jul 31, 1990	May CAHN

MINOCYCLINE HYDROCHLORIDE

AB	SUN PHARM INDS INC	EQ 50MG BASE	A090867	001	May 13, 2013	Jul CAHN
AB		EQ 75MG BASE	A090867	002	May 13, 2013	Jul CAHN
AB		EQ 100MG BASE	A090867	003	May 13, 2013	Jul CAHN

TABLET, EXTENDED RELEASE; ORAL

MINOCYCLINE HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 80MG BASE	A203443	002	Aug 22, 2014	Aug NEWA
AB		EQ 105MG BASE	A203443	003	Aug 22, 2014	Aug NEWA
>A> AB	RANBAXY LABS LTD	EQ 45MG BASE	A091118	001	Sep 25, 2014	Sep NEWA
>A> AB		EQ 80MG BASE	A091118	004	Sep 25, 2014	Sep NEWA
>A> AB		EQ 90MG BASE	A091118	005	Sep 25, 2014	Sep NEWA
>A> AB		EQ 105MG BASE	A091118	006	Sep 25, 2014	Sep NEWA
>A> AB		EQ 135MG BASE	A091118	008	Sep 25, 2014	Sep NEWA

SOLODYN

AB	+ MEDICIS	EQ 80MG BASE	N050808	007	Aug 27, 2010	Aug CTEC
AB		EQ 105MG BASE	N050808	006	Aug 27, 2010	Aug CTEC

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

	@ ACTAVIS ELIZABETH	15MG	A076241	001	Jun 25, 2003	Aug CAHN
	@	30MG	A076241	002	Jun 25, 2003	Aug CAHN
	@	45MG	A076241	003	Jun 25, 2003	Aug CAHN
AB	SUN PHARM INDS INC	7.5MG	A076541	004	Apr 22, 2004	Jul CAHN
AB		15MG	A076541	001	Apr 22, 2004	Jul CAHN
AB		30MG	A076541	002	Apr 22, 2004	Jul CAHN
AB		45MG	A076541	003	Apr 22, 2004	Jul CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

MIRTAZAPINE

	@ ACTAVIS ELIZABETH	15MG	A076689	001	Aug 31, 2005	Jun CAHN
	@	30MG	A076689	002	Aug 31, 2005	Jun CAHN
	@	45MG	A076689	003	Aug 31, 2005	Jun CAHN

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

AP	EUROHLTH INTL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A076611	001	Apr 11, 2006	Aug CAHN
AP		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A076611	002	Apr 11, 2006	Aug CAHN
AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A076611	003	Apr 11, 2006	Aug CAHN

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION
MIVACURIUM CHLORIDE
@ AGILA SPECLTS

EQ 2MG BASE/ML

A078562 001 Apr 30, 2009 Feb CAHN

MODAFINIL

TABLET; ORAL
MODAFINIL

AB APOTEX INC
AB

100MG
200MG

A077667 001 Feb 03, 2014 Jan NEWA
A077667 002 Feb 03, 2014 Jan NEWA

MOMETASONE FUROATE

AEROSOL, METERED; INHALATION
ASMANEX HFA

MERCK SHARP DOHME 0.10MG/INH
+ 0.20MG/INH

N205641 001 Apr 25, 2014 Apr NEWA
N205641 002 Apr 25, 2014 Apr NEWA

POWDER; INHALATION
ASMANEX TWISTHALER

MERCK SHARP DOHME 0.11MG/INH
+ 0.22MG/INH

N021067 002 Feb 01, 2008 Mar CAHN
N021067 001 Mar 30, 2005 Mar CAHN

MOMETASONE FUROATE MONOHYDRATE

SPRAY, METERED; NASAL
NASONEX

+ MERCK SHARP DOHME EQ 0.05MG BASE/SPRAY

N020762 001 Oct 01, 1997 May CAHN

MONTELUKAST SODIUM

TABLET; ORAL
MONTELUKAST SODIUM

>A> AB HETERO LABS LTD V EQ 10MG BASE
>A> AB MACLEODS PHARMS LTD EQ 10MG BASE

A202843 001 Sep 10, 2014 Sep NEWA
A203366 001 Sep 11, 2014 Sep NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL
AVINZA

AB2 KING PHARMS LLC 30MG
AB2 45MG
AB2 60MG
AB2 75MG
AB2 90MG
AB2 + 120MG

N021260 001 Mar 20, 2002 Mar CAHN
N021260 005 Dec 18, 2008 Mar CAHN
N021260 002 Mar 20, 2002 Mar CAHN
N021260 006 Dec 18, 2008 Mar CAHN
N021260 003 Mar 20, 2002 Mar CAHN
N021260 004 Mar 20, 2002 Mar CAHN

INJECTABLE; INJECTION
MORPHINE SULFATE

@ WATSON LABS 0.5MG/ML
@ 0.5MG/ML
@ 1MG/ML
@ 1MG/ML

A073373 001 Sep 30, 1991 May DISC
A073375 001 Sep 30, 1991 May DISC
A073374 001 Sep 30, 1991 May DISC
A073376 001 Sep 30, 1991 May DISC

SOLUTION; ORAL
MORPHINE SULFATE

>D> AA CARACO 10MG/5ML
AA 10MG/5ML
>D> AA 20MG/5ML
AA 20MG/5ML
>A> AA SUN PHARM INDS INC 10MG/5ML
>A> AA 20MG/5ML

A201011 001 Feb 05, 2014 Sep CAHN
A201011 001 Feb 05, 2014 Jan NEWA
A201011 002 Feb 05, 2014 Sep CAHN
A201011 002 Feb 05, 2014 Jan NEWA
A201011 001 Feb 05, 2014 Sep CAHN
A201011 002 Feb 05, 2014 Sep CAHN

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
EMBEDA

ALPHARMA PHARMS 20MG; 0.8MG
30MG; 1.2MG
50MG; 2MG
+ 60MG; 2.4MG
80MG; 3.2MG
100MG; 4MG

N022321 001 Aug 13, 2009 Mar CAHN
N022321 002 Aug 13, 2009 Mar CAHN
N022321 003 Aug 13, 2009 Mar CAHN
N022321 004 Aug 13, 2009 Mar CAHN
N022321 005 Aug 13, 2009 Mar CAHN
N022321 006 Aug 13, 2009 Mar CAHN

MOXIFLOXACIN HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
MOXIFLOXACIN HYDROCHLORIDE

AT	LUPIN LTD	EQ 0.5% BASE	A202867	001	Sep 04, 2014	Aug NEWA
	VIGAMOX					
AT	+ ALCON PHARMS LTD	EQ 0.5% BASE	N021598	001	Apr 15, 2003	Aug CFTG
	TABLET;ORAL					
	AVELOX					
AB	+ BAYER HLTHCARE	EQ 400MG BASE	N021085	001	Dec 10, 1999	Feb CFTG
	MOXIFLOXACIN HYDROCHLORIDE					
AB	AUROBINDO PHARMA LTD	EQ 400MG BASE	A202632	001	Mar 04, 2014	Feb NEWA
AB	DR REDDYS LABS LTD	EQ 400MG BASE	A076938	001	Mar 04, 2014	Feb NEWA
AB	TEVA PHARMS USA	EQ 400MG BASE	A077437	001	Feb 18, 2014	Feb NEWA
AB	TORRENT PHARMS LTD	EQ 400MG BASE	A200160	001	Apr 03, 2014	Mar NEWA

MYCOPHENOLATE MOFETILCAPSULE;ORAL
MYCOPHENOLATE MOFETIL
STRIDES PHARMA
TABLET;ORAL
MYCOPHENOLATE MOFETIL

AB	STRIDES PHARMA	250MG	A090055	001	Jun 10, 2010	Aug CAHN
	TABLET;ORAL					
	MYCOPHENOLATE MOFETIL					
AB	STRIDES PHARMA	500MG	A090456	001	Jun 10, 2010	Aug CAHN

MYCOPHENOLIC ACIDTABLET, DELAYED RELEASE;ORAL
MYCOPHENOLIC ACID

AB	APOTEX INC	360MG	A091558	002	Aug 19, 2014	Aug NEWA
----	------------	-------	---------	-----	--------------	----------

NAFCILLIN SODIUMINJECTABLE;INJECTION
NAFCILLIN SODIUM

AP	AGILA SPECLTS	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014	Mar NEWA
AP		EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014	Mar NEWA
AP	ANTIBIOTICE	EQ 1GM BASE/VIAL	A090560	001	Oct 03, 2011	Jan CPOT
AP		EQ 2GM BASE/VIAL	A090560	002	Oct 03, 2011	Jan CPOT
AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A090002	001	Jun 30, 2011	Feb CAHN
AP		EQ 2GM BASE/VIAL	A090002	002	Jun 30, 2011	Feb CAHN
AP		EQ 10GM BASE/VIAL	A090005	001	Apr 20, 2011	Feb CAHN

>A> NALOXEGOL OXALATE>A> TABLET;ORAL
>A> MOVANTIK

>A>	ASTRAZENECA PHARMS	EQ 12.5MG BASE	N204760	001	Sep 16, 2014	Sep NEWA
>A>	+	EQ 25MG BASE	N204760	002	Sep 16, 2014	Sep NEWA

NALOXONE HYDROCHLORIDEINJECTABLE;INJECTION
NALOXONE HYDROCHLORIDE

AP	MYLAN INSTITUTIONAL	0.4MG/ML	A204997	001	Mar 06, 2014	Feb NEWA
	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS					
	EVZIO					
+	KALEO INC	0.4MG/0.4ML	N205787	001	Apr 03, 2014	Apr NEWA

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
TARGINIQ

@	PURDUE PHARMA LP	5MG;10MG	N205777	001	Jul 23, 2014	Jul DISC
@		10MG;20MG	N205777	002	Jul 23, 2014	Jul DISC
@		20MG;40MG	N205777	003	Jul 23, 2014	Jul DISC

NAPHAZOLINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
ALBALON

@	ALLERGAN	0.1%	A080248	001		Jun DISC
	NAPHAZOLINE HYDROCHLORIDE					
+	AKORN INC	0.1%	A083590	001		Jun CRLD

NAPROXEN

TABLET; ORAL

NAPROXEN

	@ DAVA PHARMS INC	250MG	A074410	001	Apr 28, 1995	Feb	DISC
	@	375MG	A074410	002	Apr 28, 1995	Feb	DISC
	@	500MG	A074410	003	Apr 28, 1995	Feb	DISC
>A>	AB	HIKMA INTL PHARMS	250MG	A076494	001	Jan 14, 2004	Sep CAHN
>A>	AB		375MG	A076494	002	Jan 14, 2004	Sep CAHN
>A>	AB		500MG	A076494	003	Jan 14, 2004	Sep CAHN
>D>	AB	HIKMA PHARMS LLC	250MG	A076494	001	Jan 14, 2004	Sep CAHN
>D>	AB		375MG	A076494	002	Jan 14, 2004	Sep CAHN
>D>	AB		500MG	A076494	003	Jan 14, 2004	Sep CAHN
	@ WATSON LABS	250MG	A074457	001	May 31, 1995	May	DISC
	@	375MG	A074457	002	May 31, 1995	May	DISC
	@	500MG	A074457	003	May 31, 1995	May	DISC

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

	@ WATSON LABS	EQ 250MG BASE	A074455	001	May 31, 1995	May	DISC
	@	EQ 500MG BASE	A074455	002	May 31, 1995	May	DISC
	TABLET, EXTENDED RELEASE; ORAL						
	NAPRELAN						
AB	ALMATICA PHARMA INC	EQ 375MG BASE	N020353	001	Jan 05, 1996	Aug	CTEC
AB		EQ 500MG BASE	N020353	002	Jan 05, 1996	Aug	CTEC
	NAPROXEN SODIUM						
AB	ACTAVIS LABS FL INC	EQ 375MG BASE	A075416	002	Apr 23, 2003	Aug	CMFD
AB		EQ 500MG BASE	A075416	001	Aug 27, 2002	Aug	CMFD

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB	APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011	Jan	CAIN
AB		EQ 2.5MG BASE	A091373	002	Apr 22, 2011	Jan	CAIN
AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	Jan	CAIN

NETUPITANT; PALONOSETRON HYDROCHLORIDE

CAPSULE; ORAL

>A>	AKYNZEO						
>A>	+	HELSINN HLTHCARE	300MG; EQ 0.5MG BASE	N205718	001	Oct 10, 2014	Sep NEWA

NEVIRAPINE

TABLET; ORAL

NEVIRAPINE

AB	STRIDES ARCOLAB LTD	200MG	A078195	001	May 22, 2012	Jan	CAHN
AB	STRIDES PHARMA	200MG	A078195	001	May 22, 2012	Aug	CAHN
	TABLET, EXTENDED RELEASE; ORAL						
	NEVIRAPINE						
AB	APOTEX INC	400MG	A205258	001	Apr 03, 2014	Mar	NEWA
AB	SANDOZ	400MG	A203411	001	Apr 03, 2014	Mar	NEWA
	VIRAMUNE XR						
AB	+	BOEHRINGER INGELHEIM	400MG	N201152	001	Mar 25, 2011	Mar CFTG

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

AB	LUPIN LTD	1GM	A090446	001	Mar 20, 2014	Mar	NEWA
AB		500MG	A090860	001	Mar 20, 2014	Mar	NEWA
AB		750MG	A090892	001	Mar 20, 2014	Mar	NEWA
AB	SUN PHARMA GLOBAL	1GM	A200484	002	Apr 23, 2014	Apr	NEWA
AB		500MG	A200484	001	Apr 23, 2014	Apr	NEWA
AB		750MG	A201273	001	Apr 23, 2014	Apr	NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

CARDENE

AB	CHIESI USA INC	20MG	N019488	001	Dec 21, 1988	Apr	CAHN
AB	+	30MG	N019488	002	Dec 21, 1988	Apr	CAHN
	NICARDIPINE HYDROCHLORIDE						
AB	ANI PHARMS INC	20MG	A074439	001	Dec 10, 1996	Jan	CAHN
AB		20MG	A074540	001	Oct 28, 1996	Jan	CAHN

CAPSULE;ORAL

NICARDIPINE HYDROCHLORIDE

AB		30MG	A074439	002	Dec 10, 1996	Jan CAHN
AB		30MG	A074540	002	Oct 28, 1996	Jan CAHN
	@ WATSON LABS	20MG	A074670	001	Oct 28, 1996	May DISC
	@	30MG	A074670	002	Oct 28, 1996	May DISC

CAPSULE, EXTENDED RELEASE;ORAL

CARDENE SR

+	CHIESI USA INC	30MG	N020005	001	Feb 21, 1992	Apr CAHN
@		45MG	N020005	002	Feb 21, 1992	Apr CAHN
+		60MG	N020005	003	Feb 21, 1992	Apr CAHN

INJECTABLE;INJECTION

CARDENE

AP	+	CHIESI USA INC	25MG/10ML (2.5MG/ML)	N019734	001	Jan 30, 1992	Apr CAHN
		NICARDIPINE HYDROCHLORIDE					
AP		LUITPOLD	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Jan CAHN

INJECTABLE;INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

+	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008	Apr CAHN
		CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER				
+	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008	Apr CAHN
		CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER				
+	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	002	Jul 31, 2008	Apr CAHN
		CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER				
+	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	005	Nov 07, 2008	Apr CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

AB2		TWI PHARMS INC	30MG	A203126	001	Apr 03, 2014	Mar NEWA
AB2			60MG	A203126	002	Apr 03, 2014	Mar NEWA
AB2			90MG	A203126	003	Apr 03, 2014	Mar NEWA

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

AB		THEPHARMANETWORK LLC	30MG	A090103	001	Apr 07, 2014	Mar NEWA
----	--	----------------------	------	---------	-----	--------------	----------

SOLUTION;ORAL

NYMALIZE

>D>	+	ARBOR PHARMS INC	60MG/20ML	N203340	001	May 10, 2013	Sep CAHN
>A>	+	ARBOR PHARMS LLC	60MG/20ML	N203340	001	May 10, 2013	Sep CAHN

NITROFURANTOIN

SUSPENSION;ORAL

NITROFURANTOIN

>D>	AB	CARACO	25MG/5ML	A201355	001	Aug 14, 2013	Sep CAHN
	AB	NOVEL LABS INC	25MG/5ML	A201693	001	Sep 08, 2014	Aug NEWA
>A>	AB	SUN PHARM INDS INC	25MG/5ML	A201355	001	Aug 14, 2013	Sep CAHN

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL

MINITRAN

AB1		VALEANT PHARM NORTH	0.1MG/HR	A089771	001	Aug 30, 1996	Aug CAHN
AB1			0.6MG/HR	A089774	001	Aug 30, 1996	Aug CAHN

NITROGLYCERIN

@	KREMERS URBAN PHARMS	0.2MG/HR	A075115	001	Aug 10, 2004	May DISC
---	----------------------	----------	---------	-----	--------------	----------

@		0.4MG/HR	A075115	002	Aug 10, 2004	May DISC
---	--	----------	---------	-----	--------------	----------

OINTMENT;INTRA-ANAL

RECTIV

+	FOREST LABS INC	0.4%	N021359	001	Jun 21, 2011	Apr CAHN
---	-----------------	------	---------	-----	--------------	----------

NIZATIDINE

CAPSULE;ORAL

NIZATIDINE

	@	ANI PHARMS INC	150MG	A075461	001	Jul 08, 2002	Jan CAHN
AB			150MG	A075668	001	Sep 12, 2002	Jan CAHN
	@		300MG	A075461	002	Jul 08, 2002	Jan CAHN
AB			300MG	A075668	002	Sep 12, 2002	Jan CAHN

NORFLOXACIN

TABLET; ORAL

NOROXIN

@ MERCK

400MG

N019384 002 Oct 31, 1986 Jul DISC

NORTRIPTYLINE HYDROCHLORIDE

SOLUTION; ORAL

NORTRIPTYLINE HYDROCHLORIDE

AA + PHARM ASSOC EQ 10MG BASE/5ML

A075606 001 Aug 28, 2000 Apr CRLD

NYSTATIN

CREAM; TOPICAL

MYCOSTATIN

@ DELCOR ASSET CORP

100,000 UNITS/GM

A060575 001

Jul CAHN

OINTMENT; TOPICAL

MYCOSTATIN

@ DELCOR ASSET CORP

100,000 UNITS/GM

A060571 001

Jul CAHN

POWDER; TOPICAL

MYCOSTATIN

@ DELCOR ASSET CORP

100,000 UNITS/GM

A060578 001

Jul CAHN

SUSPENSION; ORAL

MYCOSTATIN

@ DELCOR ASSET CORP

100,000 UNITS/ML

A061533 001

Jul CAHN

TABLET; ORAL

MYCOSTATIN

@ DELCOR ASSET CORP

500,000 UNITS

A060574 001

Jul CAHN

TABLET; VAGINAL

MYCOSTATIN

@ DELCOR ASSET CORP

100,000 UNITS

A060577 001

Jul CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYCOLOG-II

>D> @ APOTHECON 100,000 UNITS/GM; 0.1%

A060576 002 May 01, 1985 Sep CAHN

>D> @ 100,000 UNITS/GM; 0.1%

A062606 001 May 15, 1985 Sep CAHN

>A> @ DELCOR ASSET CORP 100,000 UNITS/GM; 0.1%

A060576 002 May 01, 1985 Sep CAHN

>A> @ 100,000 UNITS/GM; 0.1%

A062606 001 May 15, 1985 Sep CAHN

OINTMENT; TOPICAL

MYCOLOG-II

>D> @ APOTHECON 100,000 UNITS/GM; 0.1%

A060572 001 Jun 28, 1985 Sep CAHN

>A> @ DELCOR ASSET CORP 100,000 UNITS/GM; 0.1%

A060572 001 Jun 28, 1985 Sep CAHN

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

AP + EUROHLTH INTL EQ 0.2MG BASE/ML

A076330 001 Apr 08, 2005 Aug CAHN

AP + EQ 1MG BASE/ML

A076330 002 Apr 08, 2005 Aug CAHN

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP + EUROHLTH INTL EQ 0.05MG BASE/ML

A076313 001 Mar 28, 2005 Aug CAHN

AP + EQ 0.1MG BASE/ML

A076313 003 Mar 28, 2005 Aug CAHN

AP + EQ 0.5MG BASE/ML

A076313 002 Mar 28, 2005 Aug CAHN

OFLOXACIN

TABLET; ORAL

OFLOXACIN

>A> AB CADILA PHARMS LTD 200MG

A091656 001 Sep 18, 2014 Sep NEWA

>A> AB 300MG

A091656 002 Sep 18, 2014 Sep NEWA

>A> AB 400MG

A091656 003 Sep 18, 2014 Sep NEWA

OLANZAPINE

TABLET; ORAL

OLANZAPINE

AB MACLEODS PHARMS LTD 2.5MG

A202862 001 Aug 15, 2014 Aug NEWA

AB 5MG

A202862 002 Aug 15, 2014 Aug NEWA

AB 7.5MG

A202862 003 Aug 15, 2014 Aug NEWA

AB 10MG

A202862 004 Aug 15, 2014 Aug NEWA

AB 15MG

A202862 005 Aug 15, 2014 Aug NEWA

AB 20MG

A202862 006 Aug 15, 2014 Aug NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
OLANZAPINE

AB	AUROBINDO PHARMA LTD	5MG	A203708	001	May 15, 2014	Apr	NEWA
AB		10MG	A203708	002	May 15, 2014	Apr	NEWA
AB		15MG	A203708	003	May 15, 2014	Apr	NEWA
AB		20MG	A203708	004	May 15, 2014	Apr	NEWA
AB	JUBILANT GENERICS	5MG	A200221	001	Sep 12, 2012	Jul	CAHN
AB		10MG	A200221	002	Sep 12, 2012	Jul	CAHN
AB		15MG	A200221	003	Sep 12, 2012	Jul	CAHN
AB		20MG	A200221	004	Sep 12, 2012	Jul	CAHN
AB	MYLAN PHARMS INC	5MG	A202285	001	May 12, 2014	Apr	NEWA
AB		10MG	A202285	002	May 12, 2014	Apr	NEWA
AB		15MG	A202285	003	May 12, 2014	Apr	NEWA
AB		20MG	A202285	004	May 12, 2014	Apr	NEWA

OLODATEROL HYDROCHLORIDE

SPRAY, METERED;INHALATION
STRIVERDI RESPIMAT

>D>	+	BOEHRINGER INGELHEIM	EQ 2.5MG BASE/INH	N203108	001	Jul 31, 2014	Sep	CPOT
>A>	+		EQ 0.0025MG BASE/INH	N203108	001	Jul 31, 2014	Sep	CPOT
	+		EQ 2.5MG BASE/INH	N203108	001	Jul 31, 2014	Jul	NEWA

OLOPATADINE HYDROCHLORIDE

SPRAY, METERED;NASAL
OLOPATADINE HYDROCHLORIDE

>A>	AB	APOTEX INC	0.665MG/SPRAY	A091572	001	Oct 08, 2014	Sep	NEWA
		PATANASE						
>D>	+	ALCON PHARMS LTD	0.665MG/SPRAY	N021861	001	Apr 15, 2008	Sep	CFTG
>A>	AB	+	0.665MG/SPRAY	N021861	001	Apr 15, 2008	Sep	CFTG

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL
LOVAZA

AB	+	SMITHKLINE BEECHAM	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004	Mar	CFTG
		OMEGA-3-ACID ETHYL ESTERS						
>A>	AB	APOTEX INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A090973	001	Sep 30, 2014	Sep	NEWA
	AB	TEVA PHARMS USA	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091028	001	Apr 07, 2014	Mar	NEWA
		OMTRYG						
	+	TRYGG	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Apr	NEWA

OMEGA-3-CARBOXYLIC ACIDS

CAPSULE;ORAL
EPANOVA

+	ASTRAZENECA PHARMS	1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	N205060	001	May 05, 2014	May	NEWA
---	--------------------	--	---------	-----	--------------	-----	------

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL
ZEGERID

AB	SANTARUS INC	20MG;1.1GM	N021849	001	Feb 27, 2006	Feb	CAHN
AB	+	40MG;1.1GM	N021849	002	Feb 27, 2006	Feb	CAHN
	FOR SUSPENSION;ORAL						
	OMEPRAZOLE AND SODIUM BICARBONATE						
	@ PAR PHARM	20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Jun	DISC
	@	40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Jun	DISC
	ZEGERID						
	SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jun	CTEC
AB		20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Feb	CAHN
	+	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jun	CTEC
	+	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Feb	CAHN

ONDANSETRONFILM; ORAL
ZUPLENZGALENA BIOPHARMA INC 4MG
+ 8MGN022524 001 Jul 02, 2010 Aug CAHN
N022524 002 Jul 02, 2010 Aug CAHNONDANSETRON HYDROCHLORIDEINJECTABLE; INJECTION
ONDANSETRON HYDROCHLORIDEAP @ LANNETT EQ 2MG BASE/ML
QILU PHARM CO LTD EQ 2MG BASE/MLA090116 001 Apr 14, 2010 Jan DISC
A203711 001 Sep 08, 2014 Aug NEWA

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

AB IPCA LABS LTD EQ 4MG BASE
AB EQ 8MG BASEA203761 001 Jan 23, 2014 Jan NEWA
A203761 002 Jan 23, 2014 Jan NEWAORITAVANCIN DIPHOSPHATEPOWDER; IV (INFUSION)
ORBACTIV

+ MEDICINES CO EQ 400MG BASE/VIAL

N206334 001 Aug 06, 2014 Aug NEWA

ORPHENADRINE CITRATEINJECTABLE; INJECTION
ORPHENADRINE CITRATEAP EUROHLTH INTL 30MG/ML
@ WATSON LABS 30MG/MLA040463 001 Mar 04, 2003 Aug CAHN
A087062 001 May DISCOXACILLIN SODIUMINJECTABLE; INJECTION
OXACILLIN SODIUMAP AGILA SPECLTS EQ 1GM BASE/VIAL
AP EQ 2GM BASE/VIAL
@ ISTITUTO BIO ITA SPA EQ 1GM BASE/VIAL
@ EQ 2GM BASE/VIAL
@ EQ 125MG BASE/VIAL
@ EQ 250MG BASE/VIAL
@ EQ 500MG BASE/VIAL
>D> AP SANDOZ EQ 1GM BASE/VIAL
>D> AP EQ 2GM BASE/VIALA091486 001 Aug 25, 2014 Aug NEWA
A091486 002 Aug 25, 2014 Aug NEWA
A062798 001 Dec 11, 1995 Feb CAHN
A062798 002 Dec 11, 1995 Feb CAHN
A062798 003 Dec 11, 1995 Feb CAHN
A062798 004 Dec 11, 1995 Feb CAHN
A062798 005 Dec 11, 1995 Feb CAHN
A062737 001 Dec 23, 1986 Sep CDFR
A062737 002 Dec 23, 1986 Sep CDFRPOWDER; INTRAVENOUS
OXACILLIN SODIUM>A> AP + SANDOZ EQ 1GM BASE/VIAL
>A> AP EQ 1GM BASE/VIAL
>A> AP + EQ 2GM BASE/VIAL
>A> AP EQ 2GM BASE/VIALA062737 001 Dec 23, 1986 Sep CRLD
A062737 001 Dec 23, 1986 Sep CDFR
A062737 002 Dec 23, 1986 Sep CRLD
A062737 002 Dec 23, 1986 Sep CDFROXALIPLATININJECTABLE; IV (INFUSION)
OXALIPLATINAP ACTAVIS ELIZABETH 50MG/VIAL
AP 100MG/VIAL
AP JIANGSU HENGRUI MED 50MG/10ML (5MG/ML)
AP 100MG/20ML (5MG/ML)
AP SUN PHARMA GLOBAL 50MG/10ML (5MG/ML)
AP 100MG/20ML (5MG/ML)A078803 001 Aug 08, 2012 Aug CAHN
A078803 002 Aug 08, 2012 Aug CAHN
A203869 001 Jun 18, 2014 Jun NEWA
A203869 002 Jun 18, 2014 Jun NEWA
A202922 001 Apr 08, 2014 Mar NEWA
A202922 002 Apr 08, 2014 Mar NEWAOXANDROLONETABLET; ORAL
OXANDRINAB CREALTA PHARMS LLC 2.5MG
AB + 10MGN013718 001 Jan CAHN
N013718 002 Nov 05, 2001 Jan CAHNOXAPROZINTABLET; ORAL
OXAPROZINAB SUN PHARM INDS INC 600MG
@ WATSON LABS 600MGA075844 001 Jan 03, 2002 Jul CAHN
A075848 001 Feb 09, 2001 May DISC

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

@	IVAX SUB TEVA PHARMS	10MG	A070943	001	Aug 03, 1987	Apr	DISC
@		15MG	A070944	001	Aug 03, 1987	Apr	DISC
@		30MG	A070945	001	Aug 03, 1987	Apr	DISC
@	WATSON LABS	10MG	A072952	001	Sep 28, 1990	May	DISC
@		15MG	A072953	001	Sep 28, 1990	May	DISC
@		30MG	A072954	001	Sep 28, 1990	May	DISC

OXCARBAZEPINE

TABLET;ORAL

OXCARBAZEPINE

@	ANI PHARMS INC	150MG	A078005	001	Dec 11, 2007	Jan	CAHN
@		300MG	A078005	002	Dec 11, 2007	Jan	CAHN
@		600MG	A078005	003	Dec 11, 2007	Jan	CAHN

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYBUTYNIN

AB	BARR LABS DIV TEVA	3.9MG/24HR	A090526	001	Mar 04, 2014	Feb	NEWA
AB	+ WATSON LABS (UTAH)	3.9MG/24HR	N021351	002	Feb 26, 2003	Feb	CFTG

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

AB	LANNETT HOLDINGS INC	5MG	A203823	001	Aug 01, 2014	Jul	NEWA
----	----------------------	-----	---------	-----	--------------	-----	------

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

AA	COASTAL PHARMS	100MG/5ML	A204092	001	Jun 05, 2014	May	NEWA
AA	LANNETT HOLDINGS INC	100MG/5ML	A204085	001	Sep 09, 2014	Aug	NEWA
AA	LEHIGH VALLEY	5MG/5ML	N200535	002	Aug 22, 2013	Jun	NEWA

TABLET;ORAL

OXECTA

	ACURA PHARMS INC	5MG	N202080	001	Jun 17, 2011	May	CAHN
		7.5MG	N202080	002	Jun 17, 2011	May	CAHN

OXYCODONE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	15MG	A076636	001	Feb 06, 2004	Jul	CAHN
AB		30MG	A076636	002	Feb 06, 2004	Jul	CAHN
AB	AMNEAL PHARMS	5MG	A203638	001	Jun 03, 2014	May	NEWA
AB		10MG	A203638	002	Jun 03, 2014	May	NEWA
AB		15MG	A203638	003	Jun 03, 2014	May	NEWA
AB		20MG	A203638	004	Jun 03, 2014	May	NEWA
AB		30MG	A203638	005	Jun 03, 2014	May	NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

AB	MALLINCKRODT INC	5MG	A202946	001	Jun 27, 2014	Jun	NEWA
AB		7.5MG	A202946	002	Jun 27, 2014	Jun	NEWA
AB		10MG	A202946	003	Jun 27, 2014	Jun	NEWA
AB		15MG	A202946	004	Jun 27, 2014	Jun	NEWA
AB		20MG	A202946	005	Jun 27, 2014	Jun	NEWA
AB		30MG	A202946	006	Jun 27, 2014	Jun	NEWA
AB		40MG	A202946	007	Jun 27, 2014	Jun	NEWA

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

AP	+ HIKMA MAPLE	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		May	CAHN
AP	+	100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	May	CAHN
	PITOCIN						
AP	+ PAR STERILE PRODUCTS	10USP UNITS/ML (10USP UNITS/ML)	N018261	001		Apr	CAHN
AP		100USP UNITS/10ML (10USP UNITS/ML)	N018261	002	Jul 27, 2007	Apr	CAHN
		500USP UNITS/50ML (10USP UNITS/ML)	N018261	003	Sep 05, 2012	Apr	CAHN

SOLUTION;NASAL

SYNTOCINON

@	RETROPHIN INC	40USP UNITS/ML	N012285	001		Feb	CAHN
---	---------------	----------------	---------	-----	--	-----	------

PACLITAXELINJECTABLE; INJECTION
PACLITAXEL

AP	ACTAVIS ELIZABETH	6MG/ML	A090130	001	Dec 09, 2009	Aug CAHN
AP	EUROHLTH INTL	6MG/ML	A075190	001	Jan 28, 2002	Aug CAHN
	@ MYLAN	6MG/ML	A075278	001	Jan 25, 2002	Jun DISC

PAMIDRONATE DISODIUMINJECTABLE; INJECTION
PAMIDRONATE DISODIUM

AP	EUROHLTH INTL	30MG/VIAL	A075290	001	Apr 30, 2001	Aug CAHN
AP	+	30MG/10ML (3MG/ML)	N021113	001	Mar 04, 2002	Aug CAHN
AP		90MG/VIAL	A075290	003	Apr 30, 2001	Aug CAHN
AP	+	90MG/10ML (9MG/ML)	N021113	002	Mar 04, 2002	Aug CAHN
	@ MN PHARMS	30MG/VIAL	A078300	001	Mar 10, 2009	Jan DISC
	@	90MG/VIAL	A078300	002	Mar 10, 2009	Jan DISC

PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)CAPSULE, DELAYED RELEASE; ORAL
PANCREAZE

	JANSSEN PHARMS	10,850USP UNITS; 2,600USP UNITS; 6,200USP UNITS	N022523	005	Mar 07, 2014	Jun NEWA
--	----------------	---	---------	-----	--------------	----------

ULTRESA

	FOREST LABS INC	27,600USP UNITS; 13,800USP UNITS; 27,600USP UNITS	N022222	001	Mar 01, 2012	May CAHN
		41,400USP UNITS; 20,700USP UNITS; 41,400USP UNITS	N022222	002	Mar 01, 2012	May CAHN
+		46,000USP UNITS; 23,000USP UNITS; 46,000USP UNITS	N022222	003	Mar 01, 2012	May CAHN

ZENPEP

	APTALIS PHARMA US	218,000USP UNITS; 40,000USP UNITS; 136,000 USP UNITS	N022210	007	Mar 25, 2014	Mar NEWA
	FOREST LABS INC	218,000USP UNITS; 40,000USP UNITS; 136,000 USP UNITS	N022210	007	Mar 25, 2014	Apr CAHN
		16,000USP UNITS; 3,000USP UNITS; 10,000USP UNITS	N022210	005	Jun 15, 2011	Apr CAHN
		55,000USP UNITS; 10,000USP UNITS; 34,000USP UNITS	N022210	002	Aug 27, 2009	Apr CAHN
		82,000USP UNITS; 15,000USP UNITS; 51,000USP UNITS	N022210	003	Aug 27, 2009	Apr CAHN
		27,000USP UNITS; 5,000USP UNITS; 17,000USP UNITS	N022210	001	Aug 27, 2009	Apr CAHN
		109,000USP UNITS; 20,000USP UNITS; 68,000USP UNITS	N022210	004	Aug 27, 2009	Apr CAHN
+		136,000USP UNITS; 25,000USP UNITS; 85,000USP UNITS	N022210	006	Jul 13, 2011	Apr CAHN

TABLET; ORAL
VIOKACE

	FOREST LABS INC	39,150USP UNITS; 10,440USP UNITS; 39,150USP UNITS	N022542	001	Mar 01, 2012	Apr CAHN
+		78,300USP UNITS; 20,880USP UNITS; 78,300USP UNITS	N022542	002	Mar 01, 2012	Apr CAHN
	FOREST RES INST INC	39,150USP UNITS; 10,440USP UNITS; 39,150USP UNITS	N022542	001	Mar 01, 2012	Mar CAHN
+		78,300USP UNITS; 20,880USP UNITS; 78,300USP UNITS	N022542	002	Mar 01, 2012	Mar CAHN

PANTOPRAZOLE SODIUMTABLET, DELAYED RELEASE; ORAL
PANTOPRAZOLE SODIUM

AB	ACTAVIS ELIZABETH	EQ 20MG BASE	A090797	001	Feb 07, 2011	Aug CAHN
AB		EQ 40MG BASE	A090797	002	Feb 07, 2011	Aug CAHN
AB	HETERO LABS LTD V	EQ 20MG BASE	A202882	001	Sep 10, 2014	Aug NEWA
AB		EQ 40MG BASE	A202882	002	Sep 10, 2014	Aug NEWA
AB	JUBILANT GENERICS	EQ 20MG BASE	A090901	001	Aug 30, 2011	Jul CAHN
AB		EQ 40MG BASE	A090901	002	Aug 30, 2011	Jul CAHN
AB	PERRIGO R AND D	EQ 20MG BASE	A203024	001	May 07, 2014	Apr NEWA

PARICALCITOLCAPSULE; ORAL
PARICALCITOL

>D>	AB	ANCHEN PHARMS	1MCG	A202124	001	Jun 24, 2014	Sep CAHN
	AB		1MCG	A202124	001	Jun 24, 2014	Jun NEWA
>D>	AB		2MCG	A202124	002	Jun 24, 2014	Sep CAHN
	AB		2MCG	A202124	002	Jun 24, 2014	Jun NEWA

CAPSULE;ORAL
PARICALCITOL

>D>	AB		4MCG	A202124	003	Jun 24, 2014	Sep CAHN
	AB		4MCG	A202124	003	Jun 24, 2014	Jun NEWA
	AB	BANNER PHARMACAPS	1MCG	A202539	001	Mar 27, 2014	Mar NEWA
	AB		2MCG	A202539	002	Mar 27, 2014	Mar NEWA
	AB		4MCG	A202539	003	Mar 27, 2014	Mar NEWA
	AB	DR REDDYS LABS LTD	1MCG	A091412	001	Jun 24, 2014	Jun NEWA
	AB		2MCG	A091412	002	Jun 24, 2014	Jun NEWA
	AB		4MCG	A091412	003	Jun 24, 2014	Jun NEWA
>A>	AB	RISING PHARMS INC	1MCG	A202124	001	Jun 24, 2014	Sep CAHN
>A>	AB		2MCG	A202124	002	Jun 24, 2014	Sep CAHN
>A>	AB		4MCG	A202124	003	Jun 24, 2014	Sep CAHN

PAROMOMYCIN SULFATECAPSULE;ORAL
PAROMOMYCIN SULFATE

AA	+	SUN PHARM INDS INC	EQ 250MG BASE	A064171	001	Jun 30, 1997	Jul CAHN
----	---	--------------------	---------------	---------	-----	--------------	----------

PAROXETINE HYDROCHLORIDECAPSULE;ORAL
PAXIL

	@	APOTEX TECHNOLOGIES	EQ 10MG BASE	N020885	001	Oct 09, 1998	Feb CAHN
	@		EQ 20MG BASE	N020885	002	Oct 09, 1998	Feb CAHN
	@		EQ 30MG BASE	N020885	003	Oct 09, 1998	Feb CAHN
	@		EQ 40MG BASE	N020885	004	Oct 09, 1998	Feb CAHN

SUSPENSION;ORAL

PAXIL

AB	+	APOTEX TECHNOLOGIES	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Feb CAHN
----	---	---------------------	------------------	---------	-----	--------------	----------

TABLET;ORAL

PAROXETINE HYDROCHLORIDE

AB		SUN PHARM INDS INC	EQ 10MG BASE	A078194	001	Jun 29, 2007	Jul CAHN
AB			EQ 20MG BASE	A078194	002	Jun 29, 2007	Jul CAHN
AB			EQ 30MG BASE	A078194	003	Jun 29, 2007	Jul CAHN
AB			EQ 40MG BASE	A078194	004	Jun 29, 2007	Jul CAHN

PAXIL

AB		APOTEX TECHNOLOGIES	EQ 10MG BASE	N020031	001	Dec 29, 1992	Jan CAHN
AB			EQ 20MG BASE	N020031	002	Dec 29, 1992	Jan CAHN
AB			EQ 30MG BASE	N020031	003	Dec 29, 1992	Jan CAHN
AB	+		EQ 40MG BASE	N020031	005	Dec 29, 1992	Jan CAHN
	@		EQ 50MG BASE	N020031	004	Dec 29, 1992	Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

PAXIL CR

AB		APOTEX TECHNOLOGIES	EQ 12.5MG BASE	N020936	001	Feb 16, 1999	Feb CAHN
AB			EQ 25MG BASE	N020936	002	Feb 16, 1999	Feb CAHN
AB	+		EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Feb CAHN

PEGVISOMANTINJECTABLE;SUBCUTANEOUS
SOMAVERT

	+	PHARMACIA AND UPJOHN	25MG/VIAL	N021106	004	Jul 31, 2014	Jul NEWA
	+		30MG/VIAL	N021106	005	Jul 31, 2014	Jul NEWA

PEMIROLAST POTASSIUMSOLUTION/DROPS;OPHTHALMIC
ALAMAST

	@	SANTEN	0.1%	N021079	001	Sep 24, 1999	Jun DISC
--	---	--------	------	---------	-----	--------------	----------

PEMOLINE

TABLET;ORAL

PEMOLINE

	@	ACTAVIS ELIZABETH	18.75MG	A075595	001	Feb 28, 2000	Aug CAHN
	@		37.5MG	A075595	002	Feb 28, 2000	Aug CAHN
	@		75MG	A075595	003	Feb 28, 2000	Aug CAHN

TABLET, CHEWABLE;ORAL

PEMOLINE

	@	ACTAVIS ELIZABETH	37.5MG	A075678	001	Jul 26, 2000	Aug CAHN
--	---	-------------------	--------	---------	-----	--------------	----------

PENBUTOLOL SULFATE

TABLET; ORAL

LEVATOL

	@ AUXILIUM PHARMS LLC	10MG	N018976	001	Dec 30, 1987	Apr CAHN
>D>	+	20MG	N018976	004	Jan 05, 1989	Sep DISC
>A>	@	20MG	N018976	004	Jan 05, 1989	Sep DISC
	+	20MG	N018976	004	Jan 05, 1989	Apr CAHN

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

AP	ISTITUTO BIO ITA SPA	5,000,000 UNITS/VIAL	A065448	001	Aug 18, 2009	Feb CAHN
AP		20,000,000 UNITS/VIAL	A065448	002	Aug 18, 2009	Feb CAHN

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

PENTAM

	+	FRESENIUS KABI USA	300MG/VIAL	N019264	001	Oct 16, 1984	May CTEC
		PENTAMIDINE ISETHIONATE					
	@	WATSON LABS	300MG/VIAL	A074303	001	Aug 17, 1995	May DISC

PENTOSTATIN

INJECTABLE; INJECTION

PENTOSTATIN

AP	EUROHLTH INTL	10MG/VIAL	A077841	001	Aug 07, 2007	Aug CAHN
>A> AP	MYLAN INSTITUTIONAL	10MG/VIAL	A203554	001	Sep 19, 2014	Sep NEWA

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

>A> AB	VALEANT BERMUDA	400MG	A075028	001	Jul 20, 1998	Sep CAHN
>D> AB	VALEANT INTL	400MG	A075028	001	Jul 20, 1998	Sep CAHN
	@ WATSON LABS	400MG	A075107	001	Sep 04, 1998	May DISC
	TRENTAL					
	@ SANOFI AVENTIS US	400MG	N018631	001	Aug 30, 1984	Jun DISC

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

AB	SYMPMED PHARMS LLC	2MG	N020184	001	Dec 30, 1993	Jul CAHN
AB		4MG	N020184	002	Dec 30, 1993	Jul CAHN
AB	+	8MG	N020184	003	Dec 30, 1993	Jul CAHN
	PERINDOPRIL ERBUMINE					
AB	ANI PHARMS INC	2MG	A078138	001	Nov 10, 2009	Jan CAHN
AB		4MG	A078138	002	Nov 10, 2009	Jan CAHN
AB		8MG	A078138	003	Nov 10, 2009	Jan CAHN

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

	@ ANI PHARMS INC	8MG	A089456	001	Sep 10, 1987	Apr CAHN
	@ TEVA PHARMS USA	4MG	A089708	001	Sep 10, 1987	Apr CAHN
	@	16MG	A089457	001	Sep 10, 1987	Apr CAHN

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

AA	ELITE LABS INC	35MG	A040762	001	Jan 28, 2008	Apr CAHN
----	----------------	------	---------	-----	--------------	----------

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

AA	INVAGEN PHARMS	15MG	A202858	001	Feb 14, 2014	Feb NEWA
AA		30MG	A202858	002	Feb 14, 2014	Feb NEWA
AA		30MG	A204414	001	May 05, 2014	Apr NEWA
AA		37.5MG	A202846	001	Feb 05, 2014	Jan NEWA
>A> AA	KEN LIFESCIENCE	37.5MG	A205017	001	Sep 25, 2014	Sep NEWA

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

AA	AUROLIFE PHARMA LLC	37.5MG	A203068	001	Aug 06, 2014	Jul NEWA
AA	INVAGEN PHARMS	37.5MG	A202942	001	Feb 05, 2014	Jan NEWA

TABLET;ORAL

PHENTERMINE HYDROCHLORIDE

>A>	AA	KEN LIFESCIENCE	37.5MG	A205008	001	Sep 25, 2014	Sep NEWA
	AA	MIKAH PHARMA	37.5MG	A040190	001	May 30, 1997	May CMFD
	AA	SUN PHARM INDS INC	37.5MG	A040790	001	Aug 21, 2007	Jul CAHN

PHENTOLAMINE MESYLATE

INJECTABLE;INJECTION

PHENTOLAMINE MESYLATE

AP		EUROHLTH INTL	5MG/VIAL	A040235	001	Mar 11, 1998	Aug CAHN
----	--	---------------	----------	---------	-----	--------------	----------

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IV (INFUSION)

VAZCULEP

		ECLAT PHARMS LLC	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Jun NEWA
			50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Jun NEWA
	+		100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Jun NEWA

PHENYTOIN

TABLET, CHEWABLE;ORAL

PHENYTOIN

AB		TARO	50MG	A200565	001	Apr 17, 2014	Apr NEWA
----	--	------	------	---------	-----	--------------	----------

PHENYTOIN SODIUM

CAPSULE;ORAL

EXTENDED PHENYTOIN SODIUM

	@	ANI PHARMS INC	100MG EXTENDED	A040435	001	Jun 20, 2003	Apr CAHN
--	---	----------------	----------------	---------	-----	--------------	----------

	@		100MG EXTENDED	A089441	001	Dec 18, 1986	Jan CAHN
--	---	--	----------------	---------	-----	--------------	----------

PROMPT PHENYTOIN SODIUM

	@	ANI PHARMS INC	100MG PROMPT	A080259	001		Jan CAHN
--	---	----------------	--------------	---------	-----	--	----------

PINDOLOL

TABLET;ORAL

PINDOLOL

AB		MUTUAL PHARM	5MG	A074063	001	Jan 27, 1994	Feb CMFD
AB			10MG	A074063	002	Jan 27, 1994	Feb CMFD
AB		MYLAN PHARMS INC	5MG	A074019	001	Sep 03, 1992	Feb CTEC
AB	+		10MG	A074019	002	Sep 03, 1992	Feb CTEC

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

AB		LUPIN LTD	EQ 15MG BASE	A204133	001	Apr 07, 2014	Mar NEWA
AB			EQ 30MG BASE	A204133	002	Apr 07, 2014	Mar NEWA
AB			EQ 45MG BASE	A204133	003	Apr 07, 2014	Mar NEWA

PIPERACILLIN SODIUM

INJECTABLE;INJECTION

PIPERACILLIN

+		ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL	A065114	001	Nov 14, 2003	Feb CAHN
+			EQ 3GM BASE/VIAL	A065114	002	Nov 14, 2003	Feb CAHN
+			EQ 4GM BASE/VIAL	A065114	003	Nov 14, 2003	Feb CAHN
+			EQ 40GM BASE/VIAL	A065157	001	Jul 12, 2004	Feb CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP		AGILA SPECILTS	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	Aug NEWA
AP			EQ 3MG BASE/VIAL;EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	Aug NEWA
AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014	Aug NEWA
AP		ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065523	001	May 31, 2011	Feb CAHN
AP			EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065523	002	May 31, 2011	Feb CAHN
AP			EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065523	003	May 31, 2011	Feb CAHN
AP			EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A090498	001	May 31, 2011	Feb CAHN

PIRBUTEROL ACETATEAEROSOL, METERED; INHALATION
MAXAIR

@ VALEANT PHARM NORTH	EQ 0.2MG BASE/INH	N019009	001	Dec 30, 1986	Jul CAHN
-----------------------	-------------------	---------	-----	--------------	----------

PIROXICAMCAPSULE; ORAL
PIROXICAM

>A>	@ CYCLE PHARMS LTD	10MG	A073651	001	Feb 26, 1993	Sep CAHN
>A>	@	20MG	A073651	002	Feb 26, 1993	Sep CAHN
>D>	@ ROXANE	10MG	A073651	001	Feb 26, 1993	Sep CAHN
>D>	@	20MG	A073651	002	Feb 26, 1993	Sep CAHN
	@ WATSON LABS	10MG	A074287	001	May 16, 1996	May DISC
	@	10MG	A074460	001	Sep 29, 1995	May DISC
	@	20MG	A074287	002	May 16, 1996	May DISC
	@	20MG	A074460	002	Sep 29, 1995	May DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUSFOR SUSPENSION; ORAL
CO-LAV

@ VINTAGE PHARMS	240GM/BOT; 2.98GM/BOT; 6.72GM/BOT; 5.84GM/BOT; 22.72GM/BOT	A073428	001	Jan 28, 1992	Feb CAHN
------------------	--	---------	-----	--------------	----------

GO-EVAC

@ VINTAGE PHARMS	236GM/BOT; 2.97GM/BOT; 6.74GM/BOT; 5.86GM/BOT; 22.74GM/BOT	A073433	001	Apr 28, 1992	Feb CAHN
------------------	--	---------	-----	--------------	----------

POLYMYXIN B SULFATEINJECTABLE; INJECTION
POLYMYXIN B SULFATE

AP	+	EUROHLTH INTL	EQ 500,000 U BASE/VIAL	A060716	001	Aug CAHN
----	---	---------------	------------------------	---------	-----	----------

PORACTANT ALFASUSPENSION; INTRATRACHEAL
CUROSURF

+	CHIESI USA INC	80MG/ML	N020744	001	Nov 18, 1999	Apr CAHN
---	----------------	---------	---------	-----	--------------	----------

POSACONAZOLESOLUTION; IV (INFUSION)
NOXAFIL

+	MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N205596	001	Mar 13, 2014	Mar NEWA
---	-------------------	------------------------	---------	-----	--------------	----------

POTASSIUM CHLORIDEINJECTABLE; INJECTION
POTASSIUM CHLORIDE

@ INTL MEDICATION	2MEQ/ML	A083163	001	Mar DISC
-------------------	---------	---------	-----	----------

TABLET, EXTENDED RELEASE; ORAL
KLOR-CON

AB2		UPSHER-SMITH LABS	8MEQ	N019123	001	Apr 17, 1986	Aug CTEC
AB2	+		10MEQ	N019123	002	Apr 17, 1986	Aug CTEC
		KLOR-CON M10					
AB1		UPSHER SMITH LABS	10MEQ	A074726	002	Aug 09, 2000	Aug CTEC
		KLOR-CON M20					
AB1	+	UPSHER SMITH LABS	20MEQ	A074726	001	Nov 20, 1998	Aug CTEC
		POTASSIUM CHLORIDE					
AB1		ACTAVIS LABS FL INC	10MEQ	A075604	001	Apr 10, 2002	Aug CTEC
AB1			20MEQ	A075604	002	Apr 10, 2002	Aug CTEC
AB1		EURAND	20MEQ	A076368	001	Aug 18, 2004	Aug CTEC
AB2		MYLAN PHARMS INC	8.0MEQ	A204662	001	Aug 21, 2014	Aug NEWA
AB2			10.0MEQ	A204662	002	Aug 21, 2014	Aug NEWA

POTASSIUM CITRATEFOR SOLUTION; ORAL
POTASSIUM CITRATE

@ UT SW MEDCTR	10MEQ/PACKET	N019647	002	Oct 13, 1988	Jul CAHN
@	20MEQ/PACKET	N019647	001	Oct 13, 1988	Jul CAHN

TABLET, EXTENDED RELEASE; ORAL
POTASSIUM CITRATE

AB		ZYDUS PHARMS USA INC	5MEQ	A203546	001	Aug 06, 2014	Jul NEWA
AB			10MEQ	A203546	002	Aug 06, 2014	Jul NEWA
AB			15MEQ	A203546	003	Aug 06, 2014	Jul NEWA

TABLET, EXTENDED RELEASE;ORAL							
UROCIT-K							
AB	+	MISSION PHARMA	15MEQ	N019071	003	Dec 30, 2009	Jul CTEC
<u>PRAMIPEXOLE DIHYDROCHLORIDE</u>							
TABLET;ORAL							
PRAMIPEXOLE DIHYDROCHLORIDE							
AB		STRIDES ARCOLAB LTD	0.125MG	A202702	001	Jun 03, 2014	May NEWA
AB			0.25MG	A202702	002	Jun 03, 2014	May NEWA
AB			0.5MG	A202702	003	Jun 03, 2014	May NEWA
AB			0.75MG	A202702	004	Jun 03, 2014	May NEWA
AB			1MG	A202702	005	Jun 03, 2014	May NEWA
AB			1.5MG	A202702	006	Jun 03, 2014	May NEWA
AB		STRIDES PHARMA	0.125MG	A202702	001	Jun 03, 2014	Aug CAHN
AB			0.25MG	A202702	002	Jun 03, 2014	Aug CAHN
AB			0.5MG	A202702	003	Jun 03, 2014	Aug CAHN
AB			0.75MG	A202702	004	Jun 03, 2014	Aug CAHN
AB			1MG	A202702	005	Jun 03, 2014	Aug CAHN
AB			1.5MG	A202702	006	Jun 03, 2014	Aug CAHN
TABLET, EXTENDED RELEASE;ORAL							
MIRAPEX ER							
AB	+	BOEHRINGER INGELHEIM	0.375MG	N022421	001	Feb 19, 2010	Jan CFTG
AB			0.75MG	N022421	002	Feb 19, 2010	Jan CFTG
AB			1.5MG	N022421	003	Feb 19, 2010	Jan CFTG
AB			2.25MG	N022421	006	Jun 17, 2011	Jan CFTG
AB			3MG	N022421	004	Feb 19, 2010	Jan CFTG
AB			3.75MG	N022421	007	Jun 17, 2011	Jan CFTG
AB			4.5MG	N022421	005	Feb 19, 2010	Jan CFTG
PRAMIPEXOLE DIHYDROCHLORIDE							
AB		ANCHEN PHARMS	0.375MG	A202206	001	Feb 06, 2014	Jan NEWA
AB			0.75MG	A202206	002	Feb 06, 2014	Jan NEWA
AB			1.5MG	A202206	003	Feb 06, 2014	Jan NEWA
AB			2.25MG	A202206	004	Feb 06, 2014	Jan NEWA
AB			3MG	A202206	005	Feb 06, 2014	Jan NEWA
AB			3.75MG	A202206	006	Feb 06, 2014	Jan NEWA
AB			4.5MG	A202206	007	Feb 06, 2014	Jan NEWA
<u>PRAMLINTIDE ACETATE</u>							
INJECTABLE;SUBCUTANEOUS							
SYMPLIN							
		ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007	Feb CAHN
	+		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Feb CAHN
	@		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Feb CAHN
<u>PRAVASTATIN SODIUM</u>							
TABLET;ORAL							
PRAVASTATIN SODIUM							
AB		SANDOZ	10MG	A076397	003	Oct 23, 2006	Apr CMFD
AB			20MG	A076397	002	Oct 23, 2006	Apr CMFD
AB			40MG	A076397	001	Oct 23, 2006	Apr CMFD
AB			80MG	A077491	001	Feb 11, 2008	Aug CMFD
<u>PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM</u>							
SOLUTION/DROPS;OPHTHALMIC							
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE							
AT	+	BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995	Feb CRLD
		VASOCIDIN					
	@	NOVARTIS	EQ 0.23% PHOSPHATE;10%	N018988	001	Aug 26, 1988	Feb DISC
<u>PRIMAQUINE PHOSPHATE</u>							
TABLET;ORAL							
PRIMAQUINE							
AB	+	SANOFI AVENTIS US	EQ 15MG BASE	N008316	001		Jan CFTG
PRIMAQUINE PHOSPHATE							
AB		ALVOGEN INC	EQ 15MG BASE	A203924	001	Feb 03, 2014	Jan NEWA
AB		BAYSHORE PHARMS LLC	EQ 15MG BASE	A204476	001	Feb 25, 2014	Feb NEWA

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HYDROCHLORIDE

+	HOSPIRA	100MG/ML	A089069	001	Feb 12, 1986	Jul CTEC
+		500MG/ML	A089070	001	Feb 12, 1986	Jul CTEC
@	INTL MEDICATION	100MG/ML	A088636	001	Jul 31, 1984	Jul DISC
@		500MG/ML	A088637	001	Jul 31, 1984	Jul DISC

TABLET, EXTENDED RELEASE; ORAL

PROCAINAMIDE HYDROCHLORIDE

@	ANI PHARMS INC	1GM	A040111	001	Dec 13, 1996	Jan CAHN
@		250MG	A088958	001	Dec 02, 1985	Jan CAHN
@		500MG	A088959	001	Dec 02, 1985	Jan CAHN
@		500MG	A088974	001	Jul 22, 1985	Mar CAHN
@		750MG	A089438	001	Mar 23, 1987	Jan CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

>D>	AP	LUITPOLD	25MG/ML	A040515	001	Mar 19, 2003	Sep DISC
>A>		@	25MG/ML	A040515	001	Mar 19, 2003	Sep DISC

SUPPOSITORY; RECTAL

PHENERGAN

@	DELCOR ASSET CORP	50MG	N011689	001		Apr CAHN
---	-------------------	------	---------	-----	--	----------

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

>D>	AA	CARACO	6.25MG/5ML	A040891	001	Mar 13, 2009	Sep CAHN
>A>	AA	SUN PHARM INDS INC	6.25MG/5ML	A040891	001	Mar 13, 2009	Sep CAHN

TABLET; ORAL

PHENERGAN

@	DELCOR ASSET CORP	12.5MG	N007935	002		Jul CAHN
@		12.5MG	N007935	002		Apr CAHN
@		25MG	N007935	003		Jul CAHN
@		25MG	N007935	003		Apr CAHN
@		50MG	N007935	004		Jul CAHN
@		50MG	N007935	004		Apr CAHN
@	SHIONOGI INC	12.5MG	N007935	002		May CAHN
@		25MG	N007935	003		May CAHN
@		50MG	N007935	004		May CAHN

PROMETHAZINE HYDROCHLORIDE

AB	SANDOZ	25MG	A084176	003		Apr CMS1
AB	SUN PHARM INDS INC	12.5MG	A040863	001	Dec 30, 2008	Jun CAHN
AB		25MG	A040863	002	Dec 30, 2008	Jun CAHN
AB		50MG	A040863	003	Dec 30, 2008	Jun CAHN

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

AB	ANI PHARMS INC	150MG	A076550	001	Apr 23, 2004	Jan CAHN
AB		225MG	A076550	002	Apr 23, 2004	Jan CAHN
AB		300MG	A076550	003	Apr 23, 2004	Jan CAHN

PROPARACAINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALCAINE

AT	+	ALCON	0.5%	A080027	001		Jun CRLD
		OPHTHAINE					
	@	APOTHECON	0.5%	N008883	001		Jun DISC
		OPHTHETIC					
	@	ALLERGAN	0.5%	N012583	001		Jun DISC

PROPOFOL

INJECTABLE; INJECTION

PROPOFOL

@	EUROHLTH INTL	10MG/ML	A074848	001	Apr 19, 2005	Aug CAHN
---	---------------	---------	---------	-----	--------------	----------

PROPOXYPHENE HYDROCHLORIDE

CAPSULE;ORAL

PROPOXYPHENE HYDROCHLORIDE

@ MUTUAL PHARM

65MG

A083186 001

Aug DISC

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPRANOLOL HYDROCHLORIDE

>D> AB GLATT AIR

60MG

A078065 001 Jan 26, 2007 Sep CAHN

>D> AB

80MG

A078065 002 Jan 26, 2007 Sep CAHN

>D> AB

120MG

A078065 003 Jan 26, 2007 Sep CAHN

>D> AB

160MG

A078065 004 Jan 26, 2007 Sep CAHN

>A> AB NORTEC DEV ASSOC

60MG

A078065 001 Jan 26, 2007 Sep CAHN

>A> AB

80MG

A078065 002 Jan 26, 2007 Sep CAHN

>A> AB

120MG

A078065 003 Jan 26, 2007 Sep CAHN

>A> AB

160MG

A078065 004 Jan 26, 2007 Sep CAHN

SOLUTION;ORAL

HEMANGEOL

+ PIERRE FABRE DERMA

4.28MG/ML

N205410 001 Mar 14, 2014 Mar NEWA

TABLET;ORAL

INDERAL

@ WYETH PHARMS INC

40MG

N016418 002

Jan DISC

@

60MG

N016418 009 Oct 18, 1982 Jan DISC

PROPRANOLOL HYDROCHLORIDE

@ ANI PHARMS INC

90MG

A071977 001 Apr 06, 1988 Jan CAHN

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

@ ANI PHARMS INC

50MG

A080215 001

Jan CAHN

PYRIDOSTIGMINE BROMIDE

SYRUP;ORAL

MESTINON

+ VALEANT PHARM NORTH

60MG/5ML

N015193 001

Aug CAHN

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

AB JUBILANT GENERICS

EQ 25MG BASE

A203150 001 Nov 26, 2013 Jul CAHN

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

@ ACTAVIS ELIZABETH

EQ 5MG BASE

A076459 001 Dec 22, 2004 Aug CAHN

@

EQ 10MG BASE

A076459 002 Dec 22, 2004 Aug CAHN

@

EQ 20MG BASE

A076459 003 Dec 22, 2004 Aug CAHN

@

EQ 40MG BASE

A076459 004 Dec 22, 2004 Aug CAHN

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

@ WATSON LABS

324MG

A087810 001 Sep 29, 1982 May DISC

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

EVISTA

AB + LILLY

60MG

N020815 001 Dec 09, 1997 Feb CFTG

RALOXIFENE HYDROCHLORIDE

>A> AB INVAGEN PHARMS

60MG

A090842 001 Sep 24, 2014 Sep NEWA

AB TEVA PHARMS USA

60MG

A078193 001 Mar 04, 2014 Feb NEWA

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

AB ACCORD HLTHCARE INC

1.25MG

A202392 001 Apr 15, 2014 Mar NEWA

AB

2.5MG

A202392 002 Apr 15, 2014 Mar NEWA

AB

5MG

A202392 003 Apr 15, 2014 Mar NEWA

AB

10MG

A202392 004 Apr 15, 2014 Mar NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION
RANITIDINE HYDROCHLORIDE

AP	EUROHLTH INTL	EQ 25MG BASE/ML	A074777	001	Mar 02, 2005	Aug CAHN
AP		EQ 25MG BASE/ML	A077458	001	Feb 16, 2006	Aug CAHN
	ZANTAC					
AP	+ COVIS INJECTABLES	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Apr CAHN
	ZANTAC IN PLASTIC CONTAINER					
	@ COVIS INJECTABLES	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Apr CAHN
	@	EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	Apr CAHN
	TABLET, EFFERVESCENT;ORAL					
	ZANTAC 25					
	@ GLAXO GRP LTD	EQ 25MG BASE	N020251	003	Apr 01, 2004	Feb DISC

RASAGILINE MESYLATE

TABLET;ORAL
RASAGILINE MESYLATE

@	WATSON LABS INC	EQ 0.5MG BASE	A201823	001	Jul 01, 2013	May DISC
@		EQ 1MG BASE	A201823	002	Jul 01, 2013	May DISC

REPAGLINIDE

TABLET;ORAL
REPAGLINIDE

AB	ACTAVIS ELIZABETH	0.5MG	A090008	001	Jan 22, 2014	Aug CAHN
AB		1MG	A090008	002	Jan 22, 2014	Aug CAHN
AB		2MG	A090008	003	Jan 22, 2014	Aug CAHN
AB	ACTAVIS TOTOWA	0.5MG	A090008	001	Jan 22, 2014	Jan NEWA
AB		1MG	A090008	002	Jan 22, 2014	Jan NEWA
AB		2MG	A090008	003	Jan 22, 2014	Jan NEWA
AB	AUROBINDO PHARMA LTD	0.5MG	A203820	001	Jan 22, 2014	Jan NEWA
AB		1MG	A203820	002	Jan 22, 2014	Jan NEWA
AB		2MG	A203820	003	Jan 22, 2014	Jan NEWA
AB	MYLAN PHARMS INC	1MG	A090252	002	Jan 22, 2014	Jan NEWA
AB		2MG	A090252	003	Jan 22, 2014	Jan NEWA
AB	PADDOCK LLC	1MG	A201189	002	Jan 22, 2014	Jan NEWA
AB		2MG	A201189	003	Jan 22, 2014	Jan NEWA
AB	SANDOZ	1MG	A078555	002	Jan 22, 2014	Jan NEWA
AB		2MG	A078555	003	Jan 22, 2014	Jan NEWA
AB	SUN PHARM INDS INC	1MG	A077571	002	Jul 11, 2013	Jul CAHN
AB		2MG	A077571	003	Jul 11, 2013	Jul CAHN

RIBAVIRIN

TABLET;ORAL
RIBAVIRIN

AB	SANDOZ	200MG	A202546	001	Aug 12, 2014	Aug NEWA
AB		400MG	A202546	002	Aug 12, 2014	Aug NEWA
AB		500MG	A202546	003	Aug 12, 2014	Aug NEWA
AB		600MG	A202546	004	Aug 12, 2014	Aug NEWA
AB	ZYDUS PHARMS USA	500MG	A077094	004	Apr 18, 2008	Aug CTEC

RIFABUTIN

CAPSULE;ORAL
MYCOBUTIN

AB	+ PHARMACIA AND UPJOHN	150MG	N050689	001	Dec 23, 1992	Feb CFTG
	RIFABUTIN					
AB	LUPIN LTD	150MG	A090033	001	Feb 24, 2014	Feb NEWA

RIFAMPIN

INJECTABLE;INJECTION
RIFAMPIN

AP	EMCURE PHARMS LTD	600MG/VIAL	A204101	001	Aug 18, 2014	Aug NEWA
AP	FRESENIUS KABI USA	600MG/VIAL	A091181	001	Aug 21, 2014	Aug NEWA

RIMANTADINE HYDROCHLORIDE

TABLET;ORAL
RIMANTADINE HYDROCHLORIDE

@	ACTAVIS ELIZABETH	100MG	A076375	001	Jan 14, 2003	Aug CAHN
---	-------------------	-------	---------	-----	--------------	----------

RISEDRONATE SODIUM

TABLET;ORAL

ACTONEL

AB	+	WARNER CHILCOTT LLC	150MG	N020835	005	Apr 22, 2008	May CTEC
		RISEDRONATE SODIUM					
AB		APOTEX INC	75MG	A090877	002	Jun 10, 2014	May NEWA
AB			150MG	A090877	003	Jun 10, 2014	May NEWA
AB		MYLAN PHARMS INC	75MG	A200477	004	Jun 10, 2014	May NEWA
AB			150MG	A200477	005	Jun 10, 2014	May NEWA
AB		SUN PHARMA GLOBAL	75MG	A090886	004	Jun 10, 2014	May NEWA
AB			150MG	A090886	005	Jun 10, 2014	May NEWA
AB		TEVA PHARMS USA	150MG	A079215	001	Jun 13, 2014	Jun NEWA

RISPERIDONE

SOLUTION;ORAL

RISPERIDONE

AA		ANI PHARMS INC	1MG/ML	A076440	001	Jan 30, 2009	Jan CAHN
----	--	----------------	--------	---------	-----	--------------	----------

TABLET;ORAL

RISPERIDONE

AB		CARACO	0.25MG	A078036	001	Mar 10, 2014	Feb NEWA
AB			0.5MG	A078036	002	Mar 10, 2014	Feb NEWA
AB			1MG	A078036	003	Mar 10, 2014	Feb NEWA
AB			2MG	A078036	004	Mar 10, 2014	Feb NEWA
AB			3MG	A078036	005	Mar 10, 2014	Feb NEWA
AB			4MG	A078036	006	Mar 10, 2014	Feb NEWA
AB		SUN PHARM INDS INC	0.25MG	A078036	001	Mar 10, 2014	Jul CAHN
AB			0.5MG	A078036	002	Mar 10, 2014	Jul CAHN
AB			1MG	A078036	003	Mar 10, 2014	Jul CAHN
AB			2MG	A078036	004	Mar 10, 2014	Jul CAHN
AB			3MG	A078036	005	Mar 10, 2014	Jul CAHN
AB			4MG	A078036	006	Mar 10, 2014	Jul CAHN
>D> AB		WEST WARD PHARMS	0.25MG	A078740	001	May 29, 2009	Sep DISC
>A>	@		0.25MG	A078740	001	May 29, 2009	Sep DISC
>D> AB			0.5MG	A078740	002	May 29, 2009	Sep DISC
>A>	@		0.5MG	A078740	002	May 29, 2009	Sep DISC
>D> AB			1MG	A078740	003	May 29, 2009	Sep DISC
>A>	@		1MG	A078740	003	May 29, 2009	Sep DISC
>D> AB			2MG	A078740	004	May 29, 2009	Sep DISC
>A>	@		2MG	A078740	004	May 29, 2009	Sep DISC
>D> AB			3MG	A078740	005	May 29, 2009	Sep DISC
>A>	@		3MG	A078740	005	May 29, 2009	Sep DISC
>D> AB			4MG	A078740	006	May 29, 2009	Sep DISC
>A>	@		4MG	A078740	006	May 29, 2009	Sep DISC

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

AB		JUBILANT GENERICS	0.5MG	A090839	001	Nov 04, 2011	Jul CAHN
AB			1MG	A090839	002	Nov 04, 2011	Jul CAHN
AB			2MG	A090839	003	Nov 04, 2011	Jul CAHN
AB			3MG	A090839	004	Nov 04, 2011	Jul CAHN
AB			4MG	A090839	005	Nov 04, 2011	Jul CAHN

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

AB		MACLEODS PHARMS LTD	EQ 1.5MG BASE	A203148	001	Aug 22, 2014	Aug NEWA
AB			EQ 3MG BASE	A203148	002	Aug 22, 2014	Aug NEWA
AB			EQ 4.5MG BASE	A203148	003	Aug 22, 2014	Aug NEWA
AB			EQ 6MG BASE	A203148	004	Aug 22, 2014	Aug NEWA

SOLUTION;ORAL

EXELON

@ NOVARTIS EQ 2MG BASE/ML

N021025 001 Apr 21, 2000 Jun DISC

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

AB		MACLEODS PHARMS LTD	EQ 5MG BASE	A203147	001	Feb 11, 2014	Jan NEWA
AB			EQ 10MG BASE	A203147	002	Feb 11, 2014	Jan NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

>A> AB		MACLEODS PHARMS LTD	EQ 5MG BASE	A203146	001	Sep 19, 2014	Sep NEWA
>A> AB			EQ 10MG BASE	A203146	002	Sep 19, 2014	Sep NEWA

ROCURONIUM BROMIDEINJECTABLE; INJECTION
ROCURONIUM BROMIDE

>D>	AP	MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A079199	001	Nov 26, 2008	Sep CRLD	
>A>	AP	+	50MG/5ML (10MG/ML)	A079199	001	Nov 26, 2008	Sep CRLD	
>D>	AP		100MG/10ML (10MG/ML)	A079199	002	Nov 26, 2008	Sep CRLD	
>A>	AP	+	100MG/10ML (10MG/ML)	A079199	002	Nov 26, 2008	Sep CRLD	
>D>		ZEMURON						
>D>	AP	+	ORGANON USA INC	50MG/5ML (10MG/ML)	N020214	001	Mar 17, 1994	Sep DISC
>A>		@	50MG/5ML (10MG/ML)	N020214	001	Mar 17, 1994	Sep DISC	
>D>	AP	+	100MG/10ML (10MG/ML)	N020214	003	Mar 17, 1994	Sep DISC	
>A>		@	100MG/10ML (10MG/ML)	N020214	003	Mar 17, 1994	Sep DISC	

ROPIVACAINE HYDROCHLORIDEINJECTABLE; INJECTION
NAROPIN

>D>		FRESENIUS KABI USA	2MG/ML	N020533	001	Sep 24, 1996	Sep CTEC
>A>	AP		2MG/ML	N020533	001	Sep 24, 1996	Sep CTEC
	AP		5MG/ML	N020533	003	Sep 24, 1996	Jul CFTG
>D>			7.5MG/ML	N020533	004	Sep 24, 1996	Sep CTEC
>A>	AP		7.5MG/ML	N020533	004	Sep 24, 1996	Sep CTEC
	AP	+	10MG/ML	N020533	005	Sep 24, 1996	Jul CFTG
		ROPIVACAINE HYDROCHLORIDE					
>A>	AP	HOSPIRA	2MG/ML	A090194	001	Sep 23, 2014	Sep NEWA
>A>	AP		5MG/ML	A090194	002	Sep 23, 2014	Sep NEWA
>A>	AP		7.5MG/ML	A090194	003	Sep 23, 2014	Sep NEWA
>A>	AP		10MG/ML	A090194	004	Sep 23, 2014	Sep NEWA
	AP	NAVINTA LLC	5MG/ML	A078601	002	Jul 17, 2014	Jul NEWA
	AP		10MG/ML	A078601	003	Jul 17, 2014	Jul NEWA
>A>	AP	SAGENT STRIDES	2MG/ML	A090318	001	Sep 23, 2014	Sep NEWA
>A>	AP		5MG/ML	A090318	002	Sep 23, 2014	Sep NEWA
>A>	AP		7.5MG/ML	A090318	003	Sep 23, 2014	Sep NEWA
>A>	AP		10MG/ML	A090318	004	Sep 23, 2014	Sep NEWA

SALMETEROL XINAFOATEPOWDER; INHALATION
SEREVENT

>D>	+	GLAXO GRP LTD	EQ 0.05MG BASE/INH	N020692	001	Sep 19, 1997	Sep CAHN
>A>	+	GLAXOSMITHKLINE	EQ 0.05MG BASE/INH	N020692	001	Sep 19, 1997	Sep CAHN

SAXAGLIPTIN HYDROCHLORIDETABLET; ORAL
ONGLYZAASTRAZENECA AB
+ EQ 2.5MG BASE
EQ 5MG BASE

N022350	001	Jul 31, 2009	May CAHN
N022350	002	Jul 31, 2009	May CAHN

SELENIUM SULFIDELOTION; SHAMPOO; TOPICAL
SELENIUM SULFIDE

@ G AND W LABS INC 2.5%

A086209	001		Aug CAHN
---------	-----	--	----------

SIMEPREVIR SODIUMCAPSULE; ORAL
OLYSIO+ JANSSEN PRODS EQ 150MG BASE
+ JANSSEN RES AND DEV EQ 150MG BASE

N205123	001	Nov 22, 2013	Jun CAHN
N205123	001	Nov 22, 2013	Feb CAIN

SODIUM BENZOATE; SODIUM PHENYLACETATESOLUTION; IV (INFUSION)
AMMONUL

+ MEDICIS 10%; 10% (5GM/50ML; 5GM/50ML)

N020645	001	Feb 17, 2005	Jul CAHN
---------	-----	--------------	----------

SODIUM CHLORIDEINJECTABLE; INJECTION
SODIUM CHLORIDE 0.9%

@ MEDEFIL INC	18MG/2ML (9MG/ML)
@	22.5MG/2.5ML (9MG/ML)
@	27MG/3ML (9MG/ML)
@	45MG/5ML (9MG/ML)

N202832	002	Jan 06, 2012	Jun DISC
N202832	003	Jan 06, 2012	Jun DISC
N202832	004	Jan 06, 2012	Jun DISC
N202832	005	Jan 06, 2012	Jun DISC

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
@ MEDEFIL INC 9MG/ML (9MG/ML)

N202832	001	Jan 06, 2012	Jun DISC
---------	-----	--------------	----------

SODIUM FLUORIDE F-18INJECTABLE;INTRAVENOUS
SODIUM FLUORIDE F-18

>A>	AP	SHERTECH LABS LLC	10-200mCi/ML	A204315	001	Sep 22, 2014	Sep NEWA
	AP	UCSF RODIOPHARM	10-200mCi/ML	A204437	001	Mar 13, 2014	Mar NEWA

SODIUM POLYSTYRENE SULFONATEPOWDER;ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

AA		EPIC PHARMA LLC	453.6GM/BOT	A202333	001	Mar 19, 2014	Mar NEWA
----	--	-----------------	-------------	---------	-----	--------------	----------

SOLIFENACIN SUCCINATETABLET;ORAL
SOLIFENACIN SUCCINATE

AB		TEVA PHARMS USA	5MG	A091464	001	Apr 02, 2014	Mar NEWA
AB			10MG	A091464	002	Apr 02, 2014	Mar NEWA
		VESICARE					
AB		ASTELLAS	5MG	N021518	001	Nov 19, 2004	Mar CFTG
AB	+		10MG	N021518	002	Nov 19, 2004	Mar CFTG

SOMATROPIN RECOMBINANTINJECTABLE;INJECTION
ACCRETROPIN

	@	EMERGENT	5MG/ML (5MG/ML)	N021538	001	Jan 23, 2008	Feb CAHN
--	---	----------	-----------------	---------	-----	--------------	----------

SPIRONOLACTONETABLET;ORAL
SPIRONOLACTONE

AB		JUBILANT GENERICS	25MG	A203253	001	Apr 23, 2014	Aug CAHN
AB			50MG	A203253	002	Apr 23, 2014	Aug CAHN
AB			100MG	A203253	003	Apr 23, 2014	Aug CAHN
AB		JUBILANT LIFE	25MG	A203253	001	Apr 23, 2014	Apr NEWA
AB			50MG	A203253	002	Apr 23, 2014	Apr NEWA
AB			100MG	A203253	003	Apr 23, 2014	Apr NEWA
AB		ORION CORP ORION	25MG	A202187	001	Mar 06, 2014	Feb NEWA
AB			50MG	A202187	002	Mar 06, 2014	Feb NEWA
AB			100MG	A202187	003	Mar 06, 2014	Feb NEWA

SUCRALFATESUSPENSION;ORAL
CARAFATE

	+	FOREST LABS INC	1GM/10ML	N019183	001	Dec 16, 1993	Apr CAHN
--	---	-----------------	----------	---------	-----	--------------	----------

TABLET;ORAL
CARAFATE

AB	+	FOREST LABS INC	1GM	N018333	001		Apr CAHN
----	---	-----------------	-----	---------	-----	--	----------

SULFASALAZINETABLET;ORAL
SULFASALAZINE

	@	WATSON LABS	500MG	A087197	001		May DISC
--	---	-------------	-------	---------	-----	--	----------

>D> SULFISOXAZOLE ACETYL

SUSPENSION;ORAL

>D> GANTRISIN PEDIATRIC

>D>		@ ROCHE	EQ 500MG BASE/5ML	N009182	004		Sep DISC
>A>		@	EQ 500MG BASE/5ML	N009182	004		Sep DISC

SYRUP;ORAL

>D> GANTRISIN

>D>		@ ROCHE	EQ 500MG BASE/5ML	N009182	002		Sep DISC
>A>		@	EQ 500MG BASE/5ML	N009182	002		Sep DISC

SUMATRIPTAN SUCCINATEINJECTABLE;SUBCUTANEOUS
IMITREX STATDOSE

BX	+	GLAXOSMITHKLINE	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N020080	002	Feb 01, 2006	May CTEC
----	---	-----------------	------------------------------------	---------	-----	--------------	----------

SUMATRIPTAN SUCCINATE

AP		AGILA SPECLTS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A203322	001	Apr 14, 2014	Mar NEWA
AB		DR REDDYS LABS INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090495	001	Jan 29, 2014	Jan NEWA
AP		PAR STERILE PRODUCTS	EQ 6MG BASE/0.5ML (EQ 12MG	A077871	001	Jul 09, 2009	Jun CAHN

INJECTABLE;SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

BASE/ML)

SUMAVEL DOSEPRO									
BX	+	ENDO VENTURES LTD	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N022239	002	Nov 26, 2013	Aug	CAHN	
BX	+		EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239	001	Jul 15, 2009	Aug	CAHN	
BX	+	ZOGENIX INC	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N022239	002	Nov 26, 2013	May	NEWA	
SYSTEM;IONTOPHORESIS		ZECUITY							
	+	TEVA BRANDED PHARM	EQ 6.5MG BASE/4HR	N202278	001	Jan 17, 2013	May	CAHN	

SUNITINIB MALATE

CAPSULE;ORAL

SUNITINIB MALATE									
AB		MYLAN PHARMS INC	EQ 12.5MG BASE	A201275	001	Jan 30, 2014	Jan	NEWA	
AB			EQ 25MG BASE	A201275	002	Jan 30, 2014	Jan	NEWA	
AB			EQ 37.5MG BASE	A201275	003	Jan 30, 2014	Jan	NEWA	
AB			EQ 50MG BASE	A201275	004	Jan 30, 2014	Jan	NEWA	
SUTENT									
AB		CPPI CV	EQ 12.5MG BASE	N021938	001	Jan 26, 2006	Jan	CFTG	
AB			EQ 25MG BASE	N021938	002	Jan 26, 2006	Jan	CFTG	
AB			EQ 37.5MG BASE	N021938	004	Mar 31, 2009	Jan	CFTG	
AB	+		EQ 50MG BASE	N021938	003	Jan 26, 2006	Jan	CFTG	

SUVOREXANT

TABLET;ORAL

BELSOMRA									
		MERCK SHARP DOHME	5MG	N204569	001	Aug 13, 2014	Aug	NEWA	
			10MG	N204569	002	Aug 13, 2014	Aug	NEWA	
			15MG	N204569	003	Aug 13, 2014	Aug	NEWA	
	+		20MG	N204569	004	Aug 13, 2014	Aug	NEWA	

TACROLIMUS

CAPSULE;ORAL

TACROLIMUS									
AB		STRIDES ARCOLAB LTD	EQ 0.5MG BASE	A090687	001	Jul 22, 2014	Jul	NEWA	
AB			EQ 1MG BASE	A090687	002	Jul 22, 2014	Jul	NEWA	
AB			EQ 5MG BASE	A090687	003	Jul 22, 2014	Jul	NEWA	
AB		STRIDES PHARMA	EQ 0.5MG BASE	A090687	001	Jul 22, 2014	Aug	CAHN	
AB			EQ 1MG BASE	A090687	002	Jul 22, 2014	Aug	CAHN	
AB			EQ 5MG BASE	A090687	003	Jul 22, 2014	Aug	CAHN	
		@ WATSON LABS	EQ 5MG BASE	A090402	001	Jul 01, 2010	May	DISC	

OINTMENT;TOPICAL

PROTOPIC									
AB	+	ASTELLAS	0.03%	N050777	001	Dec 08, 2000	Aug	CFTG	
AB	+		0.1%	N050777	002	Dec 08, 2000	Aug	CFTG	
TACROLIMUS									
AB		FOUGERA PHARMS INC	0.03%	A200744	001	Sep 09, 2014	Aug	NEWA	
AB			0.1%	A200744	002	Sep 09, 2014	Aug	NEWA	

TAFLUPROSTSOLUTION/DROPS;OPHTHALMIC
ZIOPTAN

	+	OAK PHARMS INC	0.0015%	N202514	001	Feb 10, 2012	Apr	CAHN	
--	---	----------------	---------	---------	-----	--------------	-----	------	--

TASIMELTEON

CAPSULE;ORAL

HETLIOZ									
	+	VANDA PHARMS INC	20MG	N205677	001	Jan 31, 2014	Jan	NEWA	

TAVABOROLE

SOLUTION;TOPICAL

KERYDIN									
	+	ANACOR PHARMS INC	5%	N204427	001	Jul 07, 2014	Jul	NEWA	

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATORSOLUTION;INJECTION, ORAL
TECHNELITE

		@ LANTHEUS MEDCL	0.0083-2.7 CI/GENERATOR	N017771	001		May	DISC	
--	--	------------------	-------------------------	---------	-----	--	-----	------	--

SOLUTION; INJECTION, ORAL							
ULTRA-TECHNEKOW FM							
@ MALLINCKRODT	0.25-3 CI/GENERATOR	N017243	002			May	DISC
SOLUTION; INTRAVENOUS							
TECHNELITE							
+ LANTHEUS MEDCL	1-20 CI/GENERATOR	N017771	002	Feb 12, 2014		May	NEWA
@	0.0083-2.7 CI/GENERATOR	N017771	001			May	CDFR
ULTRA-TECHNEKOW FM							
+ MALLINCKRODT	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014		May	NEWA
@	0.25-3 CI/GENERATOR	N017243	002			May	CDFR
SOLUTION; INTRAVENOUS, ORAL							
TECHNETIUM TC 99M GENERATOR							
+ GE HEALTHCARE	68-2703mCi/GENERATOR	N017693	002	Dec 13, 2013		May	NEWA
	830-16600mCi/GENERATOR	N017693	001			May	CDFR
<u>TEDIZOLID PHOSPHATE</u>							
POWDER; IV (INFUSION)							
SIVEXTRO							
+ CUBIST PHARMS INC	200MG/VIAL	N205436	001	Jun 20, 2014		Jun	NEWA
TABLET; ORAL							
SIVEXTRO							
+ CUBIST PHARMS INC	200MG	N205435	001	Jun 20, 2014		Jun	NEWA
<u>TELAVANCIN HYDROCHLORIDE</u>							
POWDER; IV (INFUSION)							
VIBATIV							
THERAVANCE BIOPHARMA	EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009		Jun	CAHN
+	EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009		Jun	CAHN
<u>TELMISARTAN</u>							
TABLET; ORAL							
TELMISARTAN							
AB	ALEMBIC PHARMS LTD	20MG	A202130	001	Jul 07, 2014	Jun	NEWA
AB		40MG	A202130	002	Jul 07, 2014	Jun	NEWA
AB		80MG	A202130	003	Jul 07, 2014	Jun	NEWA
AB	GLENMARK GENERICS	20MG	A090032	001	Jul 07, 2014	Jun	NEWA
AB		40MG	A090032	002	Jul 07, 2014	Jun	NEWA
AB		80MG	A090032	003	Jul 07, 2014	Jun	NEWA
AB	MYLAN PHARMS INC	20MG	A202397	001	Jul 07, 2014	Jun	NEWA
AB		40MG	A202397	002	Jul 07, 2014	Jun	NEWA
AB		80MG	A202397	003	Jul 07, 2014	Jun	NEWA
AB	TORRENT PHARMS LTD	20MG	A203171	001	Jul 07, 2014	Jun	NEWA
AB		40MG	A203171	002	Jul 07, 2014	Jun	NEWA
AB		80MG	A203171	003	Jul 07, 2014	Jun	NEWA
AB	ZYDUS PHARMS USA INC	20MG	A203325	001	Aug 26, 2014	Aug	NEWA
AB		40MG	A203325	002	Aug 26, 2014	Aug	NEWA
AB		80MG	A203325	003	Aug 26, 2014	Aug	NEWA
<u>TEMAZEPAM</u>							
CAPSULE; ORAL							
TEMAZEPAM							
@ WATSON LABS	15MG	A071446	001	May 21, 1993		May	DISC
@	30MG	A071447	001	May 21, 1993		May	DISC
<u>TEMOZOLOMIDE</u>							
CAPSULE; ORAL							
TEMOZOLOMIDE							
AB	SUN PHARMA GLOBAL	5MG	A201742	001	Feb 12, 2014	Feb	NEWA
AB		20MG	A201742	002	Feb 12, 2014	Feb	NEWA
AB		100MG	A201742	003	Feb 12, 2014	Feb	NEWA
AB		140MG	A201742	004	Feb 12, 2014	Feb	NEWA
AB		180MG	A201742	005	Feb 12, 2014	Feb	NEWA
AB		250MG	A201742	006	Feb 12, 2014	Feb	NEWA
<u>TERAZOSIN HYDROCHLORIDE</u>							
CAPSULE; ORAL							
TERAZOSIN HYDROCHLORIDE							
AB	+ SANDOZ	EQ 2MG BASE	A074823	002	Mar 30, 1998	Apr	CRLD
TABLET; ORAL							
HYTRIN							
@ ABBOTT	EQ 1MG BASE	N019057	001	Aug 07, 1987		Apr	DISC
@	EQ 2MG BASE	N019057	002	Aug 07, 1987		Apr	DISC

TABLET; ORAL							
HYTRIN							
	@	EQ 5MG BASE	N019057	003	Aug 07, 1987	Apr	DISC
	@	EQ 10MG BASE	N019057	004	Aug 07, 1987	Apr	DISC
<u>TESAMORELIN ACETATE</u>							
POWDER; SUBCUTANEOUS							
EGRIFTA							
+	THERATECHNOLOGIES	EQ 1MG BASE/VIAL	N022505	001	Nov 10, 2010	Aug	CMFD
	@	EQ 1MG BASE/VIAL	N022505	001	Nov 10, 2010	May	CAHN
	@	EQ 2MG BASE/VIAL	N022505	002	Nov 29, 2011	Aug	DISC
+		EQ 2MG BASE/VIAL	N022505	002	Nov 29, 2011	May	CAHN
<u>TESTOSTERONE</u>							
GEL; TRANSDERMAL							
ANDROGEL							
AB	ABBVIE	25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jul	CTEC
AB	+	50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jul	CTEC
TESTOSTERONE							
AB	PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jul	CTEC
AB		50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jul	CTEC
BX	TEVA PHARMS	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	Jul	CTEC
BX		50MG/5GM PACKET	N202763	002	Feb 14, 2012	Jul	CTEC
VOGELXO							
	UPSHER SMITH	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jun	NEWA
GEL, METERED; NASAL							
NATESTO							
	@ TRIMEL BIOPHARMA SRL	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jun	DISC
+		5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	May	NEWA
GEL, METERED; TRANSDERMAL							
ANDROGEL							
AB	+	12.5MG/1.25GM ACTUATION	N021015	003	Sep 26, 2003	Jul	CTEC
TESTOSTERONE							
AB	PERRIGO ISRAEL	12.5MG/1.25GM ACTUATION	N203098	001	Jan 31, 2013	Jul	CTEC
	VOGELXO						
	UPSHER SMITH	12.5MG/1.25GM ACTUATION	N204399	003	Jun 04, 2014	Jun	NEWA
TABLET, EXTENDED RELEASE; BUCCAL							
STRIANT							
+	AUXILIUM PHARMS LLC	30MG	N021543	001	Jun 19, 2003	Apr	CAHN
<u>TESTOSTERONE UNDECANOATE</u>							
INJECTABLE; INTRAMUSCULAR							
AVEED							
+	ENDO PHARMS INC	750MG/3ML (250MG/ML)	N022219	001	Mar 04, 2014	Mar	NEWA
<u>THEOPHYLLINE</u>							
SOLUTION, ELIXIR; ORAL							
ELIXOPHYLLIN							
+	CARACO	80MG/15ML	A085186	001		Jun	CDFR
+	SUN PHARM INDS INC	80MG/15ML	A085186	001		Jul	CAHN
TABLET, EXTENDED RELEASE; ORAL							
THEOCHRON							
	@ CARACO	300MG	A087400	002	Jan 11, 1983	Jan	DISC
AB	SUN PHARM INDS INC	100MG	A088320	001	Feb 21, 1985	Jul	CAHN
AB		200MG	A088321	001	Feb 21, 1985	Jul	CAHN
	@	300MG	A087400	002	Jan 11, 1983	Jul	CAHN
<u>THIAMINE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
THIAMINE HYDROCHLORIDE							
	@ WATSON LABS	100MG/ML	A080571	001		May	DISC
	@	200MG/ML	A080571	002		May	DISC
<u>THIORIDAZINE HYDROCHLORIDE</u>							
CONCENTRATE; ORAL							
THIORIDAZINE HYDROCHLORIDE							
	@ ANI PHARMS INC	100MG/ML	A089603	001	Nov 09, 1987	Feb	CAHN
TABLET; ORAL							
THIORIDAZINE HYDROCHLORIDE							
	@ ANI PHARMS INC	10MG	A088270	001	Apr 14, 1983	Feb	CAHN
	@	10MG	A088493	001	May 17, 1985	Feb	CAHN

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE

@	15MG	A088271	001	Apr 14, 1983	Feb CAHN
@	25MG	A088272	001	Apr 14, 1983	Feb CAHN
@	50MG	A088194	001	Apr 14, 1983	Feb CAHN
@	100MG	A088273	001	Oct 03, 1983	Feb CAHN
@	100MG	A088456	001	May 17, 1985	Feb CAHN

THIOTEPA

INJECTABLE;INJECTION

THIOTEPA

EUROHLTH INTL	15MG/VIAL	A075547	001	Apr 02, 2001	Aug CAHN
---------------	-----------	---------	-----	--------------	----------

THIOTHIXENE

CAPSULE;ORAL

THIOTHIXENE

@ WATSON LABS	2MG	A070601	001	Jun 05, 1987	May DISC
@	5MG	A070602	001	Jun 05, 1987	May DISC

THIOTHIXENE HYDROCHLORIDE

CONCENTRATE;ORAL

THIOTHIXENE HYDROCHLORIDE INTENSOL

>A>	@ CYCLE PHARMS LTD	EQ 5MG BASE/ML	A073494	001	Jun 30, 1992	Sep CAHN
>D>	@ ROXANE	EQ 5MG BASE/ML	A073494	001	Jun 30, 1992	Sep CAHN

TICLOPIDINE HYDROCHLORIDE

TABLET;ORAL

TICLOPIDINE HYDROCHLORIDE

AB	SUN PHARM INDS INC	250MG	A075526	001	Sep 26, 2002	Jul CAHN
----	--------------------	-------	---------	-----	--------------	----------

TIMOLOL

SOLUTION/DROPS;OPHTHALMIC

BETIMOL

+	OAK PHARMS AKORN	EQ 0.25% BASE	N020439	001	Mar 31, 1995	Apr CAHN
+		EQ 0.5% BASE	N020439	002	Mar 31, 1995	Apr CAHN

>A>	<u>TIOTROPIUM BROMIDE</u>							
>A>	POWDER;INHALATION							
>A>	SPIRIVA							
>A>	+	BOEHRINGER INGELHEIM	EQ 0.018MG BASE/INH	N021395	001	Jan 30, 2004	Sep CAIN	
>A>	SPRAY, METERED;INHALATION							
>A>	SPIRIVA RESPIMAT							
>A>	+	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH	N021936	001	Sep 24, 2014	Sep NEWA	

>D>	<u>TIOTROPIUM BROMIDE MONOHYDRATE</u>						
>D>	POWDER; INHALATION						
>D>	SPIRIVA						
>D>	+	BOEHRINGER INGELHEIM	EQ 0.018MG BASE/INH	N021395	001	Jan 30, 2004	Sep CAIN

TIZANIDINE HYDROCHLORIDE

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

AB	SUN PHARM INDS INC	EQ 2MG BASE	A076416	001	Sep 29, 2003	Jul CAHN
AB		EQ 4MG BASE	A076416	002	Sep 29, 2003	Jul CAHN

TOBRAMYCIN

SOLUTION;INHALATION

BETHKIS

	CHIESI USA INC	300MG/4ML	N201820	001	Oct 12, 2012	Apr CAHN
	TOBRAMYCIN					
AN	AKORN INC	300MG/5ML	A201422	001	May 28, 2014	May NEWA

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

>A>	AP	AKORN	EQ 40MG BASE/ML	A205179	001	Sep 16, 2014	Sep NEWA
		@ WATSON LABS INC	EQ 10MG BASE/ML	A062945	001	Aug 09, 1989	May DISC
>A>	AP	XELLIA PHARMS APS	EQ 1.2GM BASE/VIAL	A205685	001	Sep 16, 2014	Sep NEWA

TOPIRAMATECAPSULE, DELAYED RELEASE;ORAL
QUDEXY XR

UPSHER SMITH	25MG	N205122	001	Mar 11, 2014	Mar NEWA
	50MG	N205122	002	Mar 11, 2014	Mar NEWA
	100MG	N205122	003	Mar 11, 2014	Mar NEWA
	150MG	N205122	004	Mar 11, 2014	Mar NEWA
+	200MG	N205122	005	Mar 11, 2014	Mar NEWA

CAPSULE, EXTENDED RELEASE;ORAL
QUDEXY XR

UPSHER SMITH	25MG	N205122	001	Mar 11, 2014	Apr CDFR
	50MG	N205122	002	Mar 11, 2014	Apr CDFR
	100MG	N205122	003	Mar 11, 2014	Apr CDFR
	150MG	N205122	004	Mar 11, 2014	Apr CDFR
+	200MG	N205122	005	Mar 11, 2014	Apr CDFR

TABLET;ORAL

TOPIRAMATE

@ WATSON LABS	25MG	A077643	001	Mar 27, 2009	May DISC
@	50MG	A077643	002	Mar 27, 2009	May DISC
@	100MG	A077643	003	Mar 27, 2009	May DISC
@	200MG	A077643	004	Mar 27, 2009	May DISC

TOPOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

TOPOTECAN HYDROCHLORIDE

AP	ACTAVIS ELIZABETH	EQ 4MG BASE/VIAL	A090620	001	Dec 02, 2010	Aug CAHN
AP	INNOPHARMA LICENSING	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	Apr CAHN

TORSEMIDE

INJECTABLE;INJECTION

TORSEMIDE

AP	+	EUROHLTH INTL	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Aug CAHN
AP	+		50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Aug CAHN

TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE

AB	ALLIED PHARMA INC	50MG	A202075	001	Nov 28, 2011	Apr CAHN
AB	AUROBINDO PHARMA LTD	50MG	A203494	001	Mar 31, 2014	Mar NEWA
AB	SUN PHARM INDS INC	50MG	A075964	001	Jun 19, 2002	Jul CAHN
	@ WATSON LABS	50MG	A075962	001	Jun 24, 2002	May DISC

TRANDOLAPRIL

TABLET;ORAL

TRANDOLAPRIL

@ COREPHARMA	1MG	A077256	001	Jun 12, 2007	Jun DISC
@	2MG	A077256	002	Jun 12, 2007	Jun DISC
@	4MG	A077256	003	Jun 12, 2007	Jun DISC

TRANEXAMIC ACID

INJECTABLE;INJECTION

TRANEXAMIC ACID

AP	ACIC FINE CHEMS	100MG/ML	A202436	001	Feb 11, 2014	Jan NEWA
AP	EMCURE PHARMS LTD	100MG/ML	A203521	001	Aug 12, 2014	Aug NEWA

TABLET;ORAL

TRANEXAMIC ACID

AB	APOTEX INC	650 MG	A202286	001	Jan 27, 2014	Jan NEWA
----	------------	--------	---------	-----	--------------	----------

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

IZBA

+	ALCON LABS INC	0.003%	N204822	001	May 15, 2014	May NEWA
+	PAR PHARM	0.004%	A091340	001	Mar 01, 2013	Feb CRLD

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

@ WATSON LABS	50MG	A070857	001	Oct 10, 1986	May DISC
@	100MG	A070858	001	Oct 10, 1986	May DISC

TREPROSTINIL

SOLUTION; INHALATION

TYVASO

>D>	+	UNITED THERAP	EQ 0.6MG BASE/ML	N022387	001	Jul 30, 2009	Sep CPOT
>A>	+		0.6MG/ML	N022387	001	Jul 30, 2009	Sep CPOT

TREPROSTINIL DIOLAMINE

TABLET, EXTENDED RELEASE; ORAL

ORENITRAM

UNITED THERAP	EQ 0.125MG BASE	N203496	001	Dec 20, 2013	Jun CAIN
	EQ 0.25MG BASE	N203496	002	Dec 20, 2013	Jun CAIN
	EQ 1MG BASE	N203496	003	Dec 20, 2013	Jun CAIN
+	EQ 2.5MG BASE	N203496	004	Dec 20, 2013	Jun CAIN

TRETINOIN

CREAM; TOPICAL

TRETINOIN

>A>	AB	MATAWAN PHARMS	0.025%	A075264	001	Dec 24, 1998	Sep CAHN
>A>	AB1		0.05%	A075265	001	Dec 24, 1998	Sep CAHN
>A>	AB		0.1%	A075213	001	Dec 24, 1998	Sep CAHN
>D>	AB	PRECISION DERMAT	0.025%	A075264	001	Dec 24, 1998	Sep CAHN
>D>	+		0.0375%	A090098	001	Mar 22, 2010	Sep CAHN
>D>	AB1		0.05%	A075265	001	Dec 24, 1998	Sep CAHN
>D>			0.075%	A202209	001	Oct 11, 2012	Sep CAHN
>D>	AB		0.1%	A075213	001	Dec 24, 1998	Sep CAHN
>A>	+	WATSON LABS INC	0.0375%	A090098	001	Mar 22, 2010	Sep CAHN
>A>			0.075%	A202209	001	Oct 11, 2012	Sep CAHN

GEL; TOPICAL

RETIN-A-MICRO

+	VALEANT INTL	0.08%	N020475	003	Jan 28, 2014	Jan NEWA	
	TRETINOIN						
>A>	AB	MATAWAN PHARMS	0.01%	A075589	001	Jun 11, 2002	Sep CAHN
>A>	AB		0.025%	A075529	001	Feb 22, 2000	Sep CAHN
>D>	AB	PRECISION DERMAT	0.01%	A075589	001	Jun 11, 2002	Sep CAHN
>D>	AB		0.025%	A075529	001	Feb 22, 2000	Sep CAHN

SOLUTION; TOPICAL

RETIN-A

+	VALEANT INTL	0.05%	N016921	001		Feb CTEC
	TRETINOIN					
@	WOCKHARDT	0.05%	A075260	001	Jan 25, 1999	Feb DISC

TRIAMCINOLONE

TABLET; ORAL

KENACORT

>D>	@	BRISTOL MYERS SQUIBB	1MG	N011283	003		Sep CAHN
>D>	@		2MG	N011283	008		Sep CAHN
>D>	@		4MG	N011283	006		Sep CAHN
>D>	@		8MG	N011283	010		Sep CAHN
>A>	@	DELCOR ASSET CORP	1MG	N011283	003		Sep CAHN
>A>	@		2MG	N011283	008		Sep CAHN
>A>	@		4MG	N011283	006		Sep CAHN
>A>	@		8MG	N011283	010		Sep CAHN

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

KENALOG

>D>	@	APOTHECON	0.5%	A083943	001		Sep CAHN
	@	DELCOR ASSET CORP	0.025%	N011601	003		Jul CAHN
	@		0.1%	N011601	006		Jul CAHN
>A>	@		0.5%	A083943	001		Sep CAHN

KENALOG-H

>D>	@	APOTHECON	0.1%	A086240	001		Sep CAHN
>A>	@	DELCOR ASSET CORP	0.1%	A086240	001		Sep CAHN

INJECTABLE; INJECTION

KENALOG-10

APOTHECON

10MG/ML

N012041 001

May CTEC

KENALOG-40

+ APOTHECON

40MG/ML

N014901 001

May CTEC

TRIAMCINOLONE ACETONIDE

@ SANDOZ

10MG/ML

A090166 001 May 27, 2009

May DISC

@ SANDOZ CANADA INC

40MG/ML

A090164 001 Jun 01, 2009

May DISC

LOTION; TOPICAL

KENALOG

>D>

@ APOTHECON

0.025%

A084343 001

Sep CAHN

>D>

@

0.1%

A084343 002

Sep CAHN

>D>

@ BRISTOL MYERS SQUIBB

0.025%

N011602 003

Sep CAHN

>D>

@

0.1%

N011602 001

Sep CAHN

>A>

@ DELCOR ASSET CORP

0.025%

A084343 001

Sep CAHN

>A>

@

0.025%

N011602 003

Sep CAHN

>A>

@

0.1%

A084343 002

Sep CAHN

>A>

@

0.1%

N011602 001

Sep CAHN

TRIAMCINOLONE ACETONIDE

@ G AND W LABS INC

0.1%

A089129 001 Aug 14, 1986

Aug CAHN

@ TARO

0.1%

A089129 001 Aug 14, 1986

Mar DISC

OINTMENT; TOPICAL

KENALOG

>D>

@ APOTHECON

0.5%

A083944 001

Sep CAHN

@ DELCOR ASSET CORP

0.025%

N011600 003

Jul CAHN

@

0.1%

N011600 001

Jul CAHN

>A>

@

0.5%

A083944 001

Sep CAHN

PASTE; DENTAL

KENALOG IN ORABASE

>D>

@ APOTHECON

0.1%

N012097 001

Sep CAHN

>A>

@ DELCOR ASSET CORP

0.1%

N012097 001

Sep CAHN

TRIAMCINOLONE DIACETATE

SYRUP; ORAL

KENACORT

>D>

@ BRISTOL MYERS SQUIBB

EQ 4MG BASE/5ML

N012515 001

Sep CAHN

>A>

@ DELCOR ASSET CORP

EQ 4MG BASE/5ML

N012515 001

Sep CAHN

TRIAMTERENE

CAPSULE; ORAL

DYRENIUM

>A>

COVIS PHARMA SARL

50MG

N013174 001

Sep CAHN

>A>

+

100MG

N013174 002

Sep CAHN

>D>

WELLSPRING PHARM

50MG

N013174 001

Sep CAHN

>D>

+

100MG

N013174 002

Sep CAHN

TRIAZOLAM

TABLET; ORAL

TRIAZOLAM

@ WATSON LABS

0.125MG

A074445 001 Oct 20, 1995

May DISC

@

0.25MG

A074445 002 Oct 20, 1995

May DISC

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

@ WATSON LABS

2MG

A040184 001 Feb 06, 1998

May DISC

@

5MG

A040184 002 Feb 06, 1998

May DISC

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TIGAN

AP

+

PAR STERILE PRODUCTS

100MG/ML

N017530 001

May CAHN

UMECLIDINIUM BROMIDE

POWDER; INHALATION

INCRUSE ELLIPTA

+

GLAXO GRP ENGLAND

EQ 62.5MCG BASE/INH

N205382 001 Apr 30, 2014

Apr NEWA

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATEPOWDER; INHALATION
ANORO ELLIPTA

+	GLAXOSMITHKLINE	EQ 0.0625MG BASE/INH; EQ 0.025MG BASE/INH	N203975	001	Dec 18, 2013	Apr CAHN
---	-----------------	---	---------	-----	--------------	----------

UNOPROSTONE ISOPROPYLSOLUTION/DROPS; OPHTHALMIC
RESCULA

+	SUCAMPO PHARMS	0.15%	N021214	001	Aug 03, 2000	Aug CRLD
---	----------------	-------	---------	-----	--------------	----------

UREA C-13FOR SOLUTION; ORAL
BREATHTEK UBT FOR H-PYLORI

@	OTSUKA AMERICA	EQ 75MG /POUCH	N020586	002	May 10, 2001	May DISC
---	----------------	----------------	---------	-----	--------------	----------

URSODIOLTABLET; ORAL
URSO 250

AB	FOREST LABS INC	250MG	N020675	001	Dec 10, 1997	Apr CAHN
----	-----------------	-------	---------	-----	--------------	----------

AB	+	FOREST LABS INC	500MG	N020675	002	Jul 21, 2004	Apr CAHN
----	---	-----------------	-------	---------	-----	--------------	----------

AB	IMPAX LABS INC	250MG	A200826	001	Dec 23, 2011	Jul CAHN
----	----------------	-------	---------	-----	--------------	----------

AB		500MG	A200826	002	Dec 23, 2011	Jul CAHN
----	--	-------	---------	-----	--------------	----------

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	APOTEX INC	EQ 1GM BASE	A090500	002	Apr 04, 2014	Mar NEWA
----	------------	-------------	---------	-----	--------------	----------

AB		EQ 500MG BASE	A090500	001	Apr 04, 2014	Mar NEWA
----	--	---------------	---------	-----	--------------	----------

AB	CIPLA LTD	EQ 1GM BASE	A077135	002	May 24, 2010	Jan CAHN
----	-----------	-------------	---------	-----	--------------	----------

AB		EQ 500MG BASE	A077135	001	May 24, 2010	Jan CAHN
----	--	---------------	---------	-----	--------------	----------

AB	JUBILANT GENERICS	EQ 1GM BASE	A201506	002	Apr 03, 2012	Aug CAHN
----	-------------------	-------------	---------	-----	--------------	----------

AB		EQ 500MG BASE	A201506	001	Apr 03, 2012	Aug CAHN
----	--	---------------	---------	-----	--------------	----------

AB	WATSON LABS INC	EQ 1GM BASE	A090370	002	Mar 16, 2011	Apr CAHN
----	-----------------	-------------	---------	-----	--------------	----------

AB		EQ 500MG BASE	A090370	001	Mar 16, 2011	Apr CAHN
----	--	---------------	---------	-----	--------------	----------

VALPROIC ACID

SYRUP; ORAL

VALPROIC ACID

AA	ANI PHARMS INC	250MG/5ML	A073178	001	Aug 25, 1992	Jan CAHN
----	----------------	-----------	---------	-----	--------------	----------

VALSARTAN

TABLET; ORAL

DIOVAN

AB	NOVARTIS	40MG	N021283	004	Aug 14, 2002	Jun CFTG
----	----------	------	---------	-----	--------------	----------

AB		80MG	N021283	001	Jul 18, 2001	Jun CFTG
----	--	------	---------	-----	--------------	----------

AB		160MG	N021283	002	Jul 18, 2001	Jun CFTG
----	--	-------	---------	-----	--------------	----------

AB	+	320MG	N021283	003	Jul 18, 2001	Jun CFTG
----	---	-------	---------	-----	--------------	----------

AB	VALSARTAN					
----	-----------	--	--	--	--	--

AB	OHM LABS INC	40MG	A077492	001	Jun 26, 2014	Jun NEWA
----	--------------	------	---------	-----	--------------	----------

AB		80MG	A077492	002	Jun 26, 2014	Jun NEWA
----	--	------	---------	-----	--------------	----------

AB		160MG	A077492	003	Jun 26, 2014	Jun NEWA
----	--	-------	---------	-----	--------------	----------

AB		320MG	A077492	004	Jun 26, 2014	Jun NEWA
----	--	-------	---------	-----	--------------	----------

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HYDROCHLORIDE

AB	ANI PHARMS INC	EQ 125MG BASE	N050606	001	Apr 15, 1986	Aug CAHN
----	----------------	---------------	---------	-----	--------------	----------

AB	+	EQ 250MG BASE	N050606	002	Apr 15, 1986	Aug CAHN
----	---	---------------	---------	-----	--------------	----------

AB	SHIRE VIROPHARM INC	EQ 125MG BASE	N050606	001	Apr 15, 1986	May CAHN
----	---------------------	---------------	---------	-----	--------------	----------

AB	+	EQ 250MG BASE	N050606	002	Apr 15, 1986	May CAHN
----	---	---------------	---------	-----	--------------	----------

AB	VANCOMYCIN HYDROCHLORIDE					
----	--------------------------	--	--	--	--	--

AB	STRIDES PHARMA	EQ 125MG BASE	A065490	001	Apr 09, 2012	Aug CAHN
----	----------------	---------------	---------	-----	--------------	----------

AB		EQ 250MG BASE	A065490	002	Apr 09, 2012	Aug CAHN
----	--	---------------	---------	-----	--------------	----------

FOR SOLUTION; ORAL

VANCOCIN HYDROCHLORIDE

@	ANI PHARMS INC	EQ 250MG BASE/5ML	A061667	002	Jul 13, 1983	Aug CAHN
---	----------------	-------------------	---------	-----	--------------	----------

@		EQ 500MG BASE/6ML	A061667	001		Aug CAHN
---	--	-------------------	---------	-----	--	----------

INJECTABLE; INJECTION									
VANCOCIN HYDROCHLORIDE									
	@ ANI PHARMS INC	EQ 1GM BASE/VIAL	A060180	002	Mar 21, 1986	Aug	CAHN		
	@	EQ 1GM BASE/VIAL	A062476	002	Mar 21, 1986	Aug	CAHN		
	@	EQ 1GM BASE/VIAL	A062716	002	Mar 13, 1987	Aug	CAHN		
	@	EQ 1GM BASE/VIAL	A062812	002	Nov 17, 1987	Aug	CAHN		
	@	EQ 10GM BASE/VIAL	A062812	003	Nov 17, 1987	Aug	CAHN		
	@	EQ 500MG BASE/VIAL	A060180	001		Aug	CAHN		
	@	EQ 500MG BASE/VIAL	A062476	001	Mar 15, 1984	Aug	CAHN		
	@	EQ 500MG BASE/VIAL	A062716	001	Mar 13, 1987	Aug	CAHN		
	@	EQ 500MG BASE/VIAL	A062812	001	Nov 17, 1987	Aug	CAHN		
VANCOMYCIN HYDROCHLORIDE									
AP	AGILA SPECLTS	EQ 10GM BASE/VIAL	A091554	001	Sep 19, 2011	Feb	CAHN		
AP	MUSTAFA NEVZAT ILAC	EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	May	CAHN		
AP		EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	May	CAHN		
AP	SAGENT PHARMS	EQ 10GM BASE/VIAL	A200837	002	Sep 02, 2014	Aug	NEWA		
<u>VASOPRESSIN</u>									
SOLUTION; IV (INFUSION)									
VASOSTRICT									
	+ PAR STERILE PRODUCTS	20UNITS/ML (20UNITS/ML)	N204485	001	Apr 17, 2014	Apr	NEWA		
<u>VECURONIUM BROMIDE</u>									
INJECTABLE; INJECTION									
VECURONIUM BROMIDE									
	@ WATSON LABS	10MG/VIAL	A074334	001	Aug 31, 1995	May	DISC		
	@	20MG/VIAL	A074334	002	Aug 31, 1995	May	DISC		
<u>VENLAFAXINE HYDROCHLORIDE</u>									
TABLET; ORAL									
VENLAFAXINE HYDROCHLORIDE									
AB	SUN PHARM INDS INC	EQ 25MG BASE	A078627	001	Jun 13, 2008	Jul	CAHN		
AB		EQ 37.5MG BASE	A078627	002	Jun 13, 2008	Jul	CAHN		
AB		EQ 50MG BASE	A078627	003	Jun 13, 2008	Jul	CAHN		
AB		EQ 75MG BASE	A078627	004	Jun 13, 2008	Jul	CAHN		
AB		EQ 100MG BASE	A078627	005	Jun 13, 2008	Jul	CAHN		
<u>VERAPAMIL HYDROCHLORIDE</u>									
TABLET; ORAL									
VERAPAMIL HYDROCHLORIDE									
AB	MYLAN	80MG	A071483	002	Feb 15, 1989	Apr	CMS1		
	@ WATSON LABS	40MG	A072923	001	Jun 29, 1993	May	DISC		
	@	80MG	A070855	001	Sep 24, 1986	May	DISC		
	@	80MG	A071366	001	Oct 01, 1986	May	DISC		
	@	120MG	A070856	001	Sep 24, 1986	May	DISC		
	@	120MG	A071367	001	Oct 01, 1986	May	DISC		
TABLET, EXTENDED RELEASE; ORAL									
VERAPAMIL HYDROCHLORIDE									
AB	ANI PHARMS INC	120MG	A090529	001	Dec 30, 2011	Jun	CAHN		
AB		180MG	A090529	002	Dec 30, 2011	Jun	CAHN		
AB		240MG	A090529	003	Dec 30, 2011	Jun	CAHN		
AB	SUN PHARM INDS INC	120MG	A090529	001	Dec 30, 2011	Jul	CAHN		
AB		180MG	A090529	002	Dec 30, 2011	Jul	CAHN		
AB		240MG	A090529	003	Dec 30, 2011	Jul	CAHN		
<u>VINBLASTINE SULFATE</u>									
INJECTABLE; INJECTION									
VINBLASTINE SULFATE									
	+ EUROHLTH INTL	10MG/VIAL	A089395	001	Apr 09, 1987	Aug	CAHN		
<u>VINORELBINE TARTRATE</u>									
INJECTABLE; INJECTION									
VINORELBINE TARTRATE									
AP	ACTAVIS ELIZABETH	EQ 10MG BASE/ML	A078011	001	Jul 22, 2009	Aug	CAHN		
<u>VORAPAXAR SULFATE</u>									
TABLET; ORAL									
ZONTIVITY									
	+ MERCK SHARP DOHME	EQ 2.08MG BASE	N204886	001	May 08, 2014	Jun	CPOT		
	+	EQ 2.5MG BASE	N204886	001	May 08, 2014	May	NEWA		

VORICONAZOLEFOR SUSPENSION; ORAL
VFEND

>A>	AB	+	PF PRISM CV	200MG/5ML	N021630	001	Dec 19, 2003	Sep CAHN
>D>	AB	+	PFIZER	200MG/5ML	N021630	001	Dec 19, 2003	Sep CAHN
INJECTABLE; IV (INFUSION)								
VFEND								
>A>	AP	+	PF PRISM CV	200MG/VIAL	N021267	001	May 24, 2002	Sep CAHN
>D>	AP	+	PFIZER	200MG/VIAL	N021267	001	May 24, 2002	Sep CAHN
TABLET; ORAL								
VFEND								
>A>	AB		PF PRISM CV	50MG	N021266	001	May 24, 2002	Sep CAHN
>A>	AB	+		200MG	N021266	002	May 24, 2002	Sep CAHN
>D>	AB		PFIZER	50MG	N021266	001	May 24, 2002	Sep CAHN
>D>	AB	+		200MG	N021266	002	May 24, 2002	Sep CAHN

WARFARIN SODIUMINJECTABLE; INJECTION
COUMADIN

@ BRISTOL MYERS SQUIBB 5MG/VIAL

N009218 024 Feb 07, 1995 Mar DISC

TABLET; ORAL

COUMADIN

AB			BRISTOL MYERS SQUIBB	1MG	N009218	022	Mar 01, 1990	Apr CMFD
	@			1MG	N009218	022	Mar 01, 1990	Mar DISC
AB				2MG	N009218	013		Apr CMFD
	@			2MG	N009218	013		Mar DISC
AB				2.5MG	N009218	018		Apr CMFD
	@			2.5MG	N009218	018		Mar DISC
AB				3MG	N009218	025	Nov 18, 1996	Apr CMFD
	@			3MG	N009218	025	Nov 18, 1996	Mar DISC
AB				4MG	N009218	023	Aug 24, 1993	Apr CMFD
	@			4MG	N009218	023	Aug 24, 1993	Mar DISC
AB				5MG	N009218	007		Apr CMFD
	@			5MG	N009218	007		Mar DISC
AB				6MG	N009218	026	Nov 18, 1996	Apr CMFD
	@			6MG	N009218	026	Nov 18, 1996	Mar DISC
AB				7.5MG	N009218	016		Apr CMFD
	@			7.5MG	N009218	016		Mar DISC
AB	+			10MG	N009218	005		Apr CMFD
	@			10MG	N009218	005		Mar DISC

ZICONOTIDE ACETATEINJECTABLE; INTRATHECAL
PRIALT

@ JAZZ PHARMS INTL 200MCG/2ML (100MCG/ML)

N021060 003 Dec 28, 2004 Feb CAIN

ZIDOVUDINEINJECTABLE; INJECTION
ZIDOVUDINE

@ LIAONING CHENGDA 10MG/ML

A204538 001 Nov 26, 2013 Mar DISC

ZILEUTON

TABLET; ORAL

ZYFLO

@ CHIESI USA INC 300MG
+ 600MGN020471 001 Dec 09, 1996 Apr CAHN
N020471 003 Dec 09, 1996 Apr CAHNTABLET, EXTENDED RELEASE; ORAL
ZYFLO CR

+ CHIESI USA INC 600MG

N022052 001 May 30, 2007 Apr CAHN

ZOLEDRONIC ACIDINJECTABLE; IV (INFUSION)
ZOLEDRONIC ACID

AP			AKORN	EQ 5MG BASE/100ML	A200918	001	Aug 21, 2014	Aug NEWA
AP			AKORN INC	EQ 4MG BASE/5ML	A202548	001	May 22, 2014	May NEWA
AP			USV NORTH AMERICA	EQ 4MG BASE/VIAL	A202923	001	Sep 04, 2014	Aug NEWA

ZOLMITRIPTAN

TABLET; ORAL

ZOLMITRIPTAN

AB	INVAGEN PHARMS	2.5MG	A204284	001	Apr 09, 2014	Mar NEWA
AB		5MG	A204284	002	Apr 09, 2014	Mar NEWA
AB	TEVA PHARMS USA	2.5MG	A090861	001	Mar 04, 2014	Feb NEWA
AB		5MG	A090861	002	Mar 04, 2014	Feb NEWA

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

AB	SUN PHARM INDS INC	5MG	A077359	001	Apr 23, 2007	Jul CAHN
AB		10MG	A077359	002	Apr 23, 2007	Jul CAHN
	@ VIVIMED LABS	5MG	A076062	001	Apr 23, 2007	Apr CAHN
	@	10MG	A076062	002	Apr 23, 2007	Apr CAHN
	@ WATSON LABS	5MG	A077773	001	Apr 23, 2007	May DISC
	@	10MG	A077773	002	Apr 23, 2007	May DISC

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

>D>	AB	ANI PHARMS INC	25MG	A077639	001	Dec 22, 2005	Sep DISC
>A>		@	25MG	A077639	001	Dec 22, 2005	Sep DISC
	AB		25MG	A077639	001	Dec 22, 2005	Jan CAHN
		@	25MG	A077641	003	Dec 22, 2005	Jan CAHN
>D>	AB		50MG	A077639	002	Dec 22, 2005	Sep DISC
>A>		@	50MG	A077639	002	Dec 22, 2005	Sep DISC
	AB		50MG	A077639	002	Dec 22, 2005	Jan CAHN
		@	50MG	A077641	002	Dec 22, 2005	Jan CAHN
>D>	AB		100MG	A077639	003	Dec 22, 2005	Sep DISC
>A>		@	100MG	A077639	003	Dec 22, 2005	Sep DISC
	AB		100MG	A077639	003	Dec 22, 2005	Jan CAHN
		@	100MG	A077641	001	Dec 22, 2005	Jan CAHN
		@ SANDOZ	25MG	A077644	001	Dec 22, 2005	Feb DISC
		@	50MG	A077644	002	Dec 22, 2005	Feb DISC
		@	100MG	A077644	003	Dec 22, 2005	Feb DISC

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL
 DRIXORAL PLUS

@ SCHERING PLOUGH 500MG;3MG;60MG N019453 001 May 22, 1987 Feb DISC

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>D> CARACO 5MG/5ML A091327 001 Oct 17, 2011 Sep CAHN
 >A> SUN PHARM INDS INC 5MG/5ML A091327 001 Oct 17, 2011 Sep CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>D> CARACO 5MG/5ML A091327 002 Oct 17, 2011 Sep CAHN
 >A> SUN PHARM INDS INC 5MG/5ML A091327 002 Oct 17, 2011 Sep CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

IPCA LABS LTD 5MG A202277 002 Mar 11, 2014 Feb NEWA
 10MG A202277 004 Mar 11, 2014 Feb NEWA
 SUN PHARM INDS INC 5MG A077499 001 Dec 27, 2007 Jul CAHN
 10MG A077499 002 Dec 27, 2007 Jul CAHN

CETIRIZINE HYDROCHLORIDE HIVES

IPCA LABS LTD 5MG A202277 001 Mar 11, 2014 Feb NEWA
 10MG A202277 003 Mar 11, 2014 Feb NEWA
 SUN PHARM INDS INC 5MG A077499 003 Dec 27, 2007 Jul CAHN
 10MG A077499 004 Dec 27, 2007 Jul CAHN

TABLET, CHEWABLE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

@ CARACO 5MG A077631 004 Jan 11, 2008 Feb DISC
 @ 10MG A077631 003 Jan 11, 2008 Feb DISC
 @ SUN PHARM INDS INC 5MG A077631 004 Jan 11, 2008 Jul CAHN
 @ 10MG A077631 003 Jan 11, 2008 Jul CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@ CARACO 5MG A077631 001 Jan 11, 2008 Feb DISC
 @ 10MG A077631 002 Jan 11, 2008 Feb DISC
 @ SUN PHARM INDS INC 5MG A077631 001 Jan 11, 2008 Jul CAHN
 @ 10MG A077631 002 Jan 11, 2008 Jul CAHN

CIMETIDINE

TABLET;ORAL

CIMETIDINE

@ WATSON LABS 200MG A075425 001 Jul 29, 1999 May DISC

CLOTRIMAZOLE

CREAM, TABLET;TOPICAL, VAGINAL

GYNE-LOTRIMIN 3 COMBINATION PACK

>A> + BAYER HEALTHCARE LLC 1%,200MG N020526 002 Jul 29, 1996 Sep CAHN
 >D> + SCHERING PLOUGH 1%,200MG N020526 002 Jul 29, 1996 Sep CAHN

TABLET;VAGINAL

GYNE-LOTRIMIN 3

>A> + BAYER HEALTHCARE LLC 200MG N020525 001 Jul 29, 1996 Sep CAHN
 >D> + SCHERING PLOUGH 200MG N020525 001 Jul 29, 1996 Sep CAHN

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

+ AVANTHI INC 6MG;120MG A078648 001 Feb 27, 2013 Jan CRLD
 DISOPHROL
 @ SCHERING PLOUGH 6MG;120MG N013483 004 Sep 13, 1982 Jan DISC

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

STRIDES PHARMA 25MG;EQ 200MG FREE ACID AND A200888 001 Mar 05, 2012 Aug CAHN
 POTASSIUM SALT

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

ALEVE PM

+	BAYER HLTHCARE	25MG;220MG	N205352	001	Jan 17, 2014	Jan NEWA
---	----------------	------------	---------	-----	--------------	----------

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

NEXIUM

ASTRAZENECA LP

EQ 20MG BASE

N204655	001	Mar 28, 2014	Apr CMS2
---------	-----	--------------	----------

EQ 20MG BASE

N204655	001	Mar 28, 2014	Mar NEWA
---------	-----	--------------	----------

NEXIUM 24HR

+	ASTRAZENECA LP	EQ 20MG BASE	N204655	001	Mar 28, 2014	Apr CTNA
---	----------------	--------------	---------	-----	--------------	----------

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

@ WATSON LABS

10MG

A075404	001	Nov 28, 2001	May DISC
---------	-----	--------------	----------

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLONASE ALLERGY RELIEF

+	GLAXOSMITHKLINE CONS	0.05MG/SPRAY	N205434	001	Jul 23, 2014	Jul NEWA
---	----------------------	--------------	---------	-----	--------------	----------

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

>A>	P AND L DEV LLC	EQ 200MG FREE ACID AND POTASSIUM	A077338	001	Jul 10, 2009	Sep CAHN
-----	-----------------	----------------------------------	---------	-----	--------------	----------

SALT

>D>	PLD ACQUISITIONS	EQ 200MG FREE ACID AND POTASSIUM	A077338	001	Jul 10, 2009	Sep CAHN
-----	------------------	----------------------------------	---------	-----	--------------	----------

SALT

SUSPENSION;ORAL

CHILDREN'S ELIXSURE

MOBERG PHARMA NORTH

100MG/5ML

N021604	001	Jan 07, 2004	May CAHN
---------	-----	--------------	----------

TABLET;ORAL

IBUPROFEN

AMNEAL PHARMS

200MG

A079233	001	Mar 18, 2014	Mar NEWA
---------	-----	--------------	----------

@ WATSON LABS

200MG

A070435	001	Mar 05, 1986	May DISC
---------	-----	--------------	----------

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET;ORAL

IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE

PERRIGO R AND D

200MG;10MG

A203200	001	Jul 03, 2014	Jun NEWA
---------	-----	--------------	----------

LEVONORGESTREL

TABLET;ORAL

FALLBACK SOLO

LUPIN LTD

1.5MG

A201446	001	Jun 19, 2014	Jun NEWA
---------	-----	--------------	----------

LEVONORGESTREL

>A>	@ LUPIN LTD	0.75MG	A091328	001	Jan 23, 2013	Sep DISC
-----	-------------	--------	---------	-----	--------------	----------

PERRIGO R AND D

1.5MG

A202334	001	Aug 20, 2014	Aug NEWA
---------	-----	--------------	----------

>A>	OPCICON ONE-STEP					
-----	------------------	--	--	--	--	--

>A>	SUN PHARM INDS LTD	1.5MG	A202635	001	Sep 11, 2014	Sep NEWA
-----	--------------------	-------	---------	-----	--------------	----------

LORATADINE

TABLET;ORAL

CLARITIN

>A>	+ BAYER HEALTHCARE LLC	10MG	N019658	002	Nov 27, 2002	Sep CAHN
-----	------------------------	------	---------	-----	--------------	----------

>D>	+ SCHERING PLOUGH	10MG	N019658	002	Nov 27, 2002	Sep CAHN
-----	-------------------	------	---------	-----	--------------	----------

CLARITIN HIVES RELIEF

>A>	+ BAYER HEALTHCARE LLC	10MG	N019658	003	Nov 19, 2003	Sep CAHN
-----	------------------------	------	---------	-----	--------------	----------

>D>	+ SCHERING PLOUGH	10MG	N019658	003	Nov 19, 2003	Sep CAHN
-----	-------------------	------	---------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING;ORAL

CLARITIN HIVES RELIEF REDITAB

>A>	+ BAYER HEALTHCARE LLC	10MG	N020704	003	Nov 19, 2003	Sep CAHN
-----	------------------------	------	---------	-----	--------------	----------

>D>	+ SCHERING PLOUGH	10MG	N020704	003	Nov 19, 2003	Sep CAHN
-----	-------------------	------	---------	-----	--------------	----------

CLARITIN REDITABS

>A>	+ BAYER HEALTHCARE LLC	10MG	N020704	002	Nov 27, 2002	Sep CAHN
-----	------------------------	------	---------	-----	--------------	----------

>D>	+ SCHERING PLOUGH	10MG	N020704	002	Nov 27, 2002	Sep CAHN
-----	-------------------	------	---------	-----	--------------	----------

MINOXIDILAEROSOL, FOAM;TOPICAL
WOMEN'S ROGAINE

+ JOHNSON AND JOHNSON 5%

N021812 002 Feb 28, 2014 Feb NEWA

NONOXYNOL-9SPONGE;VAGINAL
TODAY

+ MAYER LABS INC 1GM

N018683 001 Apr 01, 1983 Aug CAHN

OXYBUTYNINFILM, EXTENDED RELEASE;TRANSDERMAL
OXYTROL FOR WOMEN

>A> + BAYER HEALTHCARE LLC 3.9MG/24HR

N202211 001 Jan 25, 2013 Sep CAHN

>D> + MSD CONSUMER 3.9MG/24HR

N202211 001 Jan 25, 2013 Sep CAHN

TRIAMCINOLONE ACETONIDESPRAY, METERED;NASAL
NASACORT ALLERGY 24 HOUR

+ SANOFI AVENTIS US 0.055MG/SPRAY

N020468 002 Oct 11, 2013 Jul CRLD

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 9 SEPTEMBER 2014

NO SEPTEMBER 2014 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO SEPTEMBER 2014 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001	>A> 5905082	May 18, 2016	DS DP		NCE	Aug 12, 2018
	>A> 5905082*PED	Nov 18, 2016				
	>A> 6294540	May 14, 2018	DS DP U-1572			
	>A> 6294540*PED	Nov 14, 2018				
	>A> 6417191	Mar 28, 2016	DP U-1572			
	>A> 8129385	Oct 05, 2027	DS DP			
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 001	>A> 8822438	Aug 24, 2027	U-1579			
	>A> 8822438	Aug 24, 2027	U-1580			
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	6488962	Jun 20, 2020	DP		NP	Mar 11, 2017
	7976870	Jun 01, 2027	U-1498			
	8372432	Mar 11, 2029	DP U-1499			
	8377453	Nov 19, 2029	DP U-1499			
	8394408	Mar 11, 2029	DP			
	8597681	Dec 21, 2030	DP			
	8658631	May 16, 2032	DP			
	8668929	Mar 11, 2029	U-1499			
	8741885	May 16, 2032	DP U-1499			
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	8653061	Aug 24, 2025	U-1373			
	8722738	Apr 06, 2032	U-1373			
<u>ACYCLOVIR - SITAVIG</u>						
N 203791 001	8592434	Jun 16, 2030	DP U-1460			
	8747896	Jun 03, 2027	DP U-1460			
	8791127	Mar 23, 2027	DP U-1460			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	6514980	Jan 24, 2019	DP U-1006		NPP	Jan 22, 2017
	6514980	Jan 24, 2019	DP U-1484			
	7223387	May 13, 2023	DP U-1006			
	7223387	May 13, 2023	DP U-1484			
	RE39264	Aug 02, 2016	DP U-1006			
	RE39264	Aug 02, 2016	DP U-1484			
<u>ADAPALENE - ADAPALENE</u>						
A 200298 001					PC	Oct 25, 2014
<u>ADAPALENE - DIFFERIN</u>						
N 021753 001	8703820	Mar 12, 2023	U-1078			
<u>ADAPALENE - DIFFERIN</u>						
N 022502 001	8709392	Sep 15, 2026	DP U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320 001	>A> 8809305	Dec 23, 2022	U-1078			
<u>ADENOSINE - ADENOSINE</u>						
A 077425 001					PC	Mar 22, 2014
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N 020983 001	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001	>A> 8834849	Jun 04, 2017	DP			
<u>ALCAFTADINE - LASTACFT</u>						
N 022134 001	8664215	Oct 05, 2029	U-1493			
<u>ALISKIREN HEMIFUMARATE - TEKTURN</u>						
N 021985 001	8617595	Feb 19, 2026	DP			
<u>ALISKIREN HEMIFUMARATE - TEKTURN</u>						
N 021985 002	8617595	Feb 19, 2026	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 001	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 002	8613949	Dec 21, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 003	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 004	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 001	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 002	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 003	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 004	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 005	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRUNA HCT</u>						
N 022107 001	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRUNA HCT</u>						
N 022107 002	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRUNA HCT</u>						
N 022107 003	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRUNA HCT</u>						
N 022107 004	8618172	Jul 13, 2028	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	8637079	Jan 23, 2029	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8112290	Jul 31, 2030	U-1443			
	8645160	Jun 18, 2029	U-1485			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	8758418	May 01, 2018	U-289			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	>A> 6413980	Dec 22, 2019	DS DP U-1200		I-661	Aug 21, 2017
	>A> 6413980	Dec 22, 2019	DS DP U-1301		I-681	Mar 03, 2017
	>A> 6413980	Dec 22, 2019	DS DP U-1302		I-690	Aug 21, 2017
	>A> 6413980	Dec 22, 2019	DS DP U-1501		I-691	Aug 21, 2017
	>A> 6967208	Feb 03, 2023	DS DP U-1167			
	>A> 6967208	Feb 03, 2023	DS DP U-1200			
	>A> 6967208	Feb 03, 2023	DS DP U-1301			
	>A> 6967208	Feb 03, 2023	DS DP U-1302			
	>A> 6967208	Feb 03, 2023	DS DP U-1323			
	>A> 6967208	Feb 03, 2023	DS DP U-1501			
	>A> 6967208	Feb 03, 2023	DS DP U-1502			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APIXABAN - ELIQUIS</u>						
N 202155 002					I-661 I-690 I-691	Aug 21, 2017 Aug 21, 2017 Aug 21, 2017
<u>APREMILAST - OTEZLA</u>						
N 205437 001	6020358	Oct 30, 2018	DS DP U-1504		>A> I-694 NCE	Sep 23, 2017
	6962940	Mar 19, 2023	U-1504			Mar 21, 2019
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8802717	Mar 19, 2023	U-1561			
<u>APREMILAST - OTEZLA</u>						
N 205437 002	6020358	Oct 30, 2018	DS DP U-1504		>A> I-694 NCE	Sep 23, 2017
	6962940	Mar 19, 2023	U-1504			Mar 21, 2019
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8802717	Mar 19, 2023	U-1561			
<u>APREMILAST - OTEZLA</u>						
N 205437 003	6020358	Oct 30, 2018	DS DP U-1504		>A> I-694 NCE	Sep 23, 2017
	6962940	Mar 19, 2023	U-1504			Mar 21, 2019
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8802717	Mar 19, 2023	U-1561			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 004	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 005	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY</u>						
N 021436 006	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021713 001	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 002	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 003	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 004	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 005	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021866 001					M-137	Jun 09, 2017
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	8022228	Apr 06, 2026	DS DP			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	8022228	Apr 06, 2026	DS DP			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 206352 001	5849911	Jun 20, 2017	DS DP U-167		NP	Jun 02, 2017
	6087383	Dec 21, 2018	DS DP			
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 001	5686104	Nov 11, 2014	DP U-1400			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 002	5686104	Nov 11, 2014	DP U-1400			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 003	5686104	Nov 11, 2014	DP U-1400			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 004	5686104	Nov 11, 2014	DP U-1400			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
<u>AVANAFIL - STENDRA</u>						
N 202276 001					>A> D-140	Sep 17, 2017
<u>AVANAFIL - STENDRA</u>						
N 202276 002					>A> D-140	Sep 17, 2017
<u>AVANAFIL - STENDRA</u>						
N 202276 003					>A> D-140	Sep 17, 2017
<u>AXITINIB - INLYTA</u>						
N 202324 001	8791140	Aug 05, 2030	DS			
<u>AXITINIB - INLYTA</u>						
N 202324 002	8791140	Aug 05, 2030	DS			
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	>A> 8815934	May 06, 2019	DP		NP	Oct 03, 2016
<u>BECLOMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911 001	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP U-645			
	6446627	Dec 18, 2017	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 40</u>						
N 020911 002	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP U-645			
	6446627	Dec 18, 2017	DP			
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	8546428	Mar 19, 2029	DS DP U-1321			
<u>BELINOSTAT - BELEODAO</u>						
N 206256 001	6888027	Sep 27, 2021	DS DP U-1544		NCE	Jul 03, 2019
	>A> 8835501	Oct 27, 2027	DP		ODE	Jul 03, 2021
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	8791270	Jan 12, 2026	DP U-1542			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	8791270	Jan 12, 2026	DP U-1542			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	8663699	Jun 03, 2029	U-124			
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288 001	8784789	Sep 05, 2024	DP			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE</u>						
A 201615 001					PC	Sep 27, 2014
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N 022185 001					NPP	Aug 29, 2017
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	8772338	Mar 16, 2025	DP U-1528			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	8263054	Jan 15, 2023	U-1277		>A> M-140	Sep 04, 2017
	8632760	Jan 15, 2023	U-1487			
	8758733	Jan 15, 2023	U-1487			
<u>BORTEZOMIB - VELCADE</u>						
N 021602 001					M-139 ODE	Aug 08, 2017 Jun 20, 2015
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	8748425	Apr 19, 2022	DP U-1524			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	8669290	Jan 16, 2024	DP			
	8754131	Jan 16, 2024	DP			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	8613947	Apr 30, 2032	DP U-976			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	8784888	Jun 09, 2020	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8616196	Apr 07, 2029	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8616196	Apr 07, 2029	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001 >A>	8834921	Sep 18, 2018	DP U-1587			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002 >A>	8834921	Sep 18, 2018	DP U-1587			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 001	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 002	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 003	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 004	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 005	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8658198	Dec 03, 2027	DP U-1494			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8658198	Dec 03, 2027	DP U-1494			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 001	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 002	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 003	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001 >A>	7375111	Mar 26, 2025	DP		>A> NC	Sep 10, 2017
>A>	7462626	Jul 20, 2024	U-1583			
>A>	8088786	Feb 03, 2029	DP			
>A>	8318788	Nov 08, 2027	U-1584			
>A>	8722085	Nov 08, 2027	U-1585			
>A>	8815889	Jul 20, 2024	U-1586			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	5847170	Mar 26, 2021	DS DP			
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563 001	8263580	Sep 27, 2028	DP U-1280			
	8269128	May 26, 2026	DP U-1280			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	7153964	Feb 26, 2021	DS DP		NCE	Apr 29, 2019
	7893074	Apr 25, 2026	DS DP		ODE	Apr 29, 2021
	7964592	Jan 13, 2027	DS DP			
	8039474	Jun 29, 2030	DS DP			
	8039479	Jun 29, 2030	DS DP			
	8377921	Nov 20, 2027	U-1179			
	8703787	Feb 02, 2032	U-1179			
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537 001 >A>	8846650	Jun 04, 2025	DP U-1578			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 001	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 002	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 003	5739152	Apr 14, 2015	DP U-893			
	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
<u>COBICISTAT - TYBOST</u>						
N 203094 001					>A> NP	Sep 24, 2017
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8633219	Oct 11, 2031	DP U-257		NP	Aug 27, 2015
	8716264	Jan 13, 2024	DP U-257			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001	8785632	Mar 01, 2025	DS			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002	8785632	Mar 01, 2025	DS			
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	8003353	Jun 11, 2024	U-817			
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	8633162	Aug 27, 2024	U-1479			
	8642556	Aug 27, 2024	DP			
	8648048	Aug 27, 2024	U-1483			
	8685930	Aug 27, 2024	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001					ODE	Apr 30, 2020
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002					ODE	Apr 30, 2020
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001					I-682	Apr 04, 2017
					I-683	Apr 04, 2017
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002					I-682	Apr 04, 2017
					I-683	Apr 04, 2017
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001					I-678	Jan 08, 2017
					ODE	Jan 09, 2021
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					I-678	Jan 08, 2017
					ODE	Jan 09, 2021
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001	6900175	Dec 25, 2023	U-1517		NCE	May 23, 2019
	7115564	Nov 14, 2023	DP		GAIN	May 23, 2024
	7119061	Nov 14, 2023	DP			
	8143212	Nov 14, 2023	U-1517			
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	8663685	Jan 18, 2025	U-1030			
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579 001	7758890	Jul 01, 2025	DP			
	8110225	Dec 24, 2022	DP			
	8604072	Dec 24, 2022	DP			
	8685460	Feb 15, 2023	U-1546			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7851502	Aug 19, 2028	DP			
	7919598	Dec 16, 2029	DS			
	8221786	Mar 21, 2028	DP			
	8361972	Mar 21, 2028	U-493			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
	8716251	Mar 21, 2028	DP			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 001	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 003	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DASATINIB - SPRYCEL</u>						
N 021986 001	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 002	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 003	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 004	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 005	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 006	8680103	Feb 04, 2025	DP			
<u>DESOXIMETASONE - TOPICORT</u>						
N 204141 001	8277780	Sep 01, 2028	DP U-1408			
	8715624	May 26, 2026	DP U-1408			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 001	6673838	Mar 01, 2022	DS	U-860		
	6673838	Mar 01, 2022	DS	U-1364		
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 002	6673838	Mar 01, 2022	DS	U-860		
	6673838	Mar 01, 2022	DS	U-1364		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001					I-686	Jun 29, 2017
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276*PED	Jul 30, 2023				
	8722084	Oct 15, 2023	DP			
	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276*PED	Jul 30, 2023				
	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001					M-61 PED	Jun 17, 2016 Dec 17, 2016
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	8648106	Jan 04, 2032	DP		M-61 PED	Jun 17, 2016 Dec 17, 2016
	8648106*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	8648106	Jan 04, 2032	DP		M-61 PED	Jun 17, 2016 Dec 17, 2016
	8648106*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078992 003					PC	May 18, 2014
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA</u>						
N 021879 001	RE38115	Jan 26, 2016	DP	Y		
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001	8679544	Apr 23, 2030	DP		I-692	Aug 22, 2017
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002	8679544	Apr 23, 2030	DP		I-692	Aug 22, 2017
<u>DICLOFENAC EPOLAMINE - FLECTOR</u>						
N 021234 001	5607690	Apr 13, 2019	DP			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001	6287594	Jan 15, 2019	DP			
	8623920	Feb 24, 2029	U-1482			
<u>DICLOFENAC SODIUM - DICLOFENAC SODIUM</u>						
A 202027 001					PC	Nov 23, 2014
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 020947 001	8741956	Jul 10, 2029	U-1435			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	8217078	Jul 10, 2029	U-1477		NP	Jan 16, 2017
	8252838	Apr 21, 2028	DP U-1489			
	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
	8563613	Oct 17, 2027	DP U-1488			
	8618164	Jul 10, 2029	U-1477			
	8741956	Jul 10, 2029	U-1435			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	8759393	Oct 29, 2019	DP			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	8759393	Oct 29, 2019	DP			
<u>DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM - ALEVE PM</u>						
N 205352 001					NC	Jan 17, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	8709478	Apr 07, 2024	U-1063			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 001	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 002	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 003	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 004	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 005	8715724	Feb 03, 2028	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532 001	8617597	Feb 08, 2030	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N 022574 001	8617597	Feb 08, 2030	DP			
<u>DROXIDOPA - NORTHERA</u>						
N 203202 001					NCE ODE	Feb 18, 2019 Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202 002					NCE ODE	Feb 18, 2019 Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202 003					NCE ODE	Feb 18, 2019 Feb 18, 2021
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 001					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 003					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 001					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 003					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 001					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 003					PC	Jun 09, 2014
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	8716264	Jan 13, 2024	DP U-257			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	7214506	Oct 05, 2021	U-281		NCE	Jun 06, 2019
	8039494	Jul 08, 2030	U-281			
	8486978	Oct 24, 2030	DP			
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494 001	>A> 6916802	Apr 29, 2022	U-1571		NCE ODE	Aug 19, 2019 Aug 19, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	>A> 6280959	Oct 30, 2018	DS DP U-930		ODE	Aug 26, 2021
	>A> 6280959	Oct 30, 2018	DS DP U-1306			
	>A> 6280959	Oct 30, 2018	DS DP U-1575			
	>A> 7160870	Nov 20, 2022	DS DP U-930			
	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1575			
	>A> 7332481	May 24, 2021	U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-1575			
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7473686	May 24, 2021	DS DP U-1575			
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-1575			
	>A> 7790704	May 24, 2021	U-930			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-1575			
	>A> 7795293	May 21, 2023	U-930			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-1575			
	>A> 8052993	Aug 01, 2027	DP U-930			
	>A> 8052993	Aug 01, 2027	DP U-1306			
	>A> 8052993	Aug 01, 2027	DP U-1575			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	>A> 6280959	Oct 30, 2018	DS DP U-930		ODE	Aug 26, 2021
	>A> 6280959	Oct 30, 2018	DS DP U-1306			
	>A> 6280959	Oct 30, 2018	DS DP U-1575			
	>A> 7160870	Nov 20, 2022	DS DP U-930			
	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1575			
	>A> 7332481	May 24, 2021	U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-1575			
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7473686	May 24, 2021	DS DP U-1575			
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-1575			
	>A> 7790704	May 24, 2021	U-930			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-1575			
	>A> 7795293	May 21, 2023	U-930			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-1575			
	>A> 8052994	Aug 01, 2027	DP U-930			
	>A> 8052994	Aug 01, 2027	DP U-1306			
	>A> 8052994	Aug 01, 2027	DP U-1575			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	>A> 6280959	Oct 30, 2018	DS DP U-930		ODE	Aug 26, 2021
	>A> 6280959	Oct 30, 2018	DS DP U-1306			
	>A> 6280959	Oct 30, 2018	DS DP U-1575			
	>A> 7160870	Nov 20, 2022	DS DP U-930			
	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1575			
	>A> 7332481	May 24, 2021	U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-1575			
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7473686	May 24, 2021	DS DP U-1575			
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-1575			
	>A> 7790704	May 24, 2021	U-930			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-1575			
	>A> 7795293	May 21, 2023	U-930			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-1575			
	>A> 8062665	Aug 01, 2027	DP U-930			
	>A> 8062665	Aug 01, 2027	DP U-1306			
	>A> 8062665	Aug 01, 2027	DP U-1575			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	>A> 6280959	Oct 30, 2018	DS DP U-930		ODE	Aug 26, 2021
	>A> 6280959	Oct 30, 2018	DS DP U-1306			
	>A> 6280959	Oct 30, 2018	DS DP U-1575			
	>A> 7160870	Nov 20, 2022	DS DP U-930			
	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1575			
	>A> 7332481	May 24, 2021	U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-1575			
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7473686	May 24, 2021	DS DP U-1575			
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-1575			
	>A> 7790704	May 24, 2021	U-930			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-1575			
	>A> 7795293	May 21, 2023	U-930			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-1575			
	>A> 8071129	Aug 01, 2027	DP U-930			
	>A> 8071129	Aug 01, 2027	DP U-1306			
	>A> 8071129	Aug 01, 2027	DP U-1575			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005	>A> 6280959	Oct 30, 2018	DS DP U-930		ODE	Aug 26, 2021
	>A> 6280959	Oct 30, 2018	DS DP U-1306			
	>A> 6280959	Oct 30, 2018	DS DP U-1575			
	>A> 7160870	Nov 20, 2022	DS DP U-930			
	>A> 7160870	Nov 20, 2022	DS DP U-1306			
	>A> 7160870	Nov 20, 2022	DS DP U-1575			
	>A> 7332481	May 24, 2021	U-930			
	>A> 7332481	May 24, 2021	U-1306			
	>A> 7332481	May 24, 2021	U-1575			
	>A> 7473686	May 24, 2021	DS DP U-930			
	>A> 7473686	May 24, 2021	DS DP U-1306			
	>A> 7473686	May 24, 2021	DS DP U-1575			
	>A> 7547719	Jul 13, 2025	DS DP U-930			
	>A> 7547719	Jul 13, 2025	DS DP U-1306			
	>A> 7547719	Jul 13, 2025	DS DP U-1575			
	>A> 7790704	May 24, 2021	U-930			
	>A> 7790704	May 24, 2021	U-1306			
	>A> 7790704	May 24, 2021	U-1575			
	>A> 7795293	May 21, 2023	U-930			
	>A> 7795293	May 21, 2023	U-1306			
	>A> 7795293	May 21, 2023	U-1575			
	>A> 8052995	Aug 01, 2027	DP U-1306			
	>A> 8052995	Aug 01, 2027	DP U-1575			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001					>A> NP	Sep 24, 2017
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002					>A> NP	Sep 24, 2017
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	8716264	Jan 13, 2024	DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 2021752 001	8716264	Jan 13, 2024	DP U-257			
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	8778366	Nov 06, 2032	U-3			
	8778366	Nov 06, 2032	U-185			
<u>ENTECAVIR - ENTECAVIR</u>						
A 202122 001					>A> PC	Feb 21, 2015
<u>ENTECAVIR - ENTECAVIR</u>						
A 202122 002					>A> PC	Feb 21, 2015
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 001					NPP	Mar 20, 2017
					PED	Sep 20, 2017
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 002					NPP	Mar 20, 2017
					PED	Sep 20, 2017
<u>ENTECAVIR - BARACLUDE</u>						
N 021798 001					NPP	Mar 20, 2017
					PED	Sep 20, 2017
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	>A> 8183274	May 15, 2026	U-1281		>A> I-693	Sep 10, 2017
	>A> 8183274	May 15, 2026	U-1588			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	5690960	Nov 25, 2014	DP U-1509		RTO	Mar 28, 2017
	5714504	Feb 03, 2015	DP U-1509			
	5877192	May 27, 2014	U-1509			
	5900424	May 04, 2016	DS U-1509			
	6369085	May 25, 2018	DS DP U-1509			
	6428810	Nov 03, 2019	DP U-1509			
	6875872	May 27, 2014	DS			
	7411070	May 25, 2018	DS			
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689 001	5877192	May 27, 2014	U-643		D-138	Mar 04, 2017
	5877192	May 27, 2014	U-1495		I-679	Mar 04, 2017
	5877192*PED	Nov 27, 2014				
	6143771	May 27, 2015	DP U-643			
	6143771	May 27, 2015	DP U-1495			
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689 002	5877192	May 27, 2014	U-643		D-138	Mar 04, 2017
	5877192	May 27, 2014	U-1495		I-679	Mar 04, 2017
	5877192*PED	Nov 27, 2014				
	6143771	May 27, 2015	DP U-643			
	6143771	May 27, 2015	DP U-1495			
<u>ESTRADIOL - EVAMIST</u>						
N 022014 001	6978945	Jul 31, 2022	DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MINASTRIN 24 FE</u>						
N 203667 001	6667050	Apr 06, 2019	DP U-1			
<u>ETHIODIZED OIL - LIPIODOL</u>						
N 009190 001					ODE	Apr 04, 2021
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529 002	8722037	Sep 28, 2027	DP			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 001	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 002	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 003	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	8216180	Jan 12, 2028	DP			
	8439864	Mar 25, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EZETIMIBE - ZETIA</u>						
N 021445 001	7612058	Oct 30, 2025	U-1027			
	7612058	Oct 30, 2025	U-1173			
	7612058*PED	Apr 30, 2026				
<u>FENTANYL - SUBSYS</u>						
N 202788 001	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	>A> 8835459	Jan 25, 2027	DP			
	>A> 8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	>A> 8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	>A> 8835459	Jan 25, 2027	DP			
	>A> 8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	>A> 8835459	Jan 25, 2027	DP			
	>A> 8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	>A> 8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	>A> 8835459	Jan 25, 2027	DP			
	>A> 8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	>A> 8835459	Jan 25, 2027	DP			
	>A> 8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 001	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 002	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 003	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 004	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 005	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CITRATE - FERRIC CITRATE</u>						
N 205874 001	>A> 5753706	Feb 03, 2017	DP U-1577			
	>A> 7767851	Feb 18, 2024	DS DP			
	>A> 8093423	Apr 21, 2026	U-1577			
	>A> 8299298	Feb 18, 2024	DP			
	>A> 8338642	Feb 18, 2024	DS DP U-1577			
	>A> 8609896	Feb 18, 2024	DP			
	>A> 8754257	Feb 18, 2024	DP			
	>A> 8754258	Feb 18, 2024	DP			
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001	6599498	Jun 30, 2023	DS DP			
<u>FLORBETABEN F-18 - NEURACEQ</u>						
N 204677 001	7907135	Mar 18, 2029	DS DP U-1497		NCE	Mar 21, 2019
<u>FLUOCINOLONE ACETONIDE - ILUVIEN</u>						
N 201923 001					>A> NP	Sep 26, 2017
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N 021112 001	8653053	Oct 25, 2022	DP			
<u>FLUOCINONIDE - FLUOCINONIDE</u>						
A 090256 001					PC	Jul 13, 2014
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	7270800	Jan 24, 2023	DS DP U-336		NCE	Oct 25, 2018
	7351401	Jan 24, 2023	DS DP U-336			
	8691185	Jan 24, 2023	U-336			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	7270800	Jan 24, 2023	DS DP U-336		NCE	Oct 25, 2018
	7351401	Jan 24, 2023	DS DP U-336			
	8691185	Jan 24, 2023	U-336			
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N 022051 001	8147461	Oct 15, 2028	DP			
	8347879	Jul 15, 2028	DP			
	8752543	Apr 05, 2026	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	5873360	Feb 23, 2016	DP		NP	Aug 20, 2017
	7101866	Aug 03, 2021	DS DP U-1559			
	7629335	Aug 03, 2021	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8201556	Feb 05, 2029	DP			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	5873360	Feb 23, 2016	DP		NP	Aug 20, 2017
	7101866	Aug 03, 2021	DS DP U-1559			
	7629335	Aug 03, 2021	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8201556	Feb 05, 2029	DP			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	>A> 8746242	Oct 11, 2030	DP		NP	May 10, 2016
	RE44874	Mar 23, 2023	DS DP U-1548			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 003	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 001	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 002	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 003	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N 022007 001	8623922	Jun 22, 2021	DP			
<u>GABAPENTIN - GRALISE</u>						
N 022544 001					>A> ODE	Jan 28, 2018
<u>GABAPENTIN - GRALISE</u>						
N 022544 002					>A> ODE	Jan 28, 2018
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 001	8686034	Jan 24, 2025	U-1231		ODE	Jun 06, 2019
	8686034	Jan 24, 2025	U-1247			
	8795725	Jun 10, 2029	DP U-1231			
	8795725	Jun 10, 2029	DP U-1247			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 002	8686034	Jan 24, 2025	U-1231		ODE	Jun 06, 2019
	8686034	Jan 24, 2025	U-1247			
	8795725	Jun 10, 2029	DP U-1231			
	8795725	Jun 10, 2029	DP U-1247			
<u>GADOBUTROL - GADAVIST</u>						
N 201277 001					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 003					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 004					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 005					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006					I-688 NCE	Jun 11, 2017 Mar 14, 2016
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	6054430	May 24, 2014	DS		NP	Jan 28, 2017
	6342476	May 24, 2014	U-441			
	6362161	May 24, 2014	DS			
	7199098	May 24, 2014	DS			
	8232250	Aug 19, 2030	U-441			
	8367605	May 24, 2014	DS			
	8399413	Sep 06, 2030	U-441			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	8642012	Sep 22, 2030	U-1383			
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	7348361	Nov 06, 2020	DP U-1087			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	6228398	Nov 01, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	6228398	Nov 01, 2019	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8476284	Dec 28, 2026	U-1456		I-680	Feb 12, 2017
	8476284	Dec 28, 2026	U-1491		I-689	Jul 28, 2017
	8497277	Dec 28, 2026	U-1456		ODE	Feb 12, 2021
	8497277	Dec 28, 2026	U-1491		ODE	Jul 28, 2021
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	8735452	Sep 30, 2029	U-981			
<u>ICATIBANT ACETATE - FIRAZYR</u>						
N 022150 001	5648333	Jul 15, 2015	DS DP U-1187			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001					NP	Jul 26, 2015
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001	6800620	Apr 24, 2021	DS U-1560		NCE	Jul 23, 2019
	6949535	Apr 24, 2021	DS U-1560			
	8138195	Apr 24, 2021	DS DP			
	8492389	Apr 24, 2021	DS DP			
	8637533	Apr 24, 2021	DS DP			
	RE44599	Jul 21, 2025	U-1558			
	RE44638	Aug 05, 2025	DS DP			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002	6800620	Apr 24, 2021	DS U-1560		NCE	Jul 23, 2019
	6949535	Apr 24, 2021	DS U-1560			
	8138195	Apr 24, 2021	DS DP			
	8492389	Apr 24, 2021	DS DP			
	8637533	Apr 24, 2021	DS DP			
	RE44599	Jul 21, 2025	U-1558			
	RE44638	Aug 05, 2025	DS DP			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 001	8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 002	8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	5618913	Jun 07, 2014	DS DP			
	5618913*PED	Dec 07, 2014				
	5866538	Jun 20, 2017	DP			
	5866538*PED	Dec 20, 2017				
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	5750497	Jun 16, 2019	DS DP U-668			
	5866538	Jun 20, 2017	DP			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8679069	Apr 12, 2025	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	8679069	Apr 12, 2025	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	6071497	May 15, 2015	DP U-1533		NP	Jun 27, 2017
	6428771	May 15, 2015	DP U-1533			
	6444226	Jun 29, 2020	DP U-1534			
	6652885	Jun 29, 2020	U-1535			
	6663898	Sep 30, 2014	DP			
	6906030	Sep 30, 2014	DP			
	7276534	Sep 30, 2014	DP U-1536			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8133514	Sep 30, 2014	DP			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8227409	Mar 08, 2031	DP U-1538			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP			
	8394414	May 15, 2015	DP U-1533			
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029	U-1537			
	8636001	Jul 12, 2032	DP			
	8729019	Jun 06, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	6071497	May 15, 2015	DP U-1533		NP	Jun 27, 2017
	6428771	May 15, 2015	DP U-1533			
	6444226	Jun 29, 2020	DP U-1534			
	6652885	Jun 29, 2020	U-1535			
	6663898	Sep 30, 2014	DP			
	6906030	Sep 30, 2014	DP			
	7276534	Sep 30, 2014	DP U-1536			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	8119593	Aug 11, 2029	U-1537			
	8133514	Sep 30, 2014	DP			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8227409	Mar 08, 2031	DP U-1538			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP			
	8394414	May 15, 2015	DP U-1533			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8636001	Jul 12, 2032	DP			
	8729019	Jun 06, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
<u>IOFLUPANE I-123 - DATSCAN</u>						
N 022454 001	5310912	Feb 25, 2015	DS			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8754224	Dec 28, 2026	DS DP			
<u>IVERMECTIN - SKLICE</u>						
N 202736 001	8791153	Oct 12, 2027	DP			
<u>KETOCONAZOLE - XOLEGEL</u>						
N 021946 001	8735393	Dec 04, 2018	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8648107	May 28, 2024	DP			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA</u>						
N 205388 001	8173707	Jul 30, 2023	U-1518		NP	May 30, 2017
	8586633	Jul 30, 2023	DP			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 001 >A>	RE38551	Mar 17, 2022	DS DP U-1566			
	>A> RE38551	Mar 17, 2022	DS DP U-1567			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 002 >A>	RE38551	Mar 17, 2022	DS DP U-1566			
	>A> RE38551	Mar 17, 2022	DS DP U-1567			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 003 >A>	RE38551	Mar 17, 2022	DS DP U-1566			
	>A> RE38551	Mar 17, 2022	DS DP U-1567			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 004 >A>	RE38551	Mar 17, 2022	DS DP U-1566			
	>A> RE38551	Mar 17, 2022	DS DP U-1567			
<u>LACOSAMIDE - VIMPAT</u>						
N 022254 001 >A>	RE38551	Mar 17, 2022	DS DP U-1565			
	>A> RE38551	Mar 17, 2022	DS DP U-1568			
<u>LACOSAMIDE - VIMPAT</u>						
N 022255 001 >A>	RE38551	Mar 17, 2022	DS DP U-1566			
	>A> RE38551	Mar 17, 2022	DS DP U-1567			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 001	8637512	Jun 14, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 002	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 003	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 004	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 005	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 006	8637512	Jun 14, 2028	DP			
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059 001 >A>	8821927	Jun 12, 2029	DS DP			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001					>A> NCE	Oct 10, 2019
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
	8741929	Mar 08, 2028	U-1414			
<u>LEUPROLIDE ACETATE; NORETHINDRONE ACETATE - LUPANETA PACK</u>						
N 203696 001 >A>	6036976	Dec 13, 2016	DP			
<u>LEUPROLIDE ACETATE; NORETHINDRONE ACETATE - LUPANETA PACK</u>						
N 203696 002 >A>	6036976	Dec 13, 2016	DP			
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730 001	8765153	Dec 08, 2023	DP			
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 001 >A>	8802142	Jun 07, 2031	DP			
	>A> 8802142*PED	Dec 07, 2031				
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 002 >A>	8802142	Jun 07, 2031	DP			
	>A> 8802142*PED	Dec 07, 2031				
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 003 >A>	8802142	Jun 07, 2031	DP			
	>A> 8802142*PED	Dec 07, 2031				
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 004 >A>	8802142	Jun 07, 2031	DP			
	>A> 8802142*PED	Dec 07, 2031				
<u>LIDOCAINE HYDROCHLORIDE - AKTEN</u>						
N 022221 001	8759401	Jul 24, 2026	DP U-1523			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8748573	Jun 20, 2031	U-1515			
	8748573	Jun 20, 2031	U-1516			
	8802628	Jul 24, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8748573	Jun 20, 2031	U-1515			
	8748573	Jun 20, 2031	U-1516			
	8802628	Jul 24, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8673927	Aug 23, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	Aug 23, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8673927	Aug 23, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	Aug 23, 2027	U-1503			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	8618135	Mar 07, 2025	U-1316			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 001	8691878	Aug 25, 2024	U-1513			
	8691878*PED	Feb 25, 2025				
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 002	8691878	Aug 25, 2024	U-1513			
	8691878*PED	Feb 25, 2025				
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8697686	Dec 20, 2025	DS DP			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	7052679	Oct 26, 2021	DP			
	7537009	Oct 28, 2024	DP			
	8074644	Jul 25, 2022	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	8748481	Sep 01, 2025	U-1520			
	8779187	Jul 23, 2027	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 002	8748481	Sep 01, 2025	U-1519			
	8779187	Jan 23, 2027	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	8729085	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	8729085	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	8729085	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	8729085	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	5532372	Jul 02, 2018	DS			
	8729085	May 26, 2026	DP			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021487 001	5061703	Apr 11, 2015	U-539			
	5061703*PED	Oct 11, 2015				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021487 002	5061703	Apr 11, 2015	U-539			
	5061703*PED	Oct 11, 2015				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021627 001	5061703	Apr 11, 2015	U-539			
	5061703*PED	Oct 11, 2015				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 001	5061703	Apr 11, 2015	U-539		M-138 PED	Jul 03, 2017 Jan 03, 2018
	5061703*PED	Oct 11, 2015				
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 002	5061703	Apr 11, 2015	U-539		M-138 PED	Jul 03, 2017 Jan 03, 2018
	5061703*PED	Oct 11, 2015				
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 003	5061703	Apr 11, 2015	U-539		M-138 PED	Jul 03, 2017 Jan 03, 2018
	5061703*PED	Oct 11, 2015				
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 004	5061703	Apr 11, 2015	U-539		M-138 PED	Jul 03, 2017 Jan 03, 2018
	5061703*PED	Oct 11, 2015				
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MENOTROPINS (FSH;LH) - MENOPUR</u>						
N 021663 001					D-139	Feb 19, 2017
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 001	8809615	Jan 03, 2030	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 002	8809615	Jan 03, 2030	DP			
<u>MERCAPTOPURINE - PURIXAN</u>						
N 205919 001					ODE	Apr 28, 2021
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001	8668931	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	8668931	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	8628799	Jul 13, 2025	DP		M-134	May 24, 2016
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002					M-134	May 24, 2016
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003					M-134	May 24, 2016
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 001	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 002	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 003	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 004	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 005	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 006	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 007	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 008	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 009	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 010	8664231	Jun 01, 2029	U-1442			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	>A> 8822490	Sep 30, 2029	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	>A> 8822490	Sep 30, 2029	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	>A> 8822490	Sep 30, 2029	DP U-1185			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8778390	Feb 15, 2031	DP U-1543			
<u>METRONIDAZOLE - METRONIDAZOLE</u>						
N 205223 001					NP	Mar 24, 2017
<u>MILTEFOSINE - IMPAVIDO</u>						
N 204684 001					NCE ODE	Mar 19, 2019 Mar 19, 2021
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 006	8722650	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 007	8722650	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 008	8722650	Jun 24, 2025	U-1078			
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812 002					NP	Feb 28, 2017
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	>A> 8835474	Nov 04, 2023	U-1527			
	RE44872	Dec 18, 2023	U-1527			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	>A> 8835474	Nov 04, 2023	U-1527			
	RE44872	Dec 18, 2023	U-1527			
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641 001	5889015	Jan 27, 2014	U-645			
	5889015*PED	Jul 27, 2014				
	6057307	Jan 27, 2014	DP U-645			
	6057307*PED	Jul 27, 2014				
	6068832	Aug 27, 2017	DP U-645			
	6365581	Jan 27, 2014	U-645			
	6365581*PED	Jul 27, 2014				
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641 002	5889015	Jan 27, 2014	U-645			
	5889015*PED	Jul 27, 2014				
	6057307	Jan 27, 2014	DP U-645			
	6057307*PED	Jul 27, 2014				
	6068832	Aug 27, 2017	DP U-645			
	6365581	Jan 27, 2014	U-645			
	6365581*PED	Jul 27, 2014				
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 001	6066339	Nov 25, 2017	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 002	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 003	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 004	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 005	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 006	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
<u>MYCOPHENOLIC ACID - MYCOPHENOLIC ACID</u>						
A 091248 001					PC	Jul 07, 2014
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001	8778365	Jan 31, 2033	DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001					>A> NCE	Sep 16, 2019
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002					>A> NCE	Sep 16, 2019

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	7731686	Jun 10, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8627816	Feb 04, 2032	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	6277384	Dec 22, 2018	DP			
	6696066	Dec 22, 2018	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	8673355	Dec 22, 2018	DP			
	8822487	Dec 22, 2018	DP			
	>A> 8846090	Apr 04, 2023	DP			
	>A> 8846091	Apr 04, 2023	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	6277384	Dec 22, 2018	DP			
	6696066	Dec 22, 2018	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	8673355	Dec 22, 2018	DP			
	8822487	Dec 22, 2018	DP			
	>A> 8846090	Apr 04, 2023	DP			
	>A> 8846091	Apr 04, 2023	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	6277384	Dec 22, 2018	DP			
	6696066	Dec 22, 2018	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	8673355	Dec 22, 2018	DP			
	8822487	Dec 22, 2018	DP			
	>A> 8846090	Apr 04, 2023	DP			
	>A> 8846091	Apr 04, 2023	DP			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001					>A> NCE	Oct 10, 2019
<u>NEVIRAPINE - NEVIRAPINE</u>						
A 203411 001					PC	Oct 12, 2014
<u>NEVIRAPINE - NEVIRAPINE</u>						
A 205258 001					PC	Oct 12, 2014
<u>NIACIN - NIACIN</u>						
A 076250 001					PC	Mar 19, 2014
<u>NIACIN - NIACIN</u>						
A 076378 001					PC	Mar 19, 2014
<u>NIACIN - NIACIN</u>						
A 076378 002					PC	Mar 19, 2014
<u>NICOTINE - NICODERM CO</u>						
N 020165 004	8663680	Feb 13, 2020	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 005	8663680	Feb 13, 2020	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NICOTINE - NICODERM CO</u>						
N 020165 006	8663680	Feb 13, 2020	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 001 >A>	8293756	Sep 25, 2027	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 002 >A>	8293756	Sep 25, 2027	DP			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 002	8776794	Jan 06, 2031	DP U-1226		M-132	Dec 21, 2013
	8776794*PED	Jul 06, 2031			PED	Jun 21, 2014
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	>A> 8846112	Jun 30, 2029	U-1286			
	>A> 8846112*PED	Dec 30, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	8776794	Jan 06, 2031	DP U-1226		M-132	Dec 21, 2013
	8776794*PED	Jul 06, 2031			PED	Jun 21, 2014
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	>A> 8846112	Jun 30, 2029	U-1286			
	>A> 8846112*PED	Dec 30, 2029				
<u>OLIVE OIL; SOYBEAN OIL - CLINOLIPID 20%</u>						
N 204508 001	5840757	Nov 24, 2015	DP		NP	Oct 03, 2016
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108 001	5964416	Oct 04, 2016	DP		NCE	Jul 31, 2019
	6149054	Dec 19, 2016	DP			
	6176442	Oct 04, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP U-1547			
	7056916	Dec 07, 2023	DS DP			
	7104470	Oct 04, 2016	DP			
	7220742	May 12, 2025	DS DP U-1547			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP U-1547			
	7491719	Nov 10, 2023	DS DP			
	7727984	Nov 10, 2023	DS			
	7786111	Nov 10, 2023	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8034809	May 12, 2025	U-1547			
	8044046	Nov 10, 2023	U-1547			
<u>OLOPATADINE HYDROCHLORIDE - PATADAY</u>						
N 021545 001	5641805	Jun 06, 2015	U-765	Y		
	5641805*PED	Dec 06, 2015				
<u>OMACETAXINE MEPESUCCINATE - SYNRIBO</u>						
N 203585 001 >A>	RE45128	Mar 16, 2019	DS DP U-1576			
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2016	DP			
	5948818	May 13, 2016	DP			
	7960370	Feb 07, 2025	DP			
	8383678	Feb 07, 2025	DP U-1511			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	>A> 5840684	Nov 24, 2015	DS DP U-1569		NCE	Aug 06, 2019
	>A> 5998581	Nov 12, 2017	DS		GAIN	Aug 06, 2024
	>A> 8420592	Aug 29, 2029	U-1570			
<u>OSPEMIFENE - OSPHENA</u>						
N 203505 001	8642079	Mar 01, 2028	DP			
	8772353	Feb 13, 2024	U-1369			
	8772353	Feb 13, 2024	U-1370			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	8821930	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	8821930	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	8821930	Apr 13, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 001	8637540	Nov 26, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 002	8637540	Nov 26, 2023	DP			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	5202333	Apr 13, 2015	DS DP U-528		I-684	May 27, 2017
	5202333*PED	Oct 13, 2015			M-136	May 27, 2017
	7947724	Jan 30, 2024	DP		PED	Nov 27, 2017
	7947724*PED	Jul 30, 2024			PED	Nov 27, 2017
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
	8729094	Jan 30, 2024	DP U-528			
	8729094*PED	Jul 30, 2024				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	5202333	Apr 13, 2015	DS DP U-901		I-684	May 27, 2017
	5202333*PED	Oct 13, 2015			M-136	May 27, 2017
	7947724	Jan 30, 2024	DP		PED	Nov 27, 2017
	7947724*PED	Jul 30, 2024			PED	Nov 27, 2017
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
N 020988 001	8754108	Nov 17, 2021	DP			
	8754108*PED	May 17, 2022				
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	8658663	Apr 06, 2029	DS DP U-904			
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 004	5849535	Mar 25, 2017	DS			
	6057292	Sep 21, 2015	U-507			
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 005	5849535	Mar 25, 2017	DS			
	6057292	Sep 21, 2015	U-507			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	8772497	May 16, 2026	DS			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	8658205	Apr 20, 2019	DP			
	8685441	Jan 13, 2019	U-665			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 001 >A>	6071537	Jun 23, 2017	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 002 >A>	6071537	Jun 23, 2017	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 003 >A>	6071537	Jun 23, 2017	U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 004 >A>	6071537	Jun 23, 2017	U-1262			
<u>POLIDOCANOL - VARITHENA</u>						
N 205098 001	8734833	May 26, 2020	DS DP			
	>A> RE40640	Oct 14, 2015	DS DP U-1462			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	>A> 8828427	Jun 21, 2031	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
>A>	8828427	Jun 21, 2031	DS DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
>A>	8828427	Jun 21, 2031	DS DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
>A>	8828427	Jun 21, 2031	DS DP			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	5661151	Jul 19, 2019	DS DP U-1454			
	5703079	Aug 26, 2014	DS DP U-1454			
	8410077	Mar 13, 2029	DP			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 001	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 002	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 003	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 004	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 005	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 006	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 007	8679533	Sep 08, 2029	DP U-219			
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410 001	8338489	Oct 16, 2028	U-1496		NP ODE	Mar 14, 2017 Mar 14, 2021
<u>RALOXIFENE HYDROCHLORIDE - RALOXIFENE HYDROCHLORIDE</u>						
A 078193 001					PC	Sep 24, 2014
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641 001					I-685	May 29, 2017
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641 002					I-685	May 29, 2017
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	8637553	Jul 08, 2029	DS DP			
	8680124	Jul 20, 2028	U-1506			
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	8518949	Feb 27, 2026	DP			
	8741904	Feb 27, 2026	DS U-1526			
>A>	8835452	Jun 19, 2024	DS DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	8642573	Oct 02, 2029	U-1481			
	8741904	Feb 27, 2026	DS U-1526			
>A>	8829017	Jul 24, 2029	U-1562			
>A>	8835452	Jun 19, 2024	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RITONAVIR - NORVIR</u>						
N 022417 001	8691878	Aug 25, 2024	U-688			
	8691878*PED	Feb 25, 2025				
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	8618142	Mar 08, 2024	DP			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	8722693	Jun 12, 2028	DS DP			
	>A> 8822481	Jun 12, 2028	U-1573			
	>A> 8829013	Jun 12, 2028	U-1201			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	8722693	Jun 12, 2028	DS DP			
	>A> 8822481	Jun 12, 2028	U-1573			
	>A> 8829013	Jun 12, 2028	U-1201			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	8722693	Jun 12, 2028	DS DP			
	>A> 8822481	Jun 12, 2028	U-1573			
	>A> 8829013	Jun 12, 2028	U-1201			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	8722693	Jun 12, 2028	DS DP			
	>A> 8822481	Jun 12, 2028	U-1573			
	>A> 8829013	Jun 12, 2028	U-1201			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	8722693	Jun 12, 2028	DS DP			
	>A> 8822481	Jun 12, 2028	U-1573			
	>A> 8829013	Jun 12, 2028	U-1201			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	7566462	Nov 16, 2025	DP		NPP	Apr 23, 2017
	7566462*PED	May 16, 2026			ODE	Dec 13, 2014
	7566714	Nov 17, 2024	U-989		PED	Jun 13, 2015
	7566714*PED	May 17, 2025			PED	Oct 23, 2017
	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	7727987	Nov 17, 2024	DP			
	7727987*PED	May 17, 2025				
	7947681	Nov 17, 2024	U-1156			
	7947681*PED	May 17, 2025				
	8003126	Nov 16, 2025				
	8003126*PED	May 17, 2015				
	8067416	Nov 17, 2024	U-989			
	8067416*PED	May 17, 2025				
	8318745	Nov 17, 2024	DP			
	8318745*PED	May 17, 2025				
	RE43797	Nov 17, 2024	U-1156			
	RE43797*PED	May 17, 2025				
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 001	>A> 7566714	Nov 17, 2024	U-1589			
	>A> 7612073	Nov 17, 2024	U-1010			
	>A> 8067416	Nov 17, 2024	U-1589			
	>A> RE43797	Nov 17, 2024	U-1590			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001					M-134	May 24, 2016
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002					M-134	May 24, 2016
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 022473 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 203109 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	8741926	Jul 28, 2026	DS U-1467			
	8754106	Jul 28, 2026	DS U-1467			
<u>SIROLIMUS - SIROLIMUS</u>						
A 201676 003					PC	Jul 15, 2014
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8731963	Dec 17, 2022	U-1110			
	8772306	Mar 15, 2033	U-1532			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	8618141	Feb 11, 2023	U-1480			
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239 001	6174304	Dec 13, 2015	DP			
	6251091	Dec 09, 2016	DP			
	6280410	Mar 27, 2017	DP			
	6681810	Dec 13, 2015	DP			
	8241243	Aug 10, 2023	DP			
	8491524	Nov 21, 2022	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 001 >A>	7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 002 >A>	7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 003 >A>	7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 004 >A>	7951797	Nov 20, 2029	DS DP U-620		NCE	Aug 13, 2019
<u>TALIGLUCERASE ALFA - ELELYSO</u>						
N 022458 001	8741620	Feb 24, 2024	DS DP		NPP	Aug 27, 2017
	>A> 8790641	Oct 18, 2025	U-1564			
	>A> 8790641	Oct 18, 2025	U-1574			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	5856529	Dec 09, 2017	DS DP U-1486		NCE	Jan 31, 2019
	8785492	Jan 25, 2033	U-1486		ODE	Jan 31, 2021
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001	7582621	May 26, 2027	U-718		NCE	Jul 07, 2019
	7767657	May 22, 2027	DP			
<u>TAZAROTENE - FABIOR</u>						
N 202428 001	8808716	Feb 24, 2030	DP			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001					I-687	Jun 13, 2017
					>A> ODE	Jun 13, 2021
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001	7816379	Feb 23, 2028	DS DP U-282		NCE	Jun 20, 2019
	8420676	Feb 23, 2028	DS DP U-282		GAIN	Jun 20, 2024
	8426389	Dec 31, 2030	DS DP U-282			
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001	7816379	Feb 23, 2028	DS DP U-282		NCE	Jun 20, 2019
	8420676	Feb 23, 2028	DS DP U-282		GAIN	Jun 20, 2024
	8426389	Dec 31, 2030	DS DP U-282			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 001					PC	Jul 07, 2014
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 002					PC	Jul 07, 2014
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 003					PC	Jul 07, 2014
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 022277 001	8623868	Feb 21, 2023	DP			
<u>TEMSIROLIMUS - TORISEL</u>						
N 022088 001	5362718	Feb 15, 2019	DS DP	Y		
	5362718*PED	Aug 15, 2019				
	8722700	Jul 25, 2023	DP			
	8722700*PED	Jan 25, 2024				
	8791097	May 10, 2032		U-1550		
	8791097	May 10, 2032		U-1551		
	RE44768	Feb 15, 2019	DS DP			
	RE44768*PED	Aug 15, 2019				
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 001	>A> 8802735	Sep 14, 2030	DP			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 002	>A> 8802735	Sep 14, 2030	DP			
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N 021318 001	>A> 7517334	Mar 25, 2025	DP			
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N 021318 002	>A> 7517334	Mar 25, 2025	DP			
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N 022505 001	5861379	May 26, 2020	DS DP	U-1100		
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026		U-1103		
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	6503894	Aug 30, 2020		U-1103		
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026		U-1103		
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	6503894	Aug 30, 2020		U-1103		
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026		U-1103		
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	8784878	Jul 13, 2023	DP	U-1545		
	>A> 8807861	Feb 26, 2027	DP	U-1563		
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	8785426	Feb 11, 2034	DP	U-1531	NP	Jun 04, 2017
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	8785426	Feb 11, 2034	DP	U-1531	NP	Jun 04, 2017
<u>TESTOSTERONE - NATESTO</u>						
N 205488 001	8574622	Feb 04, 2024	DP		NP	May 28, 2017
	8784869	Feb 04, 2024	DP			
	8784882	Feb 04, 2024	DP	U-1557		
<u>TESTOSTERONE UNDECANOATE - AVEED</u>						
N 022219 001	7718640	Mar 14, 2027	DP		NP	Mar 05, 2017
	8338395	Feb 27, 2026		U-1500		
<u>THALIDOMIDE - THALOMID</u>						
N 020785 001	8626531	Oct 23, 2020		U-1465		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N 020785 002	8626531	Oct 23, 2020	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 003	8626531	Oct 23, 2020	U-1465			
<u>THALIDOMIDE - THALOMID</u>						
N 020785 004	8626531	Oct 23, 2020	U-1465			
<u>TIMOLOL MALEATE - ISTALOL</u>						
N 021516 001	6645963	Nov 16, 2018	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001					>A> NP	Sep 24, 2017
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001					M-135	Feb 21, 2017
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	5753677	May 19, 2020	U-978			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	5753677	May 19, 2020	U-978			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	5753677	May 19, 2020	U-978			
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 001					>A> NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 002					>A> NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 003					>A> NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 004					>A> NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 005					>A> NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 006					>A> NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020844 001					>A> NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020844 002					>A> NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>						
N 020844 003					>A> NPP	Mar 28, 2017
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8663683	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8663683	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8663683	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8663683	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	8652527	Mar 19, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	>A> 8835443	Sep 13, 2025	U-1581		I-678	Jan 08, 2017
	>A> 8835443	Sep 13, 2025	U-1582		ODE	Jan 08, 2021
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	>A> 8835443	Sep 13, 2025	U-1581		I-678	Jan 08, 2017
	>A> 8835443	Sep 13, 2025	U-1582		ODE	Jan 08, 2021
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	>A> 8835443	Sep 13, 2025	U-1581		I-678	Jan 08, 2017
	>A> 8835443	Sep 13, 2025	U-1582		ODE	Jan 08, 2021
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	8791160	Mar 04, 2025	DP U-1182			
	>A> 8809394	Mar 04, 2025	DP U-1182			
<u>TRAVOPROST - IZBA</u>						
N 204822 001	8722735	Oct 10, 2029	DP		NP	May 15, 2017
	8754123	May 19, 2029	DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	8747897	Oct 08, 2029	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	8747897	Oct 08, 2029	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	8747897	Oct 08, 2029	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	8747897	Oct 08, 2029	DP			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8735380	Feb 20, 2029	DP			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	5873360	Feb 23, 2016	DP			
	7488827	Apr 27, 2025	DS DP			
	7498440	Apr 27, 2025	DS DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-1476			
	8201556	Feb 05, 2029	DP			
	8309572	Apr 27, 2025	U-1476			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	8746242	Oct 11, 2030	DP		NP	Dec 18, 2016
	RE44874	Mar 23, 2023	DS DP U-1476			
<u>UROFOLLITROPIN - BRAVELLE</u>						
N 021289 001					D-139	Feb 19, 2017
<u>VALSARTAN - VALSARTAN</u>						
A 077492 001					PC	Jan 03, 2015
<u>VALSARTAN - VALSARTAN</u>						
A 077492 002					PC	Jan 03, 2015
<u>VALSARTAN - VALSARTAN</u>						
A 077492 003					PC	Jan 03, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 09 - September 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALSARTAN - VALSARTAN</u>						
A 077492 004					PC	Jan 03, 2015
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	8642608	Feb 06, 2022	U-1490			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	8642608	Feb 06, 2022	U-1490			
<u>VARDENAFIL HYDROCHLORIDE - STAXYN</u>						
N 200179 001	8613950	Dec 23, 2028	DP			
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429 001	8741920	Jul 27, 2030	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001	8673921	Jun 05, 2022	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002	8673921	Jun 05, 2022	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003	8673921	Jun 05, 2022	DS DP			
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886 001	7235567	Jun 13, 2021	DS DP		NCE	May 08, 2019
	7304078	Apr 06, 2024	DS DP U-1512			
<u>VORINOSTAT - ZOLINZA</u>						
N 021991 001	8450372	Mar 18, 2028	U-892			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	8722684	Nov 11, 2030	DS DP			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 001	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 002	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 003	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 004	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450 003	6750237	Nov 28, 2020	DP			
	6750237*PED	May 28, 2021				
	7220767	Nov 28, 2020	DP			
	7220767*PED	May 28, 2021				

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as

described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 34th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>